<SEC-DOCUMENT>0001171843-16-011397.txt : 20160801
<SEC-HEADER>0001171843-16-011397.hdr.sgml : 20160801
<ACCEPTANCE-DATETIME>20160801164200
ACCESSION NUMBER:		0001171843-16-011397
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20160630
FILED AS OF DATE:		20160801
DATE AS OF CHANGE:		20160801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		161797822

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q_080116p.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
     <TITLE></TITLE>
</HEAD><BODY STYLE="font: 10pt Times New Roman, Times, Serif">





<p style="margin: 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: #7F0000 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: #7F0000 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><font style="font-size: 12pt"><b>UNITED STATES</b></font></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><font style="font-size: 12pt"><b>SECURITIES AND EXCHANGE COMMISSION</b></font></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: #7F0000 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><font style="font-size: 12pt"><b>FORM&nbsp;10-Q</b></font></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left">&#9746;</td><td style="width: 5pt"></td><td style="text-align: justify"><b>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15 (d)&nbsp;OF THE SECURITIES EXCHANGE
ACT OF 1934</b></td>
</tr></table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>For the quarterly period ended June 30, 2016</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left">&#9744;</td><td style="width: 5pt"></td><td style="text-align: justify"><b>TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15 (d)&nbsp;OF THE SECURITIES
EXCHANGE ACT OF 1934</b></td>
</tr></table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: #7F0000 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Commission File Number 000-21326</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><font style="font-size: 12pt"><b>Anika Therapeutics,&nbsp;Inc.</b></font></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">(Exact Name of Registrant as Specified in Its Charter)</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><b>Massachusetts</b></td>
    <td style="width: 50%; text-align: center"><b>04-3145961</b></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">(State or Other Jurisdiction of</td>
    <td style="text-align: center">(I.R.S. Employer Identification No.)</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Incorporation or Organization)</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><b>32 Wiggins Avenue, Bedford, Massachusetts</b></td>
    <td style="text-align: center"><b>01730</b></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">(Address of Principal Executive Offices)</td>
    <td style="text-align: center">(Zip Code)</td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">Registrant&#8217;s Telephone Number, Including Area Code:<b> (781)&nbsp;457-9000</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; text-indent: 49.5pt; margin: 0pt 0">Former Name, Former Address and Former Fiscal
Year, if Changed Since Last Report:<b> N/A</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 49.5pt; margin: 0pt 0">Indicate by check mark whether the registrant (1)&nbsp;has filed
all reports required to be filed by Section&nbsp;13 or 15 (d)&nbsp;of the Securities Exchange Act of 1934 during the preceding
12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90&nbsp;days. Yes &#9746; &nbsp;No &#9744;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 49.5pt; margin: 0pt 0">Indicate by check mark whether the registrant has submitted electronically
and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405
of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes &#9746; &nbsp;No &#9744;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 49.5pt; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated
filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&nbsp;12b-2 of the Exchange Act.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: top; width: 19%">Large accelerated filer&nbsp;&#9744;</td>
    <td style="vertical-align: bottom; width: 4%">&nbsp;</td>
    <td style="vertical-align: top; width: 18%; text-align: center">Accelerated filer&nbsp;&#9746;</td>
    <td style="vertical-align: bottom; width: 4%">&nbsp;</td>
    <td style="vertical-align: top; width: 28%">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0">Non-accelerated filer&nbsp;&#9744;</p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0">(Do not check if a smaller</p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0">reporting company)</p></td>
    <td style="vertical-align: bottom; width: 4%">&nbsp;</td>
    <td style="vertical-align: top; width: 23%">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0">Smaller reporting</p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0">company&nbsp;&#9744;</p></td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 49.5pt">Indicate by check mark whether the registrant is a shell company (as defined
in Rule&nbsp;12b-2 of the Exchange Act)</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 49.5pt">Yes&nbsp;&#9744; &nbsp;No&nbsp;&#9746;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 49.5pt; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 49.5pt">As of July 28, 2016 there were 14,777,663
outstanding shares of Common Stock, par value $.01&nbsp;per share.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: #7F0000 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div align="LEFT" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: #7F0000 0.75pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>ANIKA THERAPEUTICS,&nbsp;INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>TABLE OF CONTENTS</b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 9%">
        <p style="font-size: 10pt; margin: 0pt 0"></p></td>
    <td style="width: 84%">
        <p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>
        <p style="font-size: 10pt; margin: 0pt 0"></p></td>
    <td style="width: 7%">
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>
        <p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Page</b></p></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none"><font style="color: Blue"><a href="#a_001">Part&nbsp;I</a></font></td>
    <td style="text-decoration: none"><font style="color: Blue"><a href="#a_001">Financial Information</a></font></td>
    <td style="text-align: center"><font style="color: Blue">&nbsp;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none; text-indent: 10pt"><a href="#a_002"><font style="color: blue">Item&nbsp;1.</font></a></td>
    <td style="text-decoration: none"><a href="#a_002"><font style="color: blue">Financial Statements (unaudited):</font></a></td>
    <td style="text-align: center"><a href="#a_002">3</a></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="text-decoration: none"><a href="#a_003"><font style="color: blue">Condensed Consolidated Balance Sheets as of June 30, 2016 and
    December 31, 2015 </font></a></td>
    <td style="text-align: center"><a href="#a_003">3</a></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td><a href="#a_004">
        Condensed Consolidated Statements of Operations and Comprehensive
Income for the three and six months ended June 30, 2016 and 2015</a></td>
    <td style="text-align: center"><a href="#a_004">4</a></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-decoration: none"><a href="#a_005"><font style="color: blue">Condensed Consolidated Statements of Cash Flows for the six months
    ended June 30, 2016 and 2015</font></a></td>
    <td style="text-align: center"><a href="#a_005"><font style="color: blue">5</font></a></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="text-decoration: none"><a href="#a_006"><font style="color: blue">Notes to Condensed Consolidated Financial Statements</font></a></td>
    <td style="text-align: center"><a href="#a_006"><font style="color: blue">6</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none; text-indent: 10pt"><a href="#a_007"><font style="color: blue">Item&nbsp;2.</font></a></td>
    <td style="text-decoration: none"><a href="#a_007"><font style="color: blue">Management&#8217;s Discussion and Analysis of Financial Condition
    and Results of Operations</font></a></td>
    <td style="text-align: center"><a href="#a_007"><font style="color: blue">13</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none; text-indent: 10pt"><a href="#a_008"><font style="color: blue">Item&nbsp;3.</font></a></td>
    <td style="text-decoration: none"><a href="#a_008"><font style="color: blue">Quantitative and Qualitative Disclosures About Market Risk</font></a></td>
    <td style="text-align: center"><a href="#a_008"><font style="color: blue">18</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none; text-indent: 10pt"><a href="#a_009"><font style="color: blue">Item&nbsp;4.</font></a></td>
    <td style="text-decoration: none"><a href="#a_009"><font style="color: blue">Controls and Procedures</font></a></td>
    <td style="text-align: center"><a href="#a_009"><font style="color: blue">18</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none"><a href="#a_010">Part&nbsp;II</a></td>
    <td style="text-decoration: none"><a href="#a_010"><font style="color: blue">Other Information</font></a></td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none; text-indent: 10pt"><a href="#a_011"><font style="color: blue">Item&nbsp;1.</font></a></td>
    <td style="text-decoration: none"><a href="#a_011"><font style="color: blue">Legal Proceedings</font></a></td>
    <td style="text-align: center"><a href="#a_011"><font style="color: blue">19</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none; text-indent: 10pt"><a href="#a_012"><font style="color: blue">Item&nbsp;1A.&nbsp;&nbsp;</font></a></td>
    <td style="text-decoration: none"><a href="#a_012"><font style="color: blue">Risk Factors</font></a></td>
    <td style="text-align: center"><a href="#a_012"><font style="color: blue">19</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none; text-indent: 10pt"><a href="#a_013"><font style="color: blue">Item&nbsp;2.</font></a></td>
    <td style="text-decoration: none"><a href="#a_013"><font style="color: blue">Unregistered Sales of Equity Securities and Use
    of Proceeds</font></a></td>
    <td style="text-align: center"><a href="#a_013"><font style="color: blue">19</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none; text-indent: 10pt"><a href="#a_014"><font style="color: blue">Item&nbsp;3.</font></a></td>
    <td style="text-decoration: none"><a href="#a_014"><font style="color: blue">Defaults Upon Senior Securities</font></a></td>
    <td style="text-align: center"><a href="#a_014"><font style="color: blue">20</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none; text-indent: 10pt"><a href="#a_015"><font style="color: blue">Item&nbsp;4.</font></a></td>
    <td style="text-decoration: none"><a href="#a_015"><font style="color: blue">Mine Safety Disclosures</font></a></td>
    <td style="text-align: center"><a href="#a_015"><font style="color: blue">20</font></a></td></tr>
<tr style="vertical-align: top">
    <td style="text-decoration: none; text-indent: 10pt"><a href="#a_016"><font style="color: blue">Item&nbsp;6.</font></a></td>
    <td style="text-decoration: none"><a href="#a_016">Exhibits</a></td>
    <td style="text-align: center"><a href="#a_016"><font style="color: blue">20</font></a></td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="text-decoration: none"><a href="#a_017">Signatures</a></td>
    <td style="text-align: center"><a href="#a_017"><font style="color: blue">21</font></a></td></tr>
</table>
<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">References in this Quarterly Report on Form 10-Q to &#8220;we,&#8221;
&#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; and other similar references refer to Anika Therapeutics, Inc.
and its subsidiaries unless the context otherwise indicates.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">ANIKA, ANIKA THERAPEUTICS, CINGAL, HYAFF, MONOVISC, and ORTHOVISC are our registered
trademarks. This Quarterly Report on Form 10-Q also contains registered marks, trademarks, and trade names that are the property
of other companies and licensed to us.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><a name="a_001"></a><b>PART&nbsp;I: FINANCIAL INFORMATION</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><a name="a_002"></a><b>ITEM 1. FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><a name="a_003"></a>Condensed Consolidated Balance Sheets</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">(in thousands, except share data and per share data)</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</p>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">June 30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">ASSETS</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Current assets:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; font-size: 10pt; text-align: left; text-indent: 10pt">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">89,125</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">110,707</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,500</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,751</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Accounts receivable, net of reserves of $220 and $167 at June 30, 2016 and December 31, 2015, respectively</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">24,597</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">21,652</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Inventories</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,264</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,938</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Prepaid expenses and other current assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,158</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,385</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Total current assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">154,644</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">176,433</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Property and equipment, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">49,198</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">40,108</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Long-term deposits and other</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">69</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">69</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Intangible assets, net</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,259</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,656</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Goodwill</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,568</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,482</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total Assets</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">222,738</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">235,748</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Current liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">3,294</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,302</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Accrued expenses and other current liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,638</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,778</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Income taxes payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">591</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,198</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 20pt">Total current liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,523</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,278</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Other long-term liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,173</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">781</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Long-term deferred revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">56</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">66</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Deferred tax liability</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,570</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,775</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Commitments and contingencies (Note 12)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Stockholders&#8217; equity:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 0pt; padding-left: 10pt">Common stock, $.01 par value; 60,000,000 and 30,000,000 shares authorized, 14,777,663 and 15,036,808 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">148</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">150</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Additional paid-in-capital</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">59,506</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">81,685</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Accumulated other comprehensive loss</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(6,410</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(6,649</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 20pt">Retained earnings</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">151,172</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">135,662</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 20pt">Total stockholders&#8217; equity</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">204,416</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">210,848</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">222,738</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">235,748</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.<font style="font-size: 10pt"> </font></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><a name="a_004"></a>Condensed Consolidated Statements of Operations and Comprehensive Income</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">(in thousands, except per share data)</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</p>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; text-align: left">Product revenue</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,575</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">22,898</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">48,853</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">38,413</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Licensing, milestone and contract revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Total revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26,581</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,904</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,864</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">38,424</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Operating expenses:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Cost of product revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,065</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,275</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,490</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,588</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Research &amp; development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,792</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,812</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,951</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,910</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Selling, general &amp; administrative</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,255</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,388</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,245</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,993</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,112</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,475</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24,686</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,491</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,469</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,429</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">24,178</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,933</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Interest income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">49</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">121</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">48</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income before income taxes</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,518</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,453</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">24,299</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,981</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Provision for income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,903</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,634</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,789</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,646</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Net income</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,615</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,819</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,510</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,335</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Basic net income per share:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.59</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.52</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.05</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.76</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Basic weighted average common shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,679</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,961</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,778</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">14,934</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Diluted net income per share:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.57</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.51</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.02</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">0.74</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Diluted weighted average common shares outstanding</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,111</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,336</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,210</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15,332</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net income</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,615</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7,819</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">15,510</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">11,335</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Other comprehensive income (loss):</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Unrealized gain (loss) on securities, net of tax</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Foreign currency translation adjustment</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(536</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">420</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,828</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Total other comprehensive income (loss)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(536</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">417</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">238</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,831</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Comprehensive income</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,079</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,236</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,748</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">9,504</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">Anika Therapeutics, Inc. and Subsidiaries</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt"><a name="a_005"></a>Condensed Consolidated Statements of Cash Flows</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">(in thousands)</p>

<p style="text-align: center; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">(unaudited)</p>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cash flows from operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; font-size: 10pt; text-align: left; text-indent: 10pt">Net income</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">15,510</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">11,335</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Adjustments to reconcile net income to net cash provided by operating activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Depreciation and amortization</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,901</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,827</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Stock-based compensation expense</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,478</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,064</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Deferred income taxes</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(252</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(428</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Provision for doubtful accounts</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">52</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Provision for inventory</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">181</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">68</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Tax benefit from equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(419</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(934</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Changes in operating assets and liabilities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 30pt">Accounts receivable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,932</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,389</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 30pt">Inventories</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(2,438</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">496</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 30pt">Prepaid expenses, other current and long-term assets</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">186</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">459</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 30pt">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,252</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">559</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 30pt">Accrued expenses and other current liabilities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">446</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(264</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 30pt">Deferred revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(45</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(5</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 30pt">Income taxes payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(3,169</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,194</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 30pt">Other long-term liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">396</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(98</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash provided by operating activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,643</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">14,884</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cash flows from investing activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Proceeds from maturity of investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27,750</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,250</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Purchase of investments</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(22,499</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(22,018</td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Purchase of property and equipment</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(9,869</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,134</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,618</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(12,902</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cash flows from financing activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Repurchases of common stock</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(25,000</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Proceeds from exercise of equity awards</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">922</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">969</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Tax benefit from equity awards</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">419</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">934</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net cash (used in) provided by financing activities</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(23,659</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,903</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Exchange rate impact on cash</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">52</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(121</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Increase (decrease) in cash and cash equivalents</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(21,582</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,764</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Cash and cash equivalents at beginning of period</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">110,707</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">100,156</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Cash and cash equivalents at end of period</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">89,125</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">103,920</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Supplemental disclosure of cash flow information:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Non-cash Investing Activities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Purchases of property and equipment included in accounts payable and accrued expenses</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,128</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">116</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>ANIKA THERAPEUTICS, INC.</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_006"></a><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>(amounts in thousands, except per share amounts or as otherwise
noted)</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">(<b>unaudited</b>)</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b></b></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left"><b>1.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Nature of Business</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Anika Therapeutics, Inc. is a global, integrated orthopedic medicines
company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing
innovative and differentiated therapeutic pain management solutions along the continuum of care, from palliative care to regenerative
medicine. The Company has over two decades of expertise developing, manufacturing, and commercializing more than 20 products, in
markets across the globe, based on the Company&#8217;s proprietary hyaluronic acid technology. The Company&#8217;s orthopedic medicine
portfolio is comprised of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States, among others)
products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company is subject to risks common to
companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors
of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing
and new products, and compliance with U.S. Food and Drug Administration (&#8220;FDA&#8221;) and foreign regulations and approval
requirements, as well as the ability to grow the Company&#8217;s business through appropriate commercial strategies.</p></div><p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b>2.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Basis of Presentation</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The accompanying unaudited condensed consolidated financial statements
and related notes have been prepared by the Company pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission
(the &#8220;SEC&#8221;) and in accordance with accounting principles generally accepted in the United States (&#8220;US GAAP&#8221;).
The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and
balances have been eliminated. The year-end consolidated balance sheet is derived from the Company&#8217;s audited financial statements,
but does not include all disclosures required by US GAAP. In the opinion of management, these unaudited condensed consolidated
financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed
consolidated financial position of the Company as of June 30, 2016, the results of its operations for the three- and six-month
periods ended June 30, 2016 and 2015, and cash flows for the six-month periods ended June 30, 2016 and 2015.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The accompanying unaudited condensed consolidated financial statements
and related notes should be read in conjunction with the Company&#8217;s annual financial statements filed with its Annual Report
on Form&nbsp;10-K for the year ended December 31, 2015. The results of operations for the three- and six-month periods ended June
30, 2016 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2016. Certain prior
period amounts have been reclassified to conform to the current period presentation. There was no impact on operating income.</p></div><p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b>3.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Recent Accounting Pronouncements</b></td>
</tr></table>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><i>Recently Issued</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white">In
May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;)
No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 supersedes the revenue recognition requirements in &#8220;Topic
605, Revenue Recognition&#8221; and requires entities to recognize revenue in a way that depicts the transfer of promised goods
or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for
those goods or services. </font>In July 2015, the FASB issued a deferral of ASU 2014-09 of one year making it effective for annual
reporting periods beginning on or after December 15, 2017 while also providing for early adoption not to occur before the original
effective date. The Company is assessing the appropriate method for implementing ASU 2014-09, as well as the impact the adoption
of ASU 2014-09 will have on its consolidated financial statements.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic
842). ASU 2016-02 amends existing leasing accounting requirements. The most significant change will result in the recognition
of lease assets and lease liabilities by lessees for virtually all leases. The new guidance will also require significant additional
disclosures about the amount, timing and uncertainty of cash flows from leases. ASU 2016-02 is effective for fiscal years and
interim periods beginning after December 15, 2018. Upon adoption, entities are required to recognize and measure leases at the
beginning of the earliest period presented using a modified retrospective approach. Early adoption is permitted, and a number
of optional practical expedients may be elected to simplify the impact of adoption. The Company is evaluating the impact of adopting
this guidance.</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In March 2016, the FASB issued ASU No. 2016-09, Compensation (Topic
718) Stock Compensation. ASU 2016-09 identifies areas for simplification involving several aspects of accounting for share-based
payment transactions, including the income tax consequences, classification of awards as equity or liabilities, an option to recognize
gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement
of cash flows. Early adoption is permitted. The Company is assessing ASU 2016-09 and the impact that adopting this new accounting
standard will have on its consolidated financial statements and footnote disclosures.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In June 2016, the FASB issued ASU No. 2016-13, Financial
Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the
impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial
assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the
net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from
the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on
the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not
expected to have a material impact on our financial position or results of operations.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><i>Recently Adopted</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In July 2015, the FASB issued ASU No. 2015-11,&nbsp;Inventory
(Topic 330) Simplifying the Measurement of Inventory. ASU 2015-11 more closely aligns the measurement of inventory in US GAAP with
the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out
and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is
the estimated selling prices in the ordinary course of business less reasonably predictable costs of completion, disposal, and
transportation. The provisions of ASU 2015-11 are effective for annual and interim periods beginning after December 15, 2016. ASU
2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting
period. The adoption of this amendment did not have a material impact on the Company&#8217;s financial position or results of operations.</p></div><p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b>4.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Investments</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white">All of the Company&#8217;s
investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component
of accumulated other comprehensive income, net of related income taxes. The Company held bank certificates of deposit of $22.5
million and $25.8 million at June 30, 2016 and December 31, 2015, respectively. The Company also held corporate debt securities
of $2.0 million at December 31, 2015. There were no unrealized gains or losses on the Company&#8217;s available-for-sale securities
at June 30, 2016 or December 31, 2015.</font></p></div><p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white"></font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b></b></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left"><b>5.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Fair Value Measurements</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Fair value is an exit price, representing the amount that would be
received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants based
on assumptions that market participants would use in pricing an asset or liability. As a basis for classifying the fair value measurements,
a three-tier fair value hierarchy, which classifies the fair value measurements based on the inputs used in measuring fair value,
was established as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets or liabilities;
(Level 2) significant other observable inputs that are observable either directly or indirectly; and (Level 3) significant unobservable
inputs for which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires
the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair
value. On a recurring basis, the Company records its investments at fair value.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white">The Company&#8217;s investments
are all classified within Level 2 of the fair value hierarchy. These investments classified within Level 2 of the fair value hierarchy
are valued based on matrix pricing compiled by third party pricing vendors, using observable market inputs such as interest rates,
yield curves, and credit risk.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The fair value hierarchy of the Company&#8217;s cash equivalents and investments at fair
value is as follows:</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">Fair Value Measurements at Reporting</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date Using</td></tr>
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Quoted Prices in</td><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Active Markets</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Significant Other</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Significant</td></tr>
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">for Identical Assets</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Observable Inputs</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Unobservable Inputs</td></tr>
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2016</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 1)</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 2)</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 3)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cash equivalents:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Money market funds</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">67,001</td><td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">67,001</td><td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Bank certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,500</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,500</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">Fair Value Measurements at Reporting</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date Using</td></tr>
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Quoted Prices in</td><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Active Markets</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Significant Other</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Significant</td></tr>
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">for Identical Assets</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Observable Inputs</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center">Unobservable Inputs</td></tr>
<tr style="vertical-align: bottom">
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left">&nbsp;</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 1)</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 2)</td><TD NOWRAP STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <TD COLSPAN="3" NOWRAP STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 3)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Cash equivalents:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; text-align: left">Money market funds</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">61,385</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">61,385</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">-</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bank certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">250</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">250</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total cash equivalents</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">61,635</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">61,635</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Investments:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Corporate debt securities</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,001</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,001</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bank certificates of deposit</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,750</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,750</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27,751</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27,751</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p></div><p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b></b></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left"><b>6.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Equity Incentive Plan</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company estimates the fair value of stock options and stock appreciation
rights (&#8220;SARs&#8221;) using the Black-Scholes valuation model. Fair value of restricted stock awards (&#8220;RSAs&#8221;)
and restricted stock units (&#8220;RSUs&#8221;) are measured by the grant-date price of the Company&#8217;s shares. The fair value
of each stock option award during the three- and six-month periods ended June 30, 2016 and 2015, respectively, was estimated on
the grant date using the Black-Scholes option-pricing model with the following assumptions:</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Risk free interest rate</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: right">0.94%</td><td style="font-size: 10pt; text-align: center"> -</td><td style="font-size: 10pt; text-align: left">1.40%</td><td style="font-size: 10pt; text-align: center">&nbsp;</td>
    <td style="font-size: 10pt; text-align: right">1.15%</td><td style="font-size: 10pt; text-align: center"> -</td><td style="font-size: 10pt; text-align: left">1.46%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected volatility</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: right">49.47%</td><td style="font-size: 10pt; text-align: center"> -</td><td style="font-size: 10pt; text-align: left">51.61%</td><td style="font-size: 10pt; text-align: center">&nbsp;</td>
    <td style="font-size: 10pt; text-align: right">53.15%</td><td style="font-size: 10pt; text-align: center"> -</td><td style="font-size: 10pt; text-align: left">54.65%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Expected life (years)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 4%; font-size: 10pt; text-align: right">&nbsp;</td><td style="width: 5%; font-size: 10pt; text-align: center">4.5</td><td style="width: 3%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 2%; font-size: 10pt; text-align: center">&nbsp;</td>
    <td style="width: 5%; font-size: 10pt; text-align: center">&nbsp;</td><td style="width: 5%; font-size: 10pt; text-align: center">4.5</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Expected dividend yield</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: center">0.00%</td><td style="font-size: 10pt; text-align: left"></td><td style="font-size: 10pt; text-align: center">&nbsp;</td>
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; text-align: center">0.00%</td><td style="font-size: 10pt; text-align: left"></td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company recorded $0.7 million and $0.5 million of share-based
compensation expense for the three-month periods ended June 30, 2016 and 2015, respectively, for equity compensation awards. The
Company recorded $1.5 million and $1.1 million of share-based compensation expense for the six-month periods ended June 30, 2016
and 2015, respectively, for equity compensation awards. The Company presents the expenses related to stock-based compensation awards
in the same expense line items as cash compensation paid to the respective recipients.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the three-month period ended June
30, 2016, the Company granted under the Equity Incentive Plan (&ldquo;Plan&rdquo;) a total of 43,000 stock options. During the
six-month period ended June 30, 2016, the Company granted under the Plan a total of 331,705 stock options including 46,300 RSAs
and 11,805 RSUs. All of the RSUs were granted to directors of the Company and vest over a one year period. The stock options and
RSAs granted to employees generally become exercisable or vest ratably over four years from the date of grant.</P>




<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">A portion of the stock options granted during the six-month period
ended June 30, 2016 contained certain performance features, as compared to established targets, in addition to time-based vesting
conditions. For performance-based awards with financial achievement targets, the Company recognizes expense using the graded vesting
methodology based on the number of shares expected to vest. Compensation cost associated with performance grants is estimated using
the Black-Scholes valuation method multiplied by the expected number of shares to be issued, which is adjusted based on the estimated
probabilities of achieving the performance goals. Changes to the probability assessment and the estimated shares expected to vest
will result in adjustments to the related share-based compensation expense that will be recorded in the period of the change. If
the performance targets are not achieved, no compensation cost is recognized and any previously recognized compensation cost is
reversed.</p></div><p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b>7.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Earnings Per Share (&#8220;EPS&#8221;)</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white">Basic EPS is calculated by
dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although
legally issued and outstanding, are not considered outstanding for purposes of calculating basic earnings per share. Diluted EPS
is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of
outstanding stock options, SARs, RSAs, and RSUs using the treasury stock method.</font></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">&nbsp;</font></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white">The following
table provides share information used in the calculation of the Company's basic and diluted earnings per share:</font></p>

<p style="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; text-align: left">Shares used in the calculation of basic earnings per share</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">14,679</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">14,961</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">14,778</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">14,934</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Effect of dilutive securities:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Stock options, SARs, and RSAs</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">432</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">375</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">432</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">398</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Diluted shares used in the calculation of earnings per share</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,111</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,336</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,210</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,332</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white">Equity awards of 0.3 million
shares were outstanding for the three- and six-month periods ended June 30, 2016 and were not included in the computation of diluted
earnings per share because the awards&#8217; impact on earnings per share was anti-dilutive.&nbsp;Equity awards of 0.2 million
shares were outstanding for the three- and six-month periods ended June 30, 2015, respectively, and were not included in the computation
of diluted earnings per share because the awards&#8217; impact on earnings per share was anti-dilutive.</font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">On February 26, 2016, the Company entered into an accelerated stock
repurchase agreement with Morgan Stanley &amp; Co. LLC (&#8220;Morgan Stanley&#8221;) pursuant to a Fixed Dollar Accelerated Share
Repurchase Transaction (&#8220;ASR Agreement") to purchase $25.0 million of shares of its common stock. Pursuant to the terms
of the ASR Agreement, the Company paid Morgan Stanley&nbsp;$25.0 million&nbsp;in cash and received an initial delivery of 377,155
shares&nbsp;of the Company&#8217;s common stock on&nbsp;February 29, 2016 based on a closing market price of&nbsp;$46.40 and the
applicable contractual discount. This is approximately 70% of the total number of shares of expected to be repurchased under the
ASR Agreement. These shares are held by the Company as authorized but unissued shares pursuant to Massachusetts law. The initial
delivery of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares
outstanding for basic and diluted net income per share.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of June 30, 2016, the Company has approximately $7.5
million&nbsp;remaining under the ASR Agreement which was recorded as an equity forward sale contract and was included in
additional paid-in capital in stockholders' equity in the condensed consolidated balance sheet as it met the criteria for
equity accounting. Pursuant to the terms of the ASR Agreement, the final number of shares and the average purchase price will
be determined at the end of the applicable purchase period, which is expected to occur in&nbsp;the third quarter of 2016.
Upon settlement of the ASR Agreement, the Company may receive additional shares or be required to either pay additional
cash or deliver shares of our common stock (at its option) to Morgan Stanley, based on the forward price. If the ASR
Agreement&nbsp;had been settled as of June 30, 2016, based on the volume-weighted average price since the effective date of
the ASR Agreement, Morgan Stanley would have been required to deliver approximately 0.2 million additional shares
to the Company. However, the Company cannot predict the final number of shares to be received, or delivered, by it under the
ASR Agreement, and, as such, these shares are not included in the calculation of diluted weighted-average common shares
outstanding during the period because the effect is anti-dilutive.</p></div>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b>8.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Inventories</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Inventories consist of the following:</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">June 30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Raw materials</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">6,812</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">5,780</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Work-in-process</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,140</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,656</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,312</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,502</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,264</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">14,938</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Inventories are stated at the lower of cost or market, with cost
being determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor,
and manufacturing overhead. Inventory costs associated with product candidates that have not yet received regulatory approval are
capitalized if the Company believes there is probable future commercial use and future economic benefit.</p></div><p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b>9.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Intangible Assets</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In connection with the 2009 acquisition of Anika Therapeutics S.r.l.
(&#8220;Anika S.r.l.&#8221;), the Company acquired various intangible assets and goodwill.&nbsp;The Company evaluated the various
intangible assets and related cash flows from these intangible assets, as well as the useful lives and amortization methods related
to these intangible assets.&nbsp;The in-process research and development (&#8220;IPR&amp;D&#8221;) intangible assets initially
have indefinite lives and are reviewed periodically to assess the project status, valuation, and disposition, including write-off(s)
for abandoned projects.&nbsp;Until such determination is made, they are not amortized.&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Intangible assets as of June 30, 2016 and December 31, 2015 consist
of the following:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; color: Red"><b></b></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross Value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated Currency Translation Adjustment</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated Amortization</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Useful Life</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 22%; font-size: 10pt; text-align: left">Developed technology</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">17,100</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(3,108</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(6,373</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">7,619</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">7,959</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: center">15</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">In-process research &amp; development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,406</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(1,286</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,120</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,099</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: center">Indefinite</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Distributor relationships</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,700</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(415</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(4,285</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: center">5</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Patents</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,000</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(186</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(357</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">457</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">473</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: center">16</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Elevess trade name</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,000</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(937</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">63</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">125</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">9</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.25pt; text-indent: 10pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">28,206</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(4,995</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(11,952</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,259</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,656</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">&nbsp;</td><td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; margin: 0pt 0; color: Red"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The aggregate amortization expense related to intangible assets was
$0.3 million for the three-month periods ended June 30, 2016 and 2015, respectively. The aggregate amortization expense related
to intangible assets was $0.6 million and $0.5 million for the six-month periods ended June 30, 2016 and 2015, respectively.</p></div><p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b></b></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left"><b>10.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Goodwill</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Through June 30, 2016, there have not been any events or changes
in circumstances that indicate that the carrying value of goodwill may not be recoverable. Changes in the carrying value of goodwill
were as follows:</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended <br>
June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Twelve Months <br>
Ended December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Balance, beginning</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">7,482</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">8,339</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Effect of foreign currency adjustments</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">86</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(857</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance, ending</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,568</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,482</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b></b></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left"><b>11.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Accrued Expenses</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Accrued expenses consist of the following:</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">June 30,</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">December 31,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Compensation and related expenses</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">2,416</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">3,082</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Facility construction costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,769</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">415</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Research grants</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">481</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">381</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Professional fees</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">889</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">210</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Clinical trial costs</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">339</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">252</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">744</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">438</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,638</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,778</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>





<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p></div><p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b>12.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Commitments and Contingencies</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white">In certain of its contracts,
the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the
time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate,
or breach any U.S. patent or intellectual property right, trade secret, or other proprietary information of any third party. On
occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected
with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts
or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks.
Based on the Company&#8217;s historical activity, in combination with its liability insurance coverage, the Company believes the
estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties at June 30, 2016
or December 31, 2015, respectively, and has no history of claims paid.</font></p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white">The Company is also involved
in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently
difficult to predict, the Company does not expect the resolution of these legal proceedings to have a material adverse effect on
its financial position, results of operations, or cash flow.</font></p></div><p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white"></font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">&nbsp;</font></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><font style="background-color: white"><b>13.</b></font></td><td style="width: 5pt"></td><td style="text-align: justify"><font style="background-color: white"><b>Leases</b></font></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"><font style="background-color: white"><b></b></font></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">On October 9, 2015, Anika S.r.l. entered into a build-to-suit lease
agreement with Consorzio Zona Industriale E Porto Fluviale di Padova (&#8220;ZIP&#8221;), as landlord, pursuant to which Anika
S.r.l. will lease a new European headquarters facility, consisting of approximately 33,000 square feet of general office, research
and development, training, and warehousing space located in Padova, Italy. The lease has an initial term of fifteen years, which
is expected to commence during the fourth quarter of 2016 once construction of the facility is completed. The lease will automatically
renew for up to three additional six-year terms, subject to certain terms and conditions. The Company has the ability to withdraw
from this lease subject to certain financial penalties after six years and with no penalties after the ninth year. Beginning on
the commencement date, the lease provides for an initial yearly rent of approximately $0.4 million.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Construction of the new facility began in the first quarter of 2016
and is expected to be completed in late 2016. During the period of construction the Company is considered the deemed owner of the
facility. Accordingly, the landlord's costs of constructing the facility are required to be capitalized, as a non-cash transaction,
offset by a corresponding facility lease obligation in the Company&#8217;s consolidated balance sheet. As of June 30, 2016, the
Company has recorded a construction-in-process asset of&nbsp;approximately $0.9 million. This includes $0.5 million incurred by
ZIP for the construction of the new facility, which was recorded as a facility lease obligation within other long-term liabilities
on the balance sheet.</p></div><p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><font style="background-color: white">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b></b></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left"><b>14.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Income Taxes</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Provisions for income taxes were $4.9 million
and $8.8 million for the three- and six-month periods ended June 30, 2016, based on effective tax rates of 36.3% and 36.2%, respectively.
Provisions for income taxes were $4.6 million and $6.6 million for the three- and six-month periods ended June 30, 2015, based
on effective tax rates of 37% for both periods. The increase in income taxes for the three- and six-month period ended June 30,
2016 resulted from higher net income as compared to the same periods in the prior year. The net decrease in the effective tax rate
<FONT STYLE="background-color: white">for the three- and six-month period ended June 30, 2016, as compared to the same period in
2015, </FONT>was primarily due to an increase in the expected tax credit for research and development expenditures.</P>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and
in Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following
the tax year to which those filings relate. The Company&rsquo;s filings from 2012 through the present tax year remain subject to
examination by the IRS and other taxing authorities for U.S. federal and state tax purposes. The Company currently has a tax audit
in progress in the United States and does not anticipate that the audit will have a material impact on its financial statements.&nbsp;
The Company&rsquo;s filings from 2010 through the present tax year remain subject to examination by the appropriate governmental
authorities in Italy.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In connection with the preparation of the financial statements, the
Company performed an analysis to ascertain if it was more likely than not that it would be able to utilize, in future periods,
the net deferred tax assets associated with its net operating loss carryforward. The Company concluded that the positive evidence
outweighs the negative evidence and, thus, those deferred tax assets are realizable on a &#8220;more likely than not&#8221; basis.
As such, the Company did not record a valuation allowance at June 30, 2016 or December 31, 2015.&nbsp;</p></div><p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"><b></b></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left"><b>15.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>Segment and Geographic Information</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company has one reportable operating segment, for the purposes
of assessing performance and deciding how to allocate resources.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Product revenue by product group is as follows:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; text-align: left">Orthobiologics</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">23,304</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">19,283</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">42,891</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">31,255</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Surgical</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,433</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,647</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,751</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,037</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dermal</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">582</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">303</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">963</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">719</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,256</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,665</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,248</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,402</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Product Revenue</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">26,575</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,898</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,853</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">38,413</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Total revenue by geographic location and as a percentage of overall
total revenue for the three-month periods ended June 30, 2016 and 2015 are as follows:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Geographic Location:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; text-align: left; text-indent: 10pt">United States</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">21,895</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">82</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">19,218</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">84</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Europe</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,977</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,331</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,709</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,355</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt">Total Revenue</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">26,581</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,904</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table></div>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Geographic Location:</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; text-align: left; text-indent: 10pt">United States</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">39,906</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">82</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">31,809</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">83</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Europe</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,542</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,317</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,416</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,298</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,864</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">38,424</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table></div>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></div><p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><a name="a_007"><b>ITEM 2.&nbsp;</b></a></td><td style="width: 5pt"></td><td style="text-align: justify"><b></b>  <b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS (amounts in thousands, except per share amounts or as otherwise noted)</b></td>
</tr></table>
<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">You should read the following discussion in conjunction with our financial statements and related notes appearing elsewhere in this report. In addition to historical information, this
discussion contains forward-looking statements that involve risks, uncertainties, and assumptions that could cause our actual
results to differ materially from our expectations. Words such as &#8220;will,&#8221; &#8220;likely,&#8221;
&#8220;may,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
&#8220;seek,&#8221; &#8220;designed,&#8221; &#8220;develop,&#8221; &#8220;would,&#8221; &#8220;future,&#8221;
&#8220;can,&#8221; &#8220;could,&#8221; and other expressions that are predictions of or indicate future events and trends
and which do not relate to historical matters are intended to identify such forward-looking statements. These statements are
likely to relate to, among other things, our goals, plans and projections regarding our financial position, results of
operations, cash flows, market position, product development, product approvals, sales efforts, expenses, performance, and
results related to current or anticipated products. You should carefully consider forward-looking statements and understand
that such statements may be affected by inaccurate assumptions and may involve a variety of risks and uncertainties, known
and unknown, including, among others, risks related to competition in the medical device industry, reduction or
interruption in our supply, quality problems, decreasing prices, changes in applicable tax rates, adverse regulatory action,
health care policy changes, international operations, or disruption of our current plans and operations, as well as those
factors described in Part II, Item 1A. &#8220;Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended
December 31, 2015, and as may be updated in our subsequent Quarterly Reports on Form 10-Q. Consequently, no forward-looking
statements can be guaranteed and actual results may vary materially, and you should take caution not to place undue reliance
on such statements. We undertake no obligation to release publicly any revisions to forward-looking statements as a result of
new information, future events, or otherwise.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><font style="font-size: 10pt"></font><b><i>Management Overview
</i></b></p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">We are a global, integrated orthopedic medicines company committed
to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing innovative and differentiated
therapeutic pain management solutions along the continuum of care, from palliative care to regenerative medicine. We have over
two decades of expertise developing, manufacturing, and commercializing our products, in markets across the globe, based on our
proprietary hyaluronic acid (&#8220;HA&#8221;) technology. Our orthopedic medicine portfolio is comprised of marketed (ORTHOVISC
and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States, among others) products to alleviate pain and restore joint
function by replenishing depleted HA and aiding cartilage repair and regeneration.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Our therapeutic offerings consist of products in the following areas:
Orthobiologics, Dermal, Surgical, Ophthalmic, and Veterinary. All of our products are based on HA, a naturally occurring, biocompatible
polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number
of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural
integrity of tissues, and the transport of molecules to and within cells.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Our proprietary technologies for modifying the HA molecule allow
product properties to be tailored specifically to therapeutic use. Our patented technology chemically modifies HA to allow for
longer residence time in the body. We also offer products made from HA based on two other technologies: HYAFF, which is a solid
form of HA, and ACP gel, an autocross-linked polymer of HA.&nbsp;Our technologies are protected by an extensive portfolio of owned
and licensed patents.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Since our inception in 1992, we have utilized a commercial partnership
model for the distribution of our products to end-users. Our strong, worldwide network of distributors has historically provided,
and continues to provide, a solid foundation for our revenue growth and territorial expansion. In 2015, we made the strategic decision
to commercialize our next generation viscosupplementation product, CINGAL, in the United States ourselves, initially through the
engagement of a contract sales organization. Ultimately, we intend to transition the direct sales function into our company as
part of a broader buildout of our commercial capabilities. We believe that the combination of the direct and distribution commercial
models will maximize the revenue potential from our current and future product portfolio.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">We began a strategic project in 2015 to move the manufacturing
of our HYAFF-based products, which currently are manufactured by a third party in Italy, to our Bedford, Massachusetts facility.
Our main purposes behind this strategic move are to improve the efficiency of our manufacturing process and to enhance our research
and development capabilities, with the aim of accelerating future product development. We expect to expend approximately $25 million
on this project.</p>

<p style="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Please see the section captioned &#8220;Item 7. Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations-Management Overview&#8221; in our Annual Report on Form
10-K for the year ended December 31, 2015, for a description of each of the above therapeutic areas, including the individual products.</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Research and Development</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Our research and development efforts primarily consist of the development
of new medical applications for our HA-based technology, the management of clinical trials for certain product candidates, the
preparation and processing of applications for regulatory approvals or clearances at all relevant stages of product development,
and process development and scale-up manufacturing activities for our existing and new products. Our development focus includes
products for tissue protection, repair, and regeneration. We anticipate that we will continue to commit significant resources to
research and development, including in relation to clinical trials, in the future.</p>

<p style="font-size: 10pt; text-align: right; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Our second single-injection osteoarthritis product under development
is CINGAL, which is composed of our proprietary cross-linked HA material combined with an approved steroid and is designed to provide
both short- and long-term pain relief to patients. We completed the CINGAL phase III clinical trial and associated statistical
analysis during the fourth quarter of 2014. During the first half of 2015, we completed a CINGAL retreatment study with patients
who had participated in the phase III clinical trial and reported safety data related to the retreatment study. We received approval
for CINGAL from Health Canada in November 2015 for the treatment of pain in osteoarthritis of the knee. In March 2016, we received
CE Mark approval of CINGAL as a viscoelastic supplement or as a replacement for synovial fluid in human joints. We successfully
achieved commercial launch of the product in Canada during May 2016 and in the European Union during June 2016. In the United States,
after discussions with the FDA related to the regulatory pathway for CINGAL, we conducted a formal meeting with the FDA&#8217;s
Office of Combination Products (&#8220;OCP&#8221;) to present and discuss our data in September 2015, and we submitted a formal
request for designation with OCP a month later. In its response to our formal request for designation, OCP assigned the product
to the FDA&#8217;s Center for Drug Evaluation and Research (&#8220;CDER&#8221;) as the lead agency center for premarket review
and regulation. Since then, we have been in ongoing discussions with CDER to understand the requirements for submitting a New Drug
Application (&#8220;NDA&#8221;) for CINGAL, and preliminary indications from CDER suggested that additional clinical work may be
required. We are employing multiple approaches to obtain definitive feedback with respect to our prospective NDA, and we plan to
meet with the FDA to collaboratively discuss this topic.</p>

<p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">We have several research and development programs underway for new products, including for HYALOFAST (in
the United States), an innovative product for cartilage tissue repair, HYALOBONE, a bone void filler, and other early stage regenerative
medicine development programs. HYALOFAST received CE Mark approval in September 2009, and it is commercially available in Europe
and certain international countries. During the first quarter of 2015, we submitted an Investigational Device Exemption (&ldquo;IDE&rdquo;)
for HYALOFAST to the FDA, which was approved in July 2015. We commenced patient enrollment in a clinical trial in December 2015,
and we are advancing site initiations and patient enrollment activities. In the second quarter of 2016, a supplement to the HYALOFAST
IDE was approved to expand the inclusion criteria for the clinical study. The purpose of this supplement is to allow us to increase
enrollment rates with the ultimate goal of decreasing the time needed to complete the clinical trial. <FONT STYLE="font-size: 10pt">We
are also currently proceeding with other research and development programs, one of which utilizes our proprietary HA technology
to treat pain associated with common repetitive overuse injuries, such as those to the elbow, rotator cuff and Achilles tendon.
We submitted a CE mark application for this treatment during the first quarter of 2016, and we expect approval of this application
during the first half of 2017. Additionally, in the second quarter of 2016, we submitted an IDE to the FDA to conduct a phase III
pivotal clinical trial for this treatment, which was approved by the FDA in June 2016. </FONT></P>




<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In June 2015, we entered into an agreement with the Institute for
Applied Life Sciences at the University of Massachusetts Amherst to collaborate on research to develop a therapy for rheumatoid
arthritis. The purpose of this research is to develop a novel modality for the treatment of rheumatoid arthritis, and if successful,
it is expected to yield a potential product candidate that we could begin to move towards commercialization as early as 2017.</p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b>Results of Operations </b></p>

<p style="font-size: 10pt; text-indent: -0.25in; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; text-indent: -0.25in; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; text-align: center; text-indent: -0.25in; margin: 0pt 0; color: Red"></p>

<p style="text-align: left; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt">Three and Six Months Ended June 30, 2016 Compared to Three and Six Months Ended June 30, 2015</p>



<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$ Inc/(Dec)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% Inc/(Dec)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$ Inc/(Dec)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% Inc/(Dec)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center">(in thousands, except percentages)</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center">(in thousands, except percentages)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Product revenue</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">26,575</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">22,898</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">3,677</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">16</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">48,853</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">38,413</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">10,440</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">27</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td nowrap style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Licensing, milestone and contract revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Total revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">26,581</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">22,904</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,677</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">48,864</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">38,424</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">10,440</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Operating expenses:</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Cost of product revenue</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,065</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">5,275</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">790</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">15</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">11,490</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9,588</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,902</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">20</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Research&nbsp;&amp; development</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,792</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,812</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">980</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">54</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">4,951</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,910</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,041</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">27</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Selling, general&nbsp;&amp; administrative</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,255</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,388</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">867</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">26</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,245</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,993</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,252</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Total operating expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,112</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,475</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,637</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24,686</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20,491</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,195</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">20</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Income from operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,469</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,429</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,040</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">8</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">24,178</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,933</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,245</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">35</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 20pt">Interest income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">49</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">105</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">121</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">48</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">73</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">152</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Income before income taxes</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">13,518</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">12,453</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,065</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">9</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">24,299</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">17,981</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">6,318</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">35</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 20pt">Provision for income taxes</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,903</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,634</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">269</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,789</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,646</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,143</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">32</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Net income</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">8,615</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,819</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">796</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,510</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,335</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,175</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">37</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Product gross profit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">20,510</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">17,623</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,887</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">16</td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">37,363</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">28,825</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">8,538</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">30</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Product gross margin</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">77%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">77%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">77%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">75%</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
</table>



<p style="font-size: 10pt; text-align: center; text-indent: -0.25in; margin: 0pt 0; color: Red"></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Product Revenue</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Product revenue for the quarter ended June 30, 2016 was $26.6 million, an increase of 16% as compared to $22.9
million for the quarter ended June 30, 2015. <FONT STYLE="font-size: 10pt; background-color: white">Product revenue for the six-month
period ended June 30, 2016 was $48.9 million, an increase of 27% as compared to $38.4 million for the six-month period ended June
30, 2015.</FONT><FONT STYLE="font-size: 10pt"> For the three-month period ended June 30, 2016, the increase in product revenue
was driven by our orthobiologics franchise, and such increase was partially offset by decreases in our surgical and other product
revenue as a result of the timing of orders for our veterinary products. For the six-month period ended June 30, 2016, we saw orthobiologics
and dermal product revenue growth, both domestically and internationally, while surgical product revenue decreased slightly year-over-year
primarily related to our ear, nose, and throat (&ldquo;ENT&rdquo;) anti-adhesion products. Included in product revenue for the
second quarter of 2015 was approximately $1.8 million of non-recurring revenue related to a high end-user average selling
price for MONOVISC products sold to our U.S. partner, DePuy Synthes Mitek Sports Medicine (&ldquo;Mitek&rdquo;), prior to the fourth
quarter of 2014. The amount was agreed with Mitek during the second quarter of 2015, and MONOVISC product sold to Mitek after the
third quarter of 2014 is not impacted by this arrangement.</FONT></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The following tables present product revenue by group for the three-
and six-month periods ended June 30, 2016 and 2015:</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$ Inc/(Dec)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% Inc/(Dec)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center">(in thousands, except percentages)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; text-align: left">Orthobiologics</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">23,304</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">19,283</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">4,021</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">21</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Surgical</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,433</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">1,647</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(214</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(13</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dermal</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">582</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">303</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">279</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">92</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,256</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,665</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(409</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(25</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">26,575</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,898</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,677</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">16</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table>


<p style="margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="15" nowrap style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$ Inc/(Dec)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">% Inc/(Dec)</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">&nbsp;</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center">(in thousands, except percentages)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; text-align: left">Orthobiologics</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">42,891</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">31,255</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">11,636</td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 1%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 10%; font-size: 10pt; text-align: right">37</td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Surgical</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">2,751</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">3,037</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(286</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(9</td><td style="font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Dermal</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">963</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">719</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">244</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">34</td><td style="font-size: 10pt; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,248</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,402</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,154</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(34</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Total</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,853</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">38,413</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">10,440</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27</td><td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td></tr>
</table>



<p style="font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><b></b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Orthobiologics</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Our orthobiologics franchise consists of
our joint health and orthopedic products. Overall, sales increased 21% and 37% for the three- and six- month periods ended June
30, 2016, as compared to the same periods in 2015. The growth in the second quarter of 2016<FONT STYLE="background-color: white">
reflected a significant increase in product purchases as compared with the same period in the prior year during which our U.S.
commercial partner implemented a multi-month inventory reset program. Product sales to our U.S. commercial partner, Mitek, in the
second quarter of 2016 increased by approximately $2.7 million as compared to the second quarter of 2015. The volume gain was partially
offset by the impact of pricing concessions by our commercial partner aimed at growing market share. More importantly, we also
experienced growing end-user demand during the first half of 2016, resulting in increased revenue from worldwide orthobiologics
sales, including a 47% increase in international orthobiologics revenue as compared to the same period in 2015</FONT>. We expect
orthobiologics revenue to continue to grow in 2016, led by increased MONOVISC revenue in the United States, the commercial availability
of CINGAL in Canada and Europe, as well as overall revenue growth from our viscosupplementation products both domestically and
internationally.</P>




<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Surgical</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Our surgical franchise consists of products used to prevent surgical adhesions and to treat ENT disorders.
Sales of our surgical&nbsp;products decreased 13% and 9% for the three- and six-month periods ended June 30, 2016 to $1.4 million
and $2.8 million, respectively, as compared to the same periods in 2015. The decrease in surgical product revenue for the three-
and six-month periods was primarily due to the unfavorable impact from foreign currency exchange rate fluctuations and the inventory<FONT STYLE="background-color: white">
releveling by our worldwide ENT commercial partner</FONT>. As a result of these factors, we expect surgical product revenue to
decrease moderately for the full-year 2016 compared to 2015.</P>



<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Dermal</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Our dermal franchise <FONT STYLE="background-color: white">consists
of advanced wound care products, which are based on the HYAFF technology, and aesthetic dermal fillers</FONT>. Our advanced wound
care products treat complex skin wounds ranging from burns to diabetic ulcers, with HYALOMATRIX and HYALOFILL as the lead products.
For the three- and six-month periods ended June 30, 2016, dermal product sales increased 92% and 34% as compared to the same periods
in 2015. <FONT STYLE="background-color: white">This increase reflects rising domestic and international end-user demand, as well
as order timing by our distribution partners.</FONT> <FONT STYLE="background-color: white">We expect advanced wound care revenue
to increase for the full-year 2016 as compared to 2015 primarily due to increased end-user demand, increased U.S. reimbursement
coverage, and geographic expansion, particularly in the U.S., European, and Latin American markets.</FONT></P>




<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Other</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Other product revenue includes revenues
from our ophthalmic and veterinary franchises. Product revenue from each of these franchises decreased for the three- and six-month
periods ended June 30, 2016 as compared to the same periods in 2015, except for ophthamalic product revenue, which increased for
the three-month period ended June 30, 2016. We expect other product revenue to decrease for the full-year 2016, as compared to
2015,<FONT STYLE="background-color: white"> primarily as a result of lower veterinary revenue</FONT>.</P>



<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0"><i>Product gross profit and margin</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white"></FONT></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><FONT STYLE="background-color: white">Product
gross profit for the three- and six-month periods ended June 30, 2016 increased $2.9 million and $8.5 million to $20.5 and $37.4
million, respectively, or 77% of product revenue for both periods. Product gross profit for the three- and six- months ended June
30, 2015 was $17.6 million and $28.8 million</FONT>, or 77% and 75% of<FONT STYLE="background-color: white">&nbsp;product revenue
for each period, respectively. The increase in product gross margin for the three-month period ended June 30, 2016, as compared
to the same period in 2015, was primarily attributable to </FONT>the overall product mix compared to the prior year, with sales
of our higher-margin orthobiologics products accounting for a larger percentage of our total product sales. <FONT STYLE="background-color: white">This
quarter&rsquo;s product gross margin may not be indicative of the rest of the year due to dynamics such as future revenue mix.</FONT></P>


<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Research and development</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Research and development expenses for the three- and six-month
periods ended June 30, 2016 were $2.8 million and $5.0 million, or 11% and 10% of total revenue for the respective periods, representing
an increase of $1.0 million for both periods as compared to the same periods in 2015. <FONT STYLE="background-color: white">The
increase in research and development expenses was primarily due to the timing and the higher level of clinical activities associated
with the HYALOFAST phase III study, which commenced in December 2015. Furthermore, we also increased our pre-clinical product
development activities, including with respect to the CE Mark application and IDE for our program which seeks to utilize our proprietary
HA technology to treat pain associated with common repetitive overuse injuries, such as those to the elbow, rotator cuff and Achilles
tendon.</FONT> Research and development spending is expected to increase in 2016, and for the foreseeable future, as compared
to 2015, as we further develop new products and initiate new clinical trials based on our existing technology assets, including
HYALOFAST, as well as increase development activities for other products in our pipeline.</P>



<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>



<p style="font-size: 10pt; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Selling, general, and administrative</i></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Selling, general, and administrative (&ldquo;SG&amp;A&rdquo;)
expenses for the three- and six-month periods ended June 30, 2016 were $4.3 million and $8.2 million, representing 16% and 17%
of total revenue for the periods, an increase of $0.9 million and $1.3 million, respectively, as compared to the same periods in
2015. SG&amp;A expenses increased for the three- and six-month periods ending June 30, 2016 <FONT STYLE="background-color: white">primarily
as a result of increases in personnel related costs, marketing initiatives to support CINGAL international launches, and external
professional fees.&nbsp;</FONT>We expect selling, general, and administrative expenses for 2016 will increase to reflect the support
required to grow our business, both domestically and internationally.</P>



<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><i>&nbsp;</i></p>

<p style="font-size: 10pt; margin: 0pt 0"><i>Income taxes</i></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Provisions for income taxes were $4.9 million
and $8.8 million for the three- and six-month periods ended June 30, 2016, based on effective tax rates of 36.3% and 36.2%, respectively.
Provisions for income taxes were $4.6 million and $6.6 million for the three- and six-month periods ended June 30, 2015, based
on effective tax rates of 37% for both periods. The increase in income taxes for the three- and six-month period ended June 30,
2016 resulted from higher net income as compared to the same periods in the prior year. The net decrease in the effective tax rate
<FONT STYLE="background-color: white">for the three- and six-month period ended June 30, 2016, as compared to the same period in
2015, </FONT>was primarily due to an increase in the expected tax credit for research and development expenditures.</P>


<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Liquidity and Capital Resources </i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">We expect that our requirements for cash to fund operations and capital
expenditures will increase as the scope of our operations expands. Historically, we have generated positive cash flow from operations,
which together with our available cash and investments have met our cash requirements. Cash, cash equivalents, and investments
totaled approximately $111.6 million and $138.5 million at June 30, 2016 and December 31, 2015, respectively. Working capital totaled
approximately $144.1 million at June 30, 2016 and $159.2 million at December 31, 2015.&nbsp;We believe that we have adequate financial
resources to support our business for at least the next twelve months.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Cash provided by operating activities was $6.6 million for the six months ended June 30, 2016, as compared
to cash provided by operating activities of <FONT STYLE="background-color: white">$14.9 million </FONT>for the same period in 2015.&nbsp;The
decrease in cash provided by operations was due primarily to <FONT STYLE="background-color: white">a decrease in net working capital,
as compared to the same period in 2015, primarily related to the planned inventory build resulting from the transfer of outsourced
contract manufacturing from Italy to our Bedford, Massachusetts facility, and a decrease in income taxes payable due to the timing
of payments.</font></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Cash used in investing activities was $4.6 million for the six months
ended June 30, 2016, as compared to cash used in investing activities of <font style="background-color: white">$12.9 million </font>for
the same period in 2015.&nbsp;The decrease in cash used in investing activities was primarily the result of the purchase of investments
offset by maturities of investments during the first half of 2016, as well as increased expenditures on capital equipment. We expect
an increase in investing activities for the full year 2016 as a result of our on-going project to establish the additional manufacturing
capabilities at the Bedford, Massachusetts facility required to manufacture our HYAFF-based products, which were previously manufactured
by a third party in Italy. During the quarter ended June 30, 2016, we expended approximately $2.2 million for this project. We
expect to expend approximately an additional $5.1 million on this project over the course of the next 12 months.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Cash used in financing activities was $23.7
million for the six months ended June 30, 2016, as compared to cash provided by financing activities totaling <FONT STYLE="background-color: white">$1.9
million </FONT>for the same period in 2015. The increase in cash used in financing activities for the six months ended June 30,
2016 was primarily attributable to the <FONT STYLE="font-family: Times New Roman, Times, Serif">Fixed Dollar Accelerated Share
Repurchase Transaction to purchase $25.0 million of shares of our common stock. Pursuant to the terms of the ASR Agreement, we
paid Morgan Stanley&nbsp;$25.0 million in cash and received an initial delivery of 377,155 shares&nbsp;of our common stock on&nbsp;February
29, 2016 based on the closing market price of&nbsp;$46.40 and the related applicable discount. </FONT></P>



<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Critical Accounting Estimates </i></b></p>

<p style="font-size: 10pt; text-align: justify; text-indent: 49.5pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white">There were no other significant
changes in our critical accounting estimates during the three months ended June 30, 2016, as compared to the critical accounting
estimates disclosed in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in
our Annual Report on Form&nbsp;10-K for the fiscal year ended December 31, 2015.</font></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Recent Accounting Pronouncements</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><font style="background-color: white">A discussion of Recent Accounting
Pronouncements is included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and updated in Note 3
to the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.</font></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>&nbsp;</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Contractual Obligations and Other Commercial Commitments</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Our contractual obligations and other commercial commitments are
summarized in the section captioned &#8220;Part II, Item 7, Management&#8217;s Discussion and Analysis of Financial Condition and
Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2015. We had no material changes
outside the ordinary course to our contractual obligations, as reported in our 2015 Annual Report on Form 10-K, during the first
six months of 2016.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">To the extent that funds generated from our operations, together
with our existing capital resources, are insufficient to meet future requirements, we will be required to obtain additional funds
through equity or debt financings, strategic alliances with corporate partners and others, or through other sources. No assurance
can be given that any additional financing will be made available to us or will be available on acceptable terms should such a
need arise.</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><i>Off-balance Sheet Arrangements</i></b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">We do not use special purpose entities or other off-balance sheet
financing techniques, except for operating leases, that we believe have, or are reasonably likely to have, a current or future
material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
or capital resources.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><b><a name="a_008"></a>ITEM 3.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>&nbsp;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Our market risks, and the ways we manage them, are summarized in
the section captioned &#8220;Part&nbsp;II, Item&nbsp;7A, Quantitative and Qualitative Disclosures About Market Risk&#8221; in our&nbsp;Annual
Report on&nbsp;Form&nbsp;10-K for the year ended December 31, 2015. There have been no material changes in the first&nbsp;six&nbsp;months
of&nbsp;2016&nbsp;to our market risks or to our management of such risks.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><b><a name="a_009"></a>ITEM 4.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>CONTROLS AND PROCEDURES</b></td>
</tr></table>

<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: right">(a)</td><td style="width: 5pt"></td><td style="text-align: justify">Evaluation of disclosure controls and procedures.</td>
</tr></table>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></p>


<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.5in"></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: right"></td><td style="width: 5pt"></td><td style="text-align: justify">As required by Rule&nbsp;13a-15 under the Securities Exchange Act of 1934, as amended (the
                                                                            &#8220;Exchange Act&#8221;), we carried out an evaluation under the supervision and with the participation of our
                                                                            management, including our chief executive officer and chief financial officer, of the effectiveness of the design and
                                                                            operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that
                                                                            evaluation, the chief executive officer and chief financial officer have concluded that our disclosure controls and
                                                                            procedures are effective to ensure that information required to be disclosed by us in reports we file or submit under the
                                                                            Exchange Act is recorded, processed, summarized and reported, within the time periods specified in SEC rules&nbsp;and forms.
                                                                            Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information
                                                                            required to be disclosed by our company in the reports it files or submits under the Exchange Act is accumulated and
                                                                            communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow
                                                                            timely decisions regarding required disclosure. On an on-going basis, we review and document our disclosure controls and
                                                                            procedures, and our internal control over financial reporting, and may from time to time make changes aimed at enhancing
                                                                            their effectiveness and to ensure that our systems evolve with our business.</td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0 0pt 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: right">(b)</td><td style="width: 5pt"></td><td style="text-align: justify">Changes in internal controls over financial reporting.</td>
</tr></table>
<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: right"></td><td style="width: 5pt"></td><td style="text-align: justify">There were no changes in our internal control over financial reporting during the
                                                                            three-month period ended June 30, 2016 that have materially affected, or that are reasonably likely to materially affect, our
                                                                            internal controls over financial reporting.</td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b><a name="a_010"></a>PART&nbsp;II: OTHER INFORMATION</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><b><a name="a_011"></a>ITEM 1.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b>LEGAL PROCEEDINGS</b></td>
</tr></table>


<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">We are involved in various legal proceedings arising in the normal
course of business.&nbsp;Although the outcomes of these legal proceedings are inherently difficult to predict, we do not expect
the resolution of these legal proceedings to have a material adverse effect on our financial position, results of operations, or
cash flow. There have been no material changes to the information provided in the section captioned &#8220;Part I, Item 3, Legal
Proceedings&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2015.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><b><a name="a_012"></a>ITEM 1A.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b></b>  <b>RISK FACTORS</b></td>
</tr></table>
<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">There have been no material changes to the risk factors described
in the section captioned &#8220;Part I, Item 1A, Risk Factors&#8221; in our Annual Report on Form&nbsp;10-K for the year ended
December 31, 2015.&nbsp;In addition to the other information set forth in this report, you should carefully consider the factors
discussed in the section captioned &#8220;Part&nbsp;I, Item 1A, Risk Factors&#8221; in our Annual Report on Form&nbsp;10-K for
the year ended December 31, 2015, which could materially affect our business, financial condition, or future results. The risks
described in our Annual Report on Form&nbsp;10-K are not the only risks facing our Company. Additional risks and uncertainties
not currently known to us or that we currently deem to be immaterial also may have a material adverse effect on our business, financial
condition, and/or operating results.</p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><b><a name="a_013"></a>ITEM 2.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b> UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>Issuer Purchases of Equity Securities</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The following table provides information about purchases by us during
the&nbsp;quarter ended June 30, 2016&nbsp;of shares of our common stock.<font style="font-size: 10pt"> </font><font style="font-family: Sans-Serif; font-size: 9pt; color: Red"><b></b></font></p>

<p style="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B>&nbsp;</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Period</TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Total Number of Shares Repurchased <font style="font-size: 10pt; font-weight: normal; font-style: normal"><sup>(1)</sup></font></TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Average Price Paid per Share <font style="font-size: 10pt; font-weight: normal; font-style: normal"><sup>(1)</sup></font></TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Total Number of Shares Repurchased as Part of Publicly Announced Program <font style="font-size: 10pt; font-weight: normal; font-style: normal"><sup>(1)</sup></font></TD><TD STYLE="font-size: 10pt; font-weight: normal; font-style: normal; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1pt solid">Approximate Dollar Value of Shares that May Yet Be Repurchased Under the Program <font style="font-size: 10pt; font-weight: normal; font-style: normal"><sup>(1)</sup></font></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-size: 10pt">April 1 to 30, 2016</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">7,500</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">May 1 to 31, 2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">June 1 to 30, 2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Total</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">(1)</td><td>On March 2, 2016, we publicly announced that on February 26, 2016 we had entered into the ASR Agreement to repurchase an aggregate
of $25.0 million of our common stock. During the first quarter of 2016, 377,155 shares were delivered to us under the ASR Agreement,
constituting the initial delivery of shares under the ASR Agreement. Pursuant to the terms of the ASR Agreement, the final number
of shares and the average purchase price per share will be determined at the end of the applicable purchase period, which is expected
to occur in or before August 2016. All shares were repurchased in accordance with the publicly announced program.</td></tr></table>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><b><a name="a_014"></a>ITEM 3.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b></b> <b>DEFAULTS UPON SENIOR SECURITIES</b></td>
</tr></table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Not Applicable.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><b><a name="a_015"></a>ITEM 4.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b></b> <b>MINE SAFETY DISCLOSURES</b></td>
</tr></table>
<p style="font-size: 10pt; margin: 0pt 0"></p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Not Applicable.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 55pt; text-align: left"><b><a name="a_016"></a>ITEM 6.</b></td><td style="width: 5pt"></td><td style="text-align: justify"><b> EXHIBITS</b></td>
</tr></table>

<p style="font-size: 10pt; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: top; width: 10%; border-bottom: black 1pt solid"><b>Exhibit&nbsp;No.</b></td>
    <td style="vertical-align: bottom; width: 3%">&nbsp;</td>
    <td style="vertical-align: top; width: 87%; border-bottom: black 1pt solid; text-align: center"><b>Description</b></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0"><i>Restated Articles of Organization, as amended, of Anika Therapeutics, Inc. (with date
        of filing with Secretary of State of the Commonwealth of Massachusetts):</i></p>
        <p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top">3.1a</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0">Restated Articles of Organization (April 29, 1993), incorporated herein by reference
        to Exhibit 3.1a to Form 10-K, filed with SEC on March 13, 2015</p>
        <p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top">3.1b</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0">Certificate of Correction (November 10, 1993), incorporated herein by reference to Exhibit
        3.1b to Form 10-K, filed with SEC on March 13, 2015</p>
        <p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top">3.1c</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0">Certificate of Vote of Directors Establishing a Series of a Class of Stock (May 18, 1995),
        incorporated herein by reference to Exhibit 3.1c to Form 10-K, filed with SEC on March 13, 2015</p>
        <p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top">3.1d</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0">Articles of Amendment (January 9, 1997), incorporated herein by reference to Exhibit
        3.1 to Form 10-QSB, filed with SEC on January 14, 1997</p>
        <p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top">3.1e</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0">Certificate of Vote of Directors Establishing a Series of a Class of Stock (April 7,
        1998), incorporated herein by reference to Exhibit 3.1e to Form 10-K, filed with SEC on March 13, 2015</p>
        <p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top">3.1f</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0">Articles of Amendment (June 3, 1998), incorporated herein by reference to Exhibit 3.1
        to Form 10-QSB, filed with SEC on August 13, 1998</p>
        <p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top">3.1g </td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0">Articles of Amendment (April 4, 2008), incorporated herein by reference to Exhibit 3.7
        to Form 10-K, filed with SEC on March 9, 2009</p>
        <p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top">*3.1h </td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0">Articles of Amendment (June 8, 2016)</p>
        <p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top">(31)</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">Rule&nbsp;13a-14(a)/15d-14(a)&nbsp;Certifications</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"></td></tr></table>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt">&nbsp;</div>
    <!-- Field: /Page -->


<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">*31.1</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">Certification of Charles H. Sherwood, Ph.D., pursuant to Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e), as adopted pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">*31.2</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">Certification of Sylvia Cheung pursuant to Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e), as adopted pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">(32)</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">Section&nbsp;1350 Certifications</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">**32.1</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">Certification of Charles H. Sherwood, Ph.D., and Sylvia Cheung, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">(101)</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">XBRL</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">*101</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td colspan="2" style="vertical-align: top">
        <p style="font-size: 10pt; margin: 0pt 0">The following materials from Anika Therapeutics, Inc.&rsquo;s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2016, as filed with the SEC on August 1, 2016, formatted in XBRL (eXtensible Business Reporting Language), as
follows:</p>
        <p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p></td></tr>
<tr>
    <td style="vertical-align: top; width: 10%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 3%">&nbsp;</td>
    <td style="vertical-align: top; width: 2%">i.</td>
    <td style="vertical-align: top; width: 85%">Condensed Consolidated Balance Sheets as of June 30, 2016 (unaudited) and December 31, 2015 (unaudited)</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">ii.</td>
    <td style="vertical-align: top">Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2016
        and June 30, 2015 (unaudited)</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">iii.&nbsp;</td>
    <td style="vertical-align: top">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2016 and June 30, 2015 (unaudited)</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">iv.</td>
    <td style="vertical-align: top">Notes to Condensed Consolidated Financial Statements (unaudited)</td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 4%">*</td>
    <td style="width: 96%">Filed herewith</td></tr>
<tr style="vertical-align: top">
    <td>**&nbsp;</td>
    <td>Furnished herewith.</td></tr>
</table>
<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><a name="a_017"></a><b>SIGNATURES</b></p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
    <td style="width: 51%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 46%">ANIKA THERAPEUTICS,&nbsp;INC.</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>Date: August 1, 2016</td>
    <td>By:</td>
    <td style="border-bottom: black 1pt solid">/s/ SYLVIA CHEUNG</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>Sylvia Cheung</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><i>Chief Financial Officer</i></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>(Authorized Officer and Principal Financial Officer)</td></tr>
</table>
<p style="font-size: 10pt; margin: 0pt 0">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p>

<p style="font-size: 10pt; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">21</p>

<!-- Field: Rule-Page --><div align="CENTER" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>

<p style="font-size: 10pt; margin: 0pt 0"><b></b></p>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1H
<SEQUENCE>2
<FILENAME>exh_3.htm
<DESCRIPTION>EXHIBIT 3.1H
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.1h</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="exh3_1.jpg"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="exh3_2.jpg"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="exh3_3.jpg"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="exh3_4.jpg"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exh_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Exhibit&nbsp;31.1</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CERTIFICATION</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Charles H. Sherwood, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 7%">1.</TD>
    <TD STYLE="width: 87%">I have reviewed this report on Form&nbsp;10-Q for the quarterly period ended June 30, 2016 of Anika Therapeutics,&nbsp;Inc.;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>2.</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 7%">3.</TD>
    <TD STYLE="width: 87%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 7%">4.</TD>
    <TD STYLE="width: 87%">The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(a)</TD>
    <TD STYLE="width: 83%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(b)</TD>
    <TD STYLE="width: 83%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(c)</TD>
    <TD STYLE="width: 83%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(d)</TD>
    <TD STYLE="width: 83%">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 7%">5.</TD>
    <TD STYLE="width: 87%">The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(a)</TD>
    <TD STYLE="width: 83%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(b)</TD>
    <TD STYLE="width: 83%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Date: August 1, 2016</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid">/s/ CHARLES H. SHERWOOD</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Charles H. Sherwood, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exh_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Exhibit&nbsp;31.2</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">CERTIFICATION</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Sylvia Cheung, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 7%; font-size: 10pt">1.</TD>
    <TD STYLE="width: 87%">
        <P STYLE="font-size: 10pt; margin: 0pt 0">I have reviewed this report on Form&nbsp;10-Q for the quarterly period ended June 30,
        2016 of Anika Therapeutics,&nbsp;Inc.;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">2.</TD>
    <TD STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 7%">3.</TD>
    <TD STYLE="width: 87%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 7%">4.</TD>
    <TD STYLE="width: 87%">The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(a)</TD>
    <TD STYLE="width: 83%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(b)</TD>
    <TD STYLE="width: 83%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(c)</TD>
    <TD STYLE="width: 83%">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(d)</TD>
    <TD STYLE="width: 83%">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 7%">5.</TD>
    <TD STYLE="width: 87%">The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(a)</TD>
    <TD STYLE="width: 83%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 7%">(b)</TD>
    <TD STYLE="width: 83%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Date: August 1, 2016</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid">/s/ SYLVIA CHEUNG</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Sylvia Cheung</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Principal Financial Officer</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exh_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Exhibit&nbsp;32.1</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Section&nbsp;906 Certification</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 49.5pt; margin: 0pt 0">The undersigned officers of Anika Therapeutics,&nbsp;Inc. (the &ldquo;Company&rdquo;)
hereby certify to their knowledge and in their respective capacities that the Company&rsquo;s quarterly report on Form&nbsp;10-Q
to which this certification is attached (the &ldquo;Report&rdquo;), as filed with the Securities and Exchange Commission on the
date hereof, fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d), as applicable, of the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and that the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font-size: 10pt; text-indent: 49.5pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Date: August 1, 2016</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid">/s/ CHARLES H. SHERWOOD</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Charles H. Sherwood, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Principal Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;Date: August 1, 2016</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ SYLVIA CHEUNG</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Sylvia Cheung</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Principal Financial Officer</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 49.5pt; margin: 0pt 0">This certification shall not be deemed &ldquo;filed&rdquo; for any
purpose, nor shall it be deemed to be incorporated by reference into any filing, under the Securities Act of 1933, as amended,
or the Exchange Act.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>anik-20160630.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 06:06PM UTC 2016-08-01--><xbrli:xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:anik="http://www.anikatherapeutics.com/20160630" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="anik-20160630.xsd" xlink:type="simple"/>
  <anik:AccruedClinicalTrialCostsCurrent contextRef="i_2016-06-30" decimals="-3" id="c7718025" unitRef="iso4217-usd">339000</anik:AccruedClinicalTrialCostsCurrent>
  <anik:AccruedClinicalTrialCostsCurrent contextRef="i_2015-12-31" decimals="-3" id="c7718026" unitRef="iso4217-usd">252000</anik:AccruedClinicalTrialCostsCurrent>
  <anik:AccruedResearchGrantsCurrent contextRef="i_2016-06-30" decimals="-3" id="c7718021" unitRef="iso4217-usd">481000</anik:AccruedResearchGrantsCurrent>
  <anik:AccruedResearchGrantsCurrent contextRef="i_2015-12-31" decimals="-3" id="c7718022" unitRef="iso4217-usd">381000</anik:AccruedResearchGrantsCurrent>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c7717972" unitRef="iso4217-usd">-3108000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember" decimals="-3" id="c7717978" unitRef="iso4217-usd">-1286000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" decimals="-3" id="c7717984" unitRef="iso4217-usd">-415000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c7717990" unitRef="iso4217-usd">-186000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:AccumulatedCurrencyTranslationAdjustment contextRef="i_2016-06-30" decimals="-3" id="c7718002" unitRef="iso4217-usd">-4995000</anik:AccumulatedCurrencyTranslationAdjustment>
  <anik:BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation contextRef="i_2016-06-30_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember" decimals="-5" id="c7718057" unitRef="iso4217-usd">500000</anik:BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation>
  <anik:DepositsAndOtherAssetsNoncurrent contextRef="i_2016-06-30" decimals="-3" id="c7717523" unitRef="iso4217-usd">69000</anik:DepositsAndOtherAssetsNoncurrent>
  <anik:DepositsAndOtherAssetsNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c7717524" unitRef="iso4217-usd">69000</anik:DepositsAndOtherAssetsNoncurrent>
  <anik:LesseeLeasingArrangementsAbilityToWithdrawWithPenalty contextRef="d_2015-10-09_2015-10-09_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember" id="c7718050">P6Y</anik:LesseeLeasingArrangementsAbilityToWithdrawWithPenalty>
  <anik:LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty contextRef="d_2015-10-09_2015-10-09_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember" id="c7718051">P9Y</anik:LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty>
  <anik:LesseeLeasingArrangementsInitialYearlyRent contextRef="d_2015-10-09_2016-03-31_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember" decimals="-5" id="c7718052" unitRef="iso4217-usd">400000</anik:LesseeLeasingArrangementsInitialYearlyRent>
  <anik:LesseeLeasingArrangementsNumberOfRenewalTerms contextRef="i_2015-10-09_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember" decimals="INF" id="c7718048" unitRef="xbrli-pure">3</anik:LesseeLeasingArrangementsNumberOfRenewalTerms>
  <anik:LesseeLeasingArrangementsRenewalTerm contextRef="d_2015-10-09_2015-10-09_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember" id="c7718049">P6Y</anik:LesseeLeasingArrangementsRenewalTerm>
  <anik:LesseeLeasingArrangementsTermOfContract contextRef="d_2015-10-09_2015-10-09_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember" id="c7718045">P15Y</anik:LesseeLeasingArrangementsTermOfContract>
  <anik:NumberOfProductsDevelopedManufacturedAndCommercialized contextRef="i_2016-06-30" decimals="INF" id="c7717737" unitRef="xbrli-pure">20</anik:NumberOfProductsDevelopedManufacturedAndCommercialized>
  <anik:PercentageOfNetRevenue contextRef="d_2016-04-01_2016-06-30_StatementGeographicalAxis-US" decimals="2" id="c7718117" unitRef="xbrli-pure">0.82</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2015-04-01_2015-06-30_StatementGeographicalAxis-US" decimals="2" id="c7718119" unitRef="xbrli-pure">0.84</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2016-04-01_2016-06-30_StatementGeographicalAxis-EuropeMember" decimals="2" id="c7718121" unitRef="xbrli-pure">0.11</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2015-04-01_2015-06-30_StatementGeographicalAxis-EuropeMember" decimals="2" id="c7718123" unitRef="xbrli-pure">0.1</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2016-04-01_2016-06-30_StatementGeographicalAxis-OtherLocationMember" decimals="2" id="c7718125" unitRef="xbrli-pure">0.07</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2015-04-01_2015-06-30_StatementGeographicalAxis-OtherLocationMember" decimals="2" id="c7718127" unitRef="xbrli-pure">0.06</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2016-04-01_2016-06-30" decimals="2" id="c7718129" unitRef="xbrli-pure">1</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2015-04-01_2015-06-30" decimals="2" id="c7718131" unitRef="xbrli-pure">1</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2016-01-01_2016-06-30_StatementGeographicalAxis-US" decimals="2" id="c7718134" unitRef="xbrli-pure">0.82</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2015-01-01_2015-06-30_StatementGeographicalAxis-US" decimals="2" id="c7718136" unitRef="xbrli-pure">0.83</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2016-01-01_2016-06-30_StatementGeographicalAxis-EuropeMember" decimals="2" id="c7718138" unitRef="xbrli-pure">0.11</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2015-01-01_2015-06-30_StatementGeographicalAxis-EuropeMember" decimals="2" id="c7718140" unitRef="xbrli-pure">0.11</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2016-01-01_2016-06-30_StatementGeographicalAxis-OtherLocationMember" decimals="2" id="c7718142" unitRef="xbrli-pure">0.07</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2015-01-01_2015-06-30_StatementGeographicalAxis-OtherLocationMember" decimals="2" id="c7718144" unitRef="xbrli-pure">0.06</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2016-01-01_2016-06-30" decimals="2" id="c7718146" unitRef="xbrli-pure">1</anik:PercentageOfNetRevenue>
  <anik:PercentageOfNetRevenue contextRef="d_2015-01-01_2015-06-30" decimals="2" id="c7718148" unitRef="xbrli-pure">1</anik:PercentageOfNetRevenue>
  <anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June 30, 2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accumulated Currency Translation Adjustment&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accumulated Amortization&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Net Book Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Net Book Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Useful Life&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 22%; font-size: 10pt; text-align: left"&gt;Developed technology&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;17,100&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(3,108&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(6,373&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7,619&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7,959&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: center"&gt;15&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;In-process research &amp;amp; development&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,406&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1,286&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,120&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;Indefinite&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Distributor relationships&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,700&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(415&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(4,285&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Patents&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,000&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(186&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(357&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;457&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;473&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;16&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Elevess trade name&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,000&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(937&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;63&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;125&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;9&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt; text-indent: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;28,206&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(4,995&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(11,952&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;11,259&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;11,656&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock>
  <anik:ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended June 30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Geographic Location:&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left; text-indent: 10pt"&gt;United States&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;21,895&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;82&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;19,218&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;84&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Europe&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,977&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,331&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;10&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,709&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,355&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;6&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt"&gt;Total Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;26,581&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;100&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;22,904&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;100&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended June 30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Geographic Location:&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left; text-indent: 10pt"&gt;United States&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;39,906&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;82&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;31,809&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;83&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Europe&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,542&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,317&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3,416&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,298&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;6&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;48,864&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;100&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;38,424&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;100&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</anik:ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock>
  <anik:StockRepurchaseProgramPercentageRepurchased contextRef="i_2016-02-29_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember_StatementEquityComponentsAxis-CommonStockMember" decimals="1" id="c7717924" unitRef="xbrli-pure">0.7</anik:StockRepurchaseProgramPercentageRepurchased>
  <dei:AmendmentFlag contextRef="d_2016-01-01_2016-06-30" id="c-14">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2016-01-01_2016-06-30" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2016-01-01_2016-06-30" id="c-13">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2016-01-01_2016-06-30" id="c-12">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2016-01-01_2016-06-30" id="c-11">2016-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2016-01-01_2016-06-30" id="c-10">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2016-01-01_2016-06-30" id="c-2">0000898437</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2016-07-28" decimals="INF" id="c-9" unitRef="xbrli-shares">14777663</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2016-01-01_2016-06-30" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2016-01-01_2016-06-30" id="c-5">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="d_2016-01-01_2016-06-30" id="c-1">Anika Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2016-01-01_2016-06-30" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2016-01-01_2016-06-30" id="c-8">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2016-01-01_2016-06-30" id="c-3">anik</dei:TradingSymbol>
  <us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare contextRef="d_2016-02-29_2016-02-29_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c7717923" unitRef="iso4217-usd-per-xbrli-shares">46.40</us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263938">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;11.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Accrued Expenses&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Accrued expenses consist of the following:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Compensation and related expenses&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;2,416&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;3,082&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Facility construction costs&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,769&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;415&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Research grants&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;481&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;381&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Professional fees&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;889&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;210&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Clinical trial costs&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;339&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;252&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;744&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;438&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,638&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,778&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="i_2016-06-30" decimals="-3" id="c7717533" unitRef="iso4217-usd">3294000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c7717534" unitRef="iso4217-usd">8302000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2016-06-30" decimals="-3" id="c7717511" unitRef="iso4217-usd">24597000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="i_2015-12-31" decimals="-3" id="c7717512" unitRef="iso4217-usd">21652000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="i_2016-06-30" decimals="-3" id="c7717537" unitRef="iso4217-usd">591000</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="i_2015-12-31" decimals="-3" id="c7717538" unitRef="iso4217-usd">4198000</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="i_2016-06-30" decimals="-3" id="c7717535" unitRef="iso4217-usd">6638000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="i_2015-12-31" decimals="-3" id="c7717536" unitRef="iso4217-usd">4778000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2016-06-30" decimals="-3" id="c7718029" unitRef="iso4217-usd">6638000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c7718030" unitRef="iso4217-usd">4778000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2016-06-30" decimals="-3" id="c7718023" unitRef="iso4217-usd">889000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2015-12-31" decimals="-3" id="c7718024" unitRef="iso4217-usd">210000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2016-06-30" decimals="-3" id="c7717574" unitRef="iso4217-usd">-6410000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2015-12-31" decimals="-3" id="c7717575" unitRef="iso4217-usd">-6649000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2016-06-30" decimals="-3" id="c7717572" unitRef="iso4217-usd">59506000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2015-12-31" decimals="-3" id="c7717573" unitRef="iso4217-usd">81685000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="i_2016-06-30" decimals="-3" id="c7717513" unitRef="iso4217-usd">220000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="i_2015-12-31" decimals="-3" id="c7717514" unitRef="iso4217-usd">167000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2016-04-01_2016-06-30" decimals="-5" id="c7717962" unitRef="iso4217-usd">300000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2015-04-01_2015-06-30" decimals="-5" id="c7717965" unitRef="iso4217-usd">300000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2016-01-01_2016-06-30" decimals="-5" id="c7717966" unitRef="iso4217-usd">600000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="d_2015-01-01_2015-06-30" decimals="-5" id="c7717967" unitRef="iso4217-usd">500000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-06-30" decimals="INF" id="c7717909" unitRef="xbrli-shares">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-04-01_2016-06-30" decimals="INF" id="c7717910" unitRef="xbrli-shares">300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c7717912" unitRef="xbrli-shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c7717915" unitRef="xbrli-shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-06-30_2016-06-30_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember" decimals="INF" id="c7717928" unitRef="xbrli-shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AreaOfRealEstateProperty contextRef="i_2015-10-09_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember" decimals="INF" id="c7718044" unitRef="utr-sqft">33000</us-gaap:AreaOfRealEstateProperty>
  <us-gaap:Assets contextRef="i_2016-06-30" decimals="-3" id="c7717529" unitRef="iso4217-usd">222738000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2015-12-31" decimals="-3" id="c7717530" unitRef="iso4217-usd">235748000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2016-06-30" decimals="-3" id="c7717519" unitRef="iso4217-usd">154644000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2015-12-31" decimals="-3" id="c7717520" unitRef="iso4217-usd">176433000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2016-06-30_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="INF" id="c7717798" unitRef="iso4217-usd">22500000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember" decimals="INF" id="c7717799" unitRef="iso4217-usd">25800000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecurities contextRef="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember" decimals="INF" id="c7717801" unitRef="iso4217-usd">2000000</us-gaap:AvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="i_2015-12-31" decimals="INF" id="c7717793" unitRef="iso4217-usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax contextRef="i_2016-06-30" decimals="INF" id="c7717794" unitRef="iso4217-usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263922">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Basis of Presentation&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules&amp;nbsp;and regulations of the Securities and Exchange Commission (the &amp;#x201c;SEC&amp;#x201d;) and in accordance with accounting principles generally accepted in the United States (&amp;#x201c;US GAAP&amp;#x201d;). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. The year-end consolidated balance sheet is derived from the Company&amp;#x2019;s audited financial statements, but does not include all disclosures required by US GAAP. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial position of the Company as of June 30, 2016, the results of its operations for the three- and six-month periods ended June 30, 2016 and 2015, and cash flows for the six-month periods ended June 30, 2016 and 2015.&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company&amp;#x2019;s annual financial statements filed with its Annual Report on Form&amp;nbsp;10-K for the year ended December 31, 2015. The results of operations for the three- and six-month periods ended June 30, 2016 are not necessarily indicative of the results to be expected for the year ending December&amp;nbsp;31, 2016. Certain prior period amounts have been reclassified to conform to the current period presentation. There was no impact on operating income.&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717733" unitRef="iso4217-usd">2128000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717734" unitRef="iso4217-usd">116000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2016-06-30" decimals="-3" id="c7717507" unitRef="iso4217-usd">89125000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="-3" id="c7717508" unitRef="iso4217-usd">110707000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="-3" id="c7717728" unitRef="iso4217-usd">100156000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-06-30" decimals="-3" id="c7717730" unitRef="iso4217-usd">103920000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263924">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;4.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Investments&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;All of the Company&amp;#x2019;s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes. The Company held bank certificates of deposit of $22.5 million and $25.8 million at June 30, 2016 and December 31, 2015, respectively. The Company also held corporate debt securities of $2.0 million at December 31, 2015. There were no unrealized gains or losses on the Company&amp;#x2019;s available-for-sale securities at June 30, 2016 or December 31, 2015.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2016-06-30_FairValueByAssetClassAxis-MoneyMarketFundsMember" decimals="-3" id="c7717815" unitRef="iso4217-usd">67001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2016-06-30_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="-3" id="c7717817" unitRef="iso4217-usd">67001000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2015-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember" decimals="-3" id="c7717825" unitRef="iso4217-usd">61385000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2015-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="-3" id="c7717827" unitRef="iso4217-usd">61385000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2015-12-31_FairValueByAssetClassAxis-CertificatesOfDepositMember" decimals="-3" id="c7717829" unitRef="iso4217-usd">250000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2015-12-31_FairValueByAssetClassAxis-CertificatesOfDepositMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="-3" id="c7717831" unitRef="iso4217-usd">250000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2015-12-31" decimals="-3" id="c7717833" unitRef="iso4217-usd">61635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2015-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="-3" id="c7717835" unitRef="iso4217-usd">61635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717725" unitRef="iso4217-usd">-21582000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717726" unitRef="iso4217-usd">3764000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2016-06-30" id="c7718733" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2015-12-31" id="c7718734" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263940">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;12.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Commitments and Contingencies&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate, or breach any U.S. patent or intellectual property right, trade secret, or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company&amp;#x2019;s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties at June 30, 2016 or December 31, 2015, respectively, and has no history of claims paid.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;The Company is also involved in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2016-06-30" decimals="INF" id="c7717564" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c7717565" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2016-06-30" decimals="INF" id="c7717566" unitRef="xbrli-shares">60000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2015-12-31" decimals="INF" id="c7717567" unitRef="xbrli-shares">30000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2016-06-30" decimals="INF" id="c7717568" unitRef="xbrli-shares">14777663</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2015-12-31" decimals="INF" id="c7717569" unitRef="xbrli-shares">15035808</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2016-06-30" decimals="INF" id="c7717570" unitRef="xbrli-shares">14777663</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2015-12-31" decimals="INF" id="c7717571" unitRef="xbrli-shares">15035808</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2016-06-30" decimals="-3" id="c7717562" unitRef="iso4217-usd">148000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2015-12-31" decimals="-3" id="c7717563" unitRef="iso4217-usd">150000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717666" unitRef="iso4217-usd">8079000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717667" unitRef="iso4217-usd">8236000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717668" unitRef="iso4217-usd">15748000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717669" unitRef="iso4217-usd">9504000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ConstructionInProgressGross contextRef="i_2016-06-30_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember" decimals="-5" id="c7718056" unitRef="iso4217-usd">900000</us-gaap:ConstructionInProgressGross>
  <us-gaap:ConstructionPayableCurrent contextRef="i_2016-06-30" decimals="-3" id="c7718019" unitRef="iso4217-usd">1769000</us-gaap:ConstructionPayableCurrent>
  <us-gaap:ConstructionPayableCurrent contextRef="i_2015-12-31" decimals="-3" id="c7718020" unitRef="iso4217-usd">415000</us-gaap:ConstructionPayableCurrent>
  <us-gaap:CostOfGoodsSold contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717595" unitRef="iso4217-usd">6065000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717596" unitRef="iso4217-usd">5275000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717597" unitRef="iso4217-usd">11490000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717598" unitRef="iso4217-usd">9588000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostsAndExpenses contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717607" unitRef="iso4217-usd">13112000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717608" unitRef="iso4217-usd">10475000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717609" unitRef="iso4217-usd">24686000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717610" unitRef="iso4217-usd">20491000</us-gaap:CostsAndExpenses>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717678" unitRef="iso4217-usd">-252000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717679" unitRef="iso4217-usd">-428000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2016-06-30" decimals="-3" id="c7717543" unitRef="iso4217-usd">56000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c7717544" unitRef="iso4217-usd">66000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2016-06-30" decimals="INF" id="c7718080" unitRef="iso4217-usd">0</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2015-12-31" decimals="INF" id="c7718082" unitRef="iso4217-usd">0</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="i_2016-06-30" decimals="-3" id="c7717545" unitRef="iso4217-usd">6570000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c7717546" unitRef="iso4217-usd">6775000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DepreciationAndAmortization contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717674" unitRef="iso4217-usd">1901000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717675" unitRef="iso4217-usd">1827000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263928">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;6.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Equity Incentive Plan&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;The Company estimates the fair value of stock options and stock appreciation rights (&amp;#x201c;SARs&amp;#x201d;) using the Black-Scholes valuation model. Fair value of restricted stock awards (&amp;#x201c;RSAs&amp;#x201d;) and restricted stock units (&amp;#x201c;RSUs&amp;#x201d;) are measured by the grant-date price of the Company&amp;#x2019;s shares. The fair value of each stock option award during the three- and six-month periods ended June 30, 2016 and 2015, respectively, was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended June 30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk free interest rate&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.94%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt; -&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;1.40%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.15%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt; -&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;1.46%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;49.47%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt; -&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;51.61%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;53.15%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt; -&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;54.65%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Expected life (years)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%; font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-size: 10pt; text-align: center"&gt;4.5&lt;/td&gt; &lt;td style="width: 3%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-size: 10pt; text-align: center"&gt;4.5&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected dividend yield&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;0.00%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;0.00%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;  &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;The Company recorded $0.7 million and $0.5 million of share-based compensation expense for the three-month periods ended June 30, 2016 and 2015, respectively, for equity compensation awards. The Company recorded $1.5 million and $1.1 million of share-based compensation expense for the six-month periods ended June 30, 2016 and 2015, respectively, for equity compensation awards. The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to the respective recipients.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;During the three-month period ended June 30, 2016, the Company granted under the Equity Incentive Plan (&amp;#x201c;Plan&amp;#x201d;) a total of 43,000 stock options. During the six-month period ended June 30, 2016, the Company granted under the Plan a total of 331,705 stock options including 46,300 RSAs and 11,805 RSUs. All of the RSUs were granted to directors of the Company and vest over a one year period. The stock options and RSAs granted to employees generally become exercisable or vest ratably over four years from the date of grant.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 8; Value: 2 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;A portion of the stock options granted during the six-month period ended June 30, 2016 contained certain performance features, as compared to established targets, in addition to time-based vesting conditions. For performance-based awards with financial achievement targets, the Company recognizes expense using the graded vesting methodology based on the number of shares expected to vest. Compensation cost associated with performance grants is estimated using the Black-Scholes valuation method multiplied by the expected number of shares to be issued, which is adjusted based on the estimated probabilities of achieving the performance goals. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related share-based compensation expense that will be recorded in the period of the change. If the performance targets are not achieved, no compensation cost is recognized and any previously recognized compensation cost is reversed.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="d_2016-04-01_2016-06-30" decimals="INF" id="c7717632" unitRef="iso4217-usd-per-xbrli-shares">0.59</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c7717633" unitRef="iso4217-usd-per-xbrli-shares">0.52</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2016-01-01_2016-06-30" decimals="INF" id="c7717634" unitRef="iso4217-usd-per-xbrli-shares">1.05</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c7717635" unitRef="iso4217-usd-per-xbrli-shares">0.76</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2016-04-01_2016-06-30" decimals="INF" id="c7717641" unitRef="iso4217-usd-per-xbrli-shares">0.57</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-04-01_2015-06-30" decimals="INF" id="c7717642" unitRef="iso4217-usd-per-xbrli-shares">0.51</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2016-01-01_2016-06-30" decimals="INF" id="c7717643" unitRef="iso4217-usd-per-xbrli-shares">1.02</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2015-01-01_2015-06-30" decimals="INF" id="c7717644" unitRef="iso4217-usd-per-xbrli-shares">0.74</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263930">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;7.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Earnings Per Share (&amp;#x201c;EPS&amp;#x201d;)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic earnings per share. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, SARs, RSAs, and RSUs using the treasury stock method.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;The following table provides share information used in the calculation of the Company's basic and diluted earnings per share:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended June 30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended June 30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Shares used in the calculation of basic earnings per share&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,679&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,961&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,778&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,934&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Effect of dilutive securities:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Stock options, SARs, and RSAs&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;432&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;375&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;432&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;398&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Diluted shares used in the calculation of earnings per share&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;15,111&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;15,336&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;15,210&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;15,332&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;Equity awards of 0.3 million shares were outstanding for the three- and six-month periods ended June 30, 2016 and were not included in the computation of diluted earnings per share because the awards&amp;#x2019; impact on earnings per share was anti-dilutive.&amp;nbsp;Equity awards of 0.2 million shares were outstanding for the three- and six-month periods ended June 30, 2015, respectively, and were not included in the computation of diluted earnings per share because the awards&amp;#x2019; impact on earnings per share was anti-dilutive.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;On February 26, 2016, the Company entered into an accelerated stock repurchase agreement with Morgan Stanley &amp;amp; Co. LLC (&amp;#x201c;Morgan Stanley&amp;#x201d;) pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction (&amp;#x201c;ASR Agreement&amp;quot;) to purchase $25.0 million of shares of its common stock. Pursuant to the terms of the ASR Agreement, the Company paid Morgan Stanley&amp;nbsp;$25.0 million&amp;nbsp;in cash and received an initial delivery of 377,155 shares&amp;nbsp;of the Company&amp;#x2019;s common stock on&amp;nbsp;February 29, 2016 based on a closing market price of&amp;nbsp;$46.40 and the applicable contractual discount. This is approximately 70% of the total number of shares of expected to be repurchased under the ASR Agreement. These shares are held by the Company as authorized but unissued shares pursuant to Massachusetts law. The initial delivery of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares outstanding for basic and diluted net income per share.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;As of June 30, 2016, the Company has approximately $7.5 million&amp;nbsp;remaining under the ASR Agreement which was recorded as an equity forward sale contract and was included in additional paid-in capital in stockholders' equity in the condensed consolidated balance sheet as it met the criteria for equity accounting. Pursuant to the terms of the ASR Agreement, the final number of shares and the average purchase price will be determined at the end of the applicable purchase period, which is expected to occur in&amp;nbsp;the third quarter of 2016. Upon settlement of the ASR Agreement, the Company may receive additional shares or be required to either pay additional cash or deliver shares of our common stock (at its option) to Morgan Stanley, based on the forward price. If the ASR Agreement&amp;nbsp;had been settled as of June 30, 2016, based on the volume-weighted average price since the effective date of the ASR Agreement, Morgan Stanley would have been required to deliver approximately 0.2 million additional shares to the Company. However, the Company cannot predict the final number of shares to be received, or delivered, by it under the ASR Agreement, and, as such, these shares are not included in the calculation of diluted weighted-average common shares outstanding during the period because the effect is anti-dilutive.&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717723" unitRef="iso4217-usd">52000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717724" unitRef="iso4217-usd">-121000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2016-04-01_2016-06-30" decimals="3" id="c7718063" unitRef="xbrli-pure">0.363</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2016-01-01_2016-06-30" decimals="3" id="c7718064" unitRef="xbrli-pure">0.362</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2015-01-01_2015-06-30" decimals="3" id="c7718069" unitRef="xbrli-pure">0.37</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2015-04-01_2015-06-30" decimals="3" id="c7718070" unitRef="xbrli-pure">0.37</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2016-06-30" decimals="-3" id="c7718017" unitRef="iso4217-usd">2416000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c7718018" unitRef="iso4217-usd">3082000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717719" unitRef="iso4217-usd">419000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717720" unitRef="iso4217-usd">934000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717684" unitRef="iso4217-usd">419000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717685" unitRef="iso4217-usd">934000</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-15">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value Measurements at Reporting&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Date Using&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Active Markets&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Significant Other&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;for Identical Assets&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Observable Inputs&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Unobservable Inputs&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June 30, 2016&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 1)&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 2)&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 3)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Cash equivalents:&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;67,001&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;67,001&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Investments:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Bank certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;22,500&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;22,500&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value Measurements at Reporting&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Date Using&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Active Markets&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Significant Other&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;for Identical Assets&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Observable Inputs&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Unobservable Inputs&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2015&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 1)&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 2)&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 3)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Cash equivalents:&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;61,385&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;61,385&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Bank certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;250&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;250&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total cash equivalents&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;61,635&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;61,635&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Investments:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,001&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,001&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Bank certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;25,750&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;25,750&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;27,751&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;27,751&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263925">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;5.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants based on assumptions that market participants would use in pricing an asset or liability. As a basis for classifying the fair value measurements, a three-tier fair value hierarchy, which classifies the fair value measurements based on the inputs used in measuring fair value, was established as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets or liabilities; (Level 2) significant other observable inputs that are observable either directly or indirectly; and (Level 3) significant unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. On a recurring basis, the Company records its investments at fair value.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;The Company&amp;#x2019;s investments are all classified within Level 2 of the fair value hierarchy. These investments classified within Level 2 of the fair value hierarchy are valued based on matrix pricing compiled by third party pricing vendors, using observable market inputs such as interest rates, yield curves, and credit risk.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 7; Value: 2 --&gt;   &lt;!-- Field: /Page --&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;The fair value hierarchy of the Company&amp;#x2019;s cash equivalents and investments at fair value is as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;   &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value Measurements at Reporting&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Date Using&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Active Markets&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Significant Other&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;for Identical Assets&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Observable Inputs&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Unobservable Inputs&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June 30, 2016&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 1)&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 2)&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 3)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Cash equivalents:&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;67,001&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;67,001&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Investments:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Bank certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;22,500&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;22,500&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value Measurements at Reporting&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Date Using&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Quoted Prices in&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Active Markets&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Significant Other&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;for Identical Assets&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Observable Inputs&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Unobservable Inputs&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2015&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 1)&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 2)&lt;/td&gt; &lt;td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;(Level 3)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Cash equivalents:&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;61,385&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;61,385&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Bank certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;250&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;250&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total cash equivalents&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;61,635&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;61,635&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Investments:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Corporate debt securities&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,001&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,001&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Bank certificates of deposit&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;25,750&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;25,750&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Total investments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;27,751&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;27,751&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" id="c7717976">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" id="c7717988">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" id="c7717994">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" id="c7718000">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c7717973" unitRef="iso4217-usd">6373000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" decimals="-3" id="c7717985" unitRef="iso4217-usd">4285000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c7717991" unitRef="iso4217-usd">357000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" decimals="-3" id="c7717997" unitRef="iso4217-usd">937000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="i_2016-06-30" decimals="-3" id="c7718003" unitRef="iso4217-usd">11952000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:Goodwill contextRef="i_2016-06-30" decimals="-3" id="c7717527" unitRef="iso4217-usd">7568000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="i_2015-12-31" decimals="-3" id="c7717528" unitRef="iso4217-usd">7482000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="i_2014-12-31" decimals="-3" id="c7718011" unitRef="iso4217-usd">8339000</us-gaap:Goodwill>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263934">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;9.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Intangible Assets&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;In connection with the 2009 acquisition of Anika Therapeutics S.r.l. (&amp;#x201c;Anika S.r.l.&amp;#x201d;), the Company acquired various intangible assets and goodwill.&amp;nbsp;The Company evaluated the various intangible assets and related cash flows from these intangible assets, as well as the useful lives and amortization methods related to these intangible assets.&amp;nbsp;The in-process research and development (&amp;#x201c;IPR&amp;amp;D&amp;#x201d;) intangible assets initially have indefinite lives and are reviewed periodically to assess the project status, valuation, and disposition, including write-off(s) for abandoned projects.&amp;nbsp;Until such determination is made, they are not amortized.&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Intangible assets as of June 30, 2016 and December 31, 2015 consist of the following:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June 30, 2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;December 31, 2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Gross Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accumulated Currency Translation Adjustment&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Accumulated Amortization&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Net Book Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Net Book Value&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Useful Life&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 22%; font-size: 10pt; text-align: left"&gt;Developed technology&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;17,100&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(3,108&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;(6,373&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7,619&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7,959&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: center"&gt;15&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;In-process research &amp;amp; development&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,406&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(1,286&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,120&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,099&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;Indefinite&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Distributor relationships&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,700&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(415&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(4,285&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;5&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;Patents&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,000&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(186&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;(357&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;457&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;473&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;16&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Elevess trade name&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,000&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;-&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(937&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;63&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;125&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: center"&gt;9&lt;/td&gt; &lt;td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt; text-indent: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;28,206&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(4,995&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;(11,952&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;11,259&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;11,656&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;The aggregate amortization expense related to intangible assets was $0.3 million for the three-month periods ended June 30, 2016 and 2015, respectively. The aggregate amortization expense related to intangible assets was $0.6 million and $0.5 million for the six-month periods ended June 30, 2016 and 2015, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:GoodwillDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263936">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;10.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Through June 30, 2016, there have not been any events or changes in circumstances that indicate that the carrying value of goodwill may not be recoverable. Changes in the carrying value of goodwill were as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended &lt;br /&gt; June 30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Twelve Months &lt;br /&gt; Ended December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Balance, beginning&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7,482&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;8,339&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Effect of foreign currency adjustments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;86&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(857&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance, ending&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;7,568&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;7,482&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
  <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7718012" unitRef="iso4217-usd">86000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
  <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="d_2015-01-01_2015-12-31" decimals="-3" id="c7718013" unitRef="iso4217-usd">-857000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717619" unitRef="iso4217-usd">13518000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717620" unitRef="iso4217-usd">12453000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717621" unitRef="iso4217-usd">24299000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717622" unitRef="iso4217-usd">17981000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263942">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;14.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Income Taxes&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt;   &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Provisions for income taxes were $4.9 million and $8.8 million for the three- and six-month periods ended June 30, 2016, based on effective tax rates of 36.3% and 36.2%, respectively. Provisions for income taxes were $4.6 million and $6.6 million for the three- and six-month periods ended June 30, 2015, based on effective tax rates of 37% for both periods. The increase in income taxes for the three- and six-month period ended June 30, 2016 resulted from higher net income as compared to the same periods in the prior year. The net decrease in the effective tax rate &lt;div style="display: inline; background-color: white"&gt;for the three- and six-month period ended June 30, 2016, as compared to the same period in 2015, &lt;/div&gt;was primarily due to an increase in the expected tax credit for research and development expenditures.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 11; Value: 2 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. The Company&amp;#x2019;s filings from 2012 through the present tax year remain subject to examination by the IRS and other taxing authorities for U.S. federal and state tax purposes. The Company currently has a tax audit in progress in the United States and does not anticipate that the audit will have a material impact on its financial statements.&amp;nbsp; The Company&amp;#x2019;s filings from 2010 through the present tax year remain subject to examination by the appropriate governmental authorities in Italy.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;In connection with the preparation of the financial statements, the Company performed an analysis to ascertain if it was more likely than not that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carryforward. The Company concluded that the positive evidence outweighs the negative evidence and, thus, those deferred tax assets are realizable on a &amp;#x201c;more likely than not&amp;#x201d; basis. As such, the Company did not record a valuation allowance at June 30, 2016 or December 31, 2015.&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7718059" unitRef="iso4217-usd">4903000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7718060" unitRef="iso4217-usd">8789000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7718065" unitRef="iso4217-usd">4634000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7718066" unitRef="iso4217-usd">6646000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717693" unitRef="iso4217-usd">-4252000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717694" unitRef="iso4217-usd">559000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717687" unitRef="iso4217-usd">2932000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717688" unitRef="iso4217-usd">2389000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717699" unitRef="iso4217-usd">-3169000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717700" unitRef="iso4217-usd">3194000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717695" unitRef="iso4217-usd">446000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717696" unitRef="iso4217-usd">-264000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717697" unitRef="iso4217-usd">-45000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717698" unitRef="iso4217-usd">-5000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717689" unitRef="iso4217-usd">2438000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717690" unitRef="iso4217-usd">-496000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717701" unitRef="iso4217-usd">396000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717702" unitRef="iso4217-usd">-98000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717691" unitRef="iso4217-usd">-186000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717692" unitRef="iso4217-usd">-459000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c7717971" unitRef="iso4217-usd">17100000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember" decimals="-3" id="c7717977" unitRef="iso4217-usd">4406000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember" decimals="-3" id="c7717983" unitRef="iso4217-usd">4700000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c7717989" unitRef="iso4217-usd">1000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" decimals="-3" id="c7717995" unitRef="iso4217-usd">1000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2016-06-30" decimals="-3" id="c7718001" unitRef="iso4217-usd">28206000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2016-06-30" decimals="-3" id="c7717525" unitRef="iso4217-usd">11259000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2015-12-31" decimals="-3" id="c7717526" unitRef="iso4217-usd">11656000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c7717974" unitRef="iso4217-usd">7619000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember" decimals="-3" id="c7717975" unitRef="iso4217-usd">-7959000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember" decimals="-3" id="c7717980" unitRef="iso4217-usd">3120000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember" decimals="-3" id="c7717981" unitRef="iso4217-usd">-3099000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c7717992" unitRef="iso4217-usd">457000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember" decimals="-3" id="c7717993" unitRef="iso4217-usd">-473000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" decimals="-3" id="c7717998" unitRef="iso4217-usd">63000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember" decimals="-3" id="c7717999" unitRef="iso4217-usd">-125000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717615" unitRef="iso4217-usd">49000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717616" unitRef="iso4217-usd">24000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717617" unitRef="iso4217-usd">121000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717618" unitRef="iso4217-usd">48000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InventoryDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263932">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;8.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Inventories&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Inventories consist of the following:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Raw materials&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;6,812&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,780&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Work-in-process&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;6,140&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,656&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,312&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3,502&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;17,264&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;14,938&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Inventories are stated at the lower of cost or market, with cost being determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and manufacturing overhead. Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use and future economic benefit.&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2016-06-30" decimals="-3" id="c7717949" unitRef="iso4217-usd">4312000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="i_2015-12-31" decimals="-3" id="c7717950" unitRef="iso4217-usd">3502000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryNet contextRef="i_2016-06-30" decimals="-3" id="c7717951" unitRef="iso4217-usd">17264000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="i_2015-12-31" decimals="-3" id="c7717952" unitRef="iso4217-usd">14938000</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="i_2016-06-30" decimals="-3" id="c7717945" unitRef="iso4217-usd">6812000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="i_2015-12-31" decimals="-3" id="c7717946" unitRef="iso4217-usd">5780000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2016-06-30" decimals="-3" id="c7717947" unitRef="iso4217-usd">6140000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="i_2015-12-31" decimals="-3" id="c7717948" unitRef="iso4217-usd">5656000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWriteDown contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717682" unitRef="iso4217-usd">181000</us-gaap:InventoryWriteDown>
  <us-gaap:InventoryWriteDown contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717683" unitRef="iso4217-usd">68000</us-gaap:InventoryWriteDown>
  <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263941">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; background-color: white"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; background-color: white"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;On October 9, 2015, Anika S.r.l. entered into a build-to-suit lease agreement with Consorzio Zona Industriale E Porto Fluviale di Padova (&amp;#x201c;ZIP&amp;#x201d;), as landlord, pursuant to which Anika S.r.l. will lease a new European headquarters facility, consisting of approximately 33,000 square feet of general office, research and development, training, and warehousing space located in Padova, Italy. The lease has an initial term of fifteen years, which is expected to commence during the fourth quarter of 2016 once construction of the facility is completed. The lease will automatically renew for up to three additional six-year terms, subject to certain terms and conditions. The Company has the ability to withdraw from this lease subject to certain financial penalties after six years and with no penalties after the ninth year. Beginning on the commencement date, the lease provides for an initial yearly rent of approximately $0.4 million.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Construction of the new facility began in the first quarter of 2016 and is expected to be completed in late 2016. During the period of construction the Company is considered the deemed owner of the facility. Accordingly, the landlord's costs of constructing the facility are required to be capitalized, as a non-cash transaction, offset by a corresponding facility lease obligation in the Company&amp;#x2019;s consolidated balance sheet. As of June 30, 2016, the Company has recorded a construction-in-process asset of&amp;nbsp;approximately $0.9 million. This includes $0.5 million incurred by ZIP for the construction of the new facility, which was recorded as a facility lease obligation within other long-term liabilities on the balance sheet.&lt;/div&gt;&lt;/div&gt;</us-gaap:LeasesOfLesseeDisclosureTextBlock>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2016-06-30" decimals="-3" id="c7717580" unitRef="iso4217-usd">222738000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2015-12-31" decimals="-3" id="c7717581" unitRef="iso4217-usd">235748000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2016-06-30" decimals="-3" id="c7717539" unitRef="iso4217-usd">10523000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c7717540" unitRef="iso4217-usd">17278000</us-gaap:LiabilitiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2016-06-30" decimals="-3" id="c7717509" unitRef="iso4217-usd">22500000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c7717510" unitRef="iso4217-usd">27751000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2016-06-30_FairValueByAssetClassAxis-CertificatesOfDepositMember" decimals="-3" id="c7717820" unitRef="iso4217-usd">22500000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2016-06-30_FairValueByAssetClassAxis-CertificatesOfDepositMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="-3" id="c7717822" unitRef="iso4217-usd">22500000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2015-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember" decimals="-3" id="c7717838" unitRef="iso4217-usd">2001000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2015-12-31_FairValueByAssetClassAxis-CertificatesOfDepositMember" decimals="-3" id="c7717842" unitRef="iso4217-usd">25750000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:MarketableSecuritiesCurrent contextRef="i_2015-12-31_FairValueByAssetClassAxis-CertificatesOfDepositMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" decimals="-3" id="c7717844" unitRef="iso4217-usd">25750000</us-gaap:MarketableSecuritiesCurrent>
  <us-gaap:NatureOfOperations contextRef="d_2016-01-01_2016-06-30" id="s263921">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;1.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Nature of Business&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing innovative and differentiated therapeutic pain management solutions along the continuum of care, from palliative care to regenerative medicine. The Company has over two decades of expertise developing, manufacturing, and commercializing more than 20 products, in markets across the globe, based on the Company&amp;#x2019;s proprietary hyaluronic acid technology. The Company&amp;#x2019;s orthopedic medicine portfolio is comprised of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States, among others) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) and foreign regulations and approval requirements, as well as the ability to grow the Company&amp;#x2019;s business through appropriate commercial strategies.&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717721" unitRef="iso4217-usd">-23659000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717722" unitRef="iso4217-usd">1903000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717712" unitRef="iso4217-usd">-4618000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717713" unitRef="iso4217-usd">-12902000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717703" unitRef="iso4217-usd">6643000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717704" unitRef="iso4217-usd">14884000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717671" unitRef="iso4217-usd">15510000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717672" unitRef="iso4217-usd">11335000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717627" unitRef="iso4217-usd">8615000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717628" unitRef="iso4217-usd">7819000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263923">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;3.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt;  &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recently Issued&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&lt;div style="display: inline; background-color: white"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 supersedes the revenue recognition requirements in &amp;#x201c;Topic 605, Revenue Recognition&amp;#x201d; and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. &lt;/div&gt;In July 2015, the FASB issued a deferral of ASU 2014-09 of one year making it effective for annual reporting periods beginning on or after December 15, 2017 while also providing for early adoption not to occur before the original effective date. The Company is assessing the appropriate method for implementing ASU 2014-09, as well as the impact the adoption of ASU 2014-09 will have on its consolidated financial statements.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white"&gt;&amp;nbsp;&lt;/div&gt;  &lt;!-- Field: Page; Sequence: 6; Value: 2 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU 2016-02 amends existing leasing accounting requirements. The most significant change will result in the recognition of lease assets and lease liabilities by lessees for virtually all leases. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. ASU 2016-02 is effective for fiscal years and interim periods beginning after December 15, 2018. Upon adoption, entities are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. Early adoption is permitted, and a number of optional practical expedients may be elected to simplify the impact of adoption. The Company is evaluating the impact of adopting this guidance.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;In March 2016, the FASB issued ASU No. 2016-09, Compensation (Topic 718) Stock Compensation. ASU 2016-09 identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. Early adoption is permitted. The Company is assessing ASU 2016-09 and the impact that adopting this new accounting standard will have on its consolidated financial statements and footnote disclosures.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recently Adopted&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;In July 2015, the FASB issued ASU No. 2015-11,&amp;nbsp;Inventory (Topic 330) Simplifying the Measurement of Inventory. ASU 2015-11 more closely aligns the measurement of inventory in US GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business less reasonably predictable costs of completion, disposal, and transportation. The provisions of ASU 2015-11 are effective for annual and interim periods beginning after December 15, 2016. ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of this amendment did not have a material impact on the Company&amp;#x2019;s financial position or results of operations.&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:NumberOfReportableSegments contextRef="d_2016-01-01_2016-06-30" decimals="INF" id="c7718091" unitRef="xbrli-pure">1</us-gaap:NumberOfReportableSegments>
  <us-gaap:OpenTaxYear contextRef="d_2016-01-01_2016-06-30_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember_TaxPeriodAxis-EarliestTaxYearMember" id="c7718078">2012</us-gaap:OpenTaxYear>
  <us-gaap:OpenTaxYear contextRef="d_2016-01-01_2016-06-30_IncomeTaxAuthorityAxis-ForeignCountryMember_IncomeTaxAuthorityNameAxis-MinistryOfEconomicAffairsAndFinanceItalyMember_TaxPeriodAxis-EarliestTaxYearMember" id="c7718079">2010</us-gaap:OpenTaxYear>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717611" unitRef="iso4217-usd">13469000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717612" unitRef="iso4217-usd">12429000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717613" unitRef="iso4217-usd">24178000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717614" unitRef="iso4217-usd">17933000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2016-06-30" decimals="-3" id="c7718027" unitRef="iso4217-usd">744000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="-3" id="c7718028" unitRef="iso4217-usd">438000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="d_2016-04-01_2016-06-30" id="c7717654" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717655" unitRef="iso4217-usd">-3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="d_2016-01-01_2016-06-30" id="c7717656" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717657" unitRef="iso4217-usd">-3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717658" unitRef="iso4217-usd">-536000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717659" unitRef="iso4217-usd">420000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717660" unitRef="iso4217-usd">238000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717661" unitRef="iso4217-usd">-1828000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717662" unitRef="iso4217-usd">-536000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717663" unitRef="iso4217-usd">417000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717664" unitRef="iso4217-usd">238000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717665" unitRef="iso4217-usd">-1831000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="i_2016-06-30" decimals="-3" id="c7717541" unitRef="iso4217-usd">1173000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="i_2015-12-31" decimals="-3" id="c7717542" unitRef="iso4217-usd">781000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="d_2016-02-26_2016-02-26_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember" decimals="-5" id="c7717919" unitRef="iso4217-usd">25000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717715" unitRef="iso4217-usd">25000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="d_2015-01-01_2015-06-30" id="c7717716" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717708" unitRef="iso4217-usd">22499000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717709" unitRef="iso4217-usd">22018000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717710" unitRef="iso4217-usd">9869000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717711" unitRef="iso4217-usd">1134000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2016-06-30" decimals="INF" id="c7717554" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c7717555" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2016-06-30" decimals="INF" id="c7717556" unitRef="xbrli-shares">1250000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2015-12-31" decimals="INF" id="c7717557" unitRef="xbrli-shares">1250000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2016-06-30" decimals="INF" id="c7717558" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="i_2015-12-31" decimals="INF" id="c7717559" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2016-06-30" decimals="INF" id="c7717560" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="i_2015-12-31" decimals="INF" id="c7717561" unitRef="xbrli-shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue contextRef="i_2016-06-30" id="c7717552" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PreferredStockValue contextRef="i_2015-12-31" id="c7717553" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2016-06-30" decimals="-3" id="c7717517" unitRef="iso4217-usd">1158000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2015-12-31" decimals="-3" id="c7717518" unitRef="iso4217-usd">1385000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717706" unitRef="iso4217-usd">27750000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717707" unitRef="iso4217-usd">10250000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717717" unitRef="iso4217-usd">922000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717718" unitRef="iso4217-usd">969000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProductWarrantyAccrual contextRef="i_2016-06-30" decimals="INF" id="c7718034" unitRef="iso4217-usd">0</us-gaap:ProductWarrantyAccrual>
  <us-gaap:ProductWarrantyAccrual contextRef="i_2015-12-31" decimals="INF" id="c7718036" unitRef="iso4217-usd">0</us-gaap:ProductWarrantyAccrual>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2016-06-30" decimals="-3" id="c7717521" unitRef="iso4217-usd">49198000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2015-12-31" decimals="-3" id="c7717522" unitRef="iso4217-usd">40108000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717680" unitRef="iso4217-usd">52000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="d_2015-01-01_2015-06-30" id="c7717681" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717599" unitRef="iso4217-usd">2792000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717600" unitRef="iso4217-usd">1812000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717601" unitRef="iso4217-usd">4951000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717602" unitRef="iso4217-usd">3910000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2016-06-30" decimals="-3" id="c7717576" unitRef="iso4217-usd">151172000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2015-12-31" decimals="-3" id="c7717577" unitRef="iso4217-usd">135662000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717582" unitRef="iso4217-usd">26575000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717583" unitRef="iso4217-usd">22898000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717584" unitRef="iso4217-usd">48853000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717585" unitRef="iso4217-usd">38413000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-04-01_2016-06-30_ProductOrServiceAxis-OrthobiologicsMember" decimals="-3" id="c7718095" unitRef="iso4217-usd">23304000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-04-01_2015-06-30_ProductOrServiceAxis-OrthobiologicsMember" decimals="-3" id="c7718096" unitRef="iso4217-usd">19283000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-06-30_ProductOrServiceAxis-OrthobiologicsMember" decimals="-3" id="c7718097" unitRef="iso4217-usd">42891000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-01-01_2015-06-30_ProductOrServiceAxis-OrthobiologicsMember" decimals="-3" id="c7718098" unitRef="iso4217-usd">31255000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-04-01_2016-06-30_ProductOrServiceAxis-SurgicalMember" decimals="-3" id="c7718099" unitRef="iso4217-usd">1433000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-04-01_2015-06-30_ProductOrServiceAxis-SurgicalMember" decimals="-3" id="c7718100" unitRef="iso4217-usd">1647000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-06-30_ProductOrServiceAxis-SurgicalMember" decimals="-3" id="c7718101" unitRef="iso4217-usd">2751000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-01-01_2015-06-30_ProductOrServiceAxis-SurgicalMember" decimals="-3" id="c7718102" unitRef="iso4217-usd">3037000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-04-01_2016-06-30_ProductOrServiceAxis-DermalMember" decimals="-3" id="c7718103" unitRef="iso4217-usd">582000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-04-01_2015-06-30_ProductOrServiceAxis-DermalMember" decimals="-3" id="c7718104" unitRef="iso4217-usd">303000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-06-30_ProductOrServiceAxis-DermalMember" decimals="-3" id="c7718105" unitRef="iso4217-usd">963000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-01-01_2015-06-30_ProductOrServiceAxis-DermalMember" decimals="-3" id="c7718106" unitRef="iso4217-usd">719000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-04-01_2016-06-30_ProductOrServiceAxis-OtherMember" decimals="-3" id="c7718107" unitRef="iso4217-usd">1256000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-04-01_2015-06-30_ProductOrServiceAxis-OtherMember" decimals="-3" id="c7718108" unitRef="iso4217-usd">1665000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2016-01-01_2016-06-30_ProductOrServiceAxis-OtherMember" decimals="-3" id="c7718109" unitRef="iso4217-usd">2248000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="d_2015-01-01_2015-06-30_ProductOrServiceAxis-OtherMember" decimals="-3" id="c7718110" unitRef="iso4217-usd">3402000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717590" unitRef="iso4217-usd">26581000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717591" unitRef="iso4217-usd">22904000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717592" unitRef="iso4217-usd">48864000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717593" unitRef="iso4217-usd">38424000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-04-01_2016-06-30_StatementGeographicalAxis-US" decimals="-3" id="c7718116" unitRef="iso4217-usd">21895000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-04-01_2015-06-30_StatementGeographicalAxis-US" decimals="-3" id="c7718118" unitRef="iso4217-usd">19218000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-04-01_2016-06-30_StatementGeographicalAxis-EuropeMember" decimals="-3" id="c7718120" unitRef="iso4217-usd">2977000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-04-01_2015-06-30_StatementGeographicalAxis-EuropeMember" decimals="-3" id="c7718122" unitRef="iso4217-usd">2331000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-04-01_2016-06-30_StatementGeographicalAxis-OtherLocationMember" decimals="-3" id="c7718124" unitRef="iso4217-usd">1709000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-04-01_2015-06-30_StatementGeographicalAxis-OtherLocationMember" decimals="-3" id="c7718126" unitRef="iso4217-usd">1355000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-01-01_2016-06-30_StatementGeographicalAxis-US" decimals="-3" id="c7718133" unitRef="iso4217-usd">39906000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-06-30_StatementGeographicalAxis-US" decimals="-3" id="c7718135" unitRef="iso4217-usd">31809000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-01-01_2016-06-30_StatementGeographicalAxis-EuropeMember" decimals="-3" id="c7718137" unitRef="iso4217-usd">5542000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-06-30_StatementGeographicalAxis-EuropeMember" decimals="-3" id="c7718139" unitRef="iso4217-usd">4317000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2016-01-01_2016-06-30_StatementGeographicalAxis-OtherLocationMember" decimals="-3" id="c7718141" unitRef="iso4217-usd">3416000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueNet contextRef="d_2015-01-01_2015-06-30_StatementGeographicalAxis-OtherLocationMember" decimals="-3" id="c7718143" unitRef="iso4217-usd">2298000</us-gaap:SalesRevenueNet>
  <us-gaap:SalesRevenueServicesNet contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717586" unitRef="iso4217-usd">6000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717587" unitRef="iso4217-usd">6000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717588" unitRef="iso4217-usd">11000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717589" unitRef="iso4217-usd">11000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Compensation and related expenses&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;2,416&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;3,082&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Facility construction costs&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,769&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;415&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Research grants&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;481&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;381&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Professional fees&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;889&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;210&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Clinical trial costs&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;339&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;252&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;744&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;438&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;6,638&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;4,778&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended June 30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended June 30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Shares used in the calculation of basic earnings per share&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,679&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,961&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,778&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;14,934&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Effect of dilutive securities:&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Stock options, SARs, and RSAs&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;432&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;375&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;432&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;398&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt"&gt;Diluted shares used in the calculation of earnings per share&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;15,111&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;15,336&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;15,210&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;15,332&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfGoodwillTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended &lt;br /&gt; June 30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Twelve Months &lt;br /&gt; Ended December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Balance, beginning&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;7,482&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;8,339&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Effect of foreign currency adjustments&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;86&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;(857&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;Balance, ending&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;7,568&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;7,482&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;June 30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Raw materials&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;6,812&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;5,780&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Work-in-process&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;6,140&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,656&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;4,312&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3,502&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;17,264&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;14,938&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended June 30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended June 30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Orthobiologics&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;23,304&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;19,283&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;42,891&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;31,255&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Surgical&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,433&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,647&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,751&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,037&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Dermal&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;582&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;303&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;963&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;719&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,256&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,665&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,248&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3,402&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt"&gt;Product Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;26,575&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;22,898&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;48,853&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;38,413&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2016-01-01_2016-06-30" id="c-16">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended June 30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Risk free interest rate&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;0.94%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt; -&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;1.40%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1.15%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt; -&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;1.46%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;49.47%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt; -&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;51.61%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;53.15%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt; -&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;54.65%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Expected life (years)&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 4%; font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-size: 10pt; text-align: center"&gt;4.5&lt;/td&gt; &lt;td style="width: 3%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 2%; font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; font-size: 10pt; text-align: center"&gt;4.5&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Expected dividend yield&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;0.00%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: center"&gt;0.00%&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="d_2016-01-01_2016-06-30" id="s263943">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;15.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Segment and Geographic Information&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-size: 10pt; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;The Company has one reportable operating segment, for the purposes of assessing performance and deciding how to allocate resources.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Product revenue by product group is as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended June 30,&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended June 30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left"&gt;Orthobiologics&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;23,304&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;19,283&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;42,891&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;31,255&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Surgical&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,433&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;1,647&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,751&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;3,037&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;Dermal&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;582&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;303&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;963&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;719&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,256&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,665&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,248&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3,402&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt"&gt;Product Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;26,575&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;22,898&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;48,853&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;38,413&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"&gt;Total revenue by geographic location and as a percentage of overall total revenue for the three-month periods ended June 30, 2016 and 2015 are as follows:&lt;/div&gt; &lt;div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Three Months Ended June 30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Geographic Location:&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left; text-indent: 10pt"&gt;United States&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;21,895&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;82&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;19,218&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;84&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Europe&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,977&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;2,331&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;10&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,709&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;1,355&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;6&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt"&gt;Total Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;26,581&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;100&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;22,904&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;100&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Six Months Ended June 30,&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2016&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2015&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;Percentage of&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;Revenue&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Geographic Location:&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 48%; font-size: 10pt; text-align: left; text-indent: 10pt"&gt;United States&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;39,906&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;82&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;31,809&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;83&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; text-indent: 10pt"&gt;Europe&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;5,542&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;4,317&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: right"&gt;11&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt"&gt;Other&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;3,416&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;7&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;2,298&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;6&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt"&gt;Total&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;48,864&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;100&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;38,424&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-size: 10pt; padding-bottom: 2.25pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right"&gt;100&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717603" unitRef="iso4217-usd">4255000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717604" unitRef="iso4217-usd">3388000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717605" unitRef="iso4217-usd">8245000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717606" unitRef="iso4217-usd">6993000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717676" unitRef="iso4217-usd">1478000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717677" unitRef="iso4217-usd">1064000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-PlanMember" id="c7717861">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-PlanMember" id="c7717879">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-PlanMember" id="c7717880">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-PlanMember" decimals="INF" id="c7717877" unitRef="xbrli-shares">46300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-PlanMember_TitleOfIndividualAxis-BoardOfDirectorsMember" decimals="INF" id="c7717878" unitRef="xbrli-shares">11805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="d_2016-04-01_2016-06-30_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsMember" decimals="-5" id="c7717860" unitRef="iso4217-usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="d_2015-04-01_2015-06-30_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsMember" decimals="-5" id="c7717862" unitRef="iso4217-usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsMember" decimals="-5" id="c7717868" unitRef="iso4217-usd">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="d_2015-01-01_2015-06-30_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsMember" decimals="-5" id="c7717869" unitRef="iso4217-usd">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2016-01-01_2016-06-30" decimals="4" id="c7717903" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2015-01-01_2015-06-30" decimals="4" id="c7717906" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2016-01-01_2016-06-30_RangeAxis-MinimumMember" decimals="4" id="c7717890" unitRef="xbrli-pure">0.4947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2016-01-01_2016-06-30_RangeAxis-MaximumMember" decimals="4" id="c7717892" unitRef="xbrli-pure">0.5161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2015-01-01_2015-06-30_RangeAxis-MinimumMember" decimals="4" id="c7717893" unitRef="xbrli-pure">0.5315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2015-01-01_2015-06-30_RangeAxis-MaximumMember" decimals="4" id="c7717895" unitRef="xbrli-pure">0.5465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2016-01-01_2016-06-30_RangeAxis-MinimumMember" decimals="4" id="c7717884" unitRef="xbrli-pure">0.0094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2016-01-01_2016-06-30_RangeAxis-MaximumMember" decimals="4" id="c7717886" unitRef="xbrli-pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-01-01_2015-06-30_RangeAxis-MinimumMember" decimals="4" id="c7717887" unitRef="xbrli-pure">0.0115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-01-01_2015-06-30_RangeAxis-MaximumMember" decimals="4" id="c7717889" unitRef="xbrli-pure">0.0146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2016-04-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-PlanMember" decimals="INF" id="c7717874" unitRef="xbrli-shares">43000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-PlanMember" decimals="INF" id="c7717876" unitRef="xbrli-shares">331705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2016-01-01_2016-06-30" id="c7717897">P4Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2015-01-01_2015-06-30" id="c7717900">P4Y182D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="i_2016-02-26_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember_StatementEquityComponentsAxis-CommonStockMember" decimals="-5" id="c7717918" unitRef="iso4217-usd">25000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
  <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="i_2016-06-30_BalanceSheetLocationAxis-AdditionalPaidInCapitalMember_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember" decimals="-5" id="c7717925" unitRef="iso4217-usd">7500000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="d_2016-02-29_2016-02-29_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember" decimals="INF" id="c7717920" unitRef="xbrli-shares">377155</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-gaap:StockholdersEquity contextRef="i_2016-06-30" decimals="-3" id="c7717578" unitRef="iso4217-usd">204416000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31" decimals="-3" id="c7717579" unitRef="iso4217-usd">210848000</us-gaap:StockholdersEquity>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717934" unitRef="xbrli-shares">432000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717935" unitRef="xbrli-shares">375000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717936" unitRef="xbrli-shares">432000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717937" unitRef="xbrli-shares">398000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717645" unitRef="xbrli-shares">15111000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717646" unitRef="xbrli-shares">15336000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717647" unitRef="xbrli-shares">15210000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717648" unitRef="xbrli-shares">15332000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2016-04-01_2016-06-30" decimals="-3" id="c7717636" unitRef="xbrli-shares">14679000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2015-04-01_2015-06-30" decimals="-3" id="c7717637" unitRef="xbrli-shares">14961000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2016-01-01_2016-06-30" decimals="-3" id="c7717638" unitRef="xbrli-shares">14778000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2015-01-01_2015-06-30" decimals="-3" id="c7717639" unitRef="xbrli-shares">14934000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="utr-sqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2015-01-01_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anik:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_ProductOrServiceAxis-DermalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:DermalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_ProductOrServiceAxis-OrthobiologicsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:OrthobiologicsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_ProductOrServiceAxis-OtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:OtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_ProductOrServiceAxis-SurgicalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:SurgicalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_StatementGeographicalAxis-EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_StatementGeographicalAxis-OtherLocationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">anik:OtherLocationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-06-30_StatementGeographicalAxis-US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anik:ElevessTradeNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anik:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_ProductOrServiceAxis-DermalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:DermalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_ProductOrServiceAxis-OrthobiologicsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:OrthobiologicsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_ProductOrServiceAxis-OtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:OtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_ProductOrServiceAxis-SurgicalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:SurgicalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_StatementGeographicalAxis-EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_StatementGeographicalAxis-OtherLocationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">anik:OtherLocationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-04-01_2015-06-30_StatementGeographicalAxis-US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-10-09_2015-10-09_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anik:EuropeanHeadquartersFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-09</xbrli:startDate>
      <xbrli:endDate>2015-10-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-10-09_2016-03-31_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anik:EuropeanHeadquartersFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-09</xbrli:startDate>
      <xbrli:endDate>2016-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anik:PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anik:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockMember_PlanNameAxis-PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anik:PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anik:PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_AwardTypeAxis-RestrictedStockUnitsRSUMember_PlanNameAxis-PlanMember_TitleOfIndividualAxis-BoardOfDirectorsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anik:PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">anik:BoardOfDirectorsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_IncomeTaxAuthorityAxis-DomesticCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember_TaxPeriodAxis-EarliestTaxYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_IncomeTaxAuthorityAxis-ForeignCountryMember_IncomeTaxAuthorityNameAxis-MinistryOfEconomicAffairsAndFinanceItalyMember_TaxPeriodAxis-EarliestTaxYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_ProductOrServiceAxis-DermalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:DermalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_ProductOrServiceAxis-OrthobiologicsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:OrthobiologicsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_ProductOrServiceAxis-OtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:OtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_ProductOrServiceAxis-SurgicalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:SurgicalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_StatementGeographicalAxis-EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_StatementGeographicalAxis-OtherLocationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">anik:OtherLocationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_StatementGeographicalAxis-US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-02-26_2016-02-26_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">anik:MorganStanleyCoLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">anik:AcceleratedStockRepurchaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-26</xbrli:startDate>
      <xbrli:endDate>2016-02-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-02-29_2016-02-29_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">anik:MorganStanleyCoLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">anik:AcceleratedStockRepurchaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-29</xbrli:startDate>
      <xbrli:endDate>2016-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-02-29_2016-02-29_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">anik:MorganStanleyCoLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">anik:AcceleratedStockRepurchaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-29</xbrli:startDate>
      <xbrli:endDate>2016-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anik:PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_AwardTypeAxis-RestrictedStockAndRestrictedStockUnitsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anik:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_ProductOrServiceAxis-DermalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:DermalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_ProductOrServiceAxis-OrthobiologicsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:OrthobiologicsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_ProductOrServiceAxis-OtherMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:OtherMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_ProductOrServiceAxis-SurgicalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">anik:SurgicalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_StatementGeographicalAxis-EuropeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_StatementGeographicalAxis-OtherLocationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">anik:OtherLocationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-01_2016-06-30_StatementGeographicalAxis-US">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-06-30_2016-06-30_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">anik:MorganStanleyCoLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">anik:AcceleratedStockRepurchaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-06-30</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-10-09_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anik:EuropeanHeadquartersFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-10-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FairValueByAssetClassAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FairValueByAssetClassAxis-CertificatesOfDepositMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anik:ElevessTradeNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_InvestmentTypeAxis-CorporateDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-26_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">anik:MorganStanleyCoLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">anik:AcceleratedStockRepurchaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">anik:MorganStanleyCoLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">anik:AcceleratedStockRepurchaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_BalanceSheetLocationAxis-AdditionalPaidInCapitalMember_CounterpartyNameAxis-MorganStanleyCoLLCMember_ShareRepurchaseProgramAxis-AcceleratedStockRepurchaseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">anik:MorganStanleyCoLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">anik:AcceleratedStockRepurchaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_FairValueByAssetClassAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_FairValueByAssetClassAxis-CertificatesOfDepositMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_FairValueByAssetClassAxis-MoneyMarketFundsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DistributionRightsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-ElevessTradeNameMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anik:ElevessTradeNameMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_FiniteLivedIntangibleAssetsByMajorClassAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_InvestmentTypeAxis-CertificatesOfDepositMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-EuropeanHeadquartersFacilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">anik:EuropeanHeadquartersFacilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-07-28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000898437</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-07-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>anik-20160630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 06:06PM UTC 2016-08-01--><xsd:schema xmlns:anik="http://www.anikatherapeutics.com/20160630" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.anikatherapeutics.com/20160630">
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20160630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20160630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20160630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anik-20160630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-business" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Disclosure - Note 1 - Nature of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-presentation-" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-2-basis-of-presentation-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 2 - Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-recent-accounting-pronouncements-" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-3-recent-accounting-pronouncements-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 3 - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-investments" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 4 - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-measurements" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 5 - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-equity-incentive-plan" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 6 - Equity Incentive Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-earnings-per-share-eps" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 7 - Earnings Per Share ("EPS")</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-inventories" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 8 - Inventories</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-intangible-assets" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 9 - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-goodwill" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 10 - Goodwill</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-accrued-expenses" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Document - Note 11 - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-commitments-and-contingencies" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 12 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-leases" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 13 - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 14 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-and-geographic-information" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 15 - Segment and Geographic Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-measurements-tables" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 5 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-equity-incentive-plan-tables" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 6 - Equity Incentive Plan (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-earnings-per-share-eps-tables" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-inventories-tables" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 8 - Inventories (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-intangible-assets-tables" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 9 - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-goodwill-tables" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 10 - Goodwill (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-accrued-expenses-tables" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 11 - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-and-geographic-information-tables" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 15 - Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-business-details-textual" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 1 - Nature of Business (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-investments-details-textual" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 4 - Investments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-of-financial-instruments-details" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-of-financial-instruments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 5 - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-equity-incentive-plan-details-textual" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 6 - Equity Incentive Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 6 - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-earnings-per-share-eps-details-textual" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-basic-and-diluted-earnings-per-share-details" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-basic-and-diluted-earnings-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 7 - Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-inventories-details" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 8 - Inventories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-intangible-assets-details-textual" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 9 - Intangible Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-intangible-assets-details" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 9 - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-changes-in-the-carrying-value-of-goodwill-details" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-10-changes-in-the-carrying-value-of-goodwill-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 10 - Changes in the Carrying Value of Goodwill (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-accrued-expenses-details" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 11 - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-commitments-and-contingencies-details-textual" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-leases-details-textual" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 13 - Leases (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-income-taxes-details-textual" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 14 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-segment-and-geographic-information-details-textual" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 15 - Segment and Geographic Information (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-product-revenue-by-product-group-details" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-product-group-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 15 - Product Revenue by Product Group (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-product-revenue-by-geographic-location-details" roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-geographic-location-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 15 - Product Revenue by Geographic Location (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="anik_AcceleratedStockRepurchaseMember" name="AcceleratedStockRepurchaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="anik_AccruedResearchGrantsCurrent" name="AccruedResearchGrantsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="anik_AccumulatedCurrencyTranslationAdjustment" name="AccumulatedCurrencyTranslationAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="anik_BoardOfDirectorsMember" name="BoardOfDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation" name="BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="anik_DepositsAndOtherAssetsNoncurrent" name="DepositsAndOtherAssetsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="anik_DermalMember" name="DermalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_ElevessTradeNameMember" name="ElevessTradeNameMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_EuropeanHeadquartersFacilityMember" name="EuropeanHeadquartersFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty" name="LesseeLeasingArrangementsAbilityToWithdrawWithPenalty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty" name="LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_LesseeLeasingArrangementsInitialYearlyRent" name="LesseeLeasingArrangementsInitialYearlyRent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="anik_LesseeLeasingArrangementsNumberOfRenewalTerms" name="LesseeLeasingArrangementsNumberOfRenewalTerms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element id="anik_LesseeLeasingArrangementsRenewalTerm" name="LesseeLeasingArrangementsRenewalTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_LesseeLeasingArrangementsTermOfContract" name="LesseeLeasingArrangementsTermOfContract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_MorganStanleyCoLLCMember" name="MorganStanleyCoLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_NumberOfProductsDevelopedManufacturedAndCommercialized" name="NumberOfProductsDevelopedManufacturedAndCommercialized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="anik_OrthobiologicsMember" name="OrthobiologicsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_OtherLocationMember" name="OtherLocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_OtherMember" name="OtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_PercentageOfNetRevenue" name="PercentageOfNetRevenue" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_PlanMember" name="PlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_RestrictedStockAndRestrictedStockUnitsMember" name="RestrictedStockAndRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" name="ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" name="ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="anik_StockRepurchaseProgramPercentageRepurchased" name="StockRepurchaseProgramPercentageRepurchased" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="anik_SurgicalMember" name="SurgicalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-10-changes-in-the-carrying-value-of-goodwill-details" name="statement-statement-note-10-changes-in-the-carrying-value-of-goodwill-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-10-goodwill-tables" name="statement-statement-note-10-goodwill-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-11-accrued-expenses-details" name="statement-statement-note-11-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-11-accrued-expenses-tables" name="statement-statement-note-11-accrued-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-15-product-revenue-by-geographic-location-details" name="statement-statement-note-15-product-revenue-by-geographic-location-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-15-product-revenue-by-product-group-details" name="statement-statement-note-15-product-revenue-by-product-group-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-15-segment-and-geographic-information-tables" name="statement-statement-note-15-segment-and-geographic-information-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-5-fair-value-measurements-tables" name="statement-statement-note-5-fair-value-measurements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-5-fair-value-of-financial-instruments-details" name="statement-statement-note-5-fair-value-of-financial-instruments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" name="statement-statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-6-equity-incentive-plan-tables" name="statement-statement-note-6-equity-incentive-plan-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-7-basic-and-diluted-earnings-per-share-details" name="statement-statement-note-7-basic-and-diluted-earnings-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-7-earnings-per-share-eps-tables" name="statement-statement-note-7-earnings-per-share-eps-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-8-inventories-details" name="statement-statement-note-8-inventories-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-8-inventories-tables" name="statement-statement-note-8-inventories-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-9-intangible-assets-details" name="statement-statement-note-9-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="anik_statement-statement-note-9-intangible-assets-tables" name="statement-statement-note-9-intangible-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>anik-20160630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 06:07PM UTC 2016-08-01--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-details" xlink:href="anik-20160630.xsd#statement-note-8-inventories-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_DepositsAndOtherAssetsNoncurrent" xlink:label="anik_DepositsAndOtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="anik_DepositsAndOtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueServicesNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-details" xlink:href="anik-20160630.xsd#statement-note-11-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_AccruedClinicalTrialCostsCurrent" xlink:label="anik_AccruedClinicalTrialCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_AccruedResearchGrantsCurrent" xlink:label="anik_AccruedResearchGrantsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ConstructionPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="anik_AccruedResearchGrantsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="anik_AccruedClinicalTrialCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>anik-20160630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 06:06PM UTC 2016-08-01--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses" xlink:href="anik-20160630.xsd#statement-note-11-accrued-expenses" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill" xlink:href="anik-20160630.xsd#statement-note-10-goodwill" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories" xlink:href="anik-20160630.xsd#statement-note-8-inventories" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements" xlink:href="anik-20160630.xsd#statement-note-5-fair-value-measurements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-3-recent-accounting-pronouncements-" xlink:href="anik-20160630.xsd#statement-note-3-recent-accounting-pronouncements-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-3-recent-accounting-pronouncements-" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-2-basis-of-presentation-" xlink:href="anik-20160630.xsd#statement-note-2-basis-of-presentation-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-2-basis-of-presentation-" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-document-and-entity-information" xlink:href="anik-20160630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business" xlink:href="anik-20160630.xsd#statement-note-1-nature-of-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments" xlink:href="anik-20160630.xsd#statement-note-4-investments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan" xlink:href="anik-20160630.xsd#statement-note-6-equity-incentive-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_BoardOfDirectorsMember" xlink:label="anik_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_PlanMember" xlink:label="anik_PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="anik_PlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="anik_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps" xlink:href="anik-20160630.xsd#statement-note-7-earnings-per-share-eps" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_AcceleratedStockRepurchaseMember" xlink:label="anik_AcceleratedStockRepurchaseMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_MorganStanleyCoLLCMember" xlink:label="anik_MorganStanleyCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="anik_AcceleratedStockRepurchaseMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="anik_MorganStanleyCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets" xlink:href="anik-20160630.xsd#statement-note-9-intangible-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies" xlink:href="anik-20160630.xsd#statement-note-12-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases" xlink:href="anik-20160630.xsd#statement-note-13-leases" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_EuropeanHeadquartersFacilityMember" xlink:label="anik_EuropeanHeadquartersFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="anik_EuropeanHeadquartersFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes" xlink:href="anik-20160630.xsd#statement-note-14-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:label="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information" xlink:href="anik-20160630.xsd#statement-note-15-segment-and-geographic-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements-tables" xlink:href="anik-20160630.xsd#statement-note-5-fair-value-measurements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-tables" xlink:href="anik-20160630.xsd#statement-note-6-equity-incentive-plan-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-tables" xlink:href="anik-20160630.xsd#statement-note-7-earnings-per-share-eps-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-tables" xlink:href="anik-20160630.xsd#statement-note-8-inventories-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-tables" xlink:href="anik-20160630.xsd#statement-note-9-intangible-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:label="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill-tables" xlink:href="anik-20160630.xsd#statement-note-10-goodwill-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-tables" xlink:href="anik-20160630.xsd#statement-note-11-accrued-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-tables" xlink:href="anik-20160630.xsd#statement-note-15-segment-and-geographic-information-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:label="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business-details-textual" xlink:href="anik-20160630.xsd#statement-note-1-nature-of-business-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NumberOfProductsDevelopedManufacturedAndCommercialized" xlink:label="anik_NumberOfProductsDevelopedManufacturedAndCommercialized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_NumberOfProductsDevelopedManufacturedAndCommercialized" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments-details-textual" xlink:href="anik-20160630.xsd#statement-note-4-investments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-details-textual" xlink:href="anik-20160630.xsd#statement-note-6-equity-incentive-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_BoardOfDirectorsMember" xlink:label="anik_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_PlanMember" xlink:label="anik_PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="anik_PlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="anik_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-details-textual" xlink:href="anik-20160630.xsd#statement-note-7-earnings-per-share-eps-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_AcceleratedStockRepurchaseMember" xlink:label="anik_AcceleratedStockRepurchaseMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_MorganStanleyCoLLCMember" xlink:label="anik_MorganStanleyCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_StockRepurchaseProgramPercentageRepurchased" xlink:label="anik_StockRepurchaseProgramPercentageRepurchased" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="anik_AcceleratedStockRepurchaseMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="anik_MorganStanleyCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_StockRepurchaseProgramPercentageRepurchased" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details-textual" xlink:href="anik-20160630.xsd#statement-note-9-intangible-assets-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:href="anik-20160630.xsd#statement-note-12-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProductWarrantyAccrual" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases-details-textual" xlink:href="anik-20160630.xsd#statement-note-13-leases-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation" xlink:label="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_EuropeanHeadquartersFacilityMember" xlink:label="anik_EuropeanHeadquartersFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty" xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty" xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsInitialYearlyRent" xlink:label="anik_LesseeLeasingArrangementsInitialYearlyRent" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsNumberOfRenewalTerms" xlink:label="anik_LesseeLeasingArrangementsNumberOfRenewalTerms" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsRenewalTerm" xlink:label="anik_LesseeLeasingArrangementsRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsTermOfContract" xlink:label="anik_LesseeLeasingArrangementsTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="anik_EuropeanHeadquartersFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsNumberOfRenewalTerms" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsRenewalTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsInitialYearlyRent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConstructionInProgressGross" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes-details-textual" xlink:href="anik-20160630.xsd#statement-note-14-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:label="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-details-textual" xlink:href="anik-20160630.xsd#statement-note-15-segment-and-geographic-information-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-details" xlink:href="anik-20160630.xsd#statement-note-8-inventories-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_DepositsAndOtherAssetsNoncurrent" xlink:label="anik_DepositsAndOtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="anik_DepositsAndOtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:href="anik-20160630.xsd#statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueServicesNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:href="anik-20160630.xsd#statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details" xlink:href="anik-20160630.xsd#statement-note-9-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_AccumulatedCurrencyTranslationAdjustment" xlink:label="anik_AccumulatedCurrencyTranslationAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_ElevessTradeNameMember" xlink:label="anik_ElevessTradeNameMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="us-gaap_DistributionRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DistributionRightsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="anik_ElevessTradeNameMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccumulatedCurrencyTranslationAdjustment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:href="anik-20160630.xsd#statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-details" xlink:href="anik-20160630.xsd#statement-note-11-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_AccruedClinicalTrialCostsCurrent" xlink:label="anik_AccruedClinicalTrialCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_AccruedResearchGrantsCurrent" xlink:label="anik_AccruedResearchGrantsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConstructionPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccruedResearchGrantsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccruedClinicalTrialCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-product-group-details" xlink:href="anik-20160630.xsd#statement-note-15-product-revenue-by-product-group-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-product-group-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_DermalMember" xlink:label="anik_DermalMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_OrthobiologicsMember" xlink:label="anik_OrthobiologicsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_OtherMember" xlink:label="anik_OtherMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_SurgicalMember" xlink:label="anik_SurgicalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="anik_OrthobiologicsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="anik_SurgicalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="anik_DermalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="anik_OtherMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-of-financial-instruments-details" xlink:href="anik-20160630.xsd#statement-note-5-fair-value-of-financial-instruments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-of-financial-instruments-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-geographic-location-details" xlink:href="anik-20160630.xsd#statement-note-15-product-revenue-by-geographic-location-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-geographic-location-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_OtherLocationMember" xlink:label="anik_OtherLocationMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_PercentageOfNetRevenue" xlink:label="anik_PercentageOfNetRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="us-gaap_EuropeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_EuropeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="anik_OtherLocationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_PercentageOfNetRevenue" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>anik-20160630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 06:06PM UTC 2016-08-01--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_DocumentAndEntityInformation" xlink:label="anik_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="anik_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_DocumentAndEntityInformation" xlink:to="anik_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research &amp; development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="anik_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="anik_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-5-fair-value-measurements-tables" xlink:label="anik_statement-statement-note-5-fair-value-measurements-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-5-fair-value-measurements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5fairvaluemeasurementstables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-5-fair-value-measurements-tables" xlink:to="anik_statement-statement-note-5-fair-value-measurements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:label="anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-6-equity-incentive-plan-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6equityincentiveplantables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:to="anik_statement-statement-note-6-equity-incentive-plan-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:label="anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-7-earnings-per-share-eps-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7earningspershareepstables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:to="anik_statement-statement-note-7-earnings-per-share-eps-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-8-inventories-tables" xlink:label="anik_statement-statement-note-8-inventories-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-8-inventories-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote8inventoriestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-8-inventories-tables" xlink:to="anik_statement-statement-note-8-inventories-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-9-intangible-assets-tables" xlink:label="anik_statement-statement-note-9-intangible-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-9-intangible-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote9intangibleassetstables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-9-intangible-assets-tables" xlink:to="anik_statement-statement-note-9-intangible-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-10-goodwill-tables" xlink:label="anik_statement-statement-note-10-goodwill-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-10-goodwill-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote10goodwilltables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-10-goodwill-tables" xlink:to="anik_statement-statement-note-10-goodwill-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-11-accrued-expenses-tables" xlink:label="anik_statement-statement-note-11-accrued-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-11-accrued-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote11accruedexpensestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-11-accrued-expenses-tables" xlink:to="anik_statement-statement-note-11-accrued-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-15-segment-and-geographic-information-tables" xlink:label="anik_statement-statement-note-15-segment-and-geographic-information-tables" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-15-segment-and-geographic-information-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote15segmentandgeographicinformationtables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-15-segment-and-geographic-information-tables" xlink:to="anik_statement-statement-note-15-segment-and-geographic-information-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-5-fair-value-of-financial-instruments-details" xlink:label="anik_statement-statement-note-5-fair-value-of-financial-instruments-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-5-fair-value-of-financial-instruments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5fairvalueoffinancialinstrumentsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-5-fair-value-of-financial-instruments-details" xlink:to="anik_statement-statement-note-5-fair-value-of-financial-instruments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:label="anik_statement-statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6assumptionsusedtoestimatefairvalueofstockoptionsandstockappreciationrightsawardsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:to="anik_statement-statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:label="anik_statement-statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-7-basic-and-diluted-earnings-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7basicanddilutedearningspersharedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:to="anik_statement-statement-note-7-basic-and-diluted-earnings-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-8-inventories-details" xlink:label="anik_statement-statement-note-8-inventories-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-8-inventories-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote8inventoriesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-8-inventories-details" xlink:to="anik_statement-statement-note-8-inventories-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-9-intangible-assets-details" xlink:label="anik_statement-statement-note-9-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-9-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote9intangibleassetsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-9-intangible-assets-details" xlink:to="anik_statement-statement-note-9-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash Investing Activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:label="anik_statement-statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-10-changes-in-the-carrying-value-of-goodwill-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote10changesinthecarryingvalueofgoodwilldetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:to="anik_statement-statement-note-10-changes-in-the-carrying-value-of-goodwill-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-15-product-revenue-by-product-group-details" xlink:label="anik_statement-statement-note-15-product-revenue-by-product-group-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-15-product-revenue-by-product-group-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote15productrevenuebyproductgroupdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-15-product-revenue-by-product-group-details" xlink:to="anik_statement-statement-note-15-product-revenue-by-product-group-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-11-accrued-expenses-details" xlink:label="anik_statement-statement-note-11-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-11-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote11accruedexpensesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-11-accrued-expenses-details" xlink:to="anik_statement-statement-note-11-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatements" xlink:label="anik_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="anik_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_NotesToFinancialStatements" xlink:to="anik_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-15-product-revenue-by-geographic-location-details" xlink:label="anik_statement-statement-note-15-product-revenue-by-geographic-location-details" xlink:type="locator"/>
    <link:label xlink:label="anik_statement-statement-note-15-product-revenue-by-geographic-location-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote15productrevenuebygeographiclocationdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_statement-statement-note-15-product-revenue-by-geographic-location-details" xlink:to="anik_statement-statement-note-15-product-revenue-by-geographic-location-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="anik_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="anik_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProvisionForDoubtfulAccounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for doubtful accounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general &amp; administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_AccumulatedCurrencyTranslationAdjustment" xlink:label="anik_AccumulatedCurrencyTranslationAdjustment" xlink:type="locator"/>
    <link:label xlink:label="anik_AccumulatedCurrencyTranslationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_AccumulatedCurrencyTranslationAdjustment</link:label>
    <link:label xlink:label="anik_AccumulatedCurrencyTranslationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Currency Translation Adjustment</link:label>
    <link:label xlink:label="anik_AccumulatedCurrencyTranslationAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of the accumulated currency translation adjustment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_AccumulatedCurrencyTranslationAdjustment" xlink:to="anik_AccumulatedCurrencyTranslationAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsNumberOfRenewalTerms" xlink:label="anik_LesseeLeasingArrangementsNumberOfRenewalTerms" xlink:type="locator"/>
    <link:label xlink:label="anik_LesseeLeasingArrangementsNumberOfRenewalTerms-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_LesseeLeasingArrangementsNumberOfRenewalTerms</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsNumberOfRenewalTerms-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Number of Renewal Terms</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsNumberOfRenewalTerms-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of renewal terms of a leasing arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_LesseeLeasingArrangementsNumberOfRenewalTerms" xlink:to="anik_LesseeLeasingArrangementsNumberOfRenewalTerms-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_EuropeanHeadquartersFacilityMember" xlink:label="anik_EuropeanHeadquartersFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="anik_EuropeanHeadquartersFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Headquarters Facility [Member]</link:label>
    <link:label xlink:label="anik_EuropeanHeadquartersFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A build-to-suit lease agreement for a new European headquarters facility, consisting of approximately 25,000 square feet of general office, research and development, training, and warehousing space located in Padova, Italy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_EuropeanHeadquartersFacilityMember" xlink:to="anik_EuropeanHeadquartersFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on securities, net of tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsTermOfContract" xlink:label="anik_LesseeLeasingArrangementsTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="anik_LesseeLeasingArrangementsTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_LesseeLeasingArrangementsTermOfContract</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Term of Contract</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_LesseeLeasingArrangementsTermOfContract" xlink:to="anik_LesseeLeasingArrangementsTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsRenewalTerm" xlink:label="anik_LesseeLeasingArrangementsRenewalTerm" xlink:type="locator"/>
    <link:label xlink:label="anik_LesseeLeasingArrangementsRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_LesseeLeasingArrangementsRenewalTerm</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements, Renewal Term</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_LesseeLeasingArrangementsRenewalTerm" xlink:to="anik_LesseeLeasingArrangementsRenewalTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_DepositsAndOtherAssetsNoncurrent" xlink:label="anik_DepositsAndOtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="anik_DepositsAndOtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term deposits and other</link:label>
    <link:label xlink:label="anik_DepositsAndOtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents deposits and other assets, noncurrent.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_DepositsAndOtherAssetsNoncurrent" xlink:to="anik_DepositsAndOtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="us-gaap_EuropeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EuropeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EuropeMember" xlink:to="us-gaap_EuropeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AmortizationOfIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepreciationAndAmortization</link:label>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:label="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:label xlink:label="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of finite-lived and indefinite-lived intangible assets by major class.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:to="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_PlanMember" xlink:label="anik_PlanMember" xlink:type="locator"/>
    <link:label xlink:label="anik_PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan [Member]</link:label>
    <link:label xlink:label="anik_PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Anika Therapeutics, Inc. Second Amended and Restated Stock Option and Incentive Plan, as amended, (the &#8220;Plan&#8221;)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_PlanMember" xlink:to="anik_PlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, other current and long-term assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_AccruedClinicalTrialCostsCurrent" xlink:label="anik_AccruedClinicalTrialCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="anik_AccruedClinicalTrialCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_AccruedClinicalTrialCostsCurrent</link:label>
    <link:label xlink:label="anik_AccruedClinicalTrialCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label xlink:label="anik_AccruedClinicalTrialCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued clinical trial costs current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_AccruedClinicalTrialCostsCurrent" xlink:to="anik_AccruedClinicalTrialCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EarningsPerShareDiluted</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EarningsPerShareBasic</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_AccruedResearchGrantsCurrent" xlink:label="anik_AccruedResearchGrantsCurrent" xlink:type="locator"/>
    <link:label xlink:label="anik_AccruedResearchGrantsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_AccruedResearchGrantsCurrent</link:label>
    <link:label xlink:label="anik_AccruedResearchGrantsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research grants</link:label>
    <link:label xlink:label="anik_AccruedResearchGrantsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued research grants current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_AccruedResearchGrantsCurrent" xlink:to="anik_AccruedResearchGrantsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDilutedAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted net income per share:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_StockRepurchaseProgramPercentageRepurchased" xlink:label="anik_StockRepurchaseProgramPercentageRepurchased" xlink:type="locator"/>
    <link:label xlink:label="anik_StockRepurchaseProgramPercentageRepurchased-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_StockRepurchaseProgramPercentageRepurchased</link:label>
    <link:label xlink:label="anik_StockRepurchaseProgramPercentageRepurchased-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Percentage Repurchased</link:label>
    <link:label xlink:label="anik_StockRepurchaseProgramPercentageRepurchased-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of shares repurchased under the stock repurchase program.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_StockRepurchaseProgramPercentageRepurchased" xlink:to="anik_StockRepurchaseProgramPercentageRepurchased-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in the calculation of basic earnings per share (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, SARs, and RSAs (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted shares used in the calculation of earnings per share (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueServicesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing, milestone and contract revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNet" xlink:to="us-gaap_SalesRevenueServicesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NumberOfProductsDevelopedManufacturedAndCommercialized" xlink:label="anik_NumberOfProductsDevelopedManufacturedAndCommercialized" xlink:type="locator"/>
    <link:label xlink:label="anik_NumberOfProductsDevelopedManufacturedAndCommercialized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_NumberOfProductsDevelopedManufacturedAndCommercialized</link:label>
    <link:label xlink:label="anik_NumberOfProductsDevelopedManufacturedAndCommercialized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Products Developed, Manufactured, and Commercialized</link:label>
    <link:label xlink:label="anik_NumberOfProductsDevelopedManufacturedAndCommercialized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of products the Company has developed, manufactured, and commercialized throughout the course of its existence.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_NumberOfProductsDevelopedManufacturedAndCommercialized" xlink:to="anik_NumberOfProductsDevelopedManufacturedAndCommercialized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecurities</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic net income per share:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SalesRevenueNet</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label xlink:label="us-gaap_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InternalRevenueServiceIRSMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:label="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ministry of Economic Affairs and Finance, Italy [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:to="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_ElevessTradeNameMember" xlink:label="anik_ElevessTradeNameMember" xlink:type="locator"/>
    <link:label xlink:label="anik_ElevessTradeNameMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elevess Trade Name [Member]</link:label>
    <link:label xlink:label="anik_ElevessTradeNameMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Elevess trade name.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_ElevessTradeNameMember" xlink:to="anik_ElevessTradeNameMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_OrthobiologicsMember" xlink:label="anik_OrthobiologicsMember" xlink:type="locator"/>
    <link:label xlink:label="anik_OrthobiologicsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orthobiologics [Member]</link:label>
    <link:label xlink:label="anik_OrthobiologicsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Orthobiologics.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_OrthobiologicsMember" xlink:to="anik_OrthobiologicsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_BoardOfDirectorsMember" xlink:label="anik_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="anik_BoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board of Directors [Member]</link:label>
    <link:label xlink:label="anik_BoardOfDirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Board of Directors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_BoardOfDirectorsMember" xlink:to="anik_BoardOfDirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_SurgicalMember" xlink:label="anik_SurgicalMember" xlink:type="locator"/>
    <link:label xlink:label="anik_SurgicalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Surgical [Member]</link:label>
    <link:label xlink:label="anik_SurgicalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Surgical.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_SurgicalMember" xlink:to="anik_SurgicalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_DermalMember" xlink:label="anik_DermalMember" xlink:type="locator"/>
    <link:label xlink:label="anik_DermalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dermal [Member]</link:label>
    <link:label xlink:label="anik_DermalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Dermal.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_DermalMember" xlink:to="anik_DermalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredRevenue</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarliestTaxYearMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earliest Tax Year [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation" xlink:label="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation" xlink:type="locator"/>
    <link:label xlink:label="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation</link:label>
    <link:label xlink:label="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Build-to-suit Lease Agreement, Offsetting Facility Lease Obligation</link:label>
    <link:label xlink:label="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of the offsetting facility lease obligation under a build-to-suit lease agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation" xlink:to="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</link:label>
    <link:label xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:label xlink:label="country_US-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</link:label>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange rate impact on cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of reserves of $220 and $167 at June 30, 2016 and December 31, 2015, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of reserves</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeRelatedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_OtherLocationMember" xlink:label="anik_OtherLocationMember" xlink:type="locator"/>
    <link:label xlink:label="anik_OtherLocationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Location [Member]</link:label>
    <link:label xlink:label="anik_OtherLocationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents other location.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_OtherLocationMember" xlink:to="anik_OtherLocationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:label="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]</link:label>
    <link:label xlink:label="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents schedule of revenue and operating income, by geographical areas.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:to="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_PercentageOfNetRevenue" xlink:label="anik_PercentageOfNetRevenue" xlink:type="locator"/>
    <link:label xlink:label="anik_PercentageOfNetRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_PercentageOfNetRevenue</link:label>
    <link:label xlink:label="anik_PercentageOfNetRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Revenue</link:label>
    <link:label xlink:label="anik_PercentageOfNetRevenue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of net revenue.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_PercentageOfNetRevenue" xlink:to="anik_PercentageOfNetRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product revenue</link:label>
    <link:label xlink:label="us-gaap_SalesRevenueGoodsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAccruedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</link:label>
    <link:label xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign currency adjustments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForRepurchaseOfCommonStock</link:label>
    <link:label xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchases of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $.01 par value; 60,000,000 and 30,000,000 shares authorized, 14,777,663 and 15,036,808 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of equity awards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWriteDown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryWriteDown</link:label>
    <link:label xlink:label="us-gaap_InventoryWriteDown-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockRepurchaseProgramAuthorizedAmount1</link:label>
    <link:label xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareRepurchaseProgramDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="us-gaap_ShareRepurchaseProgramDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="us-gaap_DistributionRightsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DistributionRightsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DistributionRightsMember" xlink:to="us-gaap_DistributionRightsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareRepurchaseProgramAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InProcessResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</link:label>
    <link:label xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="anik_RestrictedStockAndRestrictedStockUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock and Restricted Stock Units [Member]</link:label>
    <link:label xlink:label="anik_RestrictedStockAndRestrictedStockUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to Restricted Stock and Restricted Stock Units (RSUs).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:to="anik_RestrictedStockAndRestrictedStockUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from equity awards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryFinishedGoodsNetOfReserves</link:label>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryWorkInProcessNetOfReserves</link:label>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryRawMaterialsNetOfReserves</link:label>
    <link:label xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturity of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IntangibleAssetsGrossExcludingGoodwill</link:label>
    <link:label xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillDisclosureTextBlock" xlink:to="us-gaap_GoodwillDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_OtherMember" xlink:label="anik_OtherMember" xlink:type="locator"/>
    <link:label xlink:label="anik_OtherMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other [Member]</link:label>
    <link:label xlink:label="anik_OtherMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a product group classified as other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_OtherMember" xlink:to="anik_OtherMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DevelopedTechnologyRightsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsInitialYearlyRent" xlink:label="anik_LesseeLeasingArrangementsInitialYearlyRent" xlink:type="locator"/>
    <link:label xlink:label="anik_LesseeLeasingArrangementsInitialYearlyRent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_LesseeLeasingArrangementsInitialYearlyRent</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsInitialYearlyRent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements Initial Yearly Rent</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsInitialYearlyRent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of the lessee's leasing arrangement initial yearly rent.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_LesseeLeasingArrangementsInitialYearlyRent" xlink:to="anik_LesseeLeasingArrangementsInitialYearlyRent-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty" xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty" xlink:type="locator"/>
    <link:label xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements Ability to Withdraw With Penalty</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of the lessee's leasing arrangement ability to withdraw with penalties, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty" xlink:to="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConstructionInProgressGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConstructionInProgressGross</link:label>
    <link:label xlink:label="us-gaap_ConstructionInProgressGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty" xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty" xlink:type="locator"/>
    <link:label xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Leasing Arrangements Ability to Withdrawn Without Penalty</link:label>
    <link:label xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of the lessee's leasing arrangement ability to withdraw without penalties, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty" xlink:to="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetUsefulLife</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_AcceleratedStockRepurchaseMember" xlink:label="anik_AcceleratedStockRepurchaseMember" xlink:type="locator"/>
    <link:label xlink:label="anik_AcceleratedStockRepurchaseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Stock Repurchase [Member]</link:label>
    <link:label xlink:label="anik_AcceleratedStockRepurchaseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the program of accelerated stock repurchase.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_AcceleratedStockRepurchaseMember" xlink:to="anik_AcceleratedStockRepurchaseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductWarrantyAccrual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProductWarrantyAccrual</link:label>
    <link:label xlink:label="us-gaap_ProductWarrantyAccrual-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrual" xlink:to="us-gaap_ProductWarrantyAccrual-label" xlink:type="arc"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_MorganStanleyCoLLCMember" xlink:label="anik_MorganStanleyCoLLCMember" xlink:type="locator"/>
    <link:label xlink:label="anik_MorganStanleyCoLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Morgan Stanley &amp; Co., LLC [Member]</link:label>
    <link:label xlink:label="anik_MorganStanleyCoLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Morgan Stanley &amp; Co., LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anik_MorganStanleyCoLLCMember" xlink:to="anik_MorganStanleyCoLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare</link:label>
    <link:label xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Initial Price Paid Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of product revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConstructionPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConstructionPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_ConstructionPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility construction costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionPayableCurrent" xlink:to="us-gaap_ConstructionPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from equity awards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfGoodwillTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireMarketableSecurities</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByAssetClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfReportableSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (years)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Book Value</link:label>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net Book Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>anik-20160630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 06:06PM UTC 2016-08-01--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses" xlink:href="anik-20160630.xsd#statement-note-11-accrued-expenses" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill" xlink:href="anik-20160630.xsd#statement-note-10-goodwill" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories" xlink:href="anik-20160630.xsd#statement-note-8-inventories" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements" xlink:href="anik-20160630.xsd#statement-note-5-fair-value-measurements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-3-recent-accounting-pronouncements-" xlink:href="anik-20160630.xsd#statement-note-3-recent-accounting-pronouncements-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-3-recent-accounting-pronouncements-" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-2-basis-of-presentation-" xlink:href="anik-20160630.xsd#statement-note-2-basis-of-presentation-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-2-basis-of-presentation-" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-document-and-entity-information" xlink:href="anik-20160630.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_DocumentAndEntityInformation" xlink:label="anik_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_DocumentAndEntityInformation" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business" xlink:href="anik-20160630.xsd#statement-note-1-nature-of-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments" xlink:href="anik-20160630.xsd#statement-note-4-investments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan" xlink:href="anik-20160630.xsd#statement-note-6-equity-incentive-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_BoardOfDirectorsMember" xlink:label="anik_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_PlanMember" xlink:label="anik_PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="anik_PlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="anik_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps" xlink:href="anik-20160630.xsd#statement-note-7-earnings-per-share-eps" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_AcceleratedStockRepurchaseMember" xlink:label="anik_AcceleratedStockRepurchaseMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_MorganStanleyCoLLCMember" xlink:label="anik_MorganStanleyCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="anik_AcceleratedStockRepurchaseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="anik_MorganStanleyCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets" xlink:href="anik-20160630.xsd#statement-note-9-intangible-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies" xlink:href="anik-20160630.xsd#statement-note-12-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases" xlink:href="anik-20160630.xsd#statement-note-13-leases" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_EuropeanHeadquartersFacilityMember" xlink:label="anik_EuropeanHeadquartersFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="anik_EuropeanHeadquartersFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes" xlink:href="anik-20160630.xsd#statement-note-14-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:label="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information" xlink:href="anik-20160630.xsd#statement-note-15-segment-and-geographic-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NotesToFinancialStatementsAbstract" xlink:label="anik_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements-tables" xlink:href="anik-20160630.xsd#statement-note-5-fair-value-measurements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-5-fair-value-measurements-tables" xlink:label="anik_statement-statement-note-5-fair-value-measurements-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-5-fair-value-measurements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-tables" xlink:href="anik-20160630.xsd#statement-note-6-equity-incentive-plan-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:label="anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-6-equity-incentive-plan-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-tables" xlink:href="anik-20160630.xsd#statement-note-7-earnings-per-share-eps-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:label="anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-7-earnings-per-share-eps-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-tables" xlink:href="anik-20160630.xsd#statement-note-8-inventories-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-8-inventories-tables" xlink:label="anik_statement-statement-note-8-inventories-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-8-inventories-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-tables" xlink:href="anik-20160630.xsd#statement-note-9-intangible-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:label="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-9-intangible-assets-tables" xlink:label="anik_statement-statement-note-9-intangible-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-9-intangible-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill-tables" xlink:href="anik-20160630.xsd#statement-note-10-goodwill-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-10-goodwill-tables" xlink:label="anik_statement-statement-note-10-goodwill-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-10-goodwill-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-tables" xlink:href="anik-20160630.xsd#statement-note-11-accrued-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-11-accrued-expenses-tables" xlink:label="anik_statement-statement-note-11-accrued-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-11-accrued-expenses-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-tables" xlink:href="anik-20160630.xsd#statement-note-15-segment-and-geographic-information-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-tables" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:label="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-15-segment-and-geographic-information-tables" xlink:label="anik_statement-statement-note-15-segment-and-geographic-information-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-15-segment-and-geographic-information-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business-details-textual" xlink:href="anik-20160630.xsd#statement-note-1-nature-of-business-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NumberOfProductsDevelopedManufacturedAndCommercialized" xlink:label="anik_NumberOfProductsDevelopedManufacturedAndCommercialized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_NumberOfProductsDevelopedManufacturedAndCommercialized-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments-details-textual" xlink:href="anik-20160630.xsd#statement-note-4-investments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="us-gaap_AvailableForSaleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecurities-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-details-textual" xlink:href="anik-20160630.xsd#statement-note-6-equity-incentive-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_BoardOfDirectorsMember" xlink:label="anik_BoardOfDirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_PlanMember" xlink:label="anik_PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:label="anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="anik_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="anik_PlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="anik_BoardOfDirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-details-textual" xlink:href="anik-20160630.xsd#statement-note-7-earnings-per-share-eps-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_AcceleratedStockRepurchaseMember" xlink:label="anik_AcceleratedStockRepurchaseMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_MorganStanleyCoLLCMember" xlink:label="anik_MorganStanleyCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_StockRepurchaseProgramPercentageRepurchased" xlink:label="anik_StockRepurchaseProgramPercentageRepurchased-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="anik_AcceleratedStockRepurchaseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="anik_MorganStanleyCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_StockRepurchaseProgramPercentageRepurchased-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details-textual" xlink:href="anik-20160630.xsd#statement-note-9-intangible-assets-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:href="anik-20160630.xsd#statement-note-12-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductWarrantyAccrual" xlink:label="us-gaap_ProductWarrantyAccrual-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProductWarrantyAccrual-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases-details-textual" xlink:href="anik-20160630.xsd#statement-note-13-leases-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation" xlink:label="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_EuropeanHeadquartersFacilityMember" xlink:label="anik_EuropeanHeadquartersFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty" xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty" xlink:label="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsInitialYearlyRent" xlink:label="anik_LesseeLeasingArrangementsInitialYearlyRent-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsNumberOfRenewalTerms" xlink:label="anik_LesseeLeasingArrangementsNumberOfRenewalTerms-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsRenewalTerm" xlink:label="anik_LesseeLeasingArrangementsRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_LesseeLeasingArrangementsTermOfContract" xlink:label="anik_LesseeLeasingArrangementsTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="us-gaap_ConstructionInProgressGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="anik_EuropeanHeadquartersFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsNumberOfRenewalTerms-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsRenewalTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_LesseeLeasingArrangementsInitialYearlyRent-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConstructionInProgressGross-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes-details-textual" xlink:href="anik-20160630.xsd#statement-note-14-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:label="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_EarliestTaxYearMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-details-textual" xlink:href="anik-20160630.xsd#statement-note-15-segment-and-geographic-information-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-details-textual" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_NoteToFinancialStatementDetailsTextual" xlink:label="anik_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-details" xlink:href="anik-20160630.xsd#statement-note-8-inventories-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-8-inventories-details" xlink:label="anik_statement-statement-note-8-inventories-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-8-inventories-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_DepositsAndOtherAssetsNoncurrent" xlink:label="anik_DepositsAndOtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="anik_DepositsAndOtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:href="anik-20160630.xsd#statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:label="anik_statement-statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited" xlink:href="anik-20160630.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueServicesNet" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:href="anik-20160630.xsd#statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:label="anik_statement-statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-7-basic-and-diluted-earnings-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details" xlink:href="anik-20160630.xsd#statement-note-9-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_AccumulatedCurrencyTranslationAdjustment" xlink:label="anik_AccumulatedCurrencyTranslationAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_ElevessTradeNameMember" xlink:label="anik_ElevessTradeNameMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-9-intangible-assets-details" xlink:label="anik_statement-statement-note-9-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="us-gaap_DistributionRightsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-9-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DistributionRightsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="anik_ElevessTradeNameMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccumulatedCurrencyTranslationAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:href="anik-20160630.xsd#statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:label="anik_statement-statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-10-changes-in-the-carrying-value-of-goodwill-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-details" xlink:href="anik-20160630.xsd#statement-note-11-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_AccruedClinicalTrialCostsCurrent" xlink:label="anik_AccruedClinicalTrialCostsCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_AccruedResearchGrantsCurrent" xlink:label="anik_AccruedResearchGrantsCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-11-accrued-expenses-details" xlink:label="anik_statement-statement-note-11-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:label="us-gaap_ConstructionPayableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-11-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConstructionPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccruedResearchGrantsCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_AccruedClinicalTrialCostsCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-product-group-details" xlink:href="anik-20160630.xsd#statement-note-15-product-revenue-by-product-group-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-product-group-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_DermalMember" xlink:label="anik_DermalMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_OrthobiologicsMember" xlink:label="anik_OrthobiologicsMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_OtherMember" xlink:label="anik_OtherMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_SurgicalMember" xlink:label="anik_SurgicalMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-15-product-revenue-by-product-group-details" xlink:label="anik_statement-statement-note-15-product-revenue-by-product-group-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-15-product-revenue-by-product-group-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="anik_OrthobiologicsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="anik_SurgicalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="anik_DermalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="anik_OtherMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueGoodsNet-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-of-financial-instruments-details" xlink:href="anik-20160630.xsd#statement-note-5-fair-value-of-financial-instruments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-of-financial-instruments-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-5-fair-value-of-financial-instruments-details" xlink:label="anik_statement-statement-note-5-fair-value-of-financial-instruments-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-5-fair-value-of-financial-instruments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-geographic-location-details" xlink:href="anik-20160630.xsd#statement-note-15-product-revenue-by-geographic-location-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-geographic-location-details" xlink:type="extended">
    <link:loc xlink:href="anik-20160630.xsd#anik_OtherLocationMember" xlink:label="anik_OtherLocationMember" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_PercentageOfNetRevenue" xlink:label="anik_PercentageOfNetRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="anik-20160630.xsd#anik_statement-statement-note-15-product-revenue-by-geographic-location-details" xlink:label="anik_statement-statement-note-15-product-revenue-by-geographic-location-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd#country_US" xlink:label="country_US" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EuropeMember" xlink:label="us-gaap_EuropeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anik_statement-statement-note-15-product-revenue-by-geographic-location-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="country_US" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_EuropeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="anik_OtherLocationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesRevenueNet-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="anik_PercentageOfNetRevenue-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exh3_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh3_1.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X0U]17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  'H2    G
M$  >A(   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#<Z
M,C8@,34Z,C4Z-#       Z !  ,    !  $  * "  0    !   #CZ #  0
M   !   $FP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   Q'
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M         0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:  P# 0 "$0,1 #\ [KZP]<S>F6ULQ**;OU;*S;C?::AZ>)]G
M]2NM[:[OTEGVKZ=GZ-GIK7Q[A?17>UKF"UC7AKQ#@'#=M>W\URYOZW/S'YW3
ML3"Z=B]1R'5Y%]3<FAEQ8^EV(UA99=DX;<2MSLC]-D,^T6_S7IXUJL]$Z[DY
M_4[L:^_%EGVC=@5L?]HH]"YN-4[*M-EE7ZS6[UF[Z<3_ +K?::?5M24[Z ,W
M#=DNQ&WUG)9&Z@/;Z@D;QNJG?]'W(ZS\CH/3,FRZRZLN.0YMEHWN@N:PXX>&
M[MK'>@[T_9_Y\24W3;4+!47M%C@7-9(W%H@.<&_NMW*2HV=$Z=:]SWUN_2,J
MKL:U[VM<VAWJ8^]K'-_FW._]**O_ ,V^@X]>\8Y:VJO9[7VD[ _[5LAK]S_T
MWO24ZP<TD@$$C0QV[J(NJ<[8U[2[4;01/MC?I_(W>Y<\_IF+7EM=A4T&O]$*
MA8[(:\$;VN#7M]2MOTZMCVL_XW^9K4\?$9CVTVX^+0VRELL8;<CVSOH#_5?0
M[?\ HK-G\RS9^^DIV[,O%J#C9=6P-=L<7. AQ;ZFQTGZ?IGU-O[B(RQCVA['
M!S7 %K@9!!&X$%<V[ Q?L;,'[-0['8\V>DZW))#HLI<_>:O4MWTN^@[\_?\
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M:?2Y1=8\TE/_V?_M$BA0:&]T;W-H;W @,RXP #A"24T$)0      $
M               X0DE- ^T      !  R     $  0#(     0 !.$))300F
M       .             #^    X0DE-! T       0    >.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-! H       $  #A"
M24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      U4    &              2;   #CP   !  90!X &@
M,P!? %  80!G &4 7P Q "  8P!O '  >0    $
M     0             #CP  !)L                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   2;     %)G:'1L;VYG   #CP    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     $_\        #A"24T$%
M    !     $X0DE-! P     #&,    !    ?    *    %T  #H@   #$<
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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MO^KO2+&EKZ207.>3O?)+OI^[=N_S?_)J3?J_TEF[;1!>YSG'>^27&YSC]/\
M[M7_ .M=:2G03H.)B8^'0*,9NRL.>^))]UCG76NW/+G>^RQ[D9)2DDDDE/\
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M=(WO+_:S9K^[_P!<1*,J\%WK2\%P;7%-K"-)=OW,=_VY]!)3;]1O@?\ -/\
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M!=N=[18KB22D5617:2&AX(U]['L_\^-:BI))*4DDDDI__]7U55<K#=<\O:6
ME@:-S7$@AV_Z5=M2M))*:!Z?>6G])7)#9]MOYHVMG]92=TZQP'O8-OT1%L
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M         /;6  $     TRU(4" @
M                               18W!R=    5     S9&5S8P   80
M  !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@
M BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E
M9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D
M=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P
M  @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D
M($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M       2<U)'0B!)14,V,3DV-BTR+C$
M                                     %A96B        #S40 !
M 1;,6%E:(                     !865H@        ;Z(  #CU   #D%A9
M6B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T
M<#HO+W=W=RYI96,N8V@
M                    9&5S8P         N245#(#8Q.38V+3(N,2!$969A
M=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                     &1E<V,         +%)E9F5R96YC92!6:65W:6YG
M($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                      !V:65W       3I/X %%\N !#/%  #[<P !!,+
M  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                  */     G-I9R      0U)4(&-U<G8        $
M  4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T
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MR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:  P# 0 "$0,1 #\
M]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_T/5.*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]'U3BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5?_2]4XJ[%78JQW\P_,MUY8\D:SY@M(DGN=-
MMFGBAEKP8K39N)#4^6*OG+_H<#SM_P!6+317_+G_ .:L4T[_ *'!\Z_]6+3/
M^#G_ .:L5IDOE7_G+S3[JZ@M?,NC-I\<A1)-0M)#+&A)H7:)E5Q&/\EI&X_S
M8K3Z!TW4K#4[&"_T^X2ZLKE!+;W$3!D=&W#*PQ0B<5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BK__3]4XJ[%78JP;\\?\ R4?FK_MGR?PQ4/E7\@?+&@^9OS(M])UVS2^T
M^2UN)'MW+*"\:J5-4*MM7QQ9%]/M_P X^?DZ5(_PU *CJ);@'Z/WF+&WB?YY
M?\X]Z9Y5T5_,WEAY_P!'6[1KJ&G3,9C&C_#ZR2D\^//@KH_+[7/G^SBD%-?^
M<3//EW]:O_)EY<%[?TC>Z2CM_=E6I<1H#^RW)9>/\WJ/^UBI?38Z8H=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BK__4]4XJ[%78JP;\\?\ R4GFK_MGR?PQ2'S3_P XN?\
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M5=BKL5?_U?5.*NQ5V*L&_/'_ ,E)YJ_[9\G\,4A\T_\ .+G_ )-ZU_Y@;O\
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M6Y+&K!AQ*2-&W+[/+%5#R_\ \Y#^5=:@@M(;.Y@\U3W26'^&YE*7"SO6I9V
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MFMF;;D #^ZDI_>0EB',1^'DO^MBJP_ECY,/G"+S=^C(1K<$7I1RA0$Y5VF*
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M@6"/].ZXET9'CXK&HL&X3O&LK?:<E6CC9FX+R_O/3^)5EVA-KLFDJ=9BBAU
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M19I?JKSR$L\OU<L8@[EOCXK\7[6*K-$\B^7]$CCBTY9XK>W+FRMFN)Y(;?U
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MUAS5T2Y$0#2&!V 2;BIY? WV?C7X,52^_P#S'\LVEG+>!YKFW05CEMX))$E
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M=9NK1K.+24G^HI*5]=Y+E!&Y<(6"1K&-DY_&[<W5/23%5&6QU<_F'%JPL_\
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MWSRK70ALDL3!ZICM;EY;FUEYT%O=QND9#LAY)+'^Z;TY,53;SS^8/Z U/1-
MT^U6_P#,7F&9X=/MI)?1B18UY23S.%=A&@_91><C?"N*L-\R_F/J^I>6?/\
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M\95F7EW\T=6N/S U;R;YBTJ+2KFPLOTG!<PW/UB,VWPU$K%(^+KRWI\/VO\
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MQ!#=W<HN)C+ LL;1*^E2W3^G'ZO!Y']'T_W@9?B^!4Q5-M(\XZI=7NCQ75M
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MJ.*N_0^K?]7RZ_Y%6G_5'%7?H?5O^KY=?\BK3_JCBKOT/JW_ %?+K_D5:?\
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MOF;S)KD&O6?E_P O6EM=:K<VTM[-)>S/#;P6\3I&"WII+([S/)QC"C]A^?\
ME*I=_P K,]+RR=0FTB[GUI+JYTY]#L%:Z?ZW:,P<>M1(TA*)ZWKS>DOI.O\
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M3BKL5=BKL5=BKL5=BKL5=BKL58+H^L:?I47FW5-=EC@^JZQ(T\C\2P00PK:
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M)MW_ -5<5=_A72*4_P!*_P"DR[_ZJXJU_A31_P#EZ_Z3+O\ ZJXJ[_"ND?\
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M"**>:Z0*74^K<DM,Q96#,)>3>HC'@_V>/'%5UUY+\LW<]S<7%BKS7@B$[<G
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M]C9R.[O!&[OQYLR*2>&ZU)'[/[.*M+IU@L#6ZVT0MVW:$(H0GW6E.V*N&G6
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M[71-(N[>.YM;Z[N+>4<HIHM0NG1E/0JRRD$8JJ_X:L?^6F^_Z3KO_JKBKO\
M#5C_ ,M-]_TG7?\ U5Q5W^&K'_EIOO\ I.N_^JN*N_PU8_\ +3??])UW_P!5
M<54+?2=$N)9X;?4;J::V8)<QQZC<LT;D5"N!*2C4WHV*J_\ AJQ_Y:;[_I.N
M_P#JKBJUO+^FK3E=WJU/$5O[L5)[#][BKAY=T\D@75\2.H^OW?\ U5Q5O_#=
MC_RTWW_2==_]5<54)=*T*&>&WFU&YCGN"1;POJ-RKR$"IX*9:ML/V<51'^&K
M'_EIOO\ I.N_^JN*M'RW8CK<WW_2==_]5<5</+=@=A<WW_2==_\ 57%5*/1M
M&DN);:._NWN8 K30+J-T70/7B642U7EQ;C7%51_+VFH*O=WJC;<W]V.IH/\
M=OB<5=_AW3ZT^M7U>M/K]W7_ ).XJI7.DZ):O"ESJ-U ]R_I6ZR:C<H9)""0
MB!I1S:@^RN*J_P#AJQ_Y:;[_ *3KO_JKBK0\MV!Z7-]_TG7?_57%6_\ #5C_
M ,M-]_TG7?\ U5Q5W^&K'_EIOO\ I.N_^JN*N_PU8_\ +3??])UW_P!5<5=_
MAJQ_Y:;[_I.N_P#JKBKO\-6/_+3??])UW_U5Q5:_E[3HU+O=WJJH+,S7]V
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M"RF0^DB^H3&D2P\))^4GQR1_NOV650B>=_,UQJ\>D1+#:WVKQ6.H:)'/;O\
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M[%78J[%78J[%78J[%78J[%78J[%78JE&KV['5]&NO3]1()I5<A>10RPLJO\
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MHWUH<9V@]?GR^T./UIHO2_WC^/G^UBJ_\O!J1N?,K7-V)X_TU=QJGIE2"HC
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M8 _:Q5J'RMY9A>*2'2+*-X)#-"Z6\2E)&^TZD+\+M^TP^+%44FDZ4D\]PEG
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M-I?:C!/ MTT2QA3<BDKEHT+DMU;_ 'Y^UBJWS1Y-;4O)TV@Z;:6-I]:>W>>
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M- >?1J+_ ,"G\B8JMMO)'E6V2T2#3HXUL4]&U +?!%RY^EN?BBY?%Z3\H_\
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M)Y!\GQK(L>F11+*DT3B,N@]*Y;G-&.+"D<C_ !F,?!S^+CBKI/(/E*2.2-[
M-'-;+8RH9)B&M4^S"1SWC6I^#_*;^;%5;_!GEDF\,EBDWZ0A2WO1,SRK+%%_
M=JZNS \/V#]I<55#Y3T R64IM:RZ=(9K.3U).22L.+.3RJ[LGP%GY?!\'V,5
M5]5T'2M6-L=0@];ZG*+BV^-UX2K]EQP*_$O;%5L?E[1HM0FU".U1;RX/*>4"
MG-N(3FR_8,G >GZG'GP^#EQQ5BZ^1K:V\U6LMEI<2^7QIMYI]Y TS%#]<DAD
MXI;OR18@L+HZ)P_O5^'X<53@>0/*!C=?T<M);;ZC*2\O)[4_[I=N7)H_!&^S
M]G%43;^4?+L$L\L=FI>ZMUL[GU&>59+=00L3K(S*R ,VQ'[;_P [8JT/)WEL
M6,=C]13ZM"ZRPBKEXWC'%&22OJ(47X$X/\"? OPXJKZ/Y=T?1TG338/JZW4S
MW,X#.W*:0U=_C+49C]JF*H>U\KZ+I$;3:1IT2W,*2&TAY%45GJS)&6YB!96_
MO#&G^MRQ5KRCH(T;2FB=(EOKR>6^U-H!Q1[NY8R2E=A503P1OVD3%6IO)'E>
M:2XEEL5>2ZN4O9G+R<C<Q#BDRGE5)%7X R<?W?[O['PXJB+7ROH%K#:P6]C$
MD%C,US91<:K#,P8%X@:^GM(X^#X?BQ5%6>F6%DDB6D"0+-+)/*(U"AI9FYR2
M&G5G8\F.*I:ODGRLMT]W'IZ1W3R33--&71A)<BD[*58<?6^U+Q_O'^-_CQ5;
M!Y$\I0")8].C]."V>QBB=G>,6LNSP>F[,AB;O&5X_"O\JXJJZ?Y0\O:=J'Z0
ML[4Q7GH+:^MZDK'T%8LL=&9AQ4L>/\O[.*NOO)WEJ_FO9KNP22748A!?M5E]
M:-1Q"R!2 WP?!O\ [K_=_8Q5;+Y*\KS2M+/8).\EJ+&3UF>4-;+TB979E9._
MQ#[7Q?:Q5'VFD:?:6IM+>+C U>:L2Y;D*'FSEF?;;XS]GX<52A?R[\F+:/9K
MID:VLD*6LD2M(%:"(\HXFHWQ1QU_=H?AC7X4^'%4?<>6-$N+NWO)K8/=VD1M
M[>YY.)5B:A*%PW)AR56^,M\?Q_:Q5#Q^2/*T5K:6L5@D<-AS%EQ:17B$O]XJ
M.&YJCT^./EP;^7%6QY+\KB*[B_1Z&.^E2>Y0ER#+%01R+4_NWCXIZ;1\&3@G
M'["XJKKY8T%;F"Z%FGKVZJL<GQ$_ 2REJG]XR.[NKR<G5V9_M8JNU7RWHFK,
MC:C:K<M&K1JS$@^G)3G&Q4KRC?BO.-OW;<?LXJW_ (>TC]+1ZO\ 5P-1AA-M
M%.&8<86()C"@\.%0IIQ_9Q5;J?EK0]4E2;4+1+B2-> 9Z_$G(/P< @2)S4-P
MDY)_DXJA-5\JV,EOK,]A$D>K:M:O;2W,K2LC? 5C]14=3P3E_NO@R_%P^UBJ
M4Z;Y-GO)HSK@F>QABB$6G7%VUX!=0N'2[24JCPR)0HOI.O-6^)$Q5-X_(_E:
M)[=X;!83:>M]5])Y(Q%]8-9O3", GJ'[7'%5.3\OO)\EI:VCZ<IMK**2WM8O
M4E"QPS"DD:T?9'7X67^3X/LXJO\ \">4R(@VG))Z!Y0F1I'91Z9B*AF8MZ9C
M9D:+^Z9?V,558_)WEN-[1X[)4>PA:ULW5G5HX&-?2#!N7 $513_=_P"Z^.*J
M2^1/*2V=M9#38_JMHC1015<@1.P9HC\7Q1,RBL3\H_\ )Q56U#RAY=U"YFN;
MRS$TUQ;FRF8O(O*V;<Q$*P7TSW6F*HC3M T?39GGLK5(9Y(HH)9@"9'C@!$2
M,YJS"/FW'D?VL53#%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%7_]#U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_1
M]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_TO5.*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]/U3BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5?_4]4XJ[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%7_U?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5_];U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_7]4XJ
M[%78J[%78J[%78J[%78J[%4'^EK0WTUF'!EMD66Y/[,:O]GFW[)8!F _E7EB
MJ#MO-6DW4*W-L[3V+.D:7Z(QMG,C<%*2_9D7G\/J1\H^3?:Q5&W^IVEA:27=
MW*L-O$ 7D8["I"J/]9F(51^TWPXJIZ=K,-\\L0BEM[B#CZUM.G"10X)1MBRL
MK4;XD9OLLOVE;%4?48JZHQ5V*I=I^NVE]J>IZ="DBS:5+'#<EU"J6EB69>!J
M>0X.,53'%75&*NJ,504FLZ8FK1Z0US&-3F@>ZBLR?WC0QLJ-(!_(K.JG%5/5
M=<M--N=-MYED9]4N?J=L44%1)Z3S?&:CBO")\53&N*NQ5V*NJ,52W5]>M-+F
MT^*X5V.I7264#( P$LBLXY[CBO&-M\53+%78JZHQ5U1BJ6:SK]KI)LOK"NPO
M[N*QA,:A@)9R0I?<<5VZXJF7+X:GKW Q5+]$UVTUB&ZEMED06EU/92B50I]6
MV<H]*$_#R'PG%4QQ5U1XXJ[%75Q5U1BJ5:QKOZ/98HK2;4+MTDF2SMC'ZIBA
MIS;]XT:]710.7Q,V*HK4-1BL-+N=1G5S%:PO/*B"K\8U+, NU6H,57Z;?17^
MGVU]""(KJ))HPVS<9%#K4>-#BJ(Q5U1BKJC%78J[%4MO=>M+/6--TJ57,^J&
M86SJ 4!MX_4?F:[?#]G;%4RJ,5=BKJC%75&*M,2!MBJ3Z1YGMM5:^6VMKA3I
MT[VL_J(JUFCW9$^(\C0K_D_%BJ)T368]6LEO(K>:WC9Y(_3N4].0-$Y1JI5O
MVE88JM37;1_,$VAJDGUN"UBO'<J!&8II'C7BU=VY1-44Q5,L5=48JZHQ5U<5
M=BKJC%4%9ZSIEY>WME:W,<UUISI%?0H:M"\B"15<=BR,K#_)Q5&U&*J=Q,L%
MO+.P++$C.57<D**T'OBJ5V_FK2)?+,/F6686FD2V::@T]Q\ CMWC$G*3KQHI
M^+%4TM[B.>%)HF#Q2*'C=34%6%01\QBJIBJ6V6NVEWK6HZ1&KK<Z8D#W#,M$
M(N0YCX&OQ?W;<L53+%78JZHQ5U1BKJC%4'JFIQV$,;E&FEFD6&WMT*AY)&W"
MKR*K]D,[5/PHK8JWI]]+=V4-S);2V<DJ@M:S\?5C)_9?@SK4?Y+,N*J&@:]:
M:WIRW]JKI TL\/&4!7#6TSP/L"?VXVIBJ98JZHQ5U1BKJC%75Q5+];URTT>W
MMY[E9&2YNK>S3TUY$274JPQEMQ1.;KR.*H\$$8JW48JZHQ5U1BKL5=48JZHQ
M5U1BK1:@KUQ5 :%K=IK6G_7K572+UKBW*RJ%;G:S/!)L"?\ =D3<?\G%4PQ5
MV*NJ,5=7%4#-K6FPZI;Z5)<QIJ-U')/;6K&DCQ0D"1U'=4+KR_UL5=?ZUIMA
M-9PWMS';RZA,+:R1VH99BI<1IXMQ1FQ5&@@BN*MXJ[%78J[%78J[%78J[%78
MJ[%78J[%78J__]#U3BKL5=BKL5=BKL5=BKL5=BKL5>6ZG#>7.B^:K69&G,GF
M*)=:@C >5M+8VP<%$JQ4V-/\KT>7^5BJ(U&_N6T3S?9RW4>H^6K?2*V&H&**
M)%G>*5'M0\02&98^$+JR)\#3>C]I,59#K"64ODN.W\T122V]Q!!#JC+7E'(W
M -*S1T,8BE^,RI_=<?5^RN*L'DU+7K2&WM)]>GO- MM;L[>#S-&R++)9R0RA
MX+F9%X2&WN%B5[GBJ2^JJM\?/%41>>;M7DU^6ST[4[J6%K75[=E>**.EW;JK
M6BQ1\3,LM.?!Y#_IG]Y'$R?855;;S'J1T;RS:VFLM!:ZC8O)<Z[=+]8"WL<4
M)6U9AZ?IM\<KT?XI'B]#[?)<59)Y_N[VU\F6]R+R6WD6ZTSZY>6ZF$B%[N%;
MARI#M%'Z3.SU_NU^UBK#;[6FTR;SOK&EZPQFL9],:W4M&Z3D6L$;&7X><G/X
MHVX,OV?AXOBK)[?7-7OO.-U:'4(["VLKF%;33S TIO;.2!',\<BLH8-(SKZ@
MY+;>E\?V\50GYH>:-2TF-X=-O9[?44M/KEK!%#'Z;^G,HD+R2!S* OPM;0IZ
MG!O5=E7XXU4N\S:[JUS'Y^?3M:N&32;>%]-M[3TBJI);*TS*4C:1^+5;ES^!
ML51?F?S)>:=J%H^@7K:K+^@]4N;2!BLQN)XI(# U%"-(>/UCTT5OWO#X.7'E
MBKM1U72I=1\I30ZY)J23:O#(3.8PB$V%VI*\$3@S-)&KPD_NF:->*<_C53+R
M3K.N:K=O<ZC>I',#<Q7>@FW826KQS<8^4G*BKP'PN4_TM766/X4Q5*//7F?4
M]/U7S+]4UE[;]$:/:WUC8IZ/%KLS3\T<%#))ZB) KQ\_LR+QX\DQ52\R><;V
MTM_,X@UB2*YLM4TZ72501L6L+B.T:7C5&#VK&2YK+^Q_OU>.*K?-WFO5+;4_
M,[6>O/;C2CI+:=;1_5S'_I,O&Y4AHV:4<-VJW[O_ "<50VKZK)<:F]C-J[SV
M6D^9['T+]FB:2&VETXL[&14X^FMQ)+'ZLB_!]GGR3%4QG\P^9(+B.R.HLFA7
M6HS06OF.>.I$"6J2(CNJQIP>Y,\,5W]F3TD3F[2\L53/3-2U*Y\\1:7<:T[Q
MP:/:7;P0QQVZ37+32B5C&ZO*H>(1L8?4^!67%4+YZ\UWNFZW#:V=_-#+!-ID
MLUN(XE@^J7%WZ-R[O(&>=?2Y\_2X+:<%DD=>?Q*H+6?-=_;:[KLBZV4@TW6-
M(MK6R)A]'ZO=_5TNPX"<W5?4G?ES_=-']KX77%4-K>NB]ET:YU/4GMM0MO,T
M44VC,T:1PP13R)$S J'=6A].87'/@_/[7'X,593YSOIK?S/Y762_GL-.GFNT
MNVA;BCR+!R@21N+;LW((O[?^OQQ5BNEZX^F+-?6VJ4CN?-]Q:S6C-%Z!MKFY
M82/]D/\ 9/JI)S^'_C'BK)?(VLZWJT[W.HWRI,1/'>:$8&66TECFXH&DK15"
M \6*?Z4K^M'\*XJ@-0UO5['S'YSDMIKB[OK&Q@N-%T8G]U,/JSL[1QA>4E)5
M;[+<N?P?R8J@=5U_68-(MKW3/,R:EJ,ES&^FV2Q);PW8X!KBWGDD/PA4K+\#
M1-:M^[?G_=XJBM%UV&]\S^7I(M;NY]-N](DDB,I5/7O!<1<HYE5./K*C4>&O
M)$7_ %VQ5-O-6M7=MK,MI<ZC)HNF+I_UFQO845VGO!(X>+XEDYF&-866W5>=
MQZS?;]/X54KTR2\OOS#\OW&JRO8:Q+Y=:6^TZ)U"I<&>W=X>)#'B:.2O+EQC
M_P G%7>=;WZOYDUNVN]0FM[,^7&ELK1GX033E[F.4 $?&P7T.0#<E^#^;%4L
MA\TZSHNFV-MI=VVK22>61?0VK".1TN+<P1@PI&J%J0R3N;?XGE^K_!\7/DJS
M[RA/<S6$\LNK1:Q$\@:WN8HC&JJ44E.7)A)\?)MN/I\O2_8Q5@^C^==1N9]9
M<:M,]F=#-Y9SW,<,)2]BDF24QQ!3Z)2D/.VF:22/X/45>?QJI9-YKUM-*NIE
M\R3^NGE6'6(A6V)_2=).2 >EOS8(&M_^(XJRI?,>L7OF<6R:C'I]K''8W%BI
M@,ZZA'.*SM$59>7$\HBJ\OJ_PW#?"V*I/I_F_4UU*UF_3#7IN-?U/3?J+- L
M36D4=P]L%XHK+^\CMXXYN7Q>K\7/DN*J=EK=O>>9/)&HWVKL;Z6&^.I6<ICB
M2TG>U'*,Q%5:%HWY1*)#\?'E\?VL50NA^9M7N[+0S=^:+A)-2T6_N[]JVB,E
MU:O$(2O[JD;%7FY)]F3T_L_"^*II9>:_,.IPZ#$=3CTWZYHUI?+?-;F9+J^?
MX;F *C1CG$0O^BK\;^J_P_NL567WFV^@US4)?TVQAL_,EEIT5D3!Z/U*XA@$
MX8!0["-Y)V]7GR1XOB^Q(N*IMY9UZ.TO?,DFL:C=2S0:Q);163(\OIPRO$EJ
M5BCC+JC\U"R?W?'X_P"=\59^.F*L%\LZO8Z)JWF;3]7D%C<2:K+>VQG^!9[>
MXBC*/ QVEHRM&Z)\:2+QX_9Y*I;<:G=PZCY=T]M4FT>TU*VU:]NHAZ4,J\I4
MGMC)ZR,T3JLLGP_S*ZMRX8JDFE^<M3F2?7+3A?:^?*.GRR6\:\W-P)YVG_<K
MNTD0?U6@7XV^%/VUQ5-=:\P:]9Z1#/9ZV-6265Y$^IQK;SS1^FI].VFE$T$]
MQ&Y:5;5E3UO]YU_N?B53CRSK>L7?F_4;2ZEDGLHHY7BDC""",K*J+!/"5]:V
MNHQRXGU)(;R/G.GV?A5:.NWTNNZS:W-Y-97NG7"+HNEQA%6]A:!)$<\E=IUF
ME,L4I0K]76/_ '4W[S%4-Y;\Q:I<7^F<[]KH7%C+-YGAD5(TTVXC44 ^%?1/
MJ^K"8I6?DD?J_LN[JL8L_-GF&;RU;D:U/>:GJGE?4KR1/W7JIJ-J(_1]%(HU
M*2-SFK%3XO2^%.2OBJ/\U>;[G3_+EM^A-8NKB[;3_KUFZK%()6CD3U.<TBMZ
MP13P:VBC]149I7;]N-55U_S;<V]UYL^H:R(3%>Z(EDZ&%^,-P\*W/I\E<,I1
MI.;4;A_-\.*J\GFW5;>WU6TMM0^L0V>NQ6#:K(JS/:V-Q;1RF9_3"!HTN6:V
M];_=2_'(W[E\51-SK-WR.F:KK;6]F=->>TU:WC%N+R8S2H4#2K*O*")8>*J?
M]*]7UE7CBJKI-^(?R/M+N"X$4D'EV/TI@5/&=+0*HWJO,2CAP(^W\.*I!K7G
M#4XK74;FUUZ2/]'^6['4K.WC,!1[XM-ZB-5&>3U D*R1<_\ =GP\&9&Q5F7Y
MCZC<KY"O;[3;F2)E%O(+NU-6$#3Q^JZD!OA]$N2W\OQ8JPW4]7%CJ'GC5M*U
MIVGTW2[">S;E$ZW,L*7!59*H3*&=EC9(^/+U%_;]-L59)IVO:MJ7FRYA_2,=
MI:VES&MKIWH&3ZY926Z2"YBE5@&5Y&;]\.:0>GZ3_:;%43K5W/%^8FBV\U_/
M:6$^G731P(P2*:[2XMN$9JIY,8VD^"OV/]EBK&X_,6M7GEF]U*_\QMH]\T+!
MM/BMU$]G?++QB@;U>2,K-^YX,J?6T_?QRI_>8JMC\SW=]:Z#-?:M<6%Q^FIK
M;S'!%*GIVK_5+CTX%D57'U;UDB]"1S^^Y?S-P15F'FK5+RTN-'B%PUEHUW+(
MFIZH  T7[NL"EG#+%ZTGPF5E^'[')6D7%6)7=[>:E_@M]2O9H'.NW<=G=*4@
MDN+-;6[CM[MT*_"\P,0Y<$5O6^POJIBK(?.5[+:>8O*R2:A/8:;--=I=R1L$
M1G6V+0K(Q5ANP;@I^TW^5BK&O*FM-I]GY?D@U7E#JFOZK9W5DYB,2P//>3*R
M@*'5O4%N4D+_ !+/Q^)9(L59%Y'UG6]4NGN-1ODCF_TB.\T$P,LEK)%-PC!D
MKLH4?"Q7_2U=94^%<50&M>;+RW\\6-E%?S+!%J<=KJ5N\<4=NEM/9/(E>0:6
M3E/Z7&ZY1Q>HWU9?C^#%4JTKS+J5U?:()_,LPBU'4M8L[U0UJBBVM7G:U9:1
M?N]HX>,G^[$D_P M<57Z7YP\QW^B>7(I-52S%]:737&NR0B57O+>54B@=8_3
M2.1XR9N'P?6./!,5;\Q^;=6L]1\P.FMLIT<Z,UK:*L21.UQ(%O$>-E,I5EW=
M#)SA_FQ59YGUQ+R*.2^U-[6YL_,MBB:35$B^IQ:A%Z,QJO.2.6'C=_6%?@K-
MZ?+]VR8JW+YIU235'8>8I4C/F=M+]!3;!!I[V_+;]V6^&3[$_+E_E8JJVGFW
M6I=.LK;]* 6TFKZG8W.O2JC^E#;2R?4EE,?!(_K$07C<?"K<4_:F7%5/S/YF
MURSEU1!K[K-IOEI-1@6&.*!9M05Y=S%(KR_OE6*MOS^S(O'XN+8JG=KKRIYV
MU2>XOKF2TCTJQO=.TZW_ 'D<]1=-<&"-5+3,.,?V&Y<N'^3BJ>>9=:D/E0ZG
MI=REN;A(7M;J<,L825E(YM0M )$;T_6:-OJ[.LLB<4;%6(:'KNI7'F'3)=0O
M-0L4FT>2:WL[GTV]6Y2[=64^BJI<D1",HT?%IH.$OP^HV*I//YQU6]TS6'AU
M>\^I"+1+RWN6$4<PCFOO2U!U6)#Z4:PA&FA9I'M.7[WT_LXJRFPUK5+OS1+8
MIJPMK6RFMUL[>:$S/J%I+"KO.DBE _*0R1^HJLMMZ7)_MXJC?,5ZUOYY\N1S
M:A/9:=/;7O-8VXQ2W,;VQAC?X35F1I^*5^)>7'[.*L7\MZY)IMEH\UMJ?J1:
MCYAU6TGLG:+T?0DGO)E9:*'5S(L#)*S_ .[U_8DCQ5DOY?:OK&KQ)?:AJ"R2
MSP!KO2/J[1R6=R&HT;LS?!PWCX,G*7CZ^*I/J>MZXVH>;[/3M;E_3NF7<*Z#
MI/&%U<26<$PC:+ASDB>1Y0\G/]TOQ^HG'%5]UYAUT7_FB:TU.2:/2M2M+98$
M6*1+:PFAMC=W C5.<K6Q:Y=:E_BC965^#+BJR_UOS'#;:KJ6EWMSJ>B^7[NU
MN8Y8@CR7MMUU&V5E3]_]60>I"\0Y-)_H_J-Q;%5[:EK.FZ[H*7VJ2M<:C;:M
M=RVTJ)*8@?3DM(A&BQR.84)3A7E,Z2?MXJ@+3S7K#6FCR7U\ZR/K]M;R7'J0
MRVMS;M;EI)+64)&_U=V9"Z./5MY>5NSXJF>B>9M8GN=':XO2U[=+<_XHTUT1
M(M,6*-VYBJUB]&<1VZ^J[K<QR>M^\X\\52KRQYOUA[326N-=-S=:EY<N+ZY:
M>..40WMN\05Q!"L3'X9)VE@'Q2+!\'Q*^*LU_+S4]2U#19Y=0]4S)<O&'DEC
MN(G540\[:>)(_6MV)/!G19%;G$_]WBK*,5=BKL5=BKL5=BKL5=BKL5=BKL5?
M_]'U3BKL5=BKL5=BKL5=BKL5=BKL526>\\OV/F)#-.D.K:A&ELD98@RA2[Q*
M1]GD/WWIU^+^\^U^RJCK_3;74$B6Y7G'%+'.L9) +PMSC+ ?:"N%<#^95Q5%
M5X[4^[%6U((J,5;Q5#W.H65M/;P3SI'/=L4M8F8!Y&52[!%ZMQ12QI^SBJ(&
M*NQ5V*NQ5HM0TIBK>*NQ50O[^SL+22[O9DM[6%>4T\K!$11W9FH!BJN.F*NQ
M5V*N.*H>UU"RNI9X;>9))K5Q'=1HP9HG90X5P/LMQ96XG]G%41BKL5=BKB :
M5%:=,5=BKL50\^H64-U;VDTR)=77+ZM S /)Z8Y/P4[MP7=L51&*M,P45.*H
M34=7T[3;?ZS?SI;05ISD-!7B6I[GBK-_JKRQ5$6]Q!<V\5Q;R)-;S(LD,T;!
MT=&%5966H96&X(Q54Q5KEO2F*MXJ[%78J[%78J[%74%:TW'0XJXF@KU]L52\
MZ_HP9E:]A5DN$LG4R+474@!2 [_WK!E/I_;Q5,,5:8T[5Q5O%78J[%4!>:[I
M-E?6]C=7*17=V0MM"Q^)V:O$#W;BW&OVN+?RXJC0XK3%5V*NQ5V*H>SU"QO5
MD>SG2X2*1X9'B8.JR1GBZ$C]I#LPQ5JXU&RMIH(9YDBFNG,5K&[ -(X4N50'
M=CP5FV_9Q5$@U%<5=BKL5< !T%,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5<0#U%>^*NQ5V*NQ59-#'-"\,BAHY%*NIZ$$4(Q5N.-(U"(H51LJJ
M*  "E !BJ[%78J[%78J[%7,*@@=<5271/+TVFZGK-\]W]8_3%RETT7IB/TVC
MACMPH()Y#TX8^O[7+%4ZQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*O__2]4XJ[%78J[%78J[%78J[%78JT_V>M,5>;6WF#6;#S)KT<H@NC>Z[
M;Z98JX=1&[Z=!.C,Y9J1)&)&X(G*2X;X6C]3X%4QN_/&L06EQ"MM;OJ=EK-G
MHMT>4BVY^NM"4FCH#)\,=S&6B;[,G-?4^R^*J_Y@NT?DIY]0MXKJ>WFL7DB#
M31Q&47<0#*49)*(YYJK-\7V9.28JA=3\Z^8[;4]2BM[2S:TT_5[#20':;U)!
MJ*6Y66JCBOI-=#DG%N:K]I<56'SSKXC2 VEL;X>8#H$LH:40\##ZRW"I3G7B
M55H^?_/3%5"YUJ_OO-^A6>HV\<=SH^NSVS3P%FAF6319YU= PY(0LH22.K\7
M_;;%59/S!UN?RMJ7F>VTN/\ 146FW.I:9+).O[SZN"RQR+&TD@+H.3?NX_09
M?2?DV*J6J^?/-&FC6C+:V,J:+!87LG!IU,L-\[H8UJ#PDC])R)/B5^2? GQ8
MJG<'FG4KWS#=:?IU@)[#3;M+'4KII41DD>))BZJSA^*"6, >FWJ_%Q9>/Q*I
M+I_Y@Z],EC-=6EM&FI+JR6ZQM*QCFTIW53(6XAHY5B;E149&Q5T6H7U_;_E]
MJ^JPV\]]J%RC)+'Z\?H_6M,FG8JHDX.W[MD/J!DXMR1%=<5:L_S$UXQV=S<:
M;%-'?'6(K>SLVD:<RZ0\H50T@"O]86!@!PY+(R?:^+BJG/E'S1J>N74L;1VL
MMI#:V\[:A9RNR>O<!F-MP93\<*JK2-ZG^[8_W:XJQO\ ,'6-9O-(\_Z8Y@&G
M:7IL?IJ4?U6:X@:2I;EQ^T*?8^SBJ=ZGYZNM#?68]8@B9M,M+2^B:V9E1Q>S
MR6T<3F2G'C-#\4WPQ^FW-E3BV*IM9:SJD6E7][KMG]2:Q]25EB=92\,<8D+A
M$:3B?M)PY?%QY_#SXXJQZ?SOYM7RX_F!-)MUL5BM[]5:='>:TEJ72 1R'G<*
MG!H>7II.[^BJ\OB95&6'G'4=1GTO3[7ZH;O5[2?4H)R7]%+6&2-%3@&YRW%9
ME]10T:Q_'_+P95(X==UC0]1\XZLT-M-#!J&F_7X49RS&6QLXG]!J 47GS1I/
MM_9;T_MXJG]QYQO8O.&GZ*(K=[:]NIK-S'*\DT9BM7N5D<JOHIR])D^KLWJ\
M>$O^2JJ4V/YC:\UI:7EWIL<RWUMJTUO9V;2--ZNE.0(ZN*-]85:+2/X7_FQ5
M7B_,>ZBL+^^N(;6\L[)+)(KZRG80S7E_((TMQZ@I&(2\7KRO+\*R(W!/C556
M3:+JU^Z+%K<,6GZA)+)';VWK1LTR(JOS1%>0CX6^).;LOV_LMBJ%\PZ]J]IK
MNC:5IL4#'5OK0:>Y,@$9MHA(**@WY_9^U\/^5BJ11_F3?'1)/,1TL?H&95&G
MW#7$:,9)+I+6(3?$[(K-)SF;TE^JK&ZLLC8JJ:RVK1^<_*C:E]7>2*747B-N
M70<?J)J']4GB>7+XN7'C_+BJC%^8VKLVIQK90W3VEO974+61EG^"[>99N*T0
MWGU9;=Y?]%_WH3^ZQ55L//\ )J&H:19M]5-EJ\2B"]0SM!<R-&[21P2A1Z,T
M856^K72Q3.C/P;]W\2J0>6[W52OD@:8EM96GZ)U61+%_7FC5K>6!!\3R&1Z(
M_%&=F;XY/Y\59'Y:\Y:GKUK;Q:;;VMG<0Z9I^HW:3L_I#](1&18H5CH1&@1A
MZS?ZOIXJH'\P]2-[J=NL%HPM]'N]5MGBEDE57M9 GI22!5BEY!T9C ?W;<H_
MB^%V505_YCFTVY\O^8]8M8KJ[_06I7TTUMZT;K%#%;SM$D;2&(M(6^TZ_#Q^
M#A\>*IY-YMUFQGO+2]MK=[P:3/K%D('<Q<8.*O#*S#E]N1.$J+^]7G^[CX?$
MJO\ *OFK5M2U%++4((8VGTJSU>%[<O15NBZM$_J=61D^%_AY?RXJH:EYZO+5
M=6OXK5&TK0;V.QOU9F^LRLZQ%WA4?NP$^L1\%<_O_C_NOAY*IEI>MZS?^:-:
MTST[=+#1Y88?4Y2&>3U[9)PW0(O%GXT^+X<54X_,NI7M_J\=@ELEMH=RMK>?
M67*R2GTHYW*$'A"OIRKZ;R<O4?E_=I\6*I!<_F7JT.F^9+E+6UGFT6SL[ZW]
M*28P2"[:1&C,G#]YZ1A;C-"/3EY?L8JCKCSY?V$^IV-];0R7UIJ-AIUK)$[1
M6[G4E0Q-*7YLGILS!^/+G\'#[6*JNI>:?,=GJ2Z%!96^HZRUO+?\8I/0C-M&
MR( 1.ZD2/(_ \7D6%>$K*W+ABK&[XEKO5&*T)\ZZ.Q'6A-O8$[CPQ5-M5_,3
M5+2]O[>."UD$.FZI?0&.1Y2DFF% JRN%$3>KZGQI&W.W9?3?EBJS5]:FLYO*
M.M:S!%=7/H7\[RVXFC,<8T]KEQ'%ZGINS^EP_>\O^*_3Q5%7/GO5[.U6:YM+
M=GOM'NM8TV.*5R%^J1I(T,[$?%R$T7&6)?\ ?B^G]EF53'RMYFU34-6>PU""
M%';3;+587MRY4)>-*AB?GU9&AV=>/)6^RN*H?7/.UY9/K]Q;6T;V/E?TSJ8E
M=A-,'@2Y<6X'PKPAD7AZG]]-RB_=?WF*K/*TNK3^;_-OUF6*6SAO+9(DX/S5
M38P21JK%BH"^HS../]XSLN*I5/YB/E_4/-DMK8HHCU*%KV[ N+CBCV$,K7,L
M"L\I1&:*&3ZJG&)/W[)\+XJOU/\ ,V_MDU%XH;7E;:7/J>GJS3-'>);P"9I+
M>X5?1EC#\X9(OW=Q#\$S)P?CBJ8ZQY]GT74]4%_;HVFV&CPZM&T;,)BTDK0M
M$_+X%7DH(D_9_;^SBJJGF?S&MS9Z7=Z?%::IJ,TBV3/)SA,,4/K/(PB:1N2G
M]TL?J)ZW][^[^SBJC^74MS!H>MRWAC$\>M:LTQC/"(D73]"_V5_USBJ0S^9=
M2UV]\NUA@MM3LM?$,ME*)XY+>1M+NV:.=77X^-2T4T+-#=)Q=&CQ5,=2_,;5
M+7R[?WRV]J+[2WU**>-Y)>,SZ80#Z$2!IN,P/]XWP6W[?J<EQ5%:EY]OK&ZU
M*::VB32-(TFVUBZ8M(UPZW/U@&)*!45D:W7XV_FQ5;J_G?S%I.DO>ZCIL=L%
M<,UR'-S%%;>F6]>6*V:6?T4EX0R3I]A7^L/'P7ABK-+&Y2XMTD5T<LB.PC?F
M!S4,*-M4$'X33XL51&*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*O_T_5.*NQ5V*NQ5V*NQ5V*NQ5V*N(!ZXJE/^$_+M+\&Q1A
MJ<BS7W(LWJ2I3A(:G9TXKP=?B7@G'["XJU-Y1\MS6$-A)8H;2"<7440+"EP'
M]02D@AFDY_'S8\N?Q_:Q5$ZOHFE:Q9&RU*W6YM&97:%B0I9#R4GB1]EOB'^5
MBJ E\C>597F>2P5WN)XKJ=B\E7G@ $4C?%]N/BO!OV>*?R+BJ2>:?(-O<#3X
MM(T^(PG5X=5U8-/)$9#$K+S!',F6K*>J?W?VL59&_E;0'DL96LT]339#-9/5
M@8Y&'%I*@[NRDJSM\3*S<OM8JIMY.\L-:WEK^CHA:Z@&%W H*HXD/*0<00%6
M1OBE5>/J-]OEBJE/Y%\ISBX6?3UD%W'%#<AGD/J1P;Q(]6^)8_V?^;L51@\M
MZ&+[Z^+.,7A1$:<5Y,(UXH7-?C9%-$=_C3]EL50EMY&\IVK6K0:=&ALFE>U'
M)R$:X-9B 6(_>DGU/Y_VL571>2O*T-O8V\.GI'!ILGJV$:%U$+\>%4HVU$^!
M?Y4^!?AQ5"W/D'RZ+/T["RBAN8%N#82.962*:Z5A(_$.I_>,U9>+*S_%\7Q8
MJH>5O+^NV5Q;3W<\T,-O:?59;)KQ[R.66J$3_O5!CX!&5.!7EZGQI\"XJF>I
M^3?+&J3W$]_IT4\UW$L%VYJ/5C2O%9.)'/CR8?%^RW'[.*JA\J>7FN+BXDL8
MYI;JV6RNC+RE$MLH($3JY9705;9A^T_\[8JB[#2[#3[;ZM:0B.'NN[$[4^)F
M)9MOA^(_9^'%4O3R7Y62.&*/3HHX[>59[=(^2"-TJ4X!2."IR;@B_ O[*XJM
MC\D>5(X8X8].C5(I9+B$@N&26?\ O61Z\T]7_=G%OWG[>*ND\C^5)(;R%].C
M]'4'22\C!<+(\5!&6 8#X %"_P O%/Y5Q5<?)GE?ZXU[^CHA>-*LYG7D']98
M_2]3D#42&(>F[_:D3X7Y8J@+_P#+WR]^C6@TVQAM[J&"ZCTZ1S*T<+W:D2'B
MKJW&1CRE"LO/%5+1?*E\Y9=9+OILED+.XTBXNFU"&9^0)F;UD7C0#@O'[?/X
MU^%,53<>6-*62Q:.$*-.E:>V'VF$KQF(N7;E)7TV9?M?%^U\*KBJ(N=!TJZU
M"TU&XMQ)?6/+ZI/5@8^?VN-#3XOVL545\J>6E2[C&FVYAO\ G];@* Q/ZIY2
M5C/P#U&^*3BO[Q_C?XL54U\F^6EGM;CZBK3V18VTK,[,I=>#;LQY53X/B_8^
M#[.*J,/D'R?!&L<&EPQ(J)$G#DI5(7YQ*I!!7T6_N:?W7Q+'Q5L51B>6- 2<
M3QV,4<JQB%60%:*JE%H%( 949D63[:HW'EBJ$@\B>4[=;=8-/2,6D<L-J%>0
M>G'.:RHE&^%9#]K_ &/\JXJJ0>2_*T M!#IL48LHA;VW'D.,"MS6$[_'"K;K
M$_*-?V5Q5UIY,\JVDWK6VF012%9D/%:#T[D\IH^/V?2D8\VB_N^?Q\>6*NMO
M)?E>UDLY(-/C1]/1XK,@L?3CD #H 3]EE"J5/[*HO["XJOM_*'EJWL[JS@L(
MX[:\C$-S&O(<HE!"Q5K41*"0L:_ O+[.*MZ=Y4\O:==I=V5FL-S';K9QR!G)
M%O'ND6[$<$K\*_LXJJ3^6]"N-234YK*)[Y"C+,1N6BKZ;,/LLT?(^FS#E'^Q
MBJI9:'I5E?7E_:VXBN]097O)@6)D91Q4M4D?"OPC_)^'%5.?RWH,^H/J$ME$
M]W*%$TA']X$%$]51\,O 'X/4#</V<50 _+WR6+-[)=)A6UDA2VDA7D%:&,\H
MXVH?B2,G]VA^&/[*?#BJ(/D[RR?KO/3XY?TD$6^$I:02^E3TRW,M\4?%>#?:
M3C\.*KY/*?ER58!+81R-;,S0R-4R R4#@R$\V60*HD5FXNJJK?97%5&3R/Y5
MDDED?3T+S7*7TIY2"MS& (Y=F^V@"A#^SQ7^5<57+Y+\J)</<+I< ED>=W/'
M8FZ_WH!'V>,_VID^Q(_QO\>*MP^3O+4)T\Q6*(=*).GT9_W7)>)X_%_)\&_[
M'P?8Q5T?DWRQ';W5O'IT20WL?H7"+4 P\BWI"A^"+DS?NTXI_DXJJZ=Y7T'3
MKP7ME:+#=+ EH)0SD^A&24C^)C\"5/$?LXJNO?+FA7U]'?7=E'-=Q\.,K#<^
MDW./D.C^FYYQ\^7!_B3%52RT+2;&\O+VUMQ'=:@XDO906)D=1Q#-4D5"CB/\
MGX<50<GDORQ+<W%S)8(UQ=RBXN)27Y/*$,?(GE_OH^E_QB_=_8^'%58^5O+I
MDNG;3X6-[&T-TI4%'C=!&Z\#\(YHJK)Q'QJJ\_LXJH6ODKRK:R&2'380[VYL
MY"P+\[8U_<R<RWJ1[[(_+CBJI_A+RY]1CL?J$9MH9%FA4\BR2(.*NCU]1&53
MP4JWPI\'V,55-)\N:/I4-Q;V-JL-O=2237$=6=7DE)+L0Y;[=?BQ50C\F>6(
M_JG#3XU-A*)[0@L#'(J>FK U_9C_ ':U^S'^[7X,54CY!\G$DMI4+EGFE;F&
M?DUT )^7(GDL]!ZR'X)/V\51-MY3\NVTTLT5BGJ3VZV<Q<M('MT!"Q.'+!D
M9OA;^9OYFQ5:/)_ED6L5J-/B]"!N4*?%\/P>GQ!K7AZ9]/T_[OA\''CBJ/MM
M,TZUN;FZMK:*&YO2C7<T:!7E,:"-"Y&[<$ 1:_LXJB<5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_]3U3BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_5]4XJ[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%7_UO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5_]?U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_0
M]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_T?5.*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]+U3BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5?_3]4XJ[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%7_U/5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5_]7U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_6]4XJ
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_U_5.*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]#U3BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5?_1]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%7_TO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
M_]/U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_4]4XJ[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_U?5.*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_];U3BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5?_7]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%7_T/5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]'U
M3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_2]4XJ[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%7_T_5.*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]3U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5?_5]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%7_UO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]?U3BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_0]4XJ[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%7_T?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5_]+U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5?_3]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_
MU/5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]7U3BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_6]4XJ[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%7_U_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5_]#U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5?_1]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_TO5.
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]/U3BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_4]4XJ[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%7_U?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5_];U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5?_7]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_T/5.*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]'U3BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_2]4XJ[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%7_T_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5_]3U3BKL5:9:BF*L:O/RX\HWEW-=W-M.UQ<.TDK+>7B*68U)"),J
M+_JJ..*J7_*K?)7_ "RW/_2???\ 5?%7?\JM\E?\LMS_ -)]]_U7Q5W_ "JW
MR5_RRW/_ $GWW_5?%7?\JM\E?\LMS_TGWW_5?%7?\JM\E?\ ++<_])]]_P!5
M\5=_RJWR5_RRW/\ TGWW_5?%7?\ *K?)7_++<_\ 2???]5\5=_RJWR5_RRW/
M_2???]5\5=_RJWR5_P LMS_TGWW_ %7Q5K_E5ODK_EEN?^D^^_ZKXJGFAZ%I
MNB67U+3D>.W+F3B\LLQY-U^.9Y'[=.6*IABKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__5]4XJ[%78J\W\Q7GF
M(>8?,UOI=_>F]M+.PFT2QB"21&[N#<U1U*$>A)]7C$ID;]TG-T96Q5/;>YU+
M6?,&IZ<UU+8V6DI;1R+;T626YGC]=F$QY?N$1D155?B?U.38JG^E6M]:V[0W
MEU]<82.89F4*_I$U17XT#.@^'G3X_P#6Q5&8J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%7__6]4XJ[%78JDL?EH1:]J&LQ7UPL^I0Q6\\7[KTU2 /Z13]WS#(9I&W
M?XN7Q?9Q523RBD3VUS%J%XFIV]JED^I&1&EGBC-5-PCHT$K\BS"3T>:\WX?:
MQ5$VN@/;75O.FH7CB S-+%)*'2=[@@EI05_W7Q_<K$8XX_L\..*IMBKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BJ0ZAYEDBL-0N[:RDE2P=H
MP[.D:2-&_"6A!9QZ9K]I/C_8Q5+KKSE?VUU/;36)BE,[0Z>A]20RHIDK*PA2
M4\*0F@16?XEY<?BXJJQ\[QK(&CL9[FV,4LBW$)5U=HFA1@BU#<!Z]3(ZI\*<
ML55;KS+=F_%K9VJ.TZ6KV<LLWP.+E)Y"6$:R$!5M64<>7-F_D^TJEP\_3&&.
MX^I#T;L!;,!WDD]7E E'2-">/*Y7^ZYO\/V<5:_QQJCRF&#2_7FDC+6BQM)1
MRKQ(6)D2->'[[E\+>HOIOS3EBJO%YUF(2=[8/:,ZVY:-VYFY,"S<55U5?3^+
MTOB?ES^+[&*HO5O,U]8K.1IQ)AL)+_A),BMRA=5>(\?4 XAN7,<N7[*MBKK[
MS%JEOJDMC'9QN#&SVLADDHW!D!Y4C8<OC)]&(R3?#]C]XF*J7E[SI#K%^EG'
M&@802O.PF!*S02I%)$(R _P&3XV<*R/^Z9>:OBK5GYLOIH$E:S4^LU@Z!931
M;?493&C,645DBI\2)\+?#\6*JUOYEO;AD$%FK)/:SW5I*\P59!%,D48/PGB)
M$D67E_E?#RQ5!1^=+ZX]"""S3ZXYD2<2/)''&T9F*U!C$H]1+68\7161N'+]
MK%4;Y9\RW6L2/Z]H;)'C6>S1V+2/"S%>9H. !^>*LDQ5V*NQ5__7]4XJ[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J@_T-
MI7.Z<VL9:\I]:JO]Y3Q&*J#^6=!<W!:QBY73B2=@*%G4L0:C[.[O]G^=_P"=
ML5<_ECR^[R2&PA#RIZ;,%XGC\)HM*<?[M/L_R+BJM<Z)I-S$8IK6-DXQH !Q
MHL7+TPI6A7AS?CQ_F;%5%_+'E]VE8V$-9E5'HM/A6E.-/L?97=?Y5_EQ5P\L
MZ (I(A8Q".551U"TV2A6G\I! -5_:^+%6SY:T FOU&+^Z%O3CMZ84* ![*./
M+[7'%5?]$:7Z(A-K&8A"UMP*@CT7IR3?]EJ?%BJC/Y=T.>>>>6RC>:Y 69R-
MVI0U]F^%?B'Q?"O\N*JMKHVDVCI);6<,,D<9B21$4,$8AF7D!7XF52V*K(=
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'%78J[%7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exh3_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh3_2.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X0T;17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  'H2    G
M$  >A(   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#<Z
M,C8@,34Z,C4Z-#       Z !  ,    !  $  * "  0    !   #CZ #  0
M   !   $FP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   OE
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M_<:WF.&>?N_G/H^U(Y;P8^SW'6) ;_G?3^BDIAZ=_P#H_P#P=_\ Y%+T[_\
M1_\ @[__ "*L5O+V!Q:YD_FNB?\ HERFDII''O-N\U MV[8-SSK.[NU2]._M
M5'D+W_\ D5;224T6XUP?8YU+7;W B;7DB&M9W9_)4A18-10T'Q%K@?P8KB22
MFIZ=_P#H_P#P=_\ Y%1LHR'@ 5Q#FN,WO.C7!Q_-5U))34%5P$-I#1X"YX_(
MU2KJN]5CG,VM;))]5S^1M^B\;59224I))))3_]+U#*<YF-<]A(<UCBTB)D#3
MZ2#;8VK6SU6 \&6G\CBB9T?8KYB/3?SQ]$\H1=1)TH_S_P#S!)3%[LIQ8ZDN
M])XTW022?<UTML^AM0WW9%4BY[6. D G2"0V3[OZZG8:-U>E'TQ^?Y._DJ8=
M0.!1_G_^8)*:[<JYX!9:QT@-!D_3(^/T-R*W+QW.#&V/<YT0T.9)GZ/YRGOH
M\*/\_P#\P2W4>%'^?_Y@DI4W>OLB[;LF-S.9_K)"YAL](&WU-?;+9T^EW53*
M-?J@L(8?3YQ]KW?2_<LK<US$?'=5Z#-X83 DW.:+#YV-8W:UZ2DIL@/+A<!5
M],DL@:!_[W[KE6&7;NV&]A>= )CD_H_S_P"4Q!N>P6W-83626NWT!K_HLK]G
MN;_./_\ /:GC7-]8AY>\/;(%S6L8SRW-;NWI*9_:[0 76L$@S[B-02SVZ_1T
MVH[;IJ;9^D>'$-+F.:1N)V:2[=])/OH\*/\ /_\ ,$'*-/I:"D$/806.!<#N
M'\VTM]UG[B2DGVO'U_2/]IVN]S="9]I]W\E3JMW6,V%Y;):XN+2) W;?:=RK
M8CV%IWNW^UO\_MK[:PUK/I_Z56&&HWU;!4#+OH.D_1_JM24W$DDDE/\ _]/U
M*VL6U/K)@/:6R.1(A-LO_P!(/\W_ ,R4W#<TB2)$2.0J=F/E^HX5.(86M <;
M3,@S]!U-NS_.]Z2D[JKG%I-@]ID>WR(\?-/LO_T@_P W_P R5449X)<'2[0A
MINTG\X?T;]U,<3-#'L#W.#O;N-Y#MNGNTQ_8_P!OYJ2FYLO_ -(/\W_S)+9?
M_I!_F_\ F2J.HSY(!)8Z9/K$.$AS?]!_5?[?_.T:>H$N@QNTUNX _.;^K'^<
M_/24V?1M]3U/4&[;M^CISN\5+9?_ *0?YO\ YD@G'L,CU;H@MT<W@@#P^DW;
M[$QQ[21^FNT$1+/\[Z'TDE)6TVM<]PL$V$./M[@-9IK_ "5+9?\ Z0?YO_F2
M",9XC])<=9@O;W&WP3-QK&G2VXB(@N:>Q'YS?-)2?9?_ *0?YO\ YDHOIM>
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M_]G_[1'&4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M    .$))30/M       0 ,@    !  $ R     $  3A"24T$)@      #@
M           _@   .$))300-       $    'CA"24T$&0      !    !XX
M0DE- _,       D           $ .$))300*       !   X0DE-)Q
M  H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!!X       0     .$))300:
M      -5    !@             $FP   X\    0 &4 > !H #, 7P!0 &$
M9P!E %\ ,@ @ &, ;P!P 'D    !                          $
M         X\   2;                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   2;     %)G:'1L;VYG   #CP    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $FP
M  !29VAT;&]N9P   X\    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M       ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M       X0DE-!"@       P    !/_         X0DE-!!0       0    !
M.$))300,      P!     0   'P   "@   !=   Z(    OE !@  ?_8_^
M$$I&248  0(  $@ 2   _^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !
M_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.
M%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_
MP  1" "@ 'P# 2(  A$! Q$!_]T !  (_\0!/P   04! 0$! 0$
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MMJ5F#C.<7.N:)DM&RGV_F^S=47>W;^<DIN[V3MW#=X3JD7L$RX"!)U[>*I#
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M?5L%0,N^@Z3]'^JU)3<22224_P#_T_4K:Q;4^LF ]I;(Y$B$VR__ $@_S?\
MS)3<-S2)(D1(Y"IV8^7ZCA4XAA:T!QM,R#/T'4V[/\[WI*3NJN<6DV#VF1[?
M(CQ\T^R__2#_ #?_ #)511G@EP=+M"&F[2?SA_1OW4QQ,T,>P/<X.]NXWD.V
MZ>[3']C_ &_FI*;FR_\ T@_S?_,DME_^D'^;_P"9*HZC/D@$ECID^L0X2'-_
MT']5_M_\[1IZ@2Z#&[36[@#\YOZL?YS\])39]&WU/4]0;MNWZ.G.[Q4ME_\
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MLO<ZS8:;&B)WG;M_!Q<C)))*4DDDDI__V0 X0DE-!"$      %4    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #(    ! #A"24T$!@
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M("
M     !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T
M   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D
M;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $
M/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H
M=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M   2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V
M+3(N,0
M            6%E:(        /-1  $    !%LQ865H@
M     %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I8
M65H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
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M<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T
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M.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^)
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MH@    <! 0$! 0          ! 4# @8!  <("0H+ 0 " @,! 0$! 0
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MX%M9Z1,WK5&L:?&/1N'MMYKA809. /K1#U.3P/\ !)^UBJWRSYO&N:AJ-IZ
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M?\JZL?\ J]:[_P!Q6[_YKQ5W_*NK'_J]:[_W%;O_ )KQ5W_*NK'_ *O6N_\
M<5N_^:\5=_RKJQ_ZO6N_]Q6[_P":\5=_RKJQ_P"KUKO_ '%;O_FO%6C^7E@/
M^EWKO_<5O/\ FO%7?\J\T_\ ZO>N_P#<5O/^:\5;_P"5=V%*_IK7:?\ ;5O/
M^:\5=_RKNP_ZO>N_]Q6\_P":\5:_Y5YI_P#U>]=_[BMY_P UXJ[_ )5[I_\
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MJQ_ZO6N_]Q6[_P":\5=_RKJQ_P"KUKO_ '%;O_FO%7?\JZL?^KUKO_<5N_\
MFO%7?\JZL?\ J]:[_P!Q6[_YKQ5W_*NK'_J]:[_W%;O_ )KQ5W_*NK'_ *O6
MN_\ <5N_^:\5=_RKJQ_ZO6N_]Q6[_P":\54?(L%Q9Z[YITMKV[O;6PO+9;0W
ML\ES(BRV,,KKZDA9N/J.S4Q5F6*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O\
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MR+ZB,S/PFD_=?$LGP_!BK)- ;6;_ ,K:>VL<K75I[6,WI@HC),R#GQJ/@/\
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M<6_[AUKBKO\ #7GO_J<6_P"X=:XJ[_#7GO\ ZG%O^X=:XJ[_  UY[_ZG%O\
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MB2$21R?#+PE3E_=\,507DGS%KNLZ?HNH7-]8/^D(GFO-/BB,<J!5-#&WK/\
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MDND7 XW,UJX0_78G++^Z^)U2B.O[IE9^?V567XJ[%78J[%6 ?G1_QP-$_P#
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MRUO-23X94;C_ "8JCI]3\P16&K7$&IZ?>&UL&N("L+<HKA59P)529@\3HO\
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MME=03%ECN;.=E<QEUJ8WBE198FX.OVUX_'R558=#U'4?,6G:[J<44*:/'/\
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MA'* XDV:%O1DJ_\ NN+C^UBK7DW2O-ND^7].T.[LK9$@:1+NZ6Y,B^B[R/\
MNT]-&]0\E7XOA7XOM?M*K=)T+S58^4XO*DJ6LL5O!^CX]6$I :T'[M6:W"!O
M7]#X31^'K?'RX8JWJ'E_5)_.5UJ<FC6FH:6^G06$*S3KZ@:":67F%:-@JL)J
M?;Y<H\597I#:FUC$VJ)%'J#+6XC@+-$K$UXJS4+<1\/.B\_M<%^SBJ-Q5BGE
M7_E,?.O_ #&V7_=.@Q5E>*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O__7]4XJ
M[%78J[%78J[%7G/YS&^ \F&P$37O^);/ZLMP66(OZ,].90,P7_57%4Z]7\U_
M^6;0?^DB\_ZHXJ[U?S7_ .6;0?\ I(O/^J.*N]7\U_\ EFT'_I(O/^J.*N]7
M\U_^6;0?^DB\_P"J.*M>I^:__++H/_21>?\ 5'%7>I^:_P#RRZ#_ -)%Y_U1
MQ5WJ?FM_RRZ#_P!)%Y_U1Q5WJ?FM_P LN@_])%Y_U1Q5WJ?FO_RRZ#_TD7G_
M %1Q5OU?S7_Y9M!_Z2+S_JCBKO5_-?\ Y9M!_P"DB\_ZHXJ[U?S7_P"6;0?^
MDB\_ZHXJA-6D_-/]%7OJ6VA"/T)>96>\)X\#6G[G%4!Y)D_,X>3=!%K;Z(;7
M]'6GH&6>[#F/T$X\PL)4-3[5#BJ=>K^:_P#RS:#_ -)%Y_U1Q5WJ_FO_ ,LV
M@_\ 21>?]4<5=ZOYK_\ +-H/_21>?]4<5:]3\U_^670?^DB\_P"J.*N]3\UO
M^670?^1]Y_U1Q5WJ?FO_ ,LN@_\ 21>?]4<5=ZGYK?\ ++H/_21>?]4<5=ZG
MYK?\LN@_])%Y_P!4<5=S_-;_ )9=!_Z2+S_JCBKO4_-;_EET'_I(O/\ JCBK
MO4_-;_EET'_I(O/^J.*N]3\UO^670?\ I(O/^J.*N]3\U_\ EET'_I(O/^J.
M*N]3\U^GU70:?\Q%Y_U1Q5WJ?FO_ ,LN@_\ 21>?]4<5=ZGYK_\ ++H/_21>
M?]4<5=S_ #6_Y9=!_P"DB\_ZHXJ[U/S6_P"670?^DB\_ZHXJ[U/S6_Y9=!_Z
M2+S_ *HXJ[U/S7_Y9=!_Z2+S_JCBKO4_-?\ Y9=!_P"DB\_ZHXJ[U/S6_P"6
M70?^DB\_ZHXJWZOYK_\ +-H/_21>?]4<5=ZOYK_\LV@_])%Y_P!4<5=ZOYK_
M /+-H/\ TD7G_5'%7>K^:_\ RS:#_P!)%Y_U1Q5A/YKR?F(=%TC](P:.L7Z=
MTGTC!-=,WK?7$],-RB7]WR_O"/BX_9Q5FWJ_FO\ \LV@_P#21>?]4<5=ZOYK
M_P#+-H/_ $D7G_5'%7>K^:__ "S:#_TD7G_5'%7>K^:__+-H/_21>?\ 5'%6
MO4_-?_EET'_I(O/^J.*N]3\UO^670?\ I(O/^J.*N]3\U_\ EET'_I(O/^J.
M*N]3\U_^670?^DB\_P"J.*N]3\U_^670?^DB\_ZHXJWZOYK_ /+-H/\ TD7G
M_5'%7>K^:_\ RS:#_P!)%Y_U1Q5WJ_FO_P LV@_])%Y_U1Q5WJ_FO_RS:#_T
MD7G_ %1Q5A/D:3\Q!YO\^?5(-(:Y.IV_U\2S7002?4(.(B*Q%F3AQY<^/Q_Y
M.*LV]7\U_P#EFT'_ *2+S_JCBKO5_-?_ )9M!_Z2+S_JCBK7J?FO_P LV@_]
M)%Y_U1Q5WJ?FM_RRZ#_TD7G_ %1Q5WJ?FM_RRZ#_ -)%Y_U1Q5W/\UO^670?
M^DB\_P"J.*NY_FM_RRZ#_P C[S_JCBKO4_-?_EET'_I(O/\ JCBKO4_-?_EE
MT'_I(O/^J.*N]3\UO^670?\ I(O/^J.*N]3\UO\ EET'_I(O/^J.*M^K^:__
M "S:#_TD7G_5'%6O4_-;_EET'_I(O/\ JCBKO4_-?_EET'_I(O/^J.*N]3\U
M_P#EET'_ *2+S_JCBKO4_-?_ )9=!_Z2+S_JCBKO4_-;_EET'_I(O/\ JCBK
MO4_-?_EET'_I(O/^J.*NY_FM_P LN@_])%Y_U1Q5WJ?FO_RRZ#_TD7G_ %1Q
M5WJ?FM_RRZ#_ ,C[S_JCBKO5_-?_ )9M!_Z2+S_JCBK?J_FO_P LV@_])%Y_
MU1Q5WJ_FO_RS:#_TD7G_ %1Q5A7F^3\Q/^5@^0S<P:.+T7&H_45CFNC$3]1;
MGZI,09?@^QP#?%]K%6:^K^:__+-H/_21>?\ 5'%6O4_-?_EET'_I(O/^J.*N
M]3\UO^670?\ I(O/^J.*N]3\UO\ EET'_I(O/^J.*N]3\UO^670?^DB\_P"J
M.*N]3\U_^670?^DB\_ZHXJ[U/S7_ .670?\ I(O/^J.*N]3\U_\ EET'_I(O
M/^J.*N]3\U_^670?^DB\_P"J.*NY_FM_RRZ#_P!)%Y_U1Q5WJ?FO_P LN@_]
M)%Y_U1Q5WJ?FO_RRZ#_TD7G_ %1Q5OU?S7_Y9M!_Z2+S_JCBJ#_+\ZP?,?G$
MZPMNE_\ 7K3U5M&=X:?H^#CQ:14>O'[7PXJSC%78J[%78J[%78J[%78J[%78
MJ[%78J[%7__0]4XJ[%78J[%78J[%6 _FQ_O7Y%_\"BR_Y,SXJS[%78J[%78J
M[%78J[%78J[%78J[%78J@M;_ ..-?_\ ,--_R;.*I=Y _P"4#\M_]LNR_P"H
M=,53[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78JP#\Z/\ C@:)_P"!%HW_ %'1XJGGYC:WJ.A>1M:U?361+ZSMFDMW
MD7FBN" "RU'("O2N*L:U?4O._EI;.\N?,MEK<=U>VNG_ *--FEM,_P!;F6'E
M;O'-(6FA#>OZ;(RM%'+]G[:*J%SY]\T7/D71OT6]M_C35;J32^#+RA2[L?5-
MZQ0&O"EK(%^TO*6+]GBV*J'G;\T=5C\J:7J?EJ2&*ZO]*N];F$R"7TH+6V!X
M%.2_%];G@B;?E\$G^7Q51VM:EYY\KQ6NHW/F.RUV*6\M;(Z2;-+6:;ZU,L5+
M>2.:1O70-ZJIZ;JR(_\ KJJ](Q5V*NQ5V*NQ5V*NQ5V*O/\ \N_^4Y_,?_MK
M6O\ W3;?%5;7O-WFVV\\:'I-OI0M?+]WJ!LKK5;B1#)<,;&>Y5;6%"S+&K14
MDGEX?&O"./C\>*LD\Q3>8H]+/Z ABFU.22*.-[D_N8D=P)9I%#(T@BCY/Z:-
MRD;X<5>=:_YZ\X>5WUC2;[4[75+F*WL9K/58[5D>V>^O!:^E/:Q-*)6]/U+J
MVXLC3>E)'Q^R^*HFT\^ZO8^7M<O9=6;5M8M%M4M-+O\ 2Y=(DBEO)OJ]N\T<
MA]5[>69UK(OV5C?]K%4^TO4/-VE^;K70->U"WU6#5;.YO+*[AMC:21RVDD*R
MQ.@DE1HBEPC1O7U.7/EBJW4=2\X:MYLU'1/+^H6VEP:+;6LUS-<6QNGGN+LR
MLL5/4B"0+'&I9U_>\W_9X?$JDWE_SAYS\Z-$FBWEIHIL]/M+K4FEMFN_4O;E
MID>",&6/C:I]7/[S^^?E^QQQ5=H_G/S9YO;3++1[JWT6X;2UU+5[E[<W=)VN
M7M1!;HTD:^EZMM=,TC_'P6'^=L599Y'UZ_UK0EN=12./4;>YN[&_6#EZ)GLK
MB2VD:+D6;TW:+DO(XJR'%78J[%78J[%78J[%78J[%78J[%78J[%78J[%6 >>
M/_)F_EQ_S$ZI_P!T]\53'\R/,>IZ'IEF]C<0:<EY=I;7FM7:-+!80E'D:>2,
M%>?(QK!'S=(EEE1Y6X8JQO1_./G:?ROHD1O]-O\ 5-?O8K/3M<@7G%Z+6KW<
M\D]M&P1;FW2&:)8DE]*258V;T^31XJRCRCJVO_IO6/+FNW$-]>:7':74&H01
M&W]:WO1(%]2+G(J2I+;S)\#<6C]-OM<L58[JOFOSQ)9>9O,VE7=G%H_EF>[A
MCTF:W9WNTTY!]::2X$@:%V=9EM_3CX_!$\G+FR8JB_-7G?S59ZKH4.E:7PT2
M^OM/M[[6;IT')+V0*(K:!2SM)1OWLLGII'^QZN*O05K05ZXJ[%78J[%78J[%
M78J[%6*>5?\ E,?.O_,;9?\ =.@Q5E>*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*O_T?5.*NQ5V*NQ5V*NQ5@/YL?[U^1?_ HLO^3,^*L^Q5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*H+6_P#CC7__ ##3?\FSBJ7>0/\ E _+?_;+LO\ J'3%4^Q5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*L _.C_ (X&B?\ @1:-_P!1T>*I[^8F@7OF#R1K.BV0C:ZO[=H8A*>,9+$;
M,:-M3VQ5?I/D+R3I%V+W2O+^G:?>J"J7%M:PQ2 'K1D4'%6.:#^7NHV/YD:E
MKT[HVB*9[G1K>O)X[O4EA%\[ CX=[;]W\;?[T2_87%4A?\HM>33O.NGQO;R6
M^H6<^G^58V:@AM[N>6\FCDHO[M?7F$=/WG[J&/\ U,5>A:5Y!\C:1>+>Z5Y?
MTZPO%!5+FVM88I #UHZ*&%<53[%78J[%78J[%78J[%78J\__ "[_ .4Y_,?_
M +:UK_W3;?%4^\S:)?:CJOEJZM@GIZ5J9O;KFU#Z1LKFW^#8\F]2=/A_EQ5#
M:QK7FBZT[7+7RU9V[ZQ87*6EJ;F?C$P:&*9YB0C4:,3%1#\7QI\3\6Q5)M%T
MC\P;;2[N*WL+;3-8>2*\?5;F]%^]_.KKZD=UPM8/222%3$C0C_1UX+!$J)QQ
M51U;R1YJ\T_I+4]5BM=&U)K&.RTBTBG:\C22&Z2]6:XD]*'DOUB"%?3C7^Z]
M3E\3?"JB+IO-L>I2^<M?T^SLT\OZ9>16&FV]XTS3RSM%)*[S-#&L:,MO''$G
MIN_/EBJ,U#2O.&F>:M0USR[96FH0ZU;6L%U;W=P]J\,]J9 LP*Q3!X3'(JO%
M\,G)/\OX54HT#R9YS\FM$^A6]EJYN]/M+34EN+B2TX7MLTSM<1D13\K=_K#?
MN?AD3C]IL57:1Y)\U^46TN]T2"UUBY32UTW5[::X>S#S+</=">"3TI^,?JW%
MT#$R\N#Q?'^[Q5E?DC0+[1-"6UU"2.;49[BZOK]X.0A^L7MP]S*(N5&]-6EX
MIRQ5D&*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L \\?^3-_+C_F)U3_N
MGOBK)?-$/F9K6";R\\)NK>99)K*Y)2*[AXLKP&4+(T+'D)(Y57^\C7U/W?/%
M7G6A?EUYRM[.SUU+:QT_5[*73KFT\OK(XMS]4M)K6Y,\Z)Q%W>174B^HD#)%
MZ-OR]7CRQ5EWE_2_-<.IZOYEU.SMH]4U3ZC:0Z7!<%TAM+1GJSW!B7U)>5S<
MS?#$OP^G#R_;Q5)=5\H^=UL_,OEO28+%]%\S3W4PU2>>19;1-00?6T:W$3>N
MW,S- 5FC_O(T?^[Y8JR3S7Y:NM0T[0[73PO'3=3TZ[D$K4/H6<H9Z&AY/Q78
M?M8JR=:T%<5=BKL5=BKL5=BKL5=BK%/*O_*8^=?^8VR_[IT&*LKQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5__]+U3BKL5=BKL5=BKL5><_G-/<6_^"YK>V:\
MGC\RV;1VL;(CR,(9_A5I"D8)_P ME7%4]_Q5YL_ZDO4/^DO3/^RK%7?XJ\V?
M]27J'_27IG_95BKO\5>;/^I+U#_I+TS_ +*L5=_BKS9_U)>H?])>F?\ 95BK
MO\5>;/\ J2]0_P"DO3/^RK%7?XJ\V?\ 4EZA_P!)>F?]E6*N_P 5>;/^I+U#
M_I+TS_LJQ5W^*O-G_4EZA_TEZ9_V58J[_%7FS_J2]0_Z2],_[*L5=_BKS9_U
M)>H?])>F?]E6*N_Q5YL_ZDO4/^DO3/\ LJQ5W^*O-G_4EZA_TEZ9_P!E6*H3
M5_-'FIM)O5;R;?HI@E!<W6FD %#OM<D[8JE_DCS-YHC\F:!'%Y0OIXDTZT6.
M=;G3E5U$" .H>X5P&'Q?&JM_-BJ=_P"*O-G_ %)>H?\ 27IG_95BKO\ %7FS
M_J2]0_Z2],_[*L5=_BKS9_U)>H?])>F?]E6*N_Q5YL_ZDO4/^DO3/^RK%7?X
MJ\V?]27J'_27IG_95BKO\5>;/^I+U#_I+TS_ +*L5=_BKS9_U)>H?])>F?\
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M#@O[;+BK-1YJ\V$?\H5J ]OK>F?]E6*M_P"*O-G_ %)>H?\ 27IG_95BKO\
M%7FS_J2]0_Z2],_[*L5=_BKS9_U)>H?])>F?]E6*N_Q5YL_ZDO4/^DO3/^RK
M%7?XJ\V?]27J'_27IG_95BKO\5>;/^I+U#_I+TS_ +*L5=_BKS9_U)>H?])>
MF?\ 95BKO\5>;/\ J2]0_P"DO3/^RK%7?XJ\V?\ 4EZA_P!)>F?]E6*N_P 5
M>;/^I+U#_I+TS_LJQ5W^*O-G_4EZA_TEZ9_V58J[_%7FS_J2]0_Z2],_[*L5
M81Y$\P^8HO.'GR6'RM>7$L^IV[7$"7-@K0,+"!0CEYU5BR@/6)G7XOYL59O_
M (J\V?\ 4EZA_P!)>F?]E6*M?XH\UUK_ (+U"O\ S%Z9_P!E6*M_XJ\V?]27
MJ'_27IG_ &58J[_%7FS_ *DO4/\ I+TS_LJQ5H^9_-9()\EZA4=/]+TS_LJQ
M5O\ Q5YL_P"I+U#_ *2],_[*L5=_BKS9_P!27J'_ $EZ9_V58J[_ !5YL_ZD
MO4/^DO3/^RK%7?XJ\V?]27J'_27IG_95BKO\5>;/^I+U#_I+TS_LJQ5W^*O-
MG_4EZA_TEZ9_V58J[_%7FS_J2]0_Z2],_P"RK%7?XJ\V?]27J'_27IG_ &58
MJ[_%7FS_ *DO4/\ I+TS_LJQ5W^*O-G_ %)>H?\ 27IG_95BKO\ %7FS_J2]
M0_Z2],_[*L5=_BKS9_U)>H?])>F?]E6*N_Q5YL_ZDO4/^DO3/^RK%7?XJ\V?
M]27J'_27IG_95BKO\5>;/^I+U#_I+TS_ +*L5=_BKS9_U)>H?])>F?\ 95BK
MO\5>;/\ J2]0_P"DO3/^RK%7?XJ\V?\ 4EZA_P!)>F?]E6*N_P 5>;/^I+U#
M_I+TS_LJQ5A/G#S#YCD_,/R'-+Y6O(98+C43!;-<V!><M8LK!"MPR+P'QMZK
M)\/V?BQ5FW^*O-G_ %)>H?\ 27IG_95BKO\ %7FS_J2]0_Z2],_[*L5=_BKS
M9_U)>H?])>F?]E6*N_Q5YL_ZDO4/^DO3/^RK%7?XJ\V?]27J'_27IG_95BKO
M\5>;/^I+U#_I+TS_ +*L5=_BKS9_U)>H?])>F?\ 95BKO\5>;/\ J2]0_P"D
MO3/^RK%7?XJ\V?\ 4EZA_P!)>F?]E6*N_P 5>;/^I+U#_I+TS_LJQ5W^*O-G
M_4EZA_TEZ9_V58J[_%7FS_J2]0_Z2],_[*L5=_BKS9_U)>H?])>F?]E6*H'R
M!>7EWYD\XSWEC+IMPU]:![.9XI'4#3X "6A>2/XA\6SXJS?%78J[%78J[%78
MJ[%78J[%78J[%78J[%7_T_5.*NQ5V*NQ5V*NQ5@/YL?[U^1?_ HLO^3,^*L^
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*H+6_P#CC7__ ##3?\FSBJ7>0/\ E _+
M?_;+LO\ J'3%4^Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*L _.C_ (X&B?\ @1:-_P!1T>*LPUW6]-T+1[O5]3F$
M%A91F6>4@M11V"CXF9C\**OQ,WPXJQ4?F#YDM8H]1UKRE=:;H4K*K7*W$5U=
MP)(W%)+FSA!:-!_NWTI9WA_;3^\X*HQ_S!MH_+>M:S+:.DVBW5Q8S6'(%Y+B
M&41PHC4%?K7.'TOA_P!V_M_M*K'_ #$A'E#3?,"V+F?4;B&R732X5X[MYO0F
MB=Z?\>SI+ZAX?[J;X4Q5*;3\S?-C^7(/-%SY1":!+9IJ4DEOJ,4UTMH\0FYB
MW:*(.ZQGDT?J\OY>3?#BKT&TNH+NUANK=N<%PBRQ/0BJ. RFAWW!Q55Q5V*N
MQ5V*NQ5V*NQ5Y_\ EW_RG/YC_P#;6M?^Z;;XJBM:_,/5=*N;ZZE\N7/^%],E
M$-_K4DJ1/M0/+!:.OJ7%O&S*OJ*Z^I\?HI)Q^-59J_YE7EE)JMU:Z#-?^7]!
ME:'6-4CGB5U:)%><V]N:M<+;A_WQ+Q?$DJ)S>/%4_P#,?FBVT31CJ9B>]]22
M&&SMK<KZEQ-<R+%"D9=E0\W=?BY?"G)\52)OS*DTZ'5$\R:1)IFHZ9:1WRV<
M,T=V+J&:0PQK;2#TN<QG"PM&R)Q>6'_?BXJLG_,VYTGZY'YHT*;2KF&SDU"R
MB@GBNQ=1QR)$T,3#TO\ 2_5FA3T:<?WT?&5L53#1?..JSZXNAZ[HK:-?SV\E
MY8D7$=U%-#$Z)(O- A6>(RQL\?%EX/R65L5:UGSGJL&MR:+H6B/K5[:017>H
MGZQ':QQ1SLZQ(K.'YW#^D[+$1&O#XFE7DN*H,?F3+J*:8GEC2'U:]U&Q&IO!
M+/':+;6Y<1<9W(EXSF7G$L2HWQ0S_'^[Q59%^9ESJ:V5OY>T*:_U:XAFN+RP
MN9XK06:VTYM9$N)/WU)?K"R1QHBMZGI2MR^#%62^5_,-OYAT6'4X(9+8NTL,
M]I/Q$T,\$C0S12!2R\XY$9=FQ5-<5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBK //'_DS?RX_P"8G5/^Z>^*LA\V^:)="ALTM+!]3U/4[@6>FV$;K$))BCRM
MSE:JQ1QPQ22NY#?"GP*[_#BJ0V7YFWLOEVUO+KR]=6^N7MS#96>D<U*7$MQ%
MZ\<D%T>,;VPAY2S2\.<*QRJ\7-..*IYY6\TW.K7.H:=J6G-I.LZ68C=V9E6=
M#'<*6BEAE4+ZD;\73D8T_>QR)^QBJ3:M^9=Y9RZM=VN@S7WE[096@U?58YXE
M=6B17G-O;FK3I;<Z3L9(N+),J<VCQ57\P_FCH>D:[I>A1I)J&I:E<VMNXME9
MHK9+M@L<MQ, 8XP]?W49;G+^SBK,@20*]<5=BKL5=BKL5=BKL5=BK%/*O_*8
M^=?^8VR_[IT&*LKQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__]3U3BKL5=BK
ML5=BKL58#^;'^]?D7_P*++_DS/BK/L5=BKL5=BKL5=BKL5=BKL5=BKL5=BJ"
MUO\ XXU__P PTW_)LXJEWD#_ )0/RW_VR[+_ *ATQ5/L5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK /SH_P".!HG_
M ($6C?\ 4='BJ??F!HE]K/E*]LM/5'U!7M[NSBE/&.2>RN([J*-VH>*2/"J,
MW\K8JDEQ^8NJ7L$-AH7E[4AYBN&C62#4;.>WM+0%E]9[BZ(6"18D+\1:S2^N
M_%8_M<\52#7/+&MW'YH+IL5O,_E?6;JR\P:E<!6]%9M+B:+T'8U3E/-%IS\?
MA=DBD^'BF*K8?+NN#\QKO39+6<^7K&:]\S:?=4;TFN;ZV%K]6# <&>.>2^FX
M?WG[V/\ 9^VJB_)7Y8/=>1="M-:US7&MY-,M([_0IIXX80/04/;.L<,5PD:G
MX&C];EQ^"3E\6*O441(T5$4*B@*J@4  V  &*MXJ[%78J[%78J[%78J\_P#R
M[_Y3G\Q_^VM:_P#=-M\52?\ ,BNNQ7NEW>@:F/,^GRR-Y0O+%)Y+9Y3PDMKE
MIUXVD?IR!/K$=Y]CTY?3]177U%5"^;5],\N><?*3Z3?WNL:[/?MI<]M;2/:7
M'Z4B'QFX ]"W6"26191<21-^ZY+]M<59!YQBFFT*UT_3X9K_ %#RO>:1?W5I
M#&P>:*WF1V$!?BCL8XY' 5F^)/2^WBK'O-=GJ?G&]U76M'TV]%M8:9:Q6D=W
M;R6<M[<0:E'?R0PQW(BD7BEHL7J2)P:2=>/]VV*M>>$U3SQ="\T/2;\0Z'IT
M[_Z9;26;7%TU[972VD*W(B8R<+!OWO%H/WJ?'BK((]9_3GG6PUZ#3]0M=)\O
M:9J N[B\LY[=GFNFMR(8HI5265XTMG=FB1X_LHK<\56?ID:'YRU/79+"_OM)
M\QV&G2Z?<V%I-=?O;<3*8'2)6>)G26.1'E6.+XN//DF*I'Y0L]2\D7&EZAK&
MG7LEO?:*EM<_4K:6\>TNTO9[ST)8[82R'DM\R>JJ>ESMW^+]XF*N\JKJ?E76
MCYCUG2;]+/7K>\>2*VMI+N:SEEU6YOH8KB*V$TG*2&]^VJ<(WA=7^VN*LW_+
M:PU"U\MR2ZA;/97.I7^H:D;*6GJPI>WDMQ'')Q)'-4D7G_E8JRG%78J[%78J
M[%78J[%78J[%78J[%78J[%78JP#SQ_Y,W\N/^8G5/^Z>^*II^8D5M)I,*WNB
M/KFF"X0W\4 =KF"+BU+F!(Z2R/#)PY+"RS>DTC1<V_=LJ\U\M)YBCT[0M9M[
M+5;SROH-UI]U;0W2RRWK";3[FUOY+>.4FZ:T@-S;R0Q,G-_3G^K)Z7IXJSKR
MU?R7/F?S!YK>QO;72KR+3--L1<6TR7$QMWF+S?5ROKQQ>I>^G62)./I23?W7
MQ8JQW5'U/3M \[>4!I%_=ZGKMUJ3:/+!;2/:SQZLO(.URH,$'U=I7287$D;?
MN>2?;3%64>==)N_T/Y:MK:)[EK36=(>=HD+4C@F7G(P%>**HY,Q^SBK-5-0#
MBKL5=BKL5=BKL5=BKL58IY5_Y3'SK_S&V7_=.@Q5E>*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*O\ _]7U3BKL5=BKL5=BKL5>=?G+=Q68\EW<RNT4'F6S=UBC
M>60@0S_8CC#.[?Y*+RQ5//\ E9/EW_EFU;_N#ZI_V3XJ[_E9/EW_ )9M6_[@
M^J?]D^*N_P"5D^7?^6;5O^X/JG_9/BKO^5D^7?\ EFU;_N#ZI_V3XJ[_ )63
MY=_Y9M6_[@^J?]D^*N_Y63Y=_P"6;5O^X/JG_9/BKO\ E9/EW_EFU;_N#ZI_
MV3XJ[_E9/EW_ )9M6_[@^J?]D^*N_P"5D^7?^6;5O^X/JG_9/BKO^5D^7?\
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MV3XJ[_E9/EW_ )9M6_[@^J?]D^*N_P"5D^7?^6;5O^X/JG_9/BKO^5D^7?\
MEFU;_N#ZI_V3XJ[_ )63Y=_Y9M6_[@^J?]D^*L(\B>>=%MO.'GVXD@U(I>:G
M;21"/3+^1PJV$"'U$2!GB;DOV951N/Q_9Q5F_P#RLGR[_P LVK?]P?5/^R?%
M7?\ *R?+O_+-JW_<'U3_ +)\50L7GCRE%>3WD5EJR7%SP^L2#1]4J_IKQ0&M
MOT4'MBJ*_P"5D^7?^6;5O^X/JG_9/BKO^5D^7?\ EFU;_N#ZI_V3XJHW?G[R
MQ=V\EO-:ZNT,JM'*GZ(U455QQ85%N#N#BJZ#\PO+$$$<$-GJL<,2A(T71M3
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MRKVW_P"IAUWQ_P".C-BKO^5>VW_4PZ[_ -Q*7%7#\O+<]/,.O?\ <1FQ5O\
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M/^WE+BKO^5>V_P#U,.N_]Q&7%7?\J\MS_P!-#KO_ '$I<5<?R]MAU\PZZ/\
MMY2XJ[_E7MM_U,.N_P#<2EQ5W_*O;;_J8==_[B4N*N_Y5Y;_ /4PZ[_W$9<5
M;_Y5W!_U,&O?]Q&;%7?\J[@_ZF#7O^XC-BKO^5=P?]3!KW_<1FQ5W_*NX/\
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M)2XJW_RKVV_ZF'7?^XE+BKO^5>V__4PZ[_W$9L5</R\MS_TT.O?]Q&;%7?\
M*O;;_J8==_[B4N*N_P"5>VW_ %,.N_\ <2EQ5W_*O;?_ *F'7?\ N(S8J[_E
M7MM_U,.N_P#<2EQ5Q_+RW'7S#KO_ '$9L5=_RKZV_P"IAUW_ +B4N*N_Y5[;
M?]3#KO\ W$I<5<?R]MAU\PZ[_P!Q*7%7?\J^MO\ J8M=_P"XE+BKO^5>V_\
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MDI\"/U_F.*H?R7YNN]5\S:YI-Y/%)'Z=OJ>C&'@#^C[GE$H:C,2ZR0EV9O\
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MF$3>CQ]4J?3+U*AJ;<J4-*XJQ"P\HZ[8^1+;RO!J%NLUO$EJ;T0R -;@ /1
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M_N&1?]5<5=_A[\PO^INB_P"X9%_U5Q5W^'OS"_ZFZ+_N&1?]5<5=_A[\PO\
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MX>_,+_J;HO\ N&1?]5<5=_A[\PO^INB_[AD7_57%7?X>_,+_ *FZ+_N&1?\
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M<BI+'+;S+\#<6C]-_P!K%6.:MYJ\[O9>9?,NE75G%I'EFXNH4TF>W9WNTTY
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M\QMY_P!DN*M_6/S3_P"K?H?_ $FWG_9+BKOK'YI_]6_0_P#I-O/^R7%6C/\
MFD34Z?H51_R^WG_9+BK?UC\T_P#JWZ'_ -)MY_V2XJ[ZQ^:?_5OT/_I-O/\
MLEQ5WUC\T_\ JWZ'_P!)MY_V2XJ[ZQ^:?_5OT/\ Z3;S_LEQ5WUC\T_^K?H?
M_2;>?]DN*N^L?FG_ -6_0_\ I-O/^R7%7?6/S3_ZM^A_])MY_P!DN*N^L?FG
M_P!6_0_^DV\_[)<5=]8_-/\ ZM^A_P#2;>?]DN*N^L?FG_U;]#_Z3;S_ +)<
M5=]8_-/_ *M^A_\ 2;>?]DN*N^L?FG_U;]#_ .DV\_[)<5=]8_-/_JWZ'_TF
MWG_9+BKOK'YI_P#5OT/_ *3;S_LEQ5WUC\T_^K?H?_2;>?\ 9+BKOK'YI_\
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M8_-/_JWZ'_TFWG_9+BKOK'YI_P#5OT/_ *3;S_LEQ5WUC\T_^K?H?_2;>?\
M9+BJ"\@-J[>9/.+:M';Q7_UZT]5+21Y80/T?!QXM(D3'X?M?!BK-\5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5?__7]4XJ[%78J[%78J[%6 _FQ_O7Y%_\"BR_
MY,SXJS[%78J[%78J[%78J[%78J[%78J[%78J@M;_ ..-?_\ ,--_R;.*I=Y
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M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L
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M_P#LLQ5W^+_,G_4E:M_R.TO_ ++,5=_B_P R?]25JW_([2_^RS%7?XO\R?\
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M #)_U)6K?\CM+_[+,5=_B_S)_P!25JW_ ".TO_LLQ5W^+_,G_4E:M_R.TO\
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M^5?^UC_W"M3_ .R;%7?\K+\J_P#:Q_[A6I_]DV*N_P"5E^5?^UC_ -PK4_\
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M:7EQZT/JK(LMJ\"JOQGAP9;C_@L591Z@Y*#L6-!4TJ>O\,5=)*L8):@44W)
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M*":"I K].*H?0M4MM8T2PU:W5EM]1MXKJ%7 #A)D$BA@"?BHV^*HWBOABKF
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M>6-Y%5EC0 LY!/10RG_9+BJ[]/:+6$?7H*W'H^@/46K_ %@,8>.^_J\']/\
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4*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exh3_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh3_3.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X0;Y17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  'H2    G
M$  >A(   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#<Z
M,C8@,34Z,C4Z,SD      Z !  ,    !  $  * "  0    !   #CZ #  0
M   !   $FP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   7#
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M         0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:  P# 0 "$0,1 #\ ]522224I))))2DDDDE*22224I))))2DD
MDDE*22224I))))3_ /_0]522224I))))2DDDDE*22224I))))2DDDDE*2222
M4I))))3_ /_1]522224I))))2DDDDE*22224I))))2DDDDE*22224I))))3_
M /_2]522224I))))2DDDDE*22224I))))2DDDDE*22224I))))3_ /_3]522
M224I))))2DDDDE*22224I))))2DDDDE*22224I))))3_ /_4]522224I))))
M2DDDDE*22224I))))2DDDDE*22224I))))3_ /_5]522224I))))2DDDDE*2
M2224I))))2DDDDE*22224I))))3_ /_6]523.)#20"X@3 Y/WJNS+<_;^KW-
M!(!W- B?'W)*;*2AZC?!W^:?[DO4;X._S7?W)*9I*O==DAS!CUM>TD^H7ES"
MT1["QHK?ZGO]G_35<9'6@1.)0X2)/K/:2.YV?9[-NW]SU/\ KB2G025&S(ZH
M PU4T//N%C76O9'N'I;7^B_Z57N?^C^G[$F97438UME%#*]T/>V]SB ?H[:S
MCU[GO_<WI*;R2AZU?CX>/?1O^<F%U9, R?  GR[?!)21)0]1O@[_ #7?W)>H
MWP=_FN_N24S24/4;X._S7?W)P\$P ?F"/RI*9))))*?_U_554N-@R;-HO(%(
M(V;/3G<=&;_=]H_Z'IJVJEN,Y^4^WTF.:ZD5[R]P<?<7;-C?9L_EI*1U.O=8
M&&S) U&Y]=8;QXBM'^SW1IDV<^%?&FG\VJYQ;0*VBB0QQ+?UFSVZ;=W".U^:
MUH IKT@0;7$Q_6-7N24R^SW3(R;/A%?_ *31:VN:T-<\V$?G$ '_ * :U1J=
M<X'UF"L@Z;7;@1_FL1$E(7X>)8\V/IK>]T;G.:"3'Q"1P\0\T5GXL;_=Y(R2
M2D/V+#_T%>AGZ#>?'A2JQZ*9]&ME>[G8T-GX[41))2DDDDE*22224I))))3_
M /_0]4)@$\QKIJ4*O):]Q;LL; !ES" 9\)_.1DDE(&Y;79#Z/3L&P!WJ%A],
MS^:RS\YR)ZC//[BII)*1NN:UI=#G0"=H!),=FH9S&"LV>G; #3'INW'=X5QO
M]G^$5A))2&G)9;6+-KV3(VO:6N$';JUP\E/U&>?W%3224P]1GG]Q2]1GG]Q4
MTDE,?4;Y_<4''S/6G=3;3 !'JMB9G0;2[Z.U6$DE,/49Y_<4X>TF!/W%2224
MI))))3__V?_M"Z10:&]T;W-H;W @,RXP #A"24T$)0      $
M           X0DE- ^T      !  R     $  0#(     0 !.$))300F
M   .             #^    X0DE-! T       0    >.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-! H       $  #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      U4    &              2;   #CP   !  90!X &@ ,P!?
M %  80!G &4 7P S "  8P!O '  >0    $
M 0             #CP  !)L                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !)L     4F=H=&QO;F<   ./    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     $_\        #A"24T$%
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M# P,#/_  !$( *  ? ,!(@ "$0$#$0'_W0 $  C_Q $_   !!0$! 0$! 0
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MVEKA!VZM</)3]1GG]Q4TDE,/49Y_<4O49Y_<5-))3'U&^?W%!Q\SUIW4VTP
M1ZK8F9T&TN^CM5A))3#U&>?W%.'M)@3]Q4DDE*22224__]D .$))300A
M  !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
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M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(                  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
M^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+
M 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"
M2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M
M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$
M2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&
M!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'
M!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ
M"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*
MF JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG
M#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/
M"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,
M$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4
M:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E
M%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:
MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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MQ5V*NQ5V*NQ5IJTVZXJQS3_* @_Q$UW<O<R>8[F26>2,&!XH6@2VBA1U8O\
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MH8J[Z]YG_P"K3;_])A_ZH8J[Z]YG_P"K3;_])A_ZH8JXW_F8==*M_P#I,/\
MU0Q5WU[S/_U:K?\ Z3#_ -4,5=]>\S_]6FW_ .DP_P#5#%7?7_,W_5JM_P#I
M,/\ U0Q5WU[S/_U:;?\ Z3#_ -4,5=]>\S_]6FW_ .DP_P#5#%6OK_F;_JU6
M_P#TF'_JABK?U[S/_P!6FW_Z3#_U0Q5WU_S-_P!6JW_Z3#_U0Q5WU[S/_P!6
MFW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6
MFW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6
MFW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6
MFW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6
MFW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6
MFW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6
MFW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6
MFW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6
MFW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q5WU[S/_P!6
MFW_Z3#_U0Q5WU[S/_P!6FW_Z3#_U0Q55MKK79)E2ZT^&" UY2I<F1AMM1?22
MN_\ E8JMT;3[VS>]^L7$EPEQ=2W%N)7]0PQR4I$K$*> 8,ZK_NOGZ7Q+'BJ:
M8J[%78J[%78J[%78J[%78J[%78J[%78J_P#_U/5.*NQ5V*NQ5V*NQ5V*NQ5H
M"G<XJWBKL5=BKL5<!3^W%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78JA=3U&VTVPGOKIN%M;HTDK
M4)/%1V W9CT51]IL505GK%"1J-Q!:W,L1NDL'95EA@4;F2K'EQ_W:X'IQM\'
M^6RJY/,FEP:=:7>JWEG8-=QK(BO<QF,AQ4<)#P604_:7%40FMZ-),D*7]L\T
MDC01QK-&6:5$]1HP :EUC/-E^UP^+%5.ZU_1[:Z:TFOK>.X16D>)Y%#(B+R9
MG%?@4+OR?CBJGI/FC0=3M8;FUOH62>-YXE9U5S%&:._ GEQ6HY']GE\6*JYU
MW0UG%N=1MA.3$HB,T?.L]?1'&M:RT_=_S_LXJKVVH6%TTBVMS%.T+<)A$ZN4
M>E>+<2>+4['%4LUCSAY=TO3M0OI]0MRFF*YNXUFCYJZ*S>F06^&1N#*JMBJA
MY5N=8NK1-4U*_MIHKJ!)&M;95,5M,"QE5)PQ]55!6-N?[<;R?"K^FBJ86_F+
M0[AP(-0MI TPMT*RH0\Q02"-#6COP8-Q3EBJEJ/F;1+%[2.XO(E:_F^KVH#*
MQ>0$ANA^RA4J[?LM\/VL52_RQKIO[R_^L7L)6:\G71[2J+*;6TXP22!?MR*T
MZ2MS^)>#)BJ;)YB\OR(LB:G:.CR&!&6>,AI0.1C!#;N%^+A]KCBJDWF/3O70
MQW5H]B;8W<EW]9C^%&8+$P45Y12?'^]Y<.2<?BY?"JK0Z_H4]B]_#J-K+8Q,
M4DNTFC:)67[2LX;B&7N*XJD_GKS#+8^7W31[N)==OS#!I"_!(3)<RK$D@C->
M<:<C(^S? K8JG-[?FS6SB!BDGN9D@599%A+"A:1D!!]1UC5G])!_P*_%BK<&
MM:1/+'#%?6\D\S2)%$DJ,S-#_>JH!JQC_P!V4^Q^UBJ1^8_,,R:_HFDZ7>1)
M-)<O/J_V)/2L+6%GFYU/[GG*]N@<_P V*II:^8M.-G#-?75I:S2VYO/2%S&Z
MBW%/WH?X0\0#)RE ]/XOM8JK)J?/4;JU!A].UCC>5Q*ID5Y.1XR1C>-0BJZN
MQ^/E_DXJQ_3_ #+]=\VZ@J:A!^@+2&TM(:F/C+J5PS2,L<U?C*PF!?24_;D^
MSBK)+C5=-M[<W,UW#%;JYB>9Y%5 X)4IR)IR##CQQ5CT^N:A?^;-,L-(N8_J
M#Z?-J5\QC#\ED*Q65&)!59',LE./QK!]O[6*I_HM^VH:19WK+P>XB5W0= Q&
MX%>U>F*HW%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_]7U
M3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BJ3>;(P^F
M1%U+017=I+< 5_NX[A'8D#J%IR;%6*Z]Y-\PZA/YBEA2VC76EMK7ZO-*9$I#
M(4>[5C$?1E>SI'Z*H_[U$;U?VL52BQ729O.Z76HRM)HMW=VSZ!?)!_HEW=6]
MOZ45LDR,ZQP6SB>6VB9(UFG=I%EE]/XE4=8?E_Y@TZ6&ZM6M#?*NH7S.Q(A7
M5+M2ELD<?I[6UK&[1Q_%^V[\.6*M-Y$\V-;:@C2V\DMQID6FVLDTSLR>O(&U
M&1G].OJSCXGE*MZLD47PQ)\.*M^9O('F'5+N\-L]G%;7-O9V+3*\D,TMLDJO
M>1.$1PD4T2B#BC,[Q(B>I'^\=U47J_D+4+^/7+T/"NL7J6]IIC+^[2WLX.'J
M>BW%FMYY_P!\1*G+T?W'^^N6*IJOE>XL_*NH6>B1PZ7K5W;-%#<AVDX2)&8X
M"TO%6_=)QX\$X1?[K7CBK&K[RE%$+2P*I#<ZS<V%@]C;N)%MM-TUWO9%+D1O
M(\K<VN)B.7J72?;^U(JR_P TZ;K6HG38K!XUM%NA+JB2,R^I"D;F-* 'U$]?
MTVEBJGJHO#GQY8JPX>0?.(L;+TY+--7@AU&XN-4]1_7_ $C>A@DJL(N!XB22
MC-'PB7T^,#^DF*IG;^3?,EDFGI836D*Z1H\UII[_ !G_ $V<CD[\E9BM(XVD
MG_O)&:;]U\?)54'/^6=]#IEO:6,B?[CK5+*":63C<W:2RPM?2RSJA:&6>WA:
MWCX\O3]23]GCQ51D?Y=&:^M);U819O='4M2LH@/2,D-NEK96<:\55K2WA%7Y
M*OJR1HW%%^!55*^\E:^UQJ]Q96VG6[75W;OI[+5'AMK2,*C(RQ%8KEG:9H^2
M2I"S\_C^&/%5P\D7\M_I:SVMO'H5A#*D>EQ7$J".29Z232,$+7,LD)9>?)'Y
MO+S;C-+BJ'\O^0?,EEJ6CW5U)9M]3EN;B^9"Y+7#+Z%NT:! /2M[1Y;:U@Y(
MMM'_ +]Y-BK(]3T/4KOS?9:JL-J;/3[.=(FEJTSW5P0*4X_!&L8(Y\_]VR_N
MOVE58S8_E[YETVWII]S;)J$6G7?U>^>K<=5U"1GFE6,)1(H*B.U^+X(FD7T_
MC?DJI2?EWYCCM-2@MDL3'=V%OIMJ)I'9XXC(9+R21_2;E/(\C3O.>;3SI'\$
M?VL53V3R9<W6OSR7BVQT>2SMK*..)2I]*(\[B$Q$%?W[)"O/FW"WC]%5Y?'B
MJ7OY*\RSPR),;.*'4=9EO]8M(R>,UH%9;>!Y!&OJ)46[7$/']XJRQ^JWJ/BJ
M&B\A^;1::=ZC:>;Z"[OM2N;OE)ZGUJXY>BT?[L)MS7X63A#]7@_WHX\<50R?
MEUYU31&TEKNV: 6=O:AEEDY.9I2VJ2NS1L6GO S<KBG-E;TXT@Y-+BK(?J^O
M:=?ZQ+;1VK:GJ*16^AVJ-(8TAMXE1'EH%6""*1YI70<F?GZ:NS<,59;I5BEA
MIMK9(>2VT21!Z4Y<13D1_E=<516*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*O\ _];U3BKL5=BKL5=BKL5=BKL5=BKL5>=+^8WGB_UC6K+0
M/)\>I6FC7SZ?)=R:G%;%Y$C20GTGB8@<9%_:Q5,O)GGK7-9\Q:MY?UO0ET34
M-*@MKEE2[2\5TNS(%^)(XPI'I8JS/%4LUKS!9:4]K!(KSWU_(8K&QAXF:9E'
M)RH8JH2)/CED9E1%_P!CBJ4:YYUOM$L9[F^T:6L2+*K13(\)!GB@*F2@*2 S
M!^'I_$BMQ?%658J@+S6;:TU&QL)(IFFU!I%@>.)WB4Q(9&]611PA!4? 9"O-
MOA7%4>.F*NQ5V*NQ5V*I*->O)]7EM+"TCN+6RF2WU2<S<'AD>$342/@PDXH\
M/+]XG][\/V,57>9_,2Z%H[ZD;<W"QS6\+1!@A'UB=(*U(/V3*&XXJG&*H+6]
M2_1>C7^I>D9_J-O+<F$$*7$2%RH8UI7CBJII=\+_ $RTO@GIB[ACG"$UXB1
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M2J:7]1$Y0W9]43B7ZN0ZR\?0]!G_ '?'U?CY8JQA(_,":(8K:VU2*5?)$=G
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M^"']<5=]:M?]_)_P0_KBKOK5K_OY/^"']<5=]:M?]_)_P0_KBKOK5K_OY/\
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6%78J[%78J[%78J[%78J[%78J[%7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exh3_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh3_4.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X0W>17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    <    <@$R  (    4    CH=I  0    !    I    -  'H2    G
M$  >A(   "<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S #(P,38Z,#<Z
M,C8@,34Z,C4Z,SD      Z !  ,    !  $  * "  0    !   #CZ #  0
M   !   $FP         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $   RH
M     $@    !    2     '_V/_@ !!*1DE&  $"  !( $@  /_M  Q!9&]B
M95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1 ?_=  0
M"/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M*22224I))))2DDDDE/\ _]G_[1*(4&AO=&]S:&]P(#,N,  X0DE-!"4
M !                      .$))30/M       0 ,@    !  $ R     $
M 3A"24T$)@      #@             _@   .$))300-       $    'CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))300*
M   !   X0DE-)Q        H  0         ".$))30/U      !( "]F9@ !
M &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M   ! #4    ! "T    &       !.$))30/X      !P  #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M      0     .$))300:      -5    !@             $FP   X\    0
M &4 > !H #, 7P!0 &$ 9P!E %\ -  @ &, ;P!P 'D    !
M              $              X\   2;                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   2;     %)G:'1L;VYG   #CP
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   $FP    !29VAT;&]N9P   X\    #=7)L5$585     $
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M0DE-!!0       0    !.$))300,      S$     0   'P   "@   !=
MZ(    RH !@  ?_8_^  $$I&248  0(  $@ 2   _^T #$%D;V)E7T--  '_
M[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5
M$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.
M#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1" "@ 'P# 2(  A$! Q$!_]T !  (_\0!/P
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MCCR26AS)L_JMK]-N[_@O35NGI?2GU->W#K8UY]78Y@:0]P;+W,_,NVL8U_\
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M28^$?]%&9A6U5^G3<*1KI76QHD_G;8*H?\W:2R#1@[IF?LI(@#V^TW_2:_\
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MF1,-V%_](?[?3KV;G,5_TZ_W0EZ;.=H24R22224I))))3__2]522224I#O\
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M &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ',
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M4D="                  #VU@ !     -,M2% @(
M                                            $6-P<G0   %0
M,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0
M  +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE
M87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (
M#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V
M+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                  !865H@
M    \U$  0    $6S%A96B                      6%E:(        &^B
M   X]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0
M +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M   6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                 &1E<V,         +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@                            !D97-C         "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M   L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0                                  =FEE=P      $Z3^ !1?+@ 0
MSQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M      $                        "CP    )S:6<@     $-25"!C=7)V
M        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0
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MBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____N  Y!9&]B90!D
M  '_VP"$  8$! 0%! 8%!08)!@4&"0L(!@8("PP*"@L*"@P0# P,# P,$ P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!!P<'#0P-&! 0&!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$(!)L#CP,!$0 "$0$#$0'_W0 $ '+_Q &B    !P$! 0$!
M   $!0,"!@$ !P@)"@L!  (" P$! 0$!          $  @,$!08'" D*"Q
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M0"5-.ZUH<57AE)(!!(ZCPKBK1=0 00:]-^N*K(+JWF1GBE1U1F5RC!@K(2K
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MUK=7E_=>G_OODJB?*WEVZMO..MZA?6 +306,<&JND ,TL$3QW#KQ8RIZC/\
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M @,Z#9OVL54&\VZ&NK6^E-,RW5VTD=HS1R"&:2$<I(XYBOI-(B@GASY?"_\
MOM^*J< @BHQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_]#U3BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL58!Y O?\.Z/<Z'YCD,&H6=]>M%=S(RI>Q7-S)<QSQ,!P=G$
MOQ1(?41UX\?LXJQ_35U/3=6LHI[^YT6Q\S:WJVH361]**2.U:W/H<N2OZ/.:
M+U]F^W-\?Q?!BJMIWG#S'J.B^7(Y=3_1\=Y97#7&M- 90][;2*D<,BJ8^$CQ
MUGX?#]8;E&J_LXJS;S1K:6.B06SW2Q:EJA2RM)&7C2:<!&E*$_"L(;U67E^S
MZ?VV7%6"K=7GE'7?,FBKJ-O;2ZQ;V^IZ7*L,@@@G4+:7$;KSG=.21PS>IR;C
MSEF2)_1DQ5O3+V;4?,NF37]Y=Z7<+HFI^JSS0O*O&^B*4N!'PDA,<1EMY>"M
M- G.3E^\Q5NPUDZKJ7E36-8U&73I+WRW/]:O+>D(^MO-:L\52KJLG)9"L/\
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MXO+5ZFGB]:[>'Z\]?JPF-S4K++\/)I/WCIBJ$\E:EYI;5?)365SK,FL.)O\
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M1\658Y5YP^H_P_\ )S%41K6G:I^B_/MEINGZA]6OK:V;1X.$]&G:'C+Z/,_
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MDKR9.7'DO\V*II0>&*NH,5=0>&*H+4M6T[3(HI+V40QS316L3$$\IIW$<2;
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ME97SS+Z4UP8HIBZBAX,Y#<@*#X3BJ)M=(TJTD:2TLX+>1U5'>*-$8J@ 525
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M^Q_1=I4?\\5Q5?=><A;>9[#0Y;*1!J,TUO;W#O&I+PP-<<Q#4R&!ECD19?\
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M97%6'^5_/>EV_EZXU'6]2?@+_5#')-')ZJV=K>R0J[QJG..*!/321Y$18_\
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M ,C++_LHQ5WZ9U+_ *L=[_R,LO\ LHQ5WZ9U+_JQWO\ R,LO^RC%7?IG4O\
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MO_\ +2W_ ")F_P":,5=_B[R__P M+?\ (F;_ )HQ5W^+O+__ "TM_P B9O\
MFC%7?XN\O_\ +2W_ ")F_P":,5=_B[R__P M+?\ (F;_ )HQ5W^+O+__ "TM
M_P B9O\ FC%7?XN\O_\ +2W_ ")F_P":,5=_B[R__P M+?\ (F;_ )HQ5W^+
MO+__ "TM_P B9O\ FC%7?XN\O_\ +2W_ ")F_P":,5=_B[R__P M+?\ (F;_
M )HQ5W^+O+__ "TM_P B9O\ FC%7?XN\O_\ +2W_ ")F_P":,5=_B[R__P M
M+?\ (F;_ )HQ5W^+O+__ "TM_P B9O\ FC%7?XN\O_\ +2W_ ")F_P":,5=_
MB[R__P M+?\ (F;_ )HQ5W^+O+__ "TM_P B9O\ FC%7?XN\O_\ +2W_ ")F
M_P":,5=_B[R__P M+?\ (F;_ )HQ5W^+O+__ "TM_P B9O\ FC%7?XN\O_\
M+2W_ ")F_P":,5=_B[R__P M+?\ (F;_ )HQ5W^+O+__ "TM_P B9O\ FC%7
M?XN\O_\ +2W_ ")F_P":,5=_B[R__P M+?\ (F;_ )HQ5W^+O+__ "TM_P B
M9O\ FC%7?XN\O_\ +2W_ ")F_P":,5=_B[R__P M+?\ (F;_ )HQ5W^+O+__
M "TM_P B9O\ FC%7?XN\O_\ +2W_ ")F_P":,5=_B[R__P M+?\ (F;_ )HQ
M5W^+O+__ "TM_P B9O\ FC%7?XN\O_\ +2W_ ")F_P":,5=_B[R__P M+?\
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M_E?ZI+I&H>K<:3!<320-I]W/_>JG&*96M6D)N(T^U'(SI]AEX*KO-'DC4Y]
MT,>7X+6'7]%N;2ZM[BX?BM8!PF621(6>3UXFDC:B)\3^IBJ=:/;>8AK>HW-_
M96T%I>"+TFBN6F<&).!#(88Q\5>SMBJ!\K_E]!Y9\R:A>Z5.8M#OHJPZ-6L-
MK<O)SF:W'^ZXI_A9HOL)(OP?;Q5;H'E77/*;7=GHGU:\T&XNIKRVLIG>WFM6
MN6,DL4;JDL<D E/.,,B.G-DYMQ7%5+S#HGGO4]">!_J,U]+J-I=QP":6&"WM
MK.XAG6(2>E(\TKF%N4ACC7E)]GBF*H[6-,\U7T>J6#PV-WI6K6_I)#<,X-L[
MQ>G*C@(PN86;]XO]R_+FO\O!5.])TF+3=$LM)1C-#96T5JK24)=84$=6_P!8
M+\6*L:T'RGK'EO3I]#M4MM7\N<Y&T^SN6:*6"*9V<VS$I-'-!'RXQ?"C^G\#
M<N'+%4%8^3?,>GZ18:-!#9/:-JDM]J\B2M'RMWNGN4@1&A<24K%$_/A^YBX+
MQY+Q51FH^5]:MO/VF^8=#MK1;(64MAK43R&%IHVD$L#1JD3CG!('W=_B25DQ
M59HNF^>=)MM;$%C8O<ZC?7-]9,]W)Z:&X5>"R@05/!Q\7#]G%6_,7Y?W6L^9
M/+6LO=".335:+6_3^#ZY .,\<16C QK>Q1R\#^QSQ5,//.DZ]J=E8PZ3#;S2
M0:A9WLWUF9X%"6=PD_%>$<M6?AQ_9XXJK_5O,'^*5O/JEO\ HPVJP-+]8;U@
M_/U"?2]+B5'V?[WEBJ76WY>V^G^>AYFTJ8VEM=K*VKZ6I_<373(%2\1 *)/Q
MY1S4_OE;FWQIBK,,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5?_U?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5)]7\R6]C<-:0V\U_?1P&[EM+;AZJP E>?[QHP>3CBB*>;MBJ:13(\2N*T9
M0PJ"#0BNX/?%5W-<5=ZB^.PZG%7"5#T-:]#BKO42M*XJV&!Z8J@M9UFQTC3+
MG4KV0QVMHI>4@%F--@JJ-V=F(5$7XG?X<54]*U*]N4F>^L9-.]-PJ+,\3\U9
M58,#&2!0MZ3K_OQ&X\UXNRJW3M:%[JNIV:0LD6F210M<L1QDDDA$S*H&_P"Z
M5TY5_:;_ "<53+U%ZXJE$_F2V:_N-/T^*74+VSX"\AM^ 6$R*'0222M'&'9"
M']/GZG#XN/Q+BJ*T?5H]2TV&^$4MNLX)$-PH25>+%2& +#JOPE3Q9?B7%4=S
M7%6O43QQ5OFOCBKN:XJT)$/?%7<U\<5=S4UIUQ5)K#S$+S7=6TM;>2-=)%N)
MKMF3TGEN$,GIK0EJQIP9^?'^\7%5:RUL7&MZAI?H.!I\<#R71(X,]P';TU'7
MDB(KM_QD3%4UQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*O_UO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5Y_YCE>Z\R6%YI,-U;>9M/O%LC&T+>C<Z9-*C71E<CTC;K&K3P2>IS2
MXC2/[4C1NJED&N>;IK5/,,T]S%++=):R:3'!+Z5G!=3+&3.K)\<MI$C,WIB1
MOK$GQO\ 566+%5?4+3S"U_>M87VK_HC3M,FNI(C*5O)[F=FFAM(0Z&AB2/>1
MOWZ^K%#S^)^*J&N8/,5]H,$E[J%YJ$^O3VUC<6MI'/%!&C.T]PRDJA1#;B2T
MY?NXOL>O))-^\Q5O1]8U;4=2T5KB"_L-,ACNKV6#_2"%@M#Z5O;R<Q^\D)/U
MB:1_BYQK!%RBY,RJ(M]/\RV/DL:[K.LW\-\$%U+8B7DL4;SB5(:E1(TJ@K')
M\3<OBMD_=\<53K4+_P P:/Y,6X0RR:I=3KZDDR>NUFE[<\F9U0?''81R\5 _
MWTO+X<58X^F:M>W6CZ9=WUZ;74-6:_M8IKF1;D:986Z/RFXF-^4]XL,_IE?]
M']?TN,7V453SS>ADU;1=.,-[/I]G'/J5XT#W!Y"U""%7E3[<JR-ZZ OZSR0K
MP5^;XJQF"3SGI6FPZFL<OZ8B2\U76=.@$C6RW%[\-O!,H7G<-%ZXGE96YQQ6
M/IQKBK._*%CJ,5I)=WVISZDUWP/&562-#&"K-$KJC4E/Q?"B0_9]*-?M.JD^
M@ZJGEK1;FPOX;BZUT7EW/+!;P2.]W)=7+R1O$U/3XR(Z5^)5A_W9Z?IXJA5O
M_,^J>9&E6:ZT^+3;Z5;JV5'$,>GVZNO)E*\;JXOI0'BX<_1M^++Q?^^5222Z
M\_66G)?W!OY#;6D]U<V8>1FDGU&;C9V=54MRA7XIY5_WE1N$7'[>*HR_MO//
MU=K.PO=0FDBTRTTR*ZE,D+2ZA=$&2X(XUC%M$!<23-\?Q-;\N7PXJU%K?F=(
M]1N&N-0B@O=2CTL7;P32"VMK5)?7O88N#4DNI$:*%4C>).5H\G-^?)5US+YY
MT^*SDEFOOJ]C'J.JWT%6E<6[%TL+$RA7:>Z/(<N1=8>'+XN*-BJI-JOF;2_J
M49;4;ZYTKR^US<)QE<7-[-\"EOA'J"'TY9'Y<I?B@^'FW[Q56O[KS5#J&G6]
MO>W*Z=?010'4)DE=G%B/C<1Q1EHKC4'N*_L,UO:OZ?HR<'55"V6H>8;R]T;2
M[F34/JT-_/!/>,LJO);:8U"TP551WO)E1^?V$L_[KU)7F?%5MO#+J5EI2365
M\BZ_J=UK.J\1-"#!$M88I&&Z".MHH65HV_T=_13]C%43Y8M/,MQJ&G75Q)<6
M5U?WT^L:K:(65(K-HFBM(+DNO*6=X_JRM&6_=>C)\'P8J]/'3%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__]?U3BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5:X#%7%0:>W3%6O338
M>'3VQ5O@,5=P&*I?>Z.EW>1333RO;Q%'%C\'H-+&Q9)&^'F64[\>?I\E1N/)
M<53#@O6F_CBJ56.A+#J4FH7-U/>W162*W>;@!##))ZC1QB-4'4(O-N4C)''R
M?X<537@OABK7IKM[=,574%*8JUP%*;T\,5=P&WMTQ5KTU^6*N]-<5;"*.FV*
MNX+BK011X_><5=P7^&*M\!2F_P!YQ5K@N*M\%VVZ8JWBKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_0]4XJ[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%7_T?5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5_]+U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5?_3]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_U/5.
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5;(&:-E5N#$$*X -">AH<5>::%YRU^Z\O6^K'7-/N-1$=[+<:1.([=&6V
M$JJ3+&9)(%5TB>61T=53G_DXJCF\ZZTC>9+E6LY8M.T[3;ZRCFF,%J&NDE:;
MG=<&;T_W89']/_8XJRE_,_E^WNA9W.IVT=Z3"IMFE0.&N-HAQ)Y#U3M'R^W^
MSBJM-YAT."[:SFO[>*Z3CS@>5%8<_L@@D;MV7%575M1M]-TRYU"X;C!:QM-(
M=A\**33?QZ8JQ[REYB@O-/M=6NM;2=-7BA>*RD]%!!,R\Y(XRBJ[#]Y''23G
MQ9/M_O..*L@DUG2HY9X9+N%);9#+<(SJ#'&HJS/O\(4;M7[.*HF">&>%)X'6
M6&50\<B$,K*PJ&4C8J1T.*MRJ[1.J/Z;LI"R4!XDC8T.QIBK"O(_GZ2_\IW=
M[Y@XP:KH]5U6.,4#*R":WEC6OV;F!XVC'^_.4?[.*J'E3SEYBO-*T:ZU5+2*
MYU;4[ZRN+=Y/1>!;:2=$BMP%?ZS*OH?O.1C_ -V2?97%656GF;R_?W7U.QU.
MVN;K]X?1AE1V/HMPEH%)KZ;GB_\ +^UBJ7:/YRL6TJ"ZUJ[L+*XGFN8(TANA
M-&YMI70B-V$;2.J)6553]V_)?V<53"T\U^6;U^%GJEK<OZ)N0L4J.3"M.4@X
MD\D6HY,OV<57Q>9- EEMXHM1MWEN[<WEJBRH3+;"E9DW^*(5%7'PXJA!Y[\E
MF-I!KEB8UC$Q<7$9'I-TDZ_W?^7]G%4[CECEC$D;!T8<E92"""*@@C%6$V/F
M^'5/,%U#%KD5@MAJ0TY-.=8F%V5A5W 9CZ@=WDXQ\&^'TF_=OR^%5VD^;-9-
MO&UU):S&7S#>:2SSR?5F$$4\L<7HHJOZT_[M!Z?P\OCDY_#BK);7S/Y=NKWZ
MA;:E;3WO*1/0CE1GY0FDJT!^U&?MK^Q^UBJI8^8-#U"3TK*_M[F3>B12H[$+
MU( -2O\ E#%4K\Z^9X-"LK4R3_5WU"\@L(IOA/IF=P'EHWPGTTY-N,51VDWM
MO%'#83ZJNHWS!I4D?TDE>)V+QU2((OP1LJ\@B\U7GBJ+M-4T^\+BTN$G]-N,
MAC8-Q;P-,58G^8'F_4](O+#2;"6"PN]4 CL=0O49[=KAIXHE@ 5D^/A(TS<C
M\2)QCY-]A5'ZQKNN:==>7(F@MVCU:\6RU \WYQ2&"2:L0 XNM863XS_P6*H?
M6/.%W9MK=U D;:;Y;,0U,2!_5?FBSS>E0@+Z-M)&Z?#)ZTG[K]W]K%5M[YSN
M8&U&^41'1=*U"'3;LL)/7+R-$DDJ4^'C"\ZCAP;U>+_&OPXJRR>Y@M;:2YN9
M%A@A4O-*Y"HBJ*LS,30*HQ5!6/F7R_?LZ66HV]PT<8F=8Y48B)NDFQ_N_P#+
M^SBK4WF;R]#:K=3:E;1VSR^@DSRHJM+0G@"3N]!7CBJ/AN(9H5GB</"ZATD4
MU5E85!!'8C%4N'FORRT%U<#5;3ZO8E5O9O7CX0F3['J-RHG.OP<OM?LXJHR>
M;_+[W*6-M?P2ZA/"\]M!SV=58QCXA6@]163_ &+_ ,N*J>E>:K%O+NGZMJUU
M:6IO(%D)BG$L!8BK>C*P0RH/Y^/V<50_ESS')<S^8Y+Z[B:RT[4O0M)AQ5!;
MM:6TZ?$/MU>=N+?M8JR."X@G@2>!Q+"XJCH:@CV(Q5!KYAT)KN:S%_;F[MXV
MEGM_53FD:&C.RUJ%0_;/['[6*H+_ !WY+],R?IRQ]-464OZ\?$1O4K)6M/3-
M#^\^QBJ9S:IIT,L,,MS&DMQ00(SJ"]>G$5WKBJ&A\S^79K[ZA#J5M+?%Y(OJ
MR2HTGJ1#E)'Q!^VBCDZ?:7%4E\T><(;36- TW3]0A%U>:HEK?6OP/(83#*[B
MG5&5HTK^UBK(5UC2CZZB[AK:"MU\:_NP.I<D_#2F]<52'RUYH;6/-WF&SM[R
M*[TS3X[ VWI!?@DG28RJS#=C\$;?%]G%65$@"IZ8JDDWG;RG"(B^J6])IS:Q
ME7#?OA&92AXUH?3'/_5Q5')KFD/?'3TO(6O@I8VH=3+1:5^"M=JBN*L<\]^<
MX--\NZK)I.H0#6;*+U%AJDCCA(BO6,G?B&HW\F*LFM]6TRXOKG3X+J*6]L^/
MUNV1@9(N8#+S4;KR4\EKBJ7ZAK-S;>8-,TY1;"VO4N3*\DQ2X#0(KJ(8>)$J
MT+>JQ=?2^'[7+%5;3O,_E[4FX:?J5M>.(A.1!*DG[HFGJ?"?L5VY_9Q5H>:_
M+/H37'Z4M1!;LBSRF9 J&5N,?(DT_>-\*?S_ +.*J\.N:/.8!#>0R&Z'*W"N
M#S&XJOW'_@<54XO,WEZ871BU&WD%B%-WPE1O2#UX%Z';G3X/YOV<55$U[1I%
MM72]@9;T VC+(I$H/0I0_%BJ^TU;3+RXGMK6ZBFN+:GUB%'#.E20.0&XW5A_
ML<58GY_\X:CHT]GIME-!87.J*T=EJ5ZI>W%R9HHHX?A9/C997F^(_8BXIR=O
MA51^MZ[K^EOY>5X;=OTI>Q6.H?&]8GDC=^4( HRUC(^,_M?M?M*J.L^;KRSE
MUR:W6-[#RU'%)J?J!Q(Y:,7$JQ$$*OI6S)(IXR>K(WI?N_M8JLO_ #I<0#4]
M0B$+:-HEW#97Q82>NS2")I9$H: 0K<)Q3B_J_'\2?#R59@A)&_4;8JWBKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?
M_]7U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL56R%PC% &<"JJ30$]@30T^[%6$:1Y*U*T\C2Z/<6MBVLI!>6]I=*
M[,H%X7)/JF%9(_[SXU5&Y\,52U?(/FHZ+YBL&%B)=8T6TTBW?UY2JR6T,L#2
M/^X^PWK<P%_DX?M<L55==\D>:M2/F$Q1V,;:U;:9!$6N)?@;3Y'D<O2#?GZG
M%./\N*H"<6D/F#5+J6TFO+&TUNWNI+&WD@?_ '(26L,0DI-Z5PWI^H)/33X/
M@7T^7QQXJ]'UJVN;G1[RVM51[B>"2*+U&*)R="M68*Y W_EQ5A6G_E[JL,FG
MF_BL-1ACTFSTNYMKDR2)#)9%OWT'P#U$F#5DAD$7QI'^\Q5%Z/Y'U'3C?\[?
M3KVY>2_FL=3NE>2=Q>LSK%<)0#BO/TIGCD;UH45?33%68:=#-#86T,ZQ)-'$
MB2+;J4A#*H!$2G=8P?L+_+BJZ[-V()#:(DEP%/I)*Q1"U-@S!7('^QQ5@ME^
M76I_I?0M5NKF.'ZK80V>NZ= S/#>2V#"2QD#LJ,%AE,CFJ\O[N/XE7%6[3R=
MYGALM$@>.S+Z;KEWJ\Y%Q*0T5RURRHG[@?O$^N?M?#^Z_P OX%5ND>3/,UG=
MZ')*EEZ>F:EJE_/Z<\A+1ZDTY5$!@%6B^L?%RXJWI_Y7PJM:9Y,\T6MWHD\D
M=DWZ+U35=1EI/(2R:EZY1%)@^U']9^/^;T_\K%5OESR-YDTZ3RV+A;,1:-;Z
ME;W#132%F.H2)(K1J85'[OT_B#,O+EBK>B^3/-MA_A=9DL)8_+FFW.F.$GF!
MF]6.%$D%8:(/W'QQ_%QY?;?%4/8>0/-%MI^G6I2P)LO+4^@.PGE^*67TN,BU
M@_N_W/Q?M?%BK./+5A=:?Y>TZPNU07-I;16\OI,70F) E59E0T/'^7%6(R>3
M/,[74DO"SX/YCCUT5N):^C' D/I_W']Y\'+^3_*Q5M?)OF<6=M"4LN<7F.37
M'_?RT]"2=YA&/W']Z/5X_P GP_:Q5#_X+\PPBW>YCLOJUOK6I:Q<\;B4$VU]
M#<1F):0<O41;K?\ XQ_#]KX55GY<&W@N]&:6UGGN;K1HH+"]#6TD4%E; ,D9
M](B4"0R?!)*GQ\.+>F_+DJRGSAHNJZK'IBV A_T/4;6_F,TC1U2V?F57BDE6
M?IOQQ5)Q^7]VU_K1F-O(NISW%Q9ZP>7U^T^LVYAX1BG#E#R;T9Q)\,/[KTOV
M\537R=Y:FT:S1+BTL8+Q8(+>>XL@W[_T ?C;F%*(69F2#]YZ?)_WK<L507G?
M0M;UF:VT]K>TU#0;IU%Y:W7)3$T:2GG55?FCL8OY&CD1>']YSB55;_RMK'U3
MRK:VTRWGZ!N8)[NZO)66:98+:2WY?"DG*63U?4;D5^S_ )6*K=8\FW=X=<M(
M6B&F>93$=3+LPF3C&MO-Z8 *MZUM%'&GQ1^C)RD_>?9Q5;>>2KJ=M1T]3#^A
MM6OXM2NRS/ZZNC1/)$@ XTE>!2).?[OXUX-\.*ISYPX_X1UL24XFPNN5>E#"
MV*L*@\E:IYG\GZ1--)!IM]#H?U*PE@9K@'ZU% S-*66$^E^X"/ OVE=_WF*I
ME=^3-4>+2FL].TVQFMM4M]2O8H9) K"WB,6TGH\I'(/P<D3@B(F*LTN('ELY
MX5X!Y49%]1>:59:#DNW)?YEQ5YG/^7?G2YTK6X+E]/>\UJQT^T)65T@A:PDD
M8B-4MUI PE_=)PY1?99I/[S%66SZ+KJ><$U^V2W>&7318W-M)*Z,DB3-.K(R
MQL'5N;1GEZ;+]OXOLXJDGEGR3YGT+]"7"FSN+C3M+.D75LTL@C($HD2>&7TB
MRDT*RQ-'\:\/WG[OXE5MQY#\Q7#7LDILB9-;BUB.V+RF">)+2.T>"8<*Q?W?
MK1,OK>G)Z?V_3^-5FNCZ>FGZ9%:16T%JJ%F^KVHI$I=RYXUX\C5JL]%YO\?'
M%6&Q>3?-2ZXNHRFQDBMX=4M+:VB9H(_3U"6.6-PBPGA)^Z N>3S>K(S3*Z_W
M6*H%/R^\U+IL%H4L"\?E9O+;-Z\M#,RJOJ[P?W7P?9^UBJ96WD341JT5Y>P6
M-_#)9V-N\-T9)?JLMB2>4'P 2QR563@_HLDR>IR;]E52B\E>9H[J.7T[((GF
M.376"W$M3#)"\/I_W'][\?+^7_*Q5P\F>:8(-%L$^J7-MI.L/J1O'FD2>:*0
M7!/J)Z3CUP;CXG#LLG'E^[_954++\M=4M_+L>G%=/_25GZ(BU0*[/>K;727(
M2[!4%$G$2K=*C2^I(WJ_Y&*I@=+\ZVNLZYK5O%9PW&I1Z;%;1J\ER/\ 17<2
MK)5+>BR1S-^^K^Z^UZ<F*LPO87N;"X@3ASEC=%]5><9Y @<UJ.2?S+BK ].\
MB>9M/&ES0SPR_HW4C>6^G3S2.D-JUE):&WCNO2]:1(VF:6!9H_W<?[CG^WBJ
M*L?(NKP-IUA)-!^C=,U.75H[Y"WUR9I'DD])T*\%JT[I++ZK>I"BKZ:\_@50
MD_D?S7_RKZ;R=&UE*$B:WM]1>66-Y$,O-7D58WX2\/[UPTGK2_'\'+%62^4]
M+UO3/KEK?B![5I3-:72RO)<N)-V%R6CC#NA^%)N7)XN'->2\F54]=T76;KS+
MH6IVD=N]MI1NFF265D=S<0^DH4".0;?:)+8JP^/\L/,TNA:9H\TMI;)::)J&
MCS7,,LCGU+QX725(S$@9$-O1T9UY+)_P2K(_,.A>:=9\L?HYX-/AO/5LG"K)
M)Z-+2XCN'(8Q5 ?TN$<7I_!RY>I^SBK7^#+MO,VH:G<065];WTMO=6\ET&>:
MSD@B6,I&O'A)'R02Q'E$T4CRM\>*I&GY=^:Y6N)=0:QF>XLK"T,=O-+;")]/
MGEE1[1HH5-KQ]826W$.UO)#P=KA9.:JHZP_+[5X-1BN=2EL]<]2UM(;B>]0K
M)#<6LKR&:*-%]*3U>8=E/H_Z1'Z_[?%54U\F^5=3T6^U":XG1;.Y"_5].B9I
M88I [M+)"TBK)!'/R5C:<I(HI.;1O\>*J?G71=:U62VL5MK34-#NY(UOK2Z#
M+P]+U).=55PZ2?NT.W*-E7A]O]VJUJ'E/6/T3Y5L+.X6].@W5K/<W5[*Z23)
M;0M$354EY22<^7Q8JNUGR?>7DFNP6[1)8^9DBCU-I"WJ1\8A;RM&H!#>K;*D
M:?$GI2KZO[S[.*K-0\DW-Q^E-/C,(T76[J&]ON3/ZZM&(EEC0 $$3+;IQ?FO
MI?'\+_#BK,$! WZUKBK>*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_];U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK18#KBKN0K2N^*K9&8*60%B*_
M"M*FG85IBK%[/S#Y>N]-N?,S6#02V<TUD[SP1_7/5MYC 8EXEF):;X(E#_'R
MQ5%MYMMHH+KZS!+!>VDL-N^GG@TKR7/'T!$5;@ZR\J!N7[$G+^[;%4?I&L)J
M'KKZ;V]Q:2>A=VTO'G')Q5Z54LK*R.CHZGXE;%4%'YMLY;Y($BD%M-<O8V]\
M0OHR7,0;G&-^76-T5RO!Y4:/^7DJZR\VVEW=01K')';7C31V%Z_#T9WMR1(%
MHW(5".\7)?WL:.ZXJWI7FNVU&YMXDAEACOHWGTV>4*%N(HRH9DH2R[.KHKCD
M\7[S^;%4]K]^*I/H>O/J5]K=J\(A&CW@LP_/EZ@:VAN.9V7A_?\ 'C_DXJF_
M(8JXL!L3BK=1BKNF*H/6-0.GZ3>WZQ^LUI!+.(:\.?I(7X\J-QK3K3%6M$U$
MZEH]CJ)3T_KMO%<>GUX^K&'XUVK3EBJ-Y#QQ5*O,/F"VT:"!I4:6>Z=HK:!.
M(+M'$\[[L0 %BAD<_P"KBJ53>>/JGE!/,>J:7>6H 0W5D%CDE@+$#D:.%>.I
M7XT9OA;XOV^*J*NKW3M%N_JMAIAEO;B.2ZD@LHXE<QQ%1)(]3'R8L]$'VI'_
M -EBK5SYRL4BCELXY=0C:S_24C6P4^G:$?#(0Q')GHW")?C?A)_+BJ>03I/;
MI/$ZR1RJ'BD7XE96%584Z@C%4HTG6M1U.\:6VAA?1!)<6XNO4;U_6M9?1;]W
MQX\#(DR_;Y+Z?^7\*J=_"Q\:;8JV2!UQ5U16F*J5Q*T<$DD8#LBE@I- :"M*
MT-,52S0-2MO,OE73M1NK5!#JUK%</9R4E0"5!)P-1Q?C7^7%4SM[>UM8$M[:
M)(8(Q2.&)0JJ/ *HH,54=5OS8Z5>7R)ZS6D$DXBY<>7IH7X\J-QY4ZTQ5)[S
MS7+;^19/-2VOJ>EIGZ4-GSXUI!ZQC]3BW;;EQQ5,-/UR*ZN[JU:">%[18':>
M6)HX)/K"<@(96^&7A3C)Q^PWPXJJ1:M&^LS:48+A9(8([@W31,+9A(S+P2;[
M+2KPY/'^PK(W[6*H[D*T[XJ[D*T[^&*I.-?<^;_\/^A\'U#Z^+KEU_?>CZ?"
MFW\W+EBJ[S1YBA\NZ/<ZO<V\]Q:6J\YUMU5W5>[49D^$?M?RXJWJFO"QN8+2
M.VEO+V='F%K!P+B&+B))#S9!2KJJC]M_AQ5!R^<['T8);.*6_66T.HLL 4LE
MJ/VV#%?C8U5(O[QV23_?>*IE>ZYI]MH[:P90]@L/UCU8_BYQE>2\!^T7J. _
M:;%4N?S?;PK/'<VTT&H0R01)I[>F99#=-Q@,9#E&5R'Y-R_=^G+R_N\5;/FZ
MV^KU]&47QNOJ'Z.HOK?60IDX5KPX>E^_]7EP]']Y_DXJF6E:M;:G:-/&&C:.
M62"XADH'CEA8JZ-0D;$5%/M)Q=?A;%5#S1K1T+RUJ>LI"+@Z=;2W(M^7#GZ*
M%RO*C<:\?Y<53&&4O$CMLS@&GS&*K^0K3OBKBZ@5)H.F*MU%:=\5:Y#%6P0?
MIQ5KD/NZXJW44KVQ5U1BJ7:[JZ:59"X:C22RPVUM&QH'GN95AB4M0T!=UKBJ
MKI<NJ/:UU2**&Z#NO&!VDC*AB$8%E1OC2C%2OP-\/Q?:Q5%DH33J1VQ5"ZCJ
M$5CI]U>>G+<"TB:5[>V0S3L$4MQCB7XGD8#X$'Q/BJK:W*W%M%.%=!*BR!)%
M*.H85HZG=6'[2XJJ\A_;BK8(/3%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%7__7]4XJ[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%4G\Y%QY1UPHS(XL+HH
MZ,492(6(*LI#*1X@XJ\^MM-\RW/EZSU3RFEY:W+:(RWL-R\D375U(L#1E1.Q
M7ZRJ"YXW/V?4D3G(ZXJC-2T:<V.C0VT>M7%G-K,-Q=Q3AT9+?T&2972 1%82
MY7FLG+U)/4D^)?BQ5Z3;V\5O"D,0(CC4*@)+$!10;FI/TXJ\\L]%U2_\HZI;
MK9SQ7<?F"?5;>WG0PM-'%JGUZ)4+T ]>->*LWV6;X\57ZGY<U'4]8NO,D5O,
MBQ7FDS6UG(@2::/3FF,K!6(*%OK<@1'^UZ'_ !:N*HZSDO=)O-8\P-832)KF
MHV4<5HQ6.98%BBM?7*L:G<-+Z/\ >^DO\_P8J@;/RUJ*VNE^7V@E5-,UR357
MO^(]%[<7,UW&5-=WD:583']I&Y2?8X<U5NE^5-0.F>6O+LL$L*>7)9VGO74&
M*1!;7%I"8]_B,RW/K<1_=<.$GQ<,51'E[0M2,_E&WN+66W_PK:2074T@'"67
MZNMH@B(/QJZ<I^:_"GPQM^\^RJC/S,M-:NM.MDTJ&2XG5W9;>CM;S/Z9"Q7'
MHM'/$KU/I7,;\;>=8Y)/@Q5C%WIFK1+YDU&WT_4(]7_3&G3:?)&L[DPI%9Q7
M+1_LR)QANHY'*_ODX_SQ8JBHHM=_Q@U^VG:E!8&'5;2Z9FGF>5FDCDM'HK<.
M!19?JWI1_P"CJWHO(LOPXJA-.T'74T7RS;W,.J06$VF<=9-L6:]75DCA1))A
M/ZK<:)+PD3X$EXRM^P^*IK OF73/,NJ:JUG->V=M:3R#ZW*8)1+&D?IPI,&^
MIW%O<!2Z%HEDM)O4YOQDQ5G:3?6]+$QC>(7$'/TFJDB\TKQ-#566O;%7D?EZ
MPU'4/(VAZAIL.HK.-&E76C*9S]>,]BT<2!'9OK#FX:.9)E'P1K]M?4XXJC_T
M=K*6GH2Z;J$D%[Y3M[%(H0Z\;^W]0,C49/0EH\?&4^GRX_WGPXJB_+-AYH.N
MZ)<W%O<O EE!'?B]$L;P-'9\&>&16$<J2S?!/:W$;2^M_I4<GI\<53G\U8+:
MZ\L2V-[I4FIV=TK1AX:F2"Y:BV\@"D2+\;']['\<;<?YL52K6]+\S?\ *J-0
MTRY6XU.^8/!IZA.=T]L)P;;UPH4>N( OK-_-]OX\53R_M[JU\VQ>9(;2>[@N
M-,-B88DI(DBS">+DK$,!+S9&8_#$R_O/A^RJD.B^5]6\L67HBUDU"2ZT&UTU
M1   MW:F=N#G]E)/K?\ ?-^[3TOB^TN*LW\O:5^B/+6FZ2[>M^C[."T:0 CG
MZ$2QE@.OQ<<5><^7=!NK*PL6GTN\31S=ZO\ I:PCCE2>0S7;RZ?*\0(>2!('
MD'%/LRRQ,Z?NN4:J.T[2-<EUKRQ#K4-]-##:ZF9R7F,<8DN8GTZ.Y>-O3>XB
MMXV1W8O^\7XI&YJS*LK\]IKC^7I!HRR/<B: SI RI<-:B9?K(@9OA$WH\_3K
M_P 2Q5@WFS2==_0#Z?HEGJ]T\UK=RZ=<SR-'Z-PK*\2B&$0>E)7>V:?BD:+(
MG^[.#JIW:I>/JFJ7&LZ??W,PN1<:'<1K+P6R,*,J!$*>D\;B19X9%]2=O]^\
MUQ5+/).FZKI$GDF)+*^MA^B);;7PZ2M&+B-(5@6;F6"\'2?TROPJG_%;)BJ=
M_F5;ZK=V45G96-U=M=PW4(DMY'2**8Q?N6E6)DD8EJB%RZ10R?'(R_ ZJI'?
MVFM7NCS0ZYIU_>P3Z!#%8I&LK,NH"*1+H3HK*RSNYB].9EX<.7&3%4LU/2M9
MN_).IZ?JND7]U+)H,-OH$44<O&.5+'TY8W1&4Q7'UKD6>1562'TE1GXLF*HO
MS!INJ7]UK,D>EWTUM)'Y=F1/2D7FME>,]ZJ*Q6KB!UYQCXI/\IEQ5':]9:^_
MF"Z?0;2]MX/T/:0QLH>*JQWWK7$$3L>,=R]ESCC>J<9&3]XC+\"JAK6G:P^F
MZH--L]1AT:>]TEK"Q7UUN T5TLFHRJJGUHK=[<*OILR\Y$EXI^]Y2*JL<&IV
M\&JV2:5J$VFG7*6=N?7CC6RFM$!=@/W\UL+L3?N4;[;(_P#<8JU^75IY@@UO
M1_TO9WJ3VN@?H^[NKE'9?K,=SSX&9B_/X!L_-U;_ 'XV*LG_ #,M[R[\B:W9
MV=O)=75S:O#!!"A=V=]@*#%5FH6]S;^:K3S-%:SW5O)ILMB]O%'^]1VFCGB+
M*W%ASHT;5_NF_O/AY<%4BT#RUJWE:&*3ZI+?RSZ)'8-%!3X+N&:>X$;-TX2&
M\9/7_NT]'D_VUQ54OM#O_P#"%MY%A@,\UAI-E-%>JR".6;3YHCZ!4GE$9O17
MTI'_ '?Q/_OIL5;U?0=1U7S-'YJBM9XX]/DTX16<B!9Y4MGNO795)^'@+[X1
M_NWT&X?WD;8JW_A_41K8\T_5I@GZ9-^;'C^_^JG3/T8)./7E_P ?'H_WGI_#
MQ]3X,53[RAI5U9PZI=3QM#)JVHSWZP.!RC1PD48:A/Q,D2R4_8Y^G^QBK"O-
M^D^:+B?S4(;&YO;:\TR_MX01)ZJ32PK%!% 4;T+JUG)YA'B6:SE]5WDXMBJ/
MN8]4L=2U0:9IVJ2Z=-HMO*((6EB>2\25C*J32U:.X-N45_VW^S_?+BJ51:;K
M_P!16RN+#4%@/F:&[2&'ZT(UTR2%/4%>1?T?4]7G!)^TW]RGV<53>#1]=2_U
M8W(U:.ZMWN8],-C)&('T\P%+?TY)5;]]&"/W4C\FO(UF;]U\6*I_^7=IJUKH
MT\>I0"*0W+F"51-'ZT7! LQMYVD>U=B&]2$-PYJTR_WN*I'=Z?YG?4[A?2NF
MUW]+QS:=J2EA91Z695+1L:^GQ^JK+#)"T?J/=,LO\LZJIG^7VGS1S:U>7=O=
MQ74NIWA@>\,X+6DDO.$1K*2OIT^RJCX,52S\QK?7[C4E33;&^D>#ZC=0WD,D
MAB AO UQ'%'&R*)OJX;U?6Y>M$RQ0H[<DQ5+KRTU4:WJ&HPV.I&<>8[*:TEX
M7+#]'&&"*[X(QX"$TN>4?'_+5?[ML51_E+07_3MWI<T4QT_RQJ,UQI]UZ\CB
M9KY5GCB<\V=Q:)(RE)?A_P!YOY<53C\S-.^OZ9I<0LI;WTM6T^=TAC:0K#%<
MH\S$+T41!_\ C7XL52"33;JWN_,]U'IFIW 34+1=.C22>,&S,%M%,(@2>5NL
ML<K310CU)8U;A_>+BJ'T.Q\PV_U"VUJPOY]!CDU6.XM$$K\'DN_5L'*!WEEM
MQ:%HHASD6!^/J<77X%43%HLMK<^<R=(O4EO+9/T5-\<[&(Z=% 8UE#N3*+A&
MY+RY_P"[/\O%4(FF^:GT62&2UOSJS6%BGE>9>:1V=Q';I')]8W"HR78>:X:9
M7]>VXQKZW]SBK>K6.LKK6MWT=GJ4ETFLZ3)I\T:W#)]6C6W2_,2U]/TF5+GF
MO#C)^RO+T\5>JQFJUZ5\=CBJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J__0]4XJ[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%4+JNG0:GIMSI]P76WNXVAF
M,;%'X.*, PZ5&V*H"UN]*T:XTKRTDDAFF@D^HB3DY,5H$#\I*4J@>/K\6*IS
M48JZHQ5U1BJ6ZQKL.F1!F@GNY6#M';6J>K,RQ+R<JE17B/\ AF55^)EQ5'H5
MECCDH14!UJ*$5'@>G7%5X%!3%78J[%78J[%78J[%6G0.I4]#UQ59/ );>2$N
MR>HI7U$-'%12JGL<50NA:-9Z)I%KI-D9#9V4:PVXE<R,L:"BKR.YXCX17%4=
MBKL5:= PH?GBK>*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*K5C522.IZG%5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N/3%4%I&D6>E6GU6
MUYE&D>6225VED>25BSN[N2S,2>_[/P_9Q5&XJ[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__1
M]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%4M\SW%U;>6]5N;-S'=P6=Q+;R* Q61(F9"%((;XATIBKSRVO?TAK/D
M1DUX2SW.F7\LM\#;22?'#:,RCX?3Z\OB9'_:Y8JUI7Y@Z_JT&F00W=C8W,ME
M/=/?7']S<2VUTUNT:@!Q\*I'--"C))QG7T67CBJ*U+SGK-G<^:[F.^BEM]$O
M+*UAM!$ACABNX;?U)[@H&GX6SS22M3]E&5E_E51@\PZW'=V>F:AJ]I!:7*WD
MIU^!8V7E (C%;<Y56V];C)+,[>G\44'!$Y<Y%52S1]8OM4\W>6]1U"[-A/)H
MFHR36Z")5DCBO;8"4)*KR+'=1)Z].7-(_P"[?[>*O2M-U"RU'3[:_L9EN+.Z
MC6:WG3=7C<55E]F&*HG%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__2]4XJ[%78J[%78J[%
M78J[%78JTQ %3TQ5##5M+(K]<@_Y&I_7%7?I73/^6R#_ )&)_7%7?I73/^6R
M#_D8G]<5=^E=,_Y;(/\ D8G]<5=^E=,_Y;(/^1B?UQ5WZ5TS_EL@_P"1B?UQ
M5WZ5TS_EL@_Y&)_7%7?I73/^6R#_ )&)_7%7?I73/^6R#_D8G]<5=^E=,_Y;
M(/\ D8G]<5=^E=+_ .6R#_D8G]<51$4J2H'C8,C;JRD$'Y$8JNQ5V*NQ5V*N
MQ50%A8@J1;Q H"$^!=@:UIMMU.*MK9VB(J+!&J(W-%"* ''[0%/M>^*KDMK9
M'=TB17D_O&"@%N^Y'7%6C9VA@$!@C,"_9B*KP%/!:4Q5LV]N9A.8D,RBBRE1
MR W_ &NO?%50  4&P'08J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_]/U3BKL5=BKL5=B
MKL5=BKL5=BJR95:-E8 JPH0>E#MBK"Q^2OY2!0?\(Z7]%LG],5;'Y*?E(17_
M  CI?_2,G],5=_RI/\I/^I2TO_I&3^F*N_Y4G^4G_4I:7_TC)_3%7?\ *D_R
MD_ZE+2_^D9/Z8J[_ )4G^4G_ %*6E_\ 2,G],5=_RI/\I/\ J4M+_P"D9/Z8
MJ[_E2?Y2?]2EI?\ TC)_3%7?\J3_ "D_ZE+2_P#I&3^F*N_Y4G^4G_4I:7_T
MC)_3%7?\J3_*7_J4M+_Z1D_IBK+-+TNQTO3X-/T^".UL;5!%;6T2\4C1>BJ.
MPQ5%8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__U/5.
M*NQ5V*NQ5V*NQ5V*NQ5V*M-2F_3%7FEG 9?->O1"SOIT@UNW$-]#=%8K5/J-
MO<-RC,O+T3+R]1/1:)O6_P"!53_2_.UQ>RZA;_HQXKK25XZC:^O$7BF9CZ:'
MHA22'C<>MRXK$W\_)<50MM^8[7GZ/2PTQ[J:_74O3 N(EC#:5,L,H$G1TD9J
MPR+]K]KABJ!O?S.6?R_=7?Z.NK6*XT&37;&5)X5E-LH4.*@2+#.GK(R5$J?\
M1Q5,9O/KVE]/9OIT\MM87]CI5S>^M&3ZFH)"89 GPLPY7$:R_9_R>6*NU7\R
M;:PCU&>/3KN]M+!GA:ZA3C"TT4RP2Q^K)QC!21^(_>-R:.5>*\5Y*LKTZ:\F
MM$EN[8VD[<N=N760K1B!\:?">0'+%43BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5
M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK__5]4XJ[%78J[%78J[%78J[%78J
MX@'KBJ1GR7H9GO9A]95M1E]:^1;NY"2OP6/XT$G'CZ:)'QIQX+QQ5#2?EUY3
ME>9Y;:5WN8O0N6:YN"94]4S#U/WGQLLK-(CM\2-]G%52'R#Y:@N4N8(IX98C
M<&(I=7("&\;G<E5]2@]9QZC_ /%GQ_:Q50?\M/*+VL5JUO/]6ALFTR.(7=T
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MZLD5%9OV_P!G]K%41KFNKHVBW>KSVTT\%C$T]Q%;A#*(XU+.0'9%;@HK]O\
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MN?\ YJQ5W_*BORC_ .I8L_N?_FK%7?\ *BORC_ZEBS^Y_P#FK%7?\J*_*/\
MZEBS^Y_^:L5=_P J*_*/_J6+/[G_ .:L59AI.E:?I.FV^FZ= MM8VB"*VMTK
MQ1%V"BI.PQ5%XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%4'J^D6&KZ
M?-I^H1>O9W"E)X2S*'4]58H5/$_M+^UBK>FZ7::;8PV%DGI6EN@C@CY,_%1T
M4,Y9J#MOBJ"E\H^7Y9)'>RC*S,9)H?B$,CL:EY(0?2D<M\7-TY8JFP4A.(.*
MI!!Y!\JPWUU?)8_Z5?,'OG:69A.RB@]56<I)0?" ZM\.*HG5_*6A:P;3](VW
MKBPD$UF \D8BD7[+H(V0<E_9;[2XJOT_RSI%A?37UM$1>3QK#+<222S.8T)9
M4K*[T4,2=L56S>5-$GUR+7I;<MK$"&*&[]24%8S0L@4/PX,0"R\>+<?BQ5O6
M_*^BZX+;]*V_UGZG*)[4<Y$"2K]F0>FR_&O[+?:7]G%5.]\GZ%?:C%J5S [W
M\,;10W"S3HR(_'FJ\)%"A^"<Z?;X_%BJ'E\@>59K86TEB&A%S]>(]6?DUU52
M)V</S>5>"<'=F9./P8JNG\A>5KA+M+BR]<7T*VMV\LT[O);J2PA+M(7]+DQY
M1\N#_MXJJ6WDKR[;RV4L=NQ;3CRL0\]Q(L1"&,%$>1DV0\1\.*J%O^7WE.WO
M+N\AL>%SJ#B2_D$T_P"_8"@,H,A$E >(Y\OA^'%4\L;&TL;=+:SACM[:,<8X
M8E"(HK795H.^*I?=^5-$N]9M]:N+?GJEHK):W/J2@QH_VE4*X4!Z#G\/Q_M8
MJJ:-Y=TK1C/^CXC"+ES+,#)+(&D8EF?]X[_$Q/Q,/M8JC(K&VAN9[F*-4EN2
MK7#@4+LBA%+>-$ 7_5Q5+=;\HZ!K=W:W>IVWUBXL6YV<GJ2H8G_F3TW2C=N7
MVN/PXJCK+2K*QC,=K$L2L2SD5+.Q_:=FJSO_ )3GEBJ$T;RMHNC2W<VFV_U>
M2_D]>\;U)7]24[%V]1F^,@#X_M8JF<T,<T;1RJKQN"KHP#*RL*$$'J,52-?(
M?E->"KID(@B99(K2C?5E=*<'6WKZ"LO%>+"/X<53'4-$TW4'CDNH1)-""(9P
M2DJ!J<@DB%9$Y4^+BWQ8JZTT73K.VEMK2!8(9BS2B.JL[.*,[.#S,C?[\Y<_
M\K%4!8>2?+-CI%SHUO81C2;SU/K5C)SFBD]6IDY+*SC]X26?^9OBQ59)Y#\L
MR2:=(]HQDTE>&FOZ]QR@4@@A#ZE153Q_U/@^SBJ>O#'+$\,RK)'("KHP!5E8
M4((.Q!&*I9:^5="M9HIH+1%>W-;4,6=83Q*_N4<LD/PGC^Z5,5:U/RKHNIZA
M9:C?6_K7NG$M8S>I*GI,PHQ4(RK5E^%C3XE^#[.*H?5_(OE76+MKS4M/CGNY
M$CCEG!>-W2%_4B$AC9/4]*0<X^?+TV^QBJOKGE/0]=MK>VU:V%W!:2+/;*SR
M+PEC^Q)5&4^HAW1R>2XJZY\IZ'<ZM9ZO<6YDU+3U*6=R990T:MLP%' ^.GQU
M'[S]OEBK>M>5=%UMK5M4M_K#64@GM3ZDL?IRCI(OILGQK^R_VEQ5%7VCV-_$
MD=[$DZQ-SA+#XHW (#QL#R1Z$_&AY8JLL="TRQ$OU6!8WGIZ\M6:62@H.<K%
MI'XU^'DWPXJMT3R]I.B0RPZ;"T,4SM(Z&260%W8NS?O&>A9F9FI]IL51=O96
M]O+/+%&J/<OZL[**%W"JG)O$\$1?]CBJOBKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5?_]+U3BKL5=BKL5=BKL5=BKL5=BK3 D;&AQ5YPU_K'EG5=9OIY+C4
M?)TMX8K^(R2RW&F?N(C]8B8LTCV9YGUXU/.V_OXO@]1551^C^:K#2=*TLL)K
MNTU.]^KP7_K^LK-=7;P6_!Y9&>9?L<O3Y>G%\>*HBW_,;ZQ<VMO%HUT6OKN]
MT^T8R6X5KC3S)ZH;]Y5498)61Z?L_97DN*K[3\R]'N[;3I;>TNY9KZ,326D4
M1FF@C,S6_*18?4%/61UJK<66.1_V,53+S5YLM?+EM'=7=M++;,RK+-'P"ISD
M6,#XV7FY9ZK&GQ<%?^7%4O\ ^5@PK>S1/IETMG;ZJNB3WP,3(EQ*4$+E _J>
MC(TT2<^/P._QKQ^/%4OF_-NPMM)CU:ZTB]BL)H[YK>4&!^<NFK*\T) D^!G2
MWG>)G^!EC^)D?BN*IA=?F#!:6EW<7&F7*_HR$7FJPJ\#26]HY?TYR!)Q<.D,
MDO!&]1(T;DO/BK*KX?/0EOYK%-*N6GM[AH9%1HF)A%L+E;E &J\4BLL2<?C]
M;]WQQ5*+OS2NL:UY=^K>K;&UU^73K^$2JR,RZ7/<<28F:.5?BB._V)5_R,5>
M@8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%7$T%<5879:A<^9/./F#3)Y)K73/+S6]JEM$[PM<37$ N&FDD0J
M_IHK(D2(R_%ZKOS^#@JF@N;?R],;(S7>I7&H.\VG:?7UIDCAB1951Y6'[I&H
MY>:3^\F]/E\:+BJG)Y\TCAI1M8;F]?66GCLXH(QR$EJC--'+ZC1B*1.#HRN?
M[Q&3%5*Q\_:=J5_IMM86MS-'J-BVI"X C58HED6)ED#.&YH[$2*@?CQ^'GBJ
M^/\ ,+03)<QS1W5JUO%:SQK/ RM.E](T-MZ*"LA>66-HUB=$EY?L8JW+YR,6
MLV&EOI%\MSJ N&16$ XI;"(N]?5*,O[]/LMR^W_JXJH?F+ZBZ18/'--"7U;3
M(6:"62%C'/>Q0RH3$RL5>-V5L559O/FDPZE<:<]O=TM+VWTZZO/3 @2>[1'@
M!8MS*R>M&G-4;XW^+%4ATO7[.Z\PW]UJME<+J%EJ\FG:*48$R&.U4^@J+*:L
MT;SW$GJ+Z"K^]=U:/X560S>?='CLK>Y]&Y>6XOAI9LUC'KQ7A!/I2J6"IL*\
M^?I\61U?TWY8JH77YCZ5:W%S!+87X-G<6EG=N(5*QSWZQM A^/DW(S1QLT:N
MJ/\ :^'XL51=KYUL+F"=HK.\-W;7CZ?+8"(&87$<0F*U5FA"&)E<2M+Z?Q?;
MY_#BJ$TCS[I^KZAI]MIUK<SQ:C8)JD=Q1(UCAED]-?45W5PP;ESXJW'_ "L5
M0OEOSG'^A+5)YKO6]687CO'';Q1W+1VEU) [M#&_HHJLGI1_O.<W'X5:3GBJ
M*OOS*\OVZ^I!'<W\ TXZPT]K&&C%FK%6DJ[1_$E/BC_O/\G%4]@UBUGO_J<:
M3&MNETESZ3BW9)&*JJS$<#)\/(QUY\.+8JCL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_3]4XJ[%78J[%78J[%78J[
M%78JTP)&W7%4OL=%@LY[N5))9#?2&6=)I&D3D1Q^%6^R.("T_E7%4E'Y9^4E
MALX8;-K>*PCCBLDAFE18E@F-Q#P ;K%*S,G_  /[*\556W_+_1+=[1XGN@]E
M<W%[;,;F0\9[SG]8?<[^IZLG7X?WC<<5:T[\O/+VFS6DUD+F&:TC>&.5;J8.
MT+R^L8I#R_>1^J6=%?\ N^<G#CS;%47YC\FZ%YADB?4X7D:*-X4*2R1_ [I(
M?L$=)(HW4_S)_+BJ1^5_)UU;:IK5_JEO(QFU-M0T^%KDR1&D"1)(8P0BS#TR
M>3?S\OM_954/*GY=1CRM)IWF""3ZQ.;^*2/ZT\BI!?3.[B J0(O4CD]-N(Y?
M:X_#BK(+KR7HMW(DMPDKR?5A97#>M(OUBW6I$5Q0CUE^)OM?%\3_ ++MBJ(N
M?*^C7-W>7DUJIN;^S&FW<JLR,UJ"Y].JD4WD>C+\2_S8JEUK^77EZUN+>>V%
MQ$]M<B^C5;B4*;E8/JWJLM:%FM_W3#['#]G%63J"!OUQ5O%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78JDM]Y9
M@EU@ZU8S-8:JT(MIKF((RS1*W)%FC<%9/3);TF^%TY-\7'X<50<GDR5[R/4Q
MJES^FXF?T]081,%BE1$D@6$KZ:P,8DEX_;];X_4^UR54T\A0P2Z-)97TL'Z%
MDN;B/DJ2F:>]#B>64L/M.TTDE$X+S;^7X<54-"_+F/1I=-EM]4N&?3K66P)*
M0CUK>:43\6HGP.LB[.G'X6_V6*H2+\IK)5E,NK7DMQ-%;1O>$1+<>K8W!N;6
MY,@3XKA)7;U'DY^M^VN*IS/Y3NI]3TW5)=5G-_IWKH'"0B-XKD()(_3*G@/W
M4;!E//ER_9;CBJ*\R>7I-;L[>U^MM:"WNK>]5XT1R7M95FC4AP1Q]1%Y?Y.*
MI3??E^UW<ZA.=4E3](:A9ZHZB*(\);#TO1121NG^CQ<^7Q-\?\^*KH?(*1RW
M-S^D)OKLNI-JUK=!(P;>X>'ZO(%6G%XY(?W;J_\ ,W%E;CQ5=+^7\#06JI?S
M+<0ZF-9NKDK&SW-V!Q!<4"(@3BBI&J_ B8JLU#\OFO;C5)CJLL?Z4O;*_D01
M1$))IYC,*H2*\?W$7/E\3?%]GEBK;_E^[&]/Z6N!]>U(:I.BI$(W80"W:&1"
MI62$HD;<7^S*BR\L5;T+\O8-$N-.FL=1G'Z.LCIBHZPD26RR^K$K_ */&=N:
M<>:XJIZ;^73:;'&]EJ]Q#J"?6HVOA'"6:&[G:Y>,HRM'^[N)&DA?CR3[#<UQ
M59/^5]@8I;:TO9K2R?1WT);951^-M(:NW-P6,K$GXF^'_)Q5D&F:+/92PNU_
M/.D5K%:?5FX+#6(G]\$5>0E845OCX<5^QBJ:XJ[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__U/5.*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]7U3BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5?_6]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78JH)?V+WDMBES$U[ B236JNIE1)"0C,@/
M)5?BW%B/BXXJU:ZCI]VTZ6MS%<-:R&"Y6)U<QRJ 3&_$G@X!'P-\6*HCD/'%
M4/?ZEIVGVS75_=0V=LK*C3SR+%&&D8(@+.0M7=E5?YFQ5$5'CBKL54)=0L(K
MR"REN8H[RY5WMK9G599%BIZC(A/)PG)>?$?#BJO4>.*H>SU"PO8WEL[F*YCC
MD>&1X7615DC/%T)4FCHPXNO[.*HCDO2HQ5U1XXJ[DOB,5=4>.*N!!Z'%75'2
MN*I5;^;?*MSJC:1;ZS8S:JA(?3X[F%KA2O4&(,9!3_5Q5-.2^(Q5NH\<5=R7
MQQ5U1XXJUR7?<;=<5;J/'%5JRQ.6".K%#Q< @\30&A\#0XJNJ/'%4MUKS-Y;
MT-8FUO5;/2UGY" WMQ%;A^%.7#U67EQY+6F*KM'\Q>7]:B>;1M3M-3BB/&22
MSGCG56(K1C&S '%4PJ/'%75'CBJ'OM0L-/M)+R_N8K2SA'*:YG=8XT%:59W(
M514]\55^2^(Q5NH\<5:Y+XC%5"[U'3[)(WO+F*V2:1((FF=8P\LIXQQJ6(Y.
M[;(@^)L51&*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]?U3BKL5=BKL5=BKL5=BKL5=BJV2-9$*-]E
M@01TV(IBK O^5#?E.!_QPAM_R]7?_5;%7?\ *AORG_ZL0_Z2;O\ ZK8JW_RH
M;\I_^K$/^DF[_P"JV*N_Y4-^4_\ U8A_TDW?_5;%7?\ *AORG_ZL0_Z2;O\
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ML5=BKL5=BKL5=BKL5=BJE=)</;NEO*L,Q'P2LGJ!3[K5:_\ !8JEOZ/\R_\
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M *0_^OV*N_1_F7_J[0?](?\ U^Q5WZ/\R_\ 5V@_Z0_^OV*N_1_F7_J[0?\
M2'_U^Q5WZ/\ ,O\ U=H/^D/_ *_8J[]'^9?^KM!_TA_]?L5:_1_F7_JZV_\
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M]?L5=^C_ #+_ -7:#_I#_P"OV*N_1_F7_J[0?](?_7[%7?H_S+_U=H/^D/\
MZ_8J[]'^9?\ J[0?](?_ %^Q5WZ/\R_]7:#_ *0_^OV*N_1_F7_J[0?](?\
MU^Q5WZ/\R_\ 5V@_Z0_^OV*N_1_F7_J[0?\ 2'_U^Q55M;+6TG5KK4(IX #R
MB2V])B:;?'ZCT_X'%4RQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_TO5.*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]/U3BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5?_4]4XJ[%78J[%78J[%78J[%78JXFF*NQ5V*NQ5V*NQ
M5V*NQ5V*NQ5V*NQ5P(.*NQ5V*NQ5V*NQ5*8?,NE3^8;[0(I6.I:?;PW5U&4(
M58K@N(R'(XFOI/W^'%4 GYB>4CY<O_,KWWIZ#8.Z2:E(C+#)Z9"%K=J?Z0C2
M?NXWBY^K)\$7/%53R;YZ\N>;K:ZGT:XD=K*7T;RUN(9+:XA<KR4212JCKR7X
ME-/BQ5&>6_,FE^8M/?4-+E:6T6>>VY,C(?4MI6AE%& /PR(PKBJ+U34[#2]/
MGU'4+B.TL;5&EN;F5@J(BBI9B<585HOYX?EYJNI6EA%?7%NVHMZ>G7%Y9W-K
M;W#G[*PSS1I&[/U0<OC_ &<59]S6E:[8J@GUW2$UF+16ND&JSV\EY%:;\S!$
MZQO)TH%#R*N^*HWDOCBKN2XJE7FKS-I7EC0[G7-6E:'3;/@;B1$:1@)'6-:(
MH+'XW7IBJ-U/4+?3M.N=0NF*6UG%)<7# %B(XE+N0!N?A7%5/1]6L]8T:QU?
M3W,EEJ-O%=6LC*4+13('0E6H5)5AL<58$W_.0/Y=K%+,9-2-I;O(D]ZNF7K6
MZ>BY21C,L1CXQLK<VY?#QQ5Z#IFHV6I:?;:C8S+<V5W&L]M<1FJ/'(.2LI\&
M4XJEWFSSCY<\IZ7^D]>O%M+8N(H1Q9Y)96^S'%&@:261OY$7%4L\J?FEY-\S
M:C+I>GW4L6JQ1^L=/OK>>SN&BZ>HD=PD;.E=BR?9Q5EG(8J[DN*J=U<1VUM)
M<2$B*%&DD(%3Q4%CM\ABJ$T'7-/UW0['6=-D:6PU"%+BUD92A:.054E6 *[8
MJ[0=<L];TJ'4K-9E@GY\%N89+>4<'9#RBE5'7=?AY+\2_']G%4?R&*NYK6E=
MSVQ5*O-/F?2?+.AW6N:M*T.G680W$J(TC+ZDBQK15!8_&ZXJFH8'IOBKBP'4
MTKTQ5@ _//\ +@ZBUF-2E]%+CZHVI_5;@:<LW+AP-Z8_JX^,\.7J<.?[6*LQ
M@US29M6GT>*Z234[6&*YN+9:EDBG9EB8FG'XS&]-\51W-=M^O3%7<EQ50U#4
M;'3K"YU"^F6WL[2)Y[F>394BB4L[M[*H)Q5NQO;6^LX+VTD$MK<QI-!* 0&C
MD4,C"M#NIQ57Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_U?5.*NQ5V*NQ5V*NQ5V*NQ5V*K9$5T*M
M]E@0=Z==L58$/R+_ "VZ?4[S_N)ZC_V48J[_ )49^6O_ "R7G_<2U#_LHQ5O
M_E1?Y;_\L=Y_W$M1_P"J^*N_Y47^6_\ RQWG_<2U'_JOBKO^5%_EO_RQWG_<
M2U'_ *KXJ[_E1?Y;_P#+'>?]Q+4?^J^*N_Y47^6__+'>?]Q+4?\ JOBKO^5%
M_EO_ ,L=Y_W$M1_ZKXJ[_E1?Y;_\L=Y_W$M1_P"J^*N_Y47^6_\ RQWG_<2U
M'_JOBK7_ "HO\M_^6.\_[B6H_P#5?%6::1I5EI.F6VFV*LEI:1K% KN\K!%%
M!5Y"SN?\IV9L51>*NQ5V*NQ5V*OG_P#,+0?.^M_FEYML_+4EN;9-%TN?5-.E
MYK)J$<4MPRZ>DB,GHQW7[R.:3E_(GV'?%4P\W>=-(\W>3?+7EO1[>'2QYHNS
MIDKWG*%-%NM-59FA]-?2_P!-@D14LX/@CDD1?M1_"RJO^5FO/IGGS4?*-_'^
ME/.UTSW7FKS"]S$J2P6Z!;%[>%1\2LDGI_5D6/ZI^\]1G^#FJR'\B;B!/(TR
MO(BM^F-8V+ '_CHS8JL_/81+HOEVYU"(S>6K37K*X\R#CSC6R3G1YEZF%+@P
M-+_D_:^'%4%^=/FRXL/*<M_%IFA^8/*?U<7%PM]>F-Y)$;G&MLB(Z2M15>-E
MD5^7V<58?^9^KZI=77F?4-/U;65E\N6T;B2#4H=)TW3IFM!<)&5J\^I32,8Z
MJ\7%V=+?DGVL5;O([RZ_,+0?-9N;V;6SY%?6TLX;B2.&:\@] K!Z*5_<3NW[
MVW7^\?BW[.*M>0M5\ZG4/)_F(7]_=#S%+''K+:IJUA+874=Q$7?ZC912-)!/
M;.M8HHHU?TXY4G^+EBJKH^K:OHVNV&N:[J]]J=C>:PULGF/1]8CNM/N#=7#1
M0V<VD3#_ $>.+BD;_5?4EC?X_6^UBK//^<B?_).>8O\ 4MO^HR'%63^>IX7\
MD>8@DBL?T9>F@()_WG?%4%^5$T/_ "K'R>GJ+S_0VGCCR%:_58^V*O+?RLM/
MSCN_(1M?+UWH%KHL]YJL<,M[#=S7L8>_G61BJM]7=E<NT:E>''CS_:Q5[#Y&
M\LVGE/RGI/EFWG,ZZ9;K#ZK_  L[#=WXU/$,Y8A?V?LXJPOS3/8V'YZ^7-0U
M\K%I,FCW%KH5W<$"WCU5IPTJAC\,<\MH.,?+^\X\$Q5K\V;G3;SS/Y$T_366
MX\U0Z[:W<"VY#3PZ<A/U^20@U2W>#]VW/X9&XK]K[*KSU1YDM?R_N/S 7S3K
M#ZK8^89+:SLGNF-BML=9^J-#+ :B93&[_%(>2_ B<8XUQ57\RZUYWU?6O.6H
MP7>I6%YY7OY;?2?0U.QL--M(K=%>&6]M;F2.2XCN_P"\EDF1T]'X;?[.*O=)
M[FYNO)CW5TB1W,^G&6>.)N<:N\')@C#[2AC\+8JD'Y*RP'\I?*$9D4M^B[4<
M>0K7TQVQ5Y-Y6G\R>9[7\K],NO,>J6B:M;^8GU6YMKITN+A;:Z C1I"68<5^
M!)/[R-/ABX8JCK/7O,4=HOD^X\P7MOI1\YWGEV7S#+,#?1V,-HMQ!;_6G'PS
M7$I]!)O[S]E/BQ5&:M=C1]3M?)>E>>;^?2M0U>WL=7NYYA->:8)+::86R:BX
M_O+Z2-$4,S2V_P!F/^\Q5)O.]Q>V7D;\SO*2ZI<ZWHFBC29+&^O)?K-Q%+=W
M*//:/<=9?2*+(O/]Y&LO#[/'%4YUS2]9UOS3^:5RWF76-/M_+2VUQI-E87;0
M1).-+6?F0*\EYKO!_=?:=EYXJ]/\H:Y=:A^6^B:WJ(:YNKG1[:]O5A6KR226
MRR2!$'5G)/%<5>56$,^G_E7->^5=<TG6?RV-G-,/+OF"$QRQ6SEI9;0W<$E?
M57EZ2>O%(RR-\3O\.*I'=P0/J?GGS9IESJ>DW(\DVFJV%@+R1! UU9W/&(HI
M7:U55,"_[HEY2)BJ?^8F\P:'Y9\DZ1::GJUX/-\XEUO4OKZ0WCR_4A*MK;7%
MTR06:W,@^%(G1^*.D/*1\50-YYK\^^7/)6OZ>MU<+#:ZOIUA:WUS?V5[JEA:
M:@P^L+<7"N\$;QD@6LUW)\*3HTG]VN*J.IV/F*+RSY]\NWUUJ46B'RY<:K%;
MZEJ]O?:G%=05H%>WDEE^HW2IQE27X&XR1I\,C8J]C_*G2X--_+S0;>&YN+M'
MLH)C+=3-/(#+&KE [;B-">,:?[K3X,599BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_];U3BKL5=BK
ML5=BKL5=BKL5=BK3 $4)IBKS_3/,=YI7GK6M*U>Y+:/>&2XT6>4EO1:T@B>\
MM2Q[<9!=0K_)ZZ_[KQ5,/(E[JU]JOF>34II"T-_#':VC'X+>![&WG2(+_/\
MOCZK?SXJS'%78J[%78J[%78J[%78J[%78J[%78J[%78J[%4#'H>E1:M<ZQ%;
MJFIWD4<%S="O-XH2QC4[T^ NU,52?4?RT\AZD-16_P!$M;E-6D2?44D2JRS1
MCBDQ'19@I(]5.,C?M-BJIHOY=>1=$-FVD:%964FGF1K.:&%%DC:5>$C"2G,E
MT^%BS?9Q5*)/R._*:34&U%_+-F;UY3<-.0_(REN?/[77EOBK-9[>&XA>"=%E
MAD4I+$X#*RL*,K*=F4@[C%6):=^3OY6Z;J?Z4LO*^G0WP/))1 A"-6O*-#5(
MV'8HJ\<51.K?E?\ E[J^MG7-4T"RO=5*>FUU-$'9EXE/C!^%SP/$,R\O^!Q5
M6E_+WR7+<Z-=2:3 ]SY?18]%F8$O;)'3@J-6O%>(XAN7'%5NF?EMY#TO7IO,
M&FZ%9VFM3EC)?11*LE7^V5[(S_ML@7E^UBJG%^6'Y?P^9CYGBT*T37S(9OT@
M(_WGJ,.+24^SS(_;X\OVOM8JG.NZ#I&O:7/I6KVJ7FG70"W%M)4HX5@X!I3H
MRJV*L>T7\H/RTT.>XGTCR_:V4UU;R6EP\8:KP34$D9JQ^%Z;XJIZ+^3/Y7:)
MJEOJND^7;6SU&T8O;W,8?FC$%:BK'L<59+HVA:3HMDMCI5LMI9J\DJP1UX\Y
MG:21MR?M2.S8J@F\L6Q\[+YIYD72Z<=+](+LT;3B?DS5WXLM$4+\/*3[7["J
M,UWR]HFOZ;+IFM64.H:?/3U+6X02(2-P:'HR_LL/B7%4M\J_EWY(\IF=O+FC
M6VF27( GE@2DCJ-PI=JOQK^S7CBJLWD?RHVBOH;:;$=(EG-W)9?%Z;3F;ZP9
M#O7EZ_[S_6Q5#ZY^6WD+7M6AU?6="L[_ %.WH(KN>)7>BFJAJ[2!?V1)RXXJ
MR">WBGA>"50T4BE'3L584(^XXJPW2?R4_*K2-1MM2TWRW:6M_:.);:Y0/S1U
MZ,*L=QBJ<Z;Y&\IZ8VFO8:;%;-HZW":64!_<+=MRN E3_NUMWQ5N7R/Y2FT_
M4].GTJWFL=9N'O-4MI4#I/<2!0TKJU?C^!/B'V>/PXJIV_Y?^2K?RX_EF'1;
M-- EKZNFB%/1<FA+,I'Q/4 ^H?C_ ,K%6H?R\\DP^6I/+$.C6L6@3$&;3HTX
M1.0RN&?C0LW)%/)CR^'%48/*V@"35I19Q^IKH5=8;>MR%B]$"3?M%^[V_9Q5
M%:=I5CIMA:Z?81"WLK*)(+6!/LQQQJ%15KV513%6-3_D_P#E?<:P-9F\L:>^
MI<_5,Y@4!I*\N;(/W;/R/+DR?:Q5':Q^7?DK6=4;5M4TBWNM2>UDL7NW!]1K
M:9&CDB)!%59)'7_98JC=3\J>7-4T3]!:EI\%YH_!(A8S('C"Q@!* ]"E/@;[
M2XJH:5Y'\H:3H<F@Z=I%I;:-.&$]@L2&&7F*/ZJL#ZO("A]3EBJ'T/\ +?R+
MH6G7NFZ1H=I96.I*4U"&.,4G1E*E)":LR<68<">/Q8JF/EWRUH7EO2X])T.S
MCL-.B9FCMHJ\%+L68BI)^)C7%4SQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O\ _]?U3BKL5=BKL5=B
MKL5=BKL5=BK3+44K3%6/7GD31+\UU$RWP74(]5A68K2*YB4*O#@J'T^(XLC<
MN:_:_:Q5&Z5Y=M]-U#4[Z*XGEDU:=;FY24H4$BQK". 5%*CTHXTW9OL_S<L5
M37%78J[%78J[%78J[%78J[%78J[%78J[%78JI75N+BW>$N\8<4+Q,4<?ZK#<
M8JEO^&H?^6_4/^DN7^N*N_PU#_RWZA_TER_UQ5W^&H?^6_4/^DN7^N*N_P -
M0_\ +?J'_27+_7%7?X:A_P"6_4/^DN7^N*N_PU#_ ,M^H?\ 27+_ %Q5W^&H
M?^6_4/\ I+E_KBKO\-0_\M^H?])<O]<5=_AJ'_EOU#_I+E_KBKO\-0_\M^H?
M])<O]<5=_AJ'_EOU#_I+E_KBKO\ #4/_ "WZA_TER_UQ5W^&H?\ EOU#_I+E
M_KBKO\-0_P#+?J'_ $ER_P!<5=_AJ'_EOU#_ *2Y?ZXJ[_#4/_+?J'_27+_7
M%7?X:A_Y;]0_Z2Y?ZXJ[_#4/_+?J'_27+_7%7?X:A_Y;]0_Z2Y?ZXJ[_  U#
M_P M^H?])<O]<5=_AJ'_ );]0_Z2Y?ZXJ[_#4/\ RWZA_P!)<O\ 7%7?X:A_
MY;]0_P"DN7^N*N_PU#_RWZA_TER_UQ5W^&H?^6_4/^DN7^N*N_PU#_RWZA_T
MER_UQ5W^&H?^6_4/^DN7^N*N_P -0_\ +?J'_27+_7%7?X:A_P"6_4/^DN7^
MN*N_PU#_ ,M^H?\ 27+_ %Q5W^&H?^6_4/\ I+E_KBKO\-0_\M^H?])<O]<5
M=_AJ'_EOU#_I+E_KBKO\-0_\M^H?])<O]<5=_AJ'_EOU#_I+E_KBKO\ #4/_
M "WZA_TER_UQ5W^&H?\ EOU#_I+E_KBKO\-0_P#+?J'_ $ER_P!<5=_AJ'_E
MOU#_ *2Y?ZXJ[_#4/_+?J'_27+_7%7?X:A_Y;]0_Z2Y?ZXJ[_#4/_+?J'_27
M+_7%7?X:A_Y;]0_Z2Y?ZXJ[_  U#_P M^H?])<O]<5=_AJ'_ );]0_Z2Y?ZX
MJ[_#4/\ RWZA_P!)<O\ 7%7?X:A_Y;]0_P"DN7^N*N_PU#_RWZA_TER_UQ5W
M^&H?^6_4/^DN7^N*N_PU#_RWZA_TER_UQ5W^&H?^6_4/^DN7^N*N_P -0_\
M+?J'_27+_7%7?X:A_P"6_4/^DN7^N*N_PU#_ ,M^H?\ 27+_ %Q55M-#BMIU
MF6[NY2M1PFN))$-13=6-,53+%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__]#U3BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_1]4XJ[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%7_TO5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O/O,7YE^8[/SA>>6/+_E&?S!/8
M6MO=W=Q'>VUJJ)<EU04N"O+>)OLG%4X\E>?+3S)IM]/<6<^C7^DSM::QI]Z4
MY6TRHLA!D4M&\9C=7616^SBK(EO[)[;ZTD\;6O$M]85U,?$=6YUXT%,52+S9
MY]\O^6_+;>8;J<7%@LL,$9MGC<R23S+"H0EE1N+/RD^+X45VQ5.GU338H(IY
M+J%()B!#,TBA'+"H",31J^V*KY]0L;<TN+B.$\6>DCJAX)3DWQ$?"M1R.*KX
M;F"=%DAD62-P&1T(96!Z$$;'%6/?F)YQ7R;Y0U#S(]I)?II_I'ZG$P1Y#-,D
M("DAN\E>F*I1>_FQI%O^5T7G]+>6:VG@BD@TY6'KO<S2"$6H._[U9B8V^']E
MOAQ5N3\T["/\K8//\MI(D-U:Q7%MIO,&626X81PP*]*<WD95'PXJGGD;S9!Y
MJ\NP:O% UI*[2P7=C(>4EO<02-%-!(:#XXW0CIBJ2^;?S$U'2_,$?ESR_P"7
M[GS-K1M?K]W;V\\-K';VQ<QHSS7!"<Y)%8)$OQ\5Y_9Q5 ?\KB%]I&CW/EOR
M_J&N:KK G(TE#';-;&SD$-RMU-,1%"8I?W:_[\;['P_%BJ8^7_S4T+4/+-_K
MFJK)H!T>Y>QUFROR/5M[I./[H<"PE]3FGH>E\4W-."\L51WDWS_I7F7R7_BM
MD;2]-#70D-\RQ-%':320L\Q/PQ?W7-E8_N\54O(?YB:7YT769]+BFCL]*O/J
M27$ZF,S_ +E)O62-@&2)Q)^[Y?;3X_AY8JI>5?S/T#S3YJU70]%+W4.E00SM
MJBG_ $:<RR/&1 ?]VHC1,IF7X.?)4^SRQ5F>*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__T_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*OGWSU<^4(?SKUP^8_.
M-_Y10Z3IOU:33[PV1N#ZEQR5R$DY^G\/'^7GBK%],DTHLD=[--K/Y/6?F*63
M4->NHY&>]DFLRT3W[J%:[M;6]XQ_69%]%E]+G\"+Q53E[#RU=^4O.;6<]QIO
MY7_IC3KC0IH+1[JR5X@K7TC6K\?4TEKD*953C!]MH_AQ5C^MS>7-2_+_ ,X+
M'INC7=A87NC7K^8=%MYX-.DF>[2*X46\Q>.*XCM7?ZP]NW%X9?WOQ8JRW67_
M "G'FR_F\ZV]O-Y,N-&L4\@?N97LOJOIO]:CLEB'!;QI?3X<!]9]/T_2^'%5
M/2_+%QKFK?E'I?GRU:]N!H^L2W5I><B6$9@-LMRIWD98O2]1)>7[Q?WGQ8JR
M_P#*#4-"\MZ9YJLIYH]/TFT\X7VF:3 Q(BC]4PB&WB&_$-+(W!/YFQ5,O^<A
M6I^4FMD&A$EA3YC4+?%6!)#?'SU-^6TL(.E:-J]]YI !(3]'O!]8M(N-?LIJ
M5T_P_9Y0_8^'%4#Y=B\P^9_*WY9^4?+L]M;3Z-IEMYEU.:]CDE@!C8PV,;)&
M\;.7E]:7AR_W4CXJS?\ +5/,GE7S]K?ECS)<VMQ)YC5O,>FSV,3PP&8,(+Z(
M)([LC5]"?CRXMZDC_P RXJ[4/,VA^2/S@US4O--TNF:7YATK3_T=J$JM]7::
MP>9)H"X%!,!,DBI_OO%6,:)^9-KY*\D>O<20Z?JOGC6M5U/05U3G#%!:7%P9
M$N[Q?MA%C*R)$GQ7'..-/VWC5>A_E''Y2G\MRR:1K,/FBYEO&N=;UH*M9]1<
M*[.5 XQ\%]-847^ZA6-<50WY#QQ3?EC''.BR1OJ&K"1' 92#J5QL0=CBJ[\K
MZ'S+^8XZC_$-*>WU"V&*M:!'%#^>7F2*)5CBCT#2E2-0 J@3W-  -ABKT?%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J_P#_U/5.
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ59--#!$TLTBQ1)NTCD*H'N3MBJ7RZGY:E;E+=V4C=*M)$3^)Q5<-6\O!/
M3%]:B.E. FC"T/:E:4Q5WZ7\O\.'UZUX4X\?5CIQZ4I6E,5:74_+:QF-;RS$
M9ZH)(@IKUVK3%7?I7R[15^NVG%""B^K'12.A KMBJXZQY?+AS?6I<5"MZL=1
M7K0UQ5 :LGD_5;1;2]N[9K=;B"[*+.B<I;:59HBQ5@326-&_RN.*HY]7\ONO
M%[ZU=3N5::,@_03BKOTOY?))-_:DD4),T=2/#KTQ5I-5\NI7A>VB5 !XRQ#8
M=.A[8JVVK^7F8,U]:EEKQ)EC)%>M-\5<^J^79!22]M''6C2QL/Q.*K9-3\M2
M$&2[LWH*#E)$U!X;G%6X]4\N1+QBO+2-2:T26)17Z#BJY-9T!%X)?6BKUXK+
M&!OOV.*M#5_+ZDE;ZU!8U8B:,5/B=\5<-7\OABXOK7F=BWK1U(^=<57_ *=T
M3_JX6W_(Z/\ KBKOT[HG_5PMO^1T?]<5=^G=$_ZN%M_R.C_KBKOT[HG_ %<+
M;_D='_7%7?IW1/\ JX6W_(Z/^N*N_3NB?]7"V_Y'1_UQ5WZ=T3_JX6W_ ".C
M_KBKOT[HG_5PMO\ D='_ %Q5WZ=T3_JX6W_(Z/\ KBKOT[HG_5PMO^1T?]<5
M=^G=$_ZN%M_R.C_KBKOT[HG_ %<+;_D='_7%7?IW1/\ JX6W_(Z/^N*N_3NB
M?]7"V_Y'1_UQ5WZ=T3_JX6W_ ".C_KBKOT[HG_5PMO\ D='_ %Q5WZ=T3_JX
M6W_(Z/\ KBKOT[HG_5PMO^1T?]<5=^G=$_ZN%M_R.C_KBKOT[HG_ %<+;_D=
M'_7%7?IW1/\ JX6W_(Z/^N*N_3NB?]7"V_Y'1_UQ5WZ=T3_JX6W_ ".C_KBK
MOT[HG_5PMO\ D='_ %Q5WZ=T3_JX6W_(Z/\ KBKOT[HG_5PMO^1T?]<5=^G=
M$_ZN%M_R.C_KBKOT[HG_ %<+;_D='_7%7?IW1/\ JX6W_(Z/^N*N_3NB?]7"
MV_Y'1_UQ5WZ=T3_JX6W_ ".C_KBKOT[HG_5PMO\ D='_ %Q5WZ=T3_JX6W_(
MZ/\ KBKOT[HG_5PMO^1T?]<5=^G=$_ZN%M_R.C_KBKOT[HG_ %<+;_D='_7%
M7?IW1/\ JX6W_(Z/^N*JD&K:5/*(H+R"65JD1I(C,:;G8&N*HK%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J__5]4XJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%5LD4<J&.10Z-LRL 0?F#BJ'_16F?\ +)#_ ,BT_IBK
MOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\
M+)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+
M3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBK
MOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\
M+)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+
M3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBK
MOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\
M+)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+
M3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBK
MOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\
M+)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+
M3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBK
MOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\
M+)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+
M3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBK
MOT5IG_+)#_R+3^F*N_16F?\ +)#_ ,BT_IBKOT5IG_+)#_R+3^F*KH].L(G#
MQ6\<;CHZ(JG?W KBJ(Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O\ _];U3BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_7]4XJ[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%7_T/5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5_]'U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BJ0^;O/'ESRE9PW.M7#1FZ
MD$-G;0QO/<3R&GP0PQ!I)"*U;BOPKBK7ECSYY5\RZ//K&E7H>RM'DBOFF5K=
MK:2$<I4G28(T+1KNW/%4*GYE>5IO*">;K-[F^T221HHI;2VGGD<I,T!9(44R
MLG-&^+C]GX_LXJ@?+_YP^4-=U^WT&S348=3NHY)H8KO3[JV!CA%7;E-&B\5^
MS7^=E3[38JG7FSSKY>\J:<E_K4[11S2K!;0QHTT\TKFBQPPQAI)7[T1?L_%B
MJ60_FUY'F\LWWF*.\D^I:9(L-_ \$R7<,SLJI$]LZK/ZCEUX+P^/]C%5;RK^
M9&@>9[Z:RTZWU&&:&(S.U[875HA4,%HKSQHK-5OL#XL53'1O.'E[6M6U;2=,
MNUNKS1'CAU,1@E(I90Q$?/[#.O!O453^[;X7^+%53S/YIT/RQI$NK:U<BVLH
MJ+6A9W=S1(XXUJ\DCG9$1>38JE&B_FEY)U;3]1OHK\VB:.GJZK#?Q2V<]M&0
M6626*=8Y CJ*H_'BW^MBJSRG^:WD[S3?MIVFS7$5\(1=16U[;3V;S0$T,L(G
M6/U44TY%/L\EQ5-M1\X>7=.UW2M!NKM5UC6C(-/L@"TCK#&TCN0*\(PJ'XV^
M%F^!?BQ5C<_YV>2HM2N-/2/4[J2UN'M)9K73;RX@]:)_3=1-%&T;<6%"5;%6
M>@UQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_]+U3BKL5=BK
ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL50NK
M6MU=Z=<6MK=-97$R%([N,!GB)VYH&JO-?V>7P\OM8JPR.'7+K7_,NDGS#>6T
M&GVEH]I<4M:QO<QS\Y')A'(*8T;%5;6O-L,[: NC:D'YZQ:VM\J;%X9896HP
M=>7IR<.<;K]OC\+_ &L53R\\Z^5K(WBW6HQQ&PBDFNJ\CQ2"GK$4!YF*H]54
MY-'^WBJ0>>//-BGE75FT?4&MM6M((;I5:-XI1 \Z)ZJI,@+PM4IZJ*R_Y7+%
M621^:_+[PW4IO%C6S9%N5E5XG4S?W7P2*KL)?]TLJ_O?]U\L562^<O+46F/J
M<MZ([..X6SE9TD5TN'D$2Q/$5]5)&=T 5D_:5OLMBJY/-WEY[%[WZWQACG:U
M=7CE243IN8O191-ZE/BX<.3+\?V<55[#S#HFH7*VUE>Q7$[VT=ZB1MRK;S,R
MQR@C8JS(PQ5Y?^9-CKEY^<OE6*RUB'0E?2-26QU&XBCN'2?U(?6%I'*1']::
M'A\4BNOH>K\&*JWY<V=OYD_Q9H'F:.Q\P?HC5X8[C6K>WCMTU$QPI*ANDAI'
M+/;,?2G7XDY+PX?S*HW\@;BWMOR@TZ>9ECA@GU-Y'- JHFH7))/8 *,57?EY
M<:WJ?EK4OS!>R-_K_F!9)]*TUY?15-/A9A86D<DG)85E3_297X?%-<,[K]G%
M4@\VWGFV^U;RAK=[8Z?Y7\X:??WD.C:-J=[]9M;^"XMD6<?6K>/C!/3^X5OM
M<?V_LXJQ:ZBGU[S)YPD\W^8+30K3ZWY>M[B]TQ3/9QWULTD\=H9IA1W7E 9K
MIUC5'_<M\/PXJSO0/TOI/YAMY)F\Q77FK1M4TF>^O#?/&]W8NCK"O[ZV$5(;
MI9&"*R*RO%RC?[6*N_+C3++1/S#_ #*L-%LHX;:S71ELK&*D:<AI[$+R-:%V
M^T[?M?$^*I=YYU#S=JFFZ-J&O:=9>3=:TC6K6X\NIJ-ZM]97URT4R&":2WC'
MU:JM^[=O]V<>.*L"_,B?SCJFL^:;S66L..GZ%IT>KVNE2R3P6\)UF&8I<22!
M#.[6T=U*Z^G^[A;T^+<_B5>F_F-K,*?F#Y#O=%C.J7EC;ZS?M963*TTUHNGG
MBBTZI-/Z"1K^U)P_DQ5YQI^MWTGYH>1]:USR[KD?FC4M3NFOY[NP,,<<$MF\
M4-E9EG+-:V/,RRL>+-^^NG_EQ5.I+1?*?D2\\X^4_P PKK47TZZGG72Y5@CL
MKN[ENF:>TEM."3K/-)(R+1U=6X/&GV<5?0-J[R6T4DB\)'4,\?\ *Q%2OT'%
M57%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78
MJ[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_]/U3BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5<:T-.O;
M%6'7?DK4;Z_\S->7<:V/F2S2Q98$=9X4B26-'#LQ5F(F/+X?V<54IO)6LR1:
M0/K%A'+IM]!>3/#:&(3_ %='2I"..+R>JS-^PG["_:Q5)?,OE4^7/R^\U(US
M;O;?4=3>TG:%4N_],$D@BDG+?O.#R<$X_'+\'+XOM*IEK'DO4O,ND>O+J%J-
M0FL5L[>X@CD-NMO)+%<2L!S+.\K6\=/WG%%7%41JGD34]0UZ\UA[V&*9_P!'
M36*K$[".XTUI64R5<>I%+]9E1T7@RKQXMRQ5J^\BZI<V>H,+R!=5U34++4+R
M8QOZ 73I(GABC0/S^S;HCR,_[3OQ^PF*J$GY=ZI)JD^J27=J]PVJ2:E!;O T
MENR36:6<D,RLQK\$*21RIQ9'^'CPQ5E5CI^I6UPI>YC:Q2WCCCLXX%BXSJS%
MI%8-]AE*JL7'X./VVQ5+/-.D:5YBM7TO7?*TFLV".&3U?J;(67H\?.=)$/O1
M&Q5?H<-OH.EPZ5HWE>XL-.MP1#:P&R5%J23M]9ZDFK'%5&RTW3['0WT*T\J7
M$.CR+,CV*M9B,K<EFF%/K/\ NPR/R_UL51NG3R:;86VGV/EV[M[.TB2"V@1[
M+BD42A41?])^RJB@Q5!^8M-TWS)I[:=KWE*;4K)F$GH7'U%U#KT9:W-4;_*7
M%4-:^7/+UKY=?RU;^2F30) 5DTWC8&!^1Y$LIN#R;E\7)OBY8JWY7\O:#Y5@
ME@\N^39-+CG8-/\ 5_J*LY'3FWUDLW&OPU/PXJCK.*&SU*^U.U\LW4-_J9B-
M_<*UGRF,">G%S_TG_=:?"N*NUN&WUW39M,UGRM<:AI\X EMKCZBZ&FX-#<;,
M#]EA\2XJ@]!T'0_+^ER:5HWDV2RTZ<L9[6(6/"3F*-ZE;@^I4'C\?[/PXJA_
M*_E+RQY5EN)O+ODF33)KI0EQ+!]2#,JDD+R-R2%J?LC%4TO(H;V_L-0NO+-U
M->Z8\DFGSL]GRA>5#$[)_I/[49XXJDX\D^3E\Q_XD'D(#7.?K?7@EAS]4_[L
M_P!Z./J=_4X\^7Q8JR8:OJ(_Z4=[_P '9?\ 93BK?Z8U'_JQWO\ P=E_V4XJ
M[],:C_U8[W_@[+_LIQ5WZ8U'_JQWO_!V7_93BKOTQJ/_ %8[W_@[+_LIQ5WZ
M8U'_ *L=[_P=E_V4XJ[],:C_ -6.]_X.R_[*<5=^F-1_ZL=[_P '9?\ 93BK
MOTQJ/_5CO?\ @[+_ +*<5=^F-1_ZL=[_ ,'9?]E.*N_3&H_]6.]_X.R_[*<5
M=^F-1_ZL=[_P=E_V4XJ[],:C_P!6.]_X.R_[*<5=^F-1_P"K'>_\'9?]E.*N
M_3&H_P#5CO?^#LO^RG%7?IC4?^K'>_\ !V7_ &4XJ[],:C_U8[W_ (.R_P"R
MG%7?IC4?^K'>_P#!V7_93BKOTQJ/_5CO?^#LO^RG%7?IC4?^K'>_\'9?]E.*
MN_3&H_\ 5CO?^#LO^RG%7?IC4?\ JQWO_!V7_93BKOTQJ/\ U8[W_@[+_LIQ
M5WZ8U'_JQWO_  =E_P!E.*N_3&H_]6.]_P"#LO\ LIQ5WZ8U'_JQWO\ P=E_
MV4XJ[],:C_U8[W_@[+_LIQ5WZ8U'_JQWO_!V7_93BKOTQJ/_ %8[W_@[+_LI
MQ5WZ8U'_ *L=[_P=E_V4XJ[],:C_ -6.]_X.R_[*<5=^F-1_ZL=[_P '9?\
M93BKOTQJ/_5CO?\ @[+_ +*<5=^F-1_ZL=[_ ,'9?]E.*JUI?7EQ(4DT^XLU
M J))FMV!->@]*64_>,51V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O\ _]3U3BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK3(K
M==QX8JY45=AT\,5;Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
MNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__]7U3BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKJC%75&*NQ5V*NQ5V*N!
M!Z8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[
M%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__];U3BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL56R/PC9Z%N()
MHHJ33P&*I#I/G?1=4-D;1;DPZB[QVEQ);31Q.\8=F7FR@*:12?:_EQ5D&*NQ
M5)KKS=H5O/';_6DFG>]CTQXX#ZK174J>HD<P6OI53X_C_9X_S8JG(W%<58!^
M=&L7>D^7]&NK>]>P1M?TF*ZN$D,(^KO=*)5D<%?W3)_><OAX_:Q5#C\YK%M)
MN=;@TBZGT::[CT[RU,A43ZO=2DK2U@<)Q@Y!N,\LBJT:/)QXKBJDWYRW-IH^
MN3:OY:N=/UWRZD%UJ.AF>*9VT^XDX_7+>>/E%/'&HD:0#['I,C?LXJF7F[S]
M;0S:IHMO;3W"0>7KK6[V_M9O0:&'BRP+$_%BL\_&5HG_ -U^ES^+%6-:9^<6
MJ^E#I&@>4M0UZ>QT;3-3GG>\@#"WO+;U?WT\P7U+@<:4IRN6]5_@X8J]*\J^
M9+#S-Y=T[7M/#BSU.WCN85D'%U605XL.G)3\)H<5><>6?S22#REHL6BZ5J7F
M#7=8FU(V.EW%W'+<>E9WDD<T]Q>3>FD4"MQ2+D/VHX5Y<<50?G?\T;J^\J^7
M-7TVWO[#4K3S78Z=KF@PM_IGJIS,UB>#!)EF^#A\7IS(R/BJ;W'YV7&F:'YG
MN==\M7&EZSY6@MKNZTAKF&<2P7CE(GBN(N49W5N0I\/'%439_G%/%>WEMYC\
ML7V@B/3+G6].,KQ7#W-G:4,H,<)9H+@*Z?N)/BQ56\J_FQ-J]G+JFI:(=,T!
M;)]076HKVUOK9(HU]1DN# W*";TB).'&1?\ BSEBK7E[\V[C4=9TNUU7RU>Z
M%I?F$'_#FJ7<D++<N$,HCEBC+/:RR1!I(4E_O./\V*I/!^?5T]O^E9?*-]%Y
M7@U%M*O]<]> I%-]:-HCI">,T\1<Q\W1?@9FC^-DQ5 ?F;^8.IOK>HZ-IFJ7
M&DZ5H1M8-3N-.BCEU*_U+4*FTTVP,G-(G9!SFF*\D_U,585'Y@\^^7=8O8-*
M?7[76]"TV37=<T7S'J$.JV$UA!2BP3HO,3RJ[E6CDC6-X.+>I^RJS&R_-VWL
M/._FFY9[K4AJ5IH+>5?+:,6FFFO+265EAC)*1 @H]S-_=Q_:?]G%4=%^85[H
M/G'SYJ&NBXDAL+30!9Z%!*;CC>7T<J?5[4'BK232\%Y*J<^//]G%4UTO\X-7
M;S%/H&O>3M0TC4(-*FUCTHY(K]IHX9$C$5LMMR]:5C)]GX>#_#_E8JWI/YNZ
MO<^8U\NZIY4GTG5;ZSN+W1+:6\M)GN?JZ<_1F6)F-G*ZLM/6^#[?Q?!BK&OR
MZ_.+S0WD;39=9T6YU3S)K%[>P:';Q3VH:]$$\K3,Q'".TM[%56WDDE_E1EY<
M\59'<_G?8VGEBZU"]TB>TU^RU&'1[S0)IH4,-Y<@-!ZETQ%NEK+&1(MVQ]+C
M_E_#BK+/)WF;4M=M;B34-'DTF:!^*'UX;NVN$.ZRVUQ":2)3[7)(V1OAXXJD
MWF/\R=1M-?N="\M^6[KS-?Z9'%-K/U>>"VCMDG!:-.<[+ZMPZ#U%@3]C]K%4
M!??G#>22>AY;\IZGK=Y:VL-]K5H?2LY;&.=2R0R).0SWA52XMHUY,GQ<OB7%
M5VH_G+;&X\N0^6]%N?,;>:+">_TSZM)%#00</AF,Q5(5_>4D=G_=NO#@[XJE
M#?G]=KI5SJ[^3=132]&F>U\U7+36X^H7$4OIR1QKRK>>GL\CP_"JNG[?)55>
MMQR"10R_9.X/L<578J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J__7]4XJ[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%5DTL4432RNL<2#D[L0
MJ@#<DD],5>8?EGK-A:^7M)>XU^W-M))<VT6F+Z9D^L27CA-T)D8(HD+<AQ5?
MWK?"F*H30/-VMZ@WEY;GS,J#5X-5:\=$L@(VL9@L#1ED(3X/M\_45_\ )^UB
MJE?_ )E:HOD[1M0BU1!J\^F66HS010P^G(SS)%</(TK<?2IR1H;9?6A;]Y(R
M)PQ54UC6[-_-D]L;VW,4'FC2C H,*'BUB&<ED"M+^\;CSDY-_NOE\.*O1_+]
MZ;HZC74$U#T+V>&J0^CZ' C_ $9MSZC15WE_;Q5)_P SO)D_F[1=/TV/ZN8[
M?5;&^NHKH$QR6]K.))8N/%PQD0%>+#@W[6*L*O?R0OY-&U'R[#=VAT"SU./6
M_*$%W&]PEM+1O7L[J%J)+9-ZCB+B_J)ZC?M<<53SR!^6EUI:ZQ-K^GZ#:KJM
MN+)],T*S]*'T/B]7U9Y +B<S<_L'C''Q^'[7+%4/Y5_*C5=*\D^9=+O+Z"[U
MK6K1]-MKZCA%LH+0V=A')4%OW:EI)>*_WDLG'GBJOY _+G6?+E[J4]Y<6\J7
MNAZ/I,?I%ZB;3+:2"5VY*O[MVDK'^UQ^TJXJB?*NG:SY"\D^7;#4[K3TT70+
M"5?,=\QF+*(DK$]M\(7A7EZWJKRX_8Q5@OY:>3_,UQY%\K>:_+%Q;6NO6/Z7
MABM]3BE-I=V&H:A).O+TZ31_9BFAE0?&OVO@;%62?\JCUO\ 1NF23ZC;W.N/
MYJM?-.O7(1X8',/PM#;1_O"O"-8XX_4/Q\><C8J[S]^56N^8Y_.TEG=6L0\S
M:9IUA9^L9!Z<EE,\LC2\4/P,K_!PY?Y7'%60Z_Y/UC4?.FF^8+*]CLDLM(O]
M.$O'U)DGO&B,4R1NIB=8O2+,LAQ5@^D_DEY@O=:>Y\RC1--M'T^\TZ]/EJ&:
MUFU(7T/H,UZ&"1 1C]]&L:M^_P#VN*XJGFB?E[YYEU+R]%YKU73[K1?*$@FT
MD6$,L5S=S) UO#+=\V*1>E$[?NX/AED^U\/PXJHS_E5KLGY5W?D\75J-0N-7
M;4DG)D]$1'51?\2>'/GZ0X?9_O/\GXL589^95M=>7/.E]-=SII5I?ZO8^9O+
MGF*]1WTT:A;6QM)["^>(,T EA!:%^/\ LN7V54HUB]BO-<U>[UCSUHVLP>:[
M>ULK[3O+(EN]5:&W9B=-T^)))%2&<R?O;F8\_P"\^"/%6=ZE^2DVLW^MZY"D
M.BZE<V^CR^4G&]QI=UI<++Z4ICY1^DY*12)$\J-'_E)'BJ#\^>4=1L;#S5YL
M\QWD=F^H+Y?GAN=.AFNULK_268F>6%E5GL_6D%?MOZ/+DO)<52'RW>>;OS'\
M\ZM<0ZW83%?+%WI<>LZ'#<BRL[F[GC:,":XX2S3.J-(X3^Y7[/Q8JRGR3^4'
MFK2/.'E_7[Z'R_I]OH\=U;RV&BPSQM*+F!8_K$MQ,OJ3S%E4,DGPJJ\UDYNV
M*H"#\C/-)\N:;8WSZ)?7?EF]O;C08[J&>XM+JVU&1Y)X[Z-@/3DY,ABD@Y^E
MZ?[>*L@TS\L_->G^4-2MK)O+]AK>H745TVGVNG(-(>&%0/J<X93<3))1F:Y;
M]]&W]TJJO'%57\O_ ,O/-7E6V\QW\:Z/9:MJR1#3M$TU;B+18);>,JDK*U)0
M\[-_I#1QK\")]K%5?5/)?Y@V?F+4-=\I:CIEK<^8X;9->BU"*:58;FVB]%;J
MS*$<^,?P^A-^[;@K<OM8JAG_ "\_,'1-3NM0\IZ[:7-UKEM;6VOW6N0O)*9[
M6,Q)>P?5^*&3TFX_5G58O@7X_M8JC?+OY6GR[KGE"33[A7TGRSI%YIDGK<A/
M++=/$_J!0"@!:)V8<OAY?!BJ7WWY6:[/^7OGORTMU;"]\TZK?ZA92DR>E''>
M2I(BRD(6YJ$/+@KXJ]2MU*PHAZHH4_,"F*JF*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5
MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O__0]4XJ
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%6F564JP#*=B#N",54UM+56Y+#&&_F"@'P\,5=]4M*4]&.G^J/Z8JW]6MZ
M>DE%K0<1MRV;[^^*M?5+2M?1CKX\1_3%57%4!>Z+9WDWJS-.& "CTKFXA6@K
M^S%(BUW\,54/\,:9_/>?])UY_P!5L5;_ ,,Z9_/>?])U[_U6Q5W^&=,_GO/^
MDZ]_ZK8JU_AC3/Y[S_I.O/\ JMBKCY7TLBA:[([@WUX1_P G<5=_AC3!T>['
M;_>Z\Z#_ )[8J[_#&F?SWG_2=>_]5L5;_P ,Z9_/>?\ 2=>?]5L5:_PQIG\]
MY_TG7G_5;%7?X8TS^>\_Z3KS_JMBKO\ #&F?SWG_ $G7G_5;%7?X8TS^>\_Z
M3KS_ *K8JT_E72)$:.0W3QMLR->WC*1[@RTQ5!V'Y>>4-.D:33K#ZC(XXN]M
M-/"Q'@3'(I.*H[_#.F?SWG_2=>?]5L5:_P ,:9O\=WOL?].O.G_([%7+Y6TI
M5XJUVJ]:+>W@%?HEQ5W^&-,_GO/^DZ\_ZK8J[_#&F?SW?_2=>?\ 5;%7?X8T
MRE.=Y3_F.O/^JV*N_P ,:9_/>?\ 2=>?]5L5=_AC3/Y[S_I.O/\ JMBKO\,:
M9_/>?])UY_U6Q5W^&-,_GO/^DZ\_ZK8J[_#&E_SW?_2=>?\ 5;%6_P##.F?S
MWG_2=>_]5L5=_AG3?]^7G_2=>_\ 5;%7?X9TW_?EY_TG7O\ U6Q5W^&=-_WY
M>?\ 2=>_]5L5=_AG3?\ ?EY_TG7O_5;%7?X9TW_?EY_TG7O_ %6Q5W^&=-_W
MY>?])U[_ -5L5=_AG3?]^7G_ $G7O_5;%7?X9TW_ 'Y>?])U[_U6Q5W^&=-_
MWY>?])U[_P!5L5=_AG3?]^7G_2=>_P#5;%7?X9TW_?EY_P!)U[_U6Q5W^&=-
M_P!^7G_2=>_]5L5=_AG3?]^7G_2=>_\ 5;%7?X9TW_?EY_TG7O\ U6Q5W^&=
M-_WY>?\ 2=>_]5L5=_AG3?\ ?EY_TG7O_5;%7?X9TW_?EY_TG7O_ %6Q5W^&
M=-_WY>?])U[_ -5L5=_AG3?]^7G_ $G7O_5;%7?X9TW_ 'Y>?])U[_U6Q5W^
M&=-_WY>?])U[_P!5L5=_AG3?]^7G_2=>_P#5;%7?X9TW_?EY_P!)U[_U6Q57
MM-'M;.0R0-.68<3ZUS<3"E:[+*[J#[C%4=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_ /_1]4XJ
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J
M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7_TO5.*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5Q-!7%6N:
M^.*M@@],5=BKL5=BK1=!WQ5L$$5'3%78J[%78J[%78J[%78J[%78J[%6N:UI
M7%6\5:#*30&N*MXJ[%6BZ@T)WQ5L,"*CIBKL5=BKL5=BK1= :$[C%6P014=,
M5:+J#QKOX8JWBKL5=BKL5<S!14F@'4XJUR%*]L5=R!%>V*N5E85!J/'%6\5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK08$T[XJWBKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBK__T_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N
MQ5V*NQ5V*NQ51O4YV<R\VBJC 21GBZ[=5-#N,58=HMQJ=[^4MIJ<NI7/Z5N=
M)2_:^#1^J)VMQ*2HX>GQY_L<./'%4>//'ENPCF@NKZ0'3###J=U)#,T<+RQH
MZ&><)Z2<ED1O4+</B_9Q5,&\U:*NH"Q-T/6,WU;F%<Q"XX\_0,P'I"8K_NHO
MSQ50C\[>7Y-0;3UN6^L+=MIS$PS"(7:IZIA,K((N?I_$GQ_'^Q\6*I[(Q5.0
MK0;F@J:>PQ5@/E#S-9ZW>VEY<WFH6>HZC)J$=OISK*MK)':S-$ O.(1AX4C6
M2JLDGJ._J<_L(J[R9YFU:72O)0O=021M6L)I+M9H9)+BXEBC60.DR$11\!R,
MBNG[SX?2^RV*I]IGGSRSJ48EM;W]PUJU_'<3Q2V\;VL9 DF5YD162,D>I0_!
M^WBJ+TCS5HFJW!M;2<F[$*7)@DBEB<0R$B.0K*J'A)Q;@?VN+?RXJF]:],52
M>U\U:+=:J-+M[GU+QEF>-1'($<6[K'/PE*^D[0NZI(J/R3%4PO[ZTL+.6\NY
MDM[6!2\TTAXJJCJ23BJ6'S=I"@!VF25W].*W>VN%FE/ O^YB,8DE 0%F:-65
M?VL56/YV\O V"QW+7#ZG')-8QVT,T[21P<1*0(T;B8RZAU?BZM\/'%5*U\_>
M5[J7TK6],Y^J2W_)(9N/U>!_2E;GQX\HI/W<D5?51_A9,53G2]1MM2TZWO[8
MLUM<H)86>-XF*,*J2D@5UJ/YEQ5!2>:=$74!8BZ!F,WU7GQ<PBXX\O0:8#TE
MF*](B_/%4C\O:G^GO,>J2.U_;OHM^]K!$#-';21);I7U%*B)V=YV?BW[SX(G
M7X/M*I_K?F*QT>2PBN5F>349FM[9((7F8NL3S&H0$[1Q.V*L;\G^;(2;VTU*
M]EDNGUO4+*TDG23@.%P_HV_J\!$&])/W:<N3?Z^*HVS\Y6]N^JIJM]'+);:C
M/;6\-M;3B58HX8Y^!C_>23O%')ZDL\2^EQ9<590DGJ1+(A!# ,K#H0=Z_=BK
M X_,]G?>9;U;^[U#3AIVKP:78B))EMIG:"*3A-^Z:+_2)+CA\?["Q-$\?+FZ
MKO+WF'5UT_0O7OU<7VM:I8SFYBDFEF2&XNQ!%')'QCA9$@'QRCCZ<?#[>*L@
MM_.WEZXOQ8PW3&8W,UB&:&9(OK5NI>6'U601<U1&:G/XE7X.6*JNE^<?+VIW
M4-K:78DGN8C<6R%)$]6!33UHRZJ'A)^S*OP-^SBJ*U[7-/T/2I]5U&1H;&V'
M.XF2.28HM:<BD2N_$?M'C\.*H";SMH4-S>VSR3"?3A;F\C%M<,R"[;A!0+&>
M7J-LO#E]E_Y6Q5C.G>8=9OO,&APS:B)4G77H;Q;6*2VA:2QGCBC_ '<W*3U(
M*O&6KP>3DZKQXXJR7\O;V[OO(OE^]O9FN+NYT^VEN)WW9Y'B5F8TIN2<52O4
M/,ITS\P;V"\N+@Z8FC070MXHI)DC?ZS,LLI6)'9?@1.3-BJ=/YQ\N)/:0MJ$
M/.]6%[8@U5EN#Q@;D/A7UF^&+D?C;X5Q5.))(XT9Y&"(H+,S&@  J22<58Z?
MS!\L>E-*+IRD#6RR$6]P:"^/&VD X?%#,PXI,O[KE^WBKKS\P/+-F]^MQ=.C
M::9%O%^KW#%!"BR2O\,;<XXDDC>61/W<:R)R;XL52'SMYFU6'2_-R6FHI&;#
M3[2\T_ZO%)'/")RX+M,Y:*596B;AZ2_NU5^?Q8JRH>:-"EU==%2ZK>RF6.-5
M23@SP --&LO'TO5B#5:/GS7^7X6Q5B_DCSBEYY+TN"_OISK5[9SM'<S1NAFE
MB#LYBE*"%Y$ Y<4_E^SQ7%4P\O><=-LO)WENYUS452[O=,M+F>:8U9B\*&2:
M0C9$YM\4C<4Q5F%<58S=_F%Y8MH+Z9KII%T^U>_E].*5@]O$QC>2%N(295D'
M!C&S</V_AQ5/K&[%U;K.J2(K]%FC>)Q0TW1PK#%4EU#SYY<T^74TNKB2,Z.8
M!J/^CSD1?6JB$U"$.KT^U'R7^;%51_.N@IJL>DL\ZZA+*8(HC:W'%I5@%RT8
MD]/T^0@/J4Y_\-BJ#F_,SRE#IT&I274WU&Y:589A:73 F&58)*A8B4XS2)'\
M?'X\51C^=="2YO;4RS&XT^X@M+J-;:<E9KJGHKLAY>IS4AEY+Q;EBJ)D\R:5
M'J)TY[@?6E^&4!79(V],RA)9 #'$YB'J!9&7X/BQ5#P>=O+,]M<7,6HQ-%;&
M,2G<-^_)6'BM.3>LPXP\1^]_8Q5%PZ[8R6%Q?.[6UM:AS<O=1R6WIB->;LPF
M5"$"?%S^SBJ72>>M%6XL[<"Z>>^EEAAC6UN.0:&(3,60H&"\'1E:GQ\_A^'E
MBKF\^>6Q%?2)=F0:=:/J$Y6*4AK5"P:6)N(69 R,I:(OBJZ3SSY>@M+:YO+H
MV2W2"1$ND>%U2H!D=7 *1@M_>-^[_P K%4?K&OZ;H\$4^HRF&.>:*UBXQR2%
MIYVXQH%C5FJ[;+MBJ7V7GSRW=W,%M%<R"6XNI+&/U+:XC7ZW"K/);LSHJI,$
M1FX.?B7[.*HG3O->B:AJ+:?9W0FN5B-P $D5'A63TFDCD91'*JR? WILW%O]
M;%5/4?.6A:;'JDEY<M&NBK%)J9$,S^E'."8W^!&YH>+<F3EP_;X\<517^(--
M.I_HU9B;H-P<+&[(C^GZWIO( 8XY/2_>A'96:/X\523R[YBB32DO[^X=YM:G
MN;O3K1 ]S*;7G^Z]*./U&]-8!'(_#]VK2?Y>*ID/.7E_UHHFNZ&4Q(S&.4+&
M\ZAHDG8J%MY) R\8YC&_Q*O'DRXJKV_F72KG6+G2+>5Y+VS8)=H(9N$3-&)5
M5I2OI5:-N2_'\6*IKBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BK_]3U3BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=B
MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL56R ,C*14$4(\:XJQ'3/)VK6&B)Y
M;CU0-HD8,$+/ 3=K:$[6_JE_28+'^X60P\O2_P"+/CQ5)K#3CK7F3SUI"WD*
MZ3=7%M;WD"+6<QG3H(I1')SX(IX^BW[IN#+)^W]A5.!Y'<%K$7@.A-J8U@V8
MB/KBX$XN_3$_+CZ/UL";^Z]3C^YY\,50TGD+6&N9)AJ4 ]374UX+]6D-&2)8
M1#7UNG% ?4_F_8Q5F\A<1_!0-VY=*]JXJP;2?(>M:=)HLJZC;2-H\FHRJ#;2
M 2'4G:1A_?'CZ3/_ +/%5^D^1-6TZ'RO&FHP2'RU#/ K-;2#UA-'Z08TF^#B
MH!/VN3?RXJ@H_(&H:9H]F)[F'4;?1M%U#2VM19R.]S'=!'/P"8U;_1T3TA_>
M<W7^3%4/Y=75[FRDM]'E#7EW86[GS!#=F\:"2W*"&VE6>%4],K),[1KRE_O^
M7&61'Q5Z9&" =N^*L0T[R;JUOYH@UVZU7ZXUO]=BBB>)U/U:\>.18Q24Q(T'
MHQQJT<*>JGQ2JTOQXJG7FO0(_,&@W6DO.]K]8"-'<Q %XI8G66*10WPGA*B-
MQ;[7V<52ZX\NZY<7]CJ[W\ U?3Q-%"5MW^K-#<A/61HS+ZG)FBB=7$WP<./'
MXGQ5C-QI<NB^<?*6FV%_#]>:+6;F[FNH^0DFO9(9I"(TDC]/U9C(T2\F^"-H
M_B^UBJ*U#RI9'7-!T:QN)!=0R7U_K,H5?WME?LSW,<FW%/K=WZ80)\2I')P^
MRV*O0^-%H/HQ5B!\CS<VL_KO^X)M3_3#VGI5N/K'K_7.'K\N/H_6QZW]UZG'
M]SSX8JFGEG0KS2KC69;BYCG&J7S7ZK'$T?IEXTB*$L\G/X8D/+X?BY8JWYDT
M*ZU*XTB[M+E+:YTB\-W'ZL1EC</;RV[HP#QD?!.S*W+[2XJD"^0M7%G# =2@
M+1:ZVO%Q;24)>9I_1X^L:?&[?'_J_!BJCJ7Y;7NHG54GU&-8]2OVU"-HH)(Y
M[:0P10))!.LP>.XA$"-'(OP-SD26)X\59Y&K);JM2Q50.3&K&FU2?'%6%7?D
M769I[R5=1MT^M:W;:X@-M(W%K6.*-821,*AA;H2_^4_P_9Q5?:>2-6M[71X&
MU"!AI6K7.KL1;2#U/K37#&(?OCQX?7)?C^+[,?P_:Q517R%JZ21ROJ,#K#K4
M^NLGU60EC/#)"8/[[H%F;X_^%Q5+OR[D,4NEI!;1W7J6/U>XG2XD>33X8/BC
MMVMY(U^KAG^!H/5:6-D1?WL<7)57HM[:VUY:2VER@EM[A&BFC85#(ZE64CW!
MIBK$-(_+>+3KS1;]M2N+FYTRW:WO6E  OJ<?J[7'7>U*_N<54M,\A:Y8ZE:7
MWZ1M7^J2:K,J?5I &;5YA.X)]<[1. J_S)BK)?*.BS:'Y9TW1IIEN6TZWCM5
MG1#&'6)0BMQ+/0E1\7Q8J@]1\N:FWF:37-.OX[:2XL(].ECD@,O%8Y9)5EC(
M=!S!E/PNK)BJ T3\OXM"O_4TR=18/%:126UQ"LLB&RC$*O#*2/3]6-$$JLC+
M\/./@W+%65WD+S0/&CF-G5D#J 2I84Y4((VQ5A5A^6TYAUB'7-1_2@UVPAL-
M2D].1'9K?U>,Z,TLO!F]=F*+\$<BIZ/!/AQ5=JGY>:C>>7X-$36I$MY+.ZMM
M7E>*KW<UX@#W3>D\7&4.9']-N<#>I\4?P1\55/5OR^UK4;?6(FU*WC.KZ;9Z
M8["VD/IBS:1O4%9OBY^N_P /[/%/\K%45#Y)UH^9[/7;O5Q<FQN)YK>W,+A5
MBNHO3DA4"7TQP/Q12"/U&_W?ZGVL54],\@WUIH^F:9+J$4\&A^H^F'ZNR$S/
M%)"LDU)#R]))Y/AC]/GBK6E?E]>:<^F21W\4DUGI=OH]UZMJ'CDBLR3!/$KN
M3#.H=ZU:2-N?Q)\"8JSA5"C;%7G5W^6&J7OZ0:_UQKF74--O-)DG:!N:PW,G
MJ1.%]4QJT7%49(DCBD7]A';%6>V OEMD6^DCEN0/WDD*-$A/^2C-(0/]FV*I
M#KODG3]8UKZ]=R/]5DLY;&^L@!Z=RK'E"TA._*W+S&+_ "I?\G%4.?(/+R?8
M:,VJ7#ZC8RPW*:XRJ;IIXWJ\I[<I8R\+?\5OBK=E^7NF6K:_#SDDTW7%*+8$
M+Z=JLD7"98=MO7?]\_\ Q9BJ&M/RZEM;RUU"#5Y_TI#I[VEU=21HXN;NA]&]
MFC.S26YDGX)7CQEX<N*8J[4OR[.JZC)=W]^]9K22RN);9#;3S136[021S%']
M*6(.[7,*M%ZL$O\ =R^G\.*JLWDB^N-$MK*?4(TOK">UNK.^M[5809K-JJ\T
M88B0S#DDRJR)Q;]UZ>*IG<Z5Y@N(P)-42(&*=)X8[5&B9Y%41,/59WXQ$.SQ
MLS>MZG%N*8JD>F_EU<:8^DS6.H+&VF75Q<I;/'++;)%=PB&2"W1Y6D@C7CZL
M:^JZ([2?#Z?%454H_P M]3DEOWU#6S>R:AI=SHT\QA99/1G9F2109&C62,/Q
M9(XXX6_82/%4=;>2M2BU*VU)[^WENQ8Q:=>*UI6)DMW9HI85>1FAF7U)*U:2
M-^?Q+^[3%43K?EG6]3CCC;4T(AU2WU*W$EOM'%:NDB6WP.G.KH:RO\7%_L_#
MBJ71>0]62XAE.HP-Z6NR:]Q^K2;M+$\1A!,NP596//\ X7%6K'R'YAM=4EU3
M]/\ JZ@UE<V$=U);%F1)91-#)P:4P\H2JHT:1QPR+^PK-BJ[7?(.IZE_B!(=
M4CAC\QZ?#8WK26QD='@CDC]5"LD:?&LOQ(5^']EL55+WR+J%SK$NL)J0L]1>
MTDMEGMHWCKZD!C"S@2\;B&&5FN+<.OKQ/Q3U^'VE4;<^4IXM1TK4=)N1;7.E
MV<FFB*>,S12VTGID*_%HW#(\",KJW\RMBJ"NO(,\\=_9-J%=)UBYCO=5A:']
M^\R",2"*57"Q1S>C%R7TG9/WG!OC7@JBX/+6MV^L:OJ$&J1P+JUY;73QI;AF
M$5M$D+0%G=@?5BC_ +Q45HW^SBK*(P0N*KL5=BKL5=BKL5=BKL5=BKL5=BKL
M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_ /_5]4XJ[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%5LG/@W"@>G
MPDBHKVJ!3;%6#:9YZO+W0M#FNY;6QU37KF>WMC1FBC6V]9W9E9P6JEN:?$OQ
MR+BK)X;[ZK!96^KW=L-2G4*2A]))9%6KF%'9FX_Y/)O];%4)Y0UZ?5;2[:\]
M*.ZAO[ZT6*,D5CL[I[=7XL6;X@E6_P K%4]62-G9%<%TIS4$5%=Q4=JXJD'G
MWS%+Y?\ +-WJ5N86NX0I@AG-%>LBHU "K&@;MBJ?>K"LBPEU$I!98R1R*C:M
M.N*K9+NUC<QR3(CA>91F /'^:A/3WQ5LSP$NGJKR1>3CD*JO6I\!BJQ;VRZ"
MXC)+^F/C7[?\O7[7^3BJJTL:NJ,X#O7@I(J:=:#O3%5JW5LTAB65&E459 P+
M  TJ1BJC::G97L9DL[B*YC4E2\3AP""01\)\0<50NB:VVH:?'<W=M^CII)98
M1:RRQ2-RCD9!\43.A+A>?$-R7[+_ !8JF$SPQH6ED$:=:L0!L*]3\L54IYUC
MBD:$?6)TB,L=LC+S>@VXU('Q'X0Q^'%5/2]1>[TVRN[J V%Q=QH[6<KHSQR,
MO(Q%D+([+O\ W;,O\N*HB2ZMHW9'F1)%0R,K, 0@ZL03]GWQ53M=3L+JWCN8
M+F*6WE*B*9'5D8N 5 (/4UQ5*/.?F"71M/MYK<PM<37ME;&*8[F.[NX[=V4
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MD2I%584(JI!Q5 IY;T=-$_0:VL?Z)]'ZN+/XB@A(IZ>YKPIMQK]G%4PBB2)
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:Q5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6746518176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jul. 28, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Anika Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000898437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">anik<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,777,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6746926576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 89,125<span></span>
</td>
<td class="nump">$ 110,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">27,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of reserves of $220 and $167 at June 30, 2016 and December 31, 2015, respectively</a></td>
<td class="nump">24,597<span></span>
</td>
<td class="nump">21,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">17,264<span></span>
</td>
<td class="nump">14,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">154,644<span></span>
</td>
<td class="nump">176,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">49,198<span></span>
</td>
<td class="nump">40,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_DepositsAndOtherAssetsNoncurrent', window );">Long-term deposits and other</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">11,259<span></span>
</td>
<td class="nump">11,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,568<span></span>
</td>
<td class="nump">7,482<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">222,738<span></span>
</td>
<td class="nump">235,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,294<span></span>
</td>
<td class="nump">8,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,638<span></span>
</td>
<td class="nump">4,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">4,198<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,523<span></span>
</td>
<td class="nump">17,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">6,570<span></span>
</td>
<td class="nump">6,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value; 1,250,000 shares authorized, no shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value; 60,000,000 and 30,000,000 shares authorized, 14,777,663 and 15,036,808 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">59,506<span></span>
</td>
<td class="nump">81,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6,410)<span></span>
</td>
<td class="num">(6,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">151,172<span></span>
</td>
<td class="nump">135,662<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">204,416<span></span>
</td>
<td class="nump">210,848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 222,738<span></span>
</td>
<td class="nump">$ 235,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents deposits and other assets, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6746565232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, net of reserves</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,777,663<span></span>
</td>
<td class="nump">15,035,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,777,663<span></span>
</td>
<td class="nump">15,035,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6740018576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
<td class="nump">$ 26,575<span></span>
</td>
<td class="nump">$ 22,898<span></span>
</td>
<td class="nump">$ 48,853<span></span>
</td>
<td class="nump">$ 38,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Licensing, milestone and contract revenue</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenue</a></td>
<td class="nump">26,581<span></span>
</td>
<td class="nump">22,904<span></span>
</td>
<td class="nump">48,864<span></span>
</td>
<td class="nump">38,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of product revenue</a></td>
<td class="nump">6,065<span></span>
</td>
<td class="nump">5,275<span></span>
</td>
<td class="nump">11,490<span></span>
</td>
<td class="nump">9,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research &amp; development</a></td>
<td class="nump">2,792<span></span>
</td>
<td class="nump">1,812<span></span>
</td>
<td class="nump">4,951<span></span>
</td>
<td class="nump">3,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general &amp; administrative</a></td>
<td class="nump">4,255<span></span>
</td>
<td class="nump">3,388<span></span>
</td>
<td class="nump">8,245<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">13,112<span></span>
</td>
<td class="nump">10,475<span></span>
</td>
<td class="nump">24,686<span></span>
</td>
<td class="nump">20,491<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">13,469<span></span>
</td>
<td class="nump">12,429<span></span>
</td>
<td class="nump">24,178<span></span>
</td>
<td class="nump">17,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">13,518<span></span>
</td>
<td class="nump">12,453<span></span>
</td>
<td class="nump">24,299<span></span>
</td>
<td class="nump">17,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">4,903<span></span>
</td>
<td class="nump">4,634<span></span>
</td>
<td class="nump">8,789<span></span>
</td>
<td class="nump">6,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 8,615<span></span>
</td>
<td class="nump">$ 7,819<span></span>
</td>
<td class="nump">$ 15,510<span></span>
</td>
<td class="nump">$ 11,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="nump">$ 0.52<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">14,679<span></span>
</td>
<td class="nump">14,961<span></span>
</td>
<td class="nump">14,778<span></span>
</td>
<td class="nump">14,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">15,111<span></span>
</td>
<td class="nump">15,336<span></span>
</td>
<td class="nump">15,210<span></span>
</td>
<td class="nump">15,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 8,615<span></span>
</td>
<td class="nump">$ 7,819<span></span>
</td>
<td class="nump">$ 15,510<span></span>
</td>
<td class="nump">$ 11,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on securities, net of tax</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(536)<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="num">(1,828)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(536)<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="num">(1,831)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 8,079<span></span>
</td>
<td class="nump">$ 8,236<span></span>
</td>
<td class="nump">$ 15,748<span></span>
</td>
<td class="nump">$ 9,504<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6746469376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 15,510<span></span>
</td>
<td class="nump">$ 11,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">1,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(252)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">52<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Tax benefit from equity awards</a></td>
<td class="num">(419)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,932)<span></span>
</td>
<td class="num">(2,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(2,438)<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current and long-term assets</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(4,252)<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">446<span></span>
</td>
<td class="num">(264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(3,169)<span></span>
</td>
<td class="nump">3,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">396<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">6,643<span></span>
</td>
<td class="nump">14,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturity of investments</a></td>
<td class="nump">27,750<span></span>
</td>
<td class="nump">10,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of investments</a></td>
<td class="num">(22,499)<span></span>
</td>
<td class="num">(22,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(9,869)<span></span>
</td>
<td class="num">(1,134)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,618)<span></span>
</td>
<td class="num">(12,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of equity awards</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities', window );">Tax benefit from equity awards</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(23,659)<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Exchange rate impact on cash</a></td>
<td class="nump">52<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(21,582)<span></span>
</td>
<td class="nump">3,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">110,707<span></span>
</td>
<td class="nump">100,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">89,125<span></span>
</td>
<td class="nump">103,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 2,128<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904883792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">1.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Nature of Business</div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing innovative and differentiated therapeutic pain management solutions along the continuum of care, from palliative care to regenerative medicine. The Company has over two decades of expertise developing, manufacturing, and commercializing more than 20 products, in markets across the globe, based on the Company&#x2019;s proprietary hyaluronic acid technology. The Company&#x2019;s orthopedic medicine portfolio is comprised of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States, among others) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and foreign regulations and approval requirements, as well as the ability to grow the Company&#x2019;s business through appropriate commercial strategies.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6629975760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">2.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Basis of Presentation</div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and in accordance with accounting principles generally accepted in the United States (&#x201c;US GAAP&#x201d;). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. The year-end consolidated balance sheet is derived from the Company&#x2019;s audited financial statements, but does not include all disclosures required by US GAAP. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial position of the Company as of June 30, 2016, the results of its operations for the three- and six-month periods ended June 30, 2016 and 2015, and cash flows for the six-month periods ended June 30, 2016 and 2015.</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company&#x2019;s annual financial statements filed with its Annual Report on Form&nbsp;10-K for the year ended December 31, 2015. The results of operations for the three- and six-month periods ended June 30, 2016 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2016. Certain prior period amounts have been reclassified to conform to the current period presentation. There was no impact on operating income.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6646975632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements and Changes in Accounting Principles [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">3.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></td> </tr>  </table>  <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><div style="display: inline; font-style: italic;">Recently Issued</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><div style="display: inline; background-color: white">In May 2014, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 supersedes the revenue recognition requirements in &#x201c;Topic 605, Revenue Recognition&#x201d; and requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </div>In July 2015, the FASB issued a deferral of ASU 2014-09 of one year making it effective for annual reporting periods beginning on or after December 15, 2017 while also providing for early adoption not to occur before the original effective date. The Company is assessing the appropriate method for implementing ASU 2014-09, as well as the impact the adoption of ASU 2014-09 will have on its consolidated financial statements.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">&nbsp;</div>  <!-- Field: Page; Sequence: 6; Value: 2 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU 2016-02 amends existing leasing accounting requirements. The most significant change will result in the recognition of lease assets and lease liabilities by lessees for virtually all leases. The new guidance will also require significant additional disclosures about the amount, timing and uncertainty of cash flows from leases. ASU 2016-02 is effective for fiscal years and interim periods beginning after December 15, 2018. Upon adoption, entities are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. Early adoption is permitted, and a number of optional practical expedients may be elected to simplify the impact of adoption. The Company is evaluating the impact of adopting this guidance.</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In March 2016, the FASB issued ASU No. 2016-09, Compensation (Topic 718) Stock Compensation. ASU 2016-09 identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. Early adoption is permitted. The Company is assessing ASU 2016-09 and the impact that adopting this new accounting standard will have on its consolidated financial statements and footnote disclosures.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><div style="display: inline; font-style: italic;">Recently Adopted</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In July 2015, the FASB issued ASU No. 2015-11,&nbsp;Inventory (Topic 330) Simplifying the Measurement of Inventory. ASU 2015-11 more closely aligns the measurement of inventory in US GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business less reasonably predictable costs of completion, disposal, and transportation. The provisions of ASU 2015-11 are effective for annual and interim periods beginning after December 15, 2016. ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of this amendment did not have a material impact on the Company&#x2019;s financial position or results of operations.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6507316<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Direct Effects of a Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=66092750<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22583-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Indirect Effects of a Change in Accounting Principle<br> -URI http://asc.fasb.org/extlink&amp;oid=6515603<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22580-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Accounting Change<br> -URI http://asc.fasb.org/extlink&amp;oid=6503790<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Retrospective Application<br> -URI http://asc.fasb.org/extlink&amp;oid=6523989<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6737442944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">4.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Investments</div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><div style="display: inline; background-color: white">All of the Company&#x2019;s investments are classified as available-for-sale and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes. The Company held bank certificates of deposit of $22.5 million and $25.8 million at June 30, 2016 and December 31, 2015, respectively. The Company also held corporate debt securities of $2.0 million at December 31, 2015. There were no unrealized gains or losses on the Company&#x2019;s available-for-sale securities at June 30, 2016 or December 31, 2015.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 6.H.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13728-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904491200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">5.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></td> </tr>  </table>  <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants based on assumptions that market participants would use in pricing an asset or liability. As a basis for classifying the fair value measurements, a three-tier fair value hierarchy, which classifies the fair value measurements based on the inputs used in measuring fair value, was established as follows: (Level 1) observable inputs such as quoted prices in active markets for identical assets or liabilities; (Level 2) significant other observable inputs that are observable either directly or indirectly; and (Level 3) significant unobservable inputs for which there is little or no market data, which requires the Company to develop its own assumptions. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. On a recurring basis, the Company records its investments at fair value.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><div style="display: inline; background-color: white">The Company&#x2019;s investments are all classified within Level 2 of the fair value hierarchy. These investments classified within Level 2 of the fair value hierarchy are valued based on matrix pricing compiled by third party pricing vendors, using observable market inputs such as interest rates, yield curves, and credit risk.</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 7; Value: 2 -->   <!-- Field: /Page -->  <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The fair value hierarchy of the Company&#x2019;s cash equivalents and investments at fair value is as follows:</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div>   <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">Fair Value Measurements at Reporting</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date Using</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Quoted Prices in</td> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Active Markets</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Significant Other</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Significant</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; text-align: left">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">for Identical Assets</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Observable Inputs</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Unobservable Inputs</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; text-align: left">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2016</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 1)</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 2)</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 3)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Cash equivalents:</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Money market funds</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">67,001</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">67,001</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Investments:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Bank certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,500</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,500</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">Fair Value Measurements at Reporting</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date Using</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Quoted Prices in</td> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Active Markets</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Significant Other</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Significant</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; text-align: left">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">for Identical Assets</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Observable Inputs</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Unobservable Inputs</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; text-align: left">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 1)</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 2)</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 3)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Cash equivalents:</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; text-align: left">Money market funds</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">61,385</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">61,385</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bank certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">250</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">250</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total cash equivalents</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">61,635</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">61,635</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Investments:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">2,001</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">2,001</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bank certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,750</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,750</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27,751</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27,751</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6593148608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">6.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Equity Incentive Plan</div></td> </tr>  </table>  <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company estimates the fair value of stock options and stock appreciation rights (&#x201c;SARs&#x201d;) using the Black-Scholes valuation model. Fair value of restricted stock awards (&#x201c;RSAs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;) are measured by the grant-date price of the Company&#x2019;s shares. The fair value of each stock option award during the three- and six-month periods ended June 30, 2016 and 2015, respectively, was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:</div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Risk free interest rate</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.94%</td> <td style="font-size: 10pt; text-align: center"> -</td> <td style="font-size: 10pt; text-align: left">1.40%</td> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.15%</td> <td style="font-size: 10pt; text-align: center"> -</td> <td style="font-size: 10pt; text-align: left">1.46%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected volatility</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: right">49.47%</td> <td style="font-size: 10pt; text-align: center"> -</td> <td style="font-size: 10pt; text-align: left">51.61%</td> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; text-align: right">53.15%</td> <td style="font-size: 10pt; text-align: center"> -</td> <td style="font-size: 10pt; text-align: left">54.65%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Expected life (years)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 4%; font-size: 10pt; text-align: right">&nbsp;</td> <td style="width: 5%; font-size: 10pt; text-align: center">4.5</td> <td style="width: 3%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt; text-align: center">&nbsp;</td> <td style="width: 5%; font-size: 10pt; text-align: center">&nbsp;</td> <td style="width: 5%; font-size: 10pt; text-align: center">4.5</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected dividend yield</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: center">0.00%</td> <td style="font-size: 10pt; text-align: left"></td> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; text-align: center">0.00%</td> <td style="font-size: 10pt; text-align: left"></td> </tr>  </table> </div>  <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div>  <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company recorded $0.7 million and $0.5 million of share-based compensation expense for the three-month periods ended June 30, 2016 and 2015, respectively, for equity compensation awards. The Company recorded $1.5 million and $1.1 million of share-based compensation expense for the six-month periods ended June 30, 2016 and 2015, respectively, for equity compensation awards. The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to the respective recipients.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the three-month period ended June 30, 2016, the Company granted under the Equity Incentive Plan (&#x201c;Plan&#x201d;) a total of 43,000 stock options. During the six-month period ended June 30, 2016, the Company granted under the Plan a total of 331,705 stock options including 46,300 RSAs and 11,805 RSUs. All of the RSUs were granted to directors of the Company and vest over a one year period. The stock options and RSAs granted to employees generally become exercisable or vest ratably over four years from the date of grant.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 8; Value: 2 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">A portion of the stock options granted during the six-month period ended June 30, 2016 contained certain performance features, as compared to established targets, in addition to time-based vesting conditions. For performance-based awards with financial achievement targets, the Company recognizes expense using the graded vesting methodology based on the number of shares expected to vest. Compensation cost associated with performance grants is estimated using the Black-Scholes valuation method multiplied by the expected number of shares to be issued, which is adjusted based on the estimated probabilities of achieving the performance goals. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related share-based compensation expense that will be recorded in the period of the change. If the performance targets are not achieved, no compensation cost is recognized and any previously recognized compensation cost is reversed.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904491200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Earnings Per Share ("EPS")<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">7.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Earnings Per Share (&#x201c;EPS&#x201d;)</div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><div style="display: inline; background-color: white">Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic earnings per share. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, SARs, RSAs, and RSUs using the treasury stock method.</div></div> <div style=" font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><div style="display: inline; background-color: white">&nbsp;</div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><div style="display: inline; background-color: white">The following table provides share information used in the calculation of the Company's basic and diluted earnings per share:</div></div> <div style=" font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left">Shares used in the calculation of basic earnings per share</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,679</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,961</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,778</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,934</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Effect of dilutive securities:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Stock options, SARs, and RSAs</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">432</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">375</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">432</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">398</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Diluted shares used in the calculation of earnings per share</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,111</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,336</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,210</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,332</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><div style="display: inline; background-color: white">Equity awards of 0.3 million shares were outstanding for the three- and six-month periods ended June 30, 2016 and were not included in the computation of diluted earnings per share because the awards&#x2019; impact on earnings per share was anti-dilutive.&nbsp;Equity awards of 0.2 million shares were outstanding for the three- and six-month periods ended June 30, 2015, respectively, and were not included in the computation of diluted earnings per share because the awards&#x2019; impact on earnings per share was anti-dilutive.</div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">On February 26, 2016, the Company entered into an accelerated stock repurchase agreement with Morgan Stanley &amp; Co. LLC (&#x201c;Morgan Stanley&#x201d;) pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction (&#x201c;ASR Agreement&quot;) to purchase $25.0 million of shares of its common stock. Pursuant to the terms of the ASR Agreement, the Company paid Morgan Stanley&nbsp;$25.0 million&nbsp;in cash and received an initial delivery of 377,155 shares&nbsp;of the Company&#x2019;s common stock on&nbsp;February 29, 2016 based on a closing market price of&nbsp;$46.40 and the applicable contractual discount. This is approximately 70% of the total number of shares of expected to be repurchased under the ASR Agreement. These shares are held by the Company as authorized but unissued shares pursuant to Massachusetts law. The initial delivery of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares outstanding for basic and diluted net income per share.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of June 30, 2016, the Company has approximately $7.5 million&nbsp;remaining under the ASR Agreement which was recorded as an equity forward sale contract and was included in additional paid-in capital in stockholders' equity in the condensed consolidated balance sheet as it met the criteria for equity accounting. Pursuant to the terms of the ASR Agreement, the final number of shares and the average purchase price will be determined at the end of the applicable purchase period, which is expected to occur in&nbsp;the third quarter of 2016. Upon settlement of the ASR Agreement, the Company may receive additional shares or be required to either pay additional cash or deliver shares of our common stock (at its option) to Morgan Stanley, based on the forward price. If the ASR Agreement&nbsp;had been settled as of June 30, 2016, based on the volume-weighted average price since the effective date of the ASR Agreement, Morgan Stanley would have been required to deliver approximately 0.2 million additional shares to the Company. However, the Company cannot predict the final number of shares to be received, or delivered, by it under the ASR Agreement, and, as such, these shares are not included in the calculation of diluted weighted-average common shares outstanding during the period because the effect is anti-dilutive.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904784128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">8.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Inventories</div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in"></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Inventories consist of the following:</div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Raw materials</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">6,812</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,780</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Work-in-process</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">6,140</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,656</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished goods</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,312</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,502</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,264</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">14,938</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Inventories are stated at the lower of cost or market, with cost being determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and manufacturing overhead. Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if the Company believes there is probable future commercial use and future economic benefit.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6737499664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">9.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Intangible Assets</div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In connection with the 2009 acquisition of Anika Therapeutics S.r.l. (&#x201c;Anika S.r.l.&#x201d;), the Company acquired various intangible assets and goodwill.&nbsp;The Company evaluated the various intangible assets and related cash flows from these intangible assets, as well as the useful lives and amortization methods related to these intangible assets.&nbsp;The in-process research and development (&#x201c;IPR&amp;D&#x201d;) intangible assets initially have indefinite lives and are reviewed periodically to assess the project status, valuation, and disposition, including write-off(s) for abandoned projects.&nbsp;Until such determination is made, they are not amortized.&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Intangible assets as of June 30, 2016 and December 31, 2015 consist of the following:</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated Currency Translation Adjustment</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated Amortization</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Useful Life</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; font-size: 10pt; text-align: left">Developed technology</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">17,100</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(3,108</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(6,373</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">7,619</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">7,959</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: center">15</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">In-process research &amp; development</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,406</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1,286</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,120</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: center">Indefinite</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Distributor relationships</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,700</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(415</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(4,285</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: center">5</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Patents</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(186</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(357</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">457</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">473</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: center">16</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Elevess trade name</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,000</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(937</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">63</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">125</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">9</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt; text-indent: 10pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">28,206</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(4,995</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(11,952</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,259</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,656</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The aggregate amortization expense related to intangible assets was $0.3 million for the three-month periods ended June 30, 2016 and 2015, respectively. The aggregate amortization expense related to intangible assets was $0.6 million and $0.5 million for the six-month periods ended June 30, 2016 and 2015, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904496384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">10.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Goodwill</div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Through June 30, 2016, there have not been any events or changes in circumstances that indicate that the carrying value of goodwill may not be recoverable. Changes in the carrying value of goodwill were as follows:</div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended <br /> June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Twelve Months <br /> Ended December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Balance, beginning</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">7,482</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">8,339</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Effect of foreign currency adjustments</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">86</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(857</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance, ending</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,568</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,482</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6629982192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">11.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Accrued Expenses</div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Accrued expenses consist of the following:</div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"><div style="display: inline; font-weight: bold;"></div></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Compensation and related expenses</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">2,416</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">3,082</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Facility construction costs</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,769</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">415</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Research grants</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">481</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">381</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Professional fees</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">889</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">210</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Clinical trial costs</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">339</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">252</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">744</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">438</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,638</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,778</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6737566752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">12.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Commitments and Contingencies</div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><div style="display: inline; background-color: white">In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate, or breach any U.S. patent or intellectual property right, trade secret, or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company&#x2019;s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties at June 30, 2016 or December 31, 2015, respectively, and has no history of claims paid.</div></div> <div style=" font-size: 10pt; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"><div style="display: inline; background-color: white">The Company is also involved in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6646977936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Leases of Lessee Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; background-color: white"><div style="display: inline; font-weight: bold;">13.</div></div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; background-color: white"><div style="display: inline; font-weight: bold;">Leases</div></div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; background-color: white"><div style="display: inline; font-weight: bold;"></div></div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">On October 9, 2015, Anika S.r.l. entered into a build-to-suit lease agreement with Consorzio Zona Industriale E Porto Fluviale di Padova (&#x201c;ZIP&#x201d;), as landlord, pursuant to which Anika S.r.l. will lease a new European headquarters facility, consisting of approximately 33,000 square feet of general office, research and development, training, and warehousing space located in Padova, Italy. The lease has an initial term of fifteen years, which is expected to commence during the fourth quarter of 2016 once construction of the facility is completed. The lease will automatically renew for up to three additional six-year terms, subject to certain terms and conditions. The Company has the ability to withdraw from this lease subject to certain financial penalties after six years and with no penalties after the ninth year. Beginning on the commencement date, the lease provides for an initial yearly rent of approximately $0.4 million.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Construction of the new facility began in the first quarter of 2016 and is expected to be completed in late 2016. During the period of construction the Company is considered the deemed owner of the facility. Accordingly, the landlord's costs of constructing the facility are required to be capitalized, as a non-cash transaction, offset by a corresponding facility lease obligation in the Company&#x2019;s consolidated balance sheet. As of June 30, 2016, the Company has recorded a construction-in-process asset of&nbsp;approximately $0.9 million. This includes $0.5 million incurred by ZIP for the construction of the new facility, which was recorded as a facility lease obligation within other long-term liabilities on the balance sheet.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904500320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">14.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Income Taxes</div></td> </tr>  </table>   <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Provisions for income taxes were $4.9 million and $8.8 million for the three- and six-month periods ended June 30, 2016, based on effective tax rates of 36.3% and 36.2%, respectively. Provisions for income taxes were $4.6 million and $6.6 million for the three- and six-month periods ended June 30, 2015, based on effective tax rates of 37% for both periods. The increase in income taxes for the three- and six-month period ended June 30, 2016 resulted from higher net income as compared to the same periods in the prior year. The net decrease in the effective tax rate <div style="display: inline; background-color: white">for the three- and six-month period ended June 30, 2016, as compared to the same period in 2015, </div>was primarily due to an increase in the expected tax credit for research and development expenditures.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div>  <!-- Field: Page; Sequence: 11; Value: 2 -->   <!-- Field: /Page --> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. The Company&#x2019;s filings from 2012 through the present tax year remain subject to examination by the IRS and other taxing authorities for U.S. federal and state tax purposes. The Company currently has a tax audit in progress in the United States and does not anticipate that the audit will have a material impact on its financial statements.&nbsp; The Company&#x2019;s filings from 2010 through the present tax year remain subject to examination by the appropriate governmental authorities in Italy.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">In connection with the preparation of the financial statements, the Company performed an analysis to ascertain if it was more likely than not that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carryforward. The Company concluded that the positive evidence outweighs the negative evidence and, thus, those deferred tax assets are realizable on a &#x201c;more likely than not&#x201d; basis. As such, the Company did not record a valuation allowance at June 30, 2016 or December 31, 2015.&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6629992608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 6pt; width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;">15.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Segment and Geographic Information</div></td> </tr>  </table> <div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"></div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">The Company has one reportable operating segment, for the purposes of assessing performance and deciding how to allocate resources.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Product revenue by product group is as follows:</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left">Orthobiologics</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">23,304</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">19,283</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">42,891</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">31,255</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Surgical</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,433</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,647</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,751</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,037</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Dermal</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">582</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">303</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">963</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">719</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,256</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,665</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,248</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,402</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Product Revenue</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">26,575</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,898</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,853</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">38,413</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">Total revenue by geographic location and as a percentage of overall total revenue for the three-month periods ended June 30, 2016 and 2015 are as follows:</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-align: center; margin: 0pt 0; color: Red"></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Geographic Location:</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; text-align: left; text-indent: 10pt">United States</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">21,895</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">82</td> <td style="width: 1%; font-size: 10pt; text-align: left">%</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">19,218</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">84</td> <td style="width: 1%; font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Europe</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,977</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">11</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,331</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">10</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,709</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,355</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt">Total Revenue</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">26,581</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,904</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td> </tr>  </table> </div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 700px;">  <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Geographic Location:</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; text-align: left; text-indent: 10pt">United States</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">39,906</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">82</td> <td style="width: 1%; font-size: 10pt; text-align: left">%</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">31,809</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">83</td> <td style="width: 1%; font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Europe</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,542</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">11</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,317</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">11</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,416</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,298</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,864</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">38,424</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8981-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 33<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8971-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8595-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8380-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 35<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8984-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9031-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8538-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8864-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8924-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904496096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">Fair Value Measurements at Reporting</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date Using</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Quoted Prices in</td> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Active Markets</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Significant Other</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Significant</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; text-align: left">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">for Identical Assets</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Observable Inputs</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Unobservable Inputs</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; text-align: left">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2016</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 1)</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 2)</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 3)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Cash equivalents:</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Money market funds</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">67,001</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">67,001</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Investments:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Bank certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,500</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,500</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; text-align: right">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center">Fair Value Measurements at Reporting</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date Using</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Quoted Prices in</td> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Active Markets</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Significant Other</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Significant</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; text-align: left">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">for Identical Assets</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Observable Inputs</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center">Unobservable Inputs</td> </tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="font-size: 10pt; text-align: left">&nbsp;</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 1)</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 2)</td> <td nowrap="nowrap" style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level 3)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Cash equivalents:</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; text-align: left">Money market funds</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">61,385</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">61,385</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">-</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bank certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">250</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">250</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total cash equivalents</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">61,635</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">61,635</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Investments:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Corporate debt securities</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">2,001</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">2,001</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bank certificates of deposit</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,750</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,750</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Total investments</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27,751</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">27,751</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6618495520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plan (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Risk free interest rate</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: right">0.94%</td> <td style="font-size: 10pt; text-align: center"> -</td> <td style="font-size: 10pt; text-align: left">1.40%</td> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1.15%</td> <td style="font-size: 10pt; text-align: center"> -</td> <td style="font-size: 10pt; text-align: left">1.46%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected volatility</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: right">49.47%</td> <td style="font-size: 10pt; text-align: center"> -</td> <td style="font-size: 10pt; text-align: left">51.61%</td> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; text-align: right">53.15%</td> <td style="font-size: 10pt; text-align: center"> -</td> <td style="font-size: 10pt; text-align: left">54.65%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Expected life (years)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 4%; font-size: 10pt; text-align: right">&nbsp;</td> <td style="width: 5%; font-size: 10pt; text-align: center">4.5</td> <td style="width: 3%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt; text-align: center">&nbsp;</td> <td style="width: 5%; font-size: 10pt; text-align: center">&nbsp;</td> <td style="width: 5%; font-size: 10pt; text-align: center">4.5</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected dividend yield</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: center">0.00%</td> <td style="font-size: 10pt; text-align: left"></td> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; text-align: center">&nbsp;</td> <td style="font-size: 10pt; text-align: center">0.00%</td> <td style="font-size: 10pt; text-align: left"></td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6646978512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Earnings Per Share ("EPS") (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left">Shares used in the calculation of basic earnings per share</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,679</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,961</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,778</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">14,934</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Effect of dilutive securities:</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Stock options, SARs, and RSAs</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">432</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">375</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">432</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">398</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt">Diluted shares used in the calculation of earnings per share</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,111</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,336</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,210</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">15,332</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6584980432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Raw materials</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">6,812</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">5,780</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Work-in-process</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">6,140</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,656</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Finished goods</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,312</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,502</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">17,264</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">14,938</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6746987248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock', window );">Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated Currency Translation Adjustment</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated Amortization</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net Book Value</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Useful Life</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; font-size: 10pt; text-align: left">Developed technology</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">17,100</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(3,108</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(6,373</td> <td style="width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">7,619</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">7,959</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: center">15</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">In-process research &amp; development</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,406</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(1,286</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,120</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,099</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: center">Indefinite</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Distributor relationships</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,700</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(415</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(4,285</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">-</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: center">5</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Patents</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,000</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(186</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">(357</td> <td style="font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">457</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">473</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: center">16</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Elevess trade name</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,000</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(937</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">63</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">125</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: center">9</td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.25pt; text-indent: 10pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">28,206</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(4,995</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(11,952</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,259</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">11,656</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: right">&nbsp;</td> <td style="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived and indefinite-lived intangible assets by major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904496384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended <br /> June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Twelve Months <br /> Ended December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Balance, beginning</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">7,482</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">8,339</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Effect of foreign currency adjustments</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">86</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(857</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.25pt">Balance, ending</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,568</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">7,482</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6629982192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">December 31,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; text-align: left">Compensation and related expenses</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">2,416</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">3,082</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Facility construction costs</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,769</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">415</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Research grants</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">481</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">381</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Professional fees</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">889</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">210</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Clinical trial costs</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">339</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">252</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">744</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">438</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">6,638</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">4,778</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906429360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" nowrap="nowrap" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left">Orthobiologics</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">23,304</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">19,283</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">42,891</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">31,255</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Surgical</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,433</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">1,647</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,751</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">3,037</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Dermal</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">582</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">303</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">963</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">719</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,256</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,665</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,248</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,402</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 10pt">Product Revenue</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">26,575</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,898</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,853</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">38,413</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock', window );">Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Geographic Location:</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; text-align: left; text-indent: 10pt">United States</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">21,895</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">82</td> <td style="width: 1%; font-size: 10pt; text-align: left">%</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">19,218</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">84</td> <td style="width: 1%; font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Europe</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,977</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">11</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">2,331</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">10</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,709</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,355</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt">Total Revenue</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">26,581</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">22,904</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse;; width: 700px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="15" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Percentage of</td> </tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Revenue</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Geographic Location:</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; text-align: left; text-indent: 10pt">United States</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">39,906</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">82</td> <td style="width: 1%; font-size: 10pt; text-align: left">%</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">31,809</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 1%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 10%; font-size: 10pt; text-align: right">83</td> <td style="width: 1%; font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; text-indent: 10pt">Europe</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">5,542</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">11</td> <td style="font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">4,317</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right">11</td> <td style="font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Other</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,416</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,298</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6</td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: 20pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">48,864</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">38,424</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">100</td> <td style="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents schedule of revenue and operating income, by geographical areas.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8813-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6629993760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Nature of Business (Details Textual)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_NumberOfProductsDevelopedManufacturedAndCommercialized', window );">Number of Products Developed, Manufactured, and Commercialized</a></td>
<td class="nump">20<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_NumberOfProductsDevelopedManufacturedAndCommercialized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of products the Company has developed, manufactured, and commercialized throughout the course of its existence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_NumberOfProductsDevelopedManufacturedAndCommercialized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6900327664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Investments (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 25,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736080800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 67,001<span></span>
</td>
<td class="nump">$ 61,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">67,001<span></span>
</td>
<td class="nump">61,385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">25,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">25,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="nump">$ 27,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26626-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6900270288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Equity Incentive Plan (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=anik_RestrictedStockAndRestrictedStockUnitsMember', window );">Restricted Stock and Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Plan [Member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=anik_RestrictedStockAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=anik_RestrictedStockAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anik_PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anik_PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=anik_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=anik_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6746938144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.94%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">49.47%<span></span>
</td>
<td class="nump">53.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">51.61%<span></span>
</td>
<td class="nump">54.65%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">4 years 182 days<span></span>
</td>
<td class="text">4 years 182 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6747000544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Earnings Per Share ("EPS") (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
<th class="th"><div>Feb. 26, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=anik_AcceleratedStockRepurchaseMember', window );">Accelerated Stock Repurchase [Member] | Morgan Stanley &amp; Co., LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare', window );">Accelerated Share Repurchases, Initial Price Paid Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_StockRepurchaseProgramPercentageRepurchased', window );">Stock Repurchase Program, Percentage Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=anik_AcceleratedStockRepurchaseMember', window );">Accelerated Stock Repurchase [Member] | Morgan Stanley &amp; Co., LLC [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock Repurchase Program, Remaining Authorized Repurchase Amount</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=anik_AcceleratedStockRepurchaseMember', window );">Accelerated Stock Repurchase [Member] | Morgan Stanley &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock Repurchased and Retired During Period, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_StockRepurchaseProgramPercentageRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of shares repurchased under the stock repurchase program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_StockRepurchaseProgramPercentageRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=anik_AcceleratedStockRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=anik_AcceleratedStockRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=anik_MorganStanleyCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=anik_MorganStanleyCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906428160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Basic and Diluted Earnings Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in the calculation of basic earnings per share (in shares)</a></td>
<td class="nump">14,679<span></span>
</td>
<td class="nump">14,961<span></span>
</td>
<td class="nump">14,778<span></span>
</td>
<td class="nump">14,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Stock options, SARs, and RSAs (in shares)</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares used in the calculation of earnings per share (in shares)</a></td>
<td class="nump">15,111<span></span>
</td>
<td class="nump">15,336<span></span>
</td>
<td class="nump">15,210<span></span>
</td>
<td class="nump">15,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736011712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 6,812<span></span>
</td>
<td class="nump">$ 5,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">6,140<span></span>
</td>
<td class="nump">5,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,312<span></span>
</td>
<td class="nump">3,502<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 17,264<span></span>
</td>
<td class="nump">$ 14,938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906059824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Intangible Assets (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736190384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,373)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="num">$ (7,959)<span></span>
</td>
<td class="nump">7,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="nump">$ 7,959<span></span>
</td>
<td class="num">(7,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="num">$ (3,099)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="nump">$ 3,099<span></span>
</td>
<td class="num">(3,120)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="num">$ (473)<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="nump">$ 473<span></span>
</td>
<td class="num">(457)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_ElevessTradeNameMember', window );">Elevess Trade Name [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(937)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="num">$ (125)<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccumulatedCurrencyTranslationAdjustment', window );">Accumulated Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,952)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="nump">$ 11,656<span></span>
</td>
<td class="nump">11,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Book Value</a></td>
<td class="num">$ (11,656)<span></span>
</td>
<td class="num">$ (11,259)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_AccumulatedCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the accumulated currency translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_AccumulatedCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_ElevessTradeNameMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anik_ElevessTradeNameMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6906494640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Changes in the Carrying Value of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="nump">$ 7,482<span></span>
</td>
<td class="nump">$ 8,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Effect of foreign currency adjustments</a></td>
<td class="nump">86<span></span>
</td>
<td class="num">(857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance</a></td>
<td class="nump">$ 7,568<span></span>
</td>
<td class="nump">$ 7,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6900469616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related expenses</a></td>
<td class="nump">$ 2,416<span></span>
</td>
<td class="nump">$ 3,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Facility construction costs</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccruedResearchGrantsCurrent', window );">Research grants</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_AccruedClinicalTrialCostsCurrent', window );">Clinical trial costs</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 6,638<span></span>
</td>
<td class="nump">$ 4,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_AccruedClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued clinical trial costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_AccruedClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_AccruedResearchGrantsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued research grants current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_AccruedResearchGrantsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736528944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Standard and Extended Product Warranty Accrual</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736435920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Leases (Details Textual) - European Headquarters Facility [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 09, 2015 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property | ft&#178;</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_LesseeLeasingArrangementsTermOfContract', window );">Lessee Leasing Arrangements, Term of Contract</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_LesseeLeasingArrangementsNumberOfRenewalTerms', window );">Lessee Leasing Arrangements, Number of Renewal Terms</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_LesseeLeasingArrangementsRenewalTerm', window );">Lessee Leasing Arrangements, Renewal Term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty', window );">Lessee Leasing Arrangements Ability to Withdraw With Penalty</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty', window );">Lessee Leasing Arrangements Ability to Withdrawn Without Penalty</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_LesseeLeasingArrangementsInitialYearlyRent', window );">Lessee Leasing Arrangements Initial Yearly Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in Progress, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation', window );">Build-to-suit Lease Agreement, Offsetting Facility Lease Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the offsetting facility lease obligation under a build-to-suit lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_BuildToSuitLeaseAgreementOffsettingFacilityLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement ability to withdraw with penalties, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_LesseeLeasingArrangementsAbilityToWithdrawWithPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement ability to withdraw without penalties, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_LesseeLeasingArrangementsAbilityToWithdrawnWithoutPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_LesseeLeasingArrangementsInitialYearlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement initial yearly rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_LesseeLeasingArrangementsInitialYearlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_LesseeLeasingArrangementsNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of renewal terms of a leasing arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_LesseeLeasingArrangementsNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_LesseeLeasingArrangementsRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_LesseeLeasingArrangementsRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_LesseeLeasingArrangementsTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_LesseeLeasingArrangementsTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=anik_EuropeanHeadquartersFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=anik_EuropeanHeadquartersFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736202800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Earliest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member] | Ministry of Economic Affairs and Finance, Italy [Member] | Earliest Tax Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 4,903,000<span></span>
</td>
<td class="nump">$ 4,634,000<span></span>
</td>
<td class="nump">$ 8,789,000<span></span>
</td>
<td class="nump">$ 6,646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">36.30%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">36.20%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6904002608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Segment and Geographic Information (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736542240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Product Revenue by Product Group (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=anik_OrthobiologicsMember', window );">Orthobiologics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
<td class="nump">$ 23,304<span></span>
</td>
<td class="nump">$ 19,283<span></span>
</td>
<td class="nump">$ 42,891<span></span>
</td>
<td class="nump">$ 31,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=anik_SurgicalMember', window );">Surgical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
<td class="nump">1,433<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
<td class="nump">2,751<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=anik_DermalMember', window );">Dermal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">963<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=anik_OtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
<td class="nump">1,256<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
<td class="nump">2,248<span></span>
</td>
<td class="nump">3,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product revenue</a></td>
<td class="nump">$ 26,575<span></span>
</td>
<td class="nump">$ 22,898<span></span>
</td>
<td class="nump">$ 48,853<span></span>
</td>
<td class="nump">$ 38,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=anik_OrthobiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=anik_OrthobiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=anik_SurgicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=anik_SurgicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=anik_DermalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=anik_DermalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=anik_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=anik_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6736201072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Product Revenue by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total Revenue</a></td>
<td class="nump">$ 21,895<span></span>
</td>
<td class="nump">$ 19,218<span></span>
</td>
<td class="nump">$ 39,906<span></span>
</td>
<td class="nump">$ 31,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_PercentageOfNetRevenue', window );">Percentage of Revenue</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total Revenue</a></td>
<td class="nump">$ 2,977<span></span>
</td>
<td class="nump">$ 2,331<span></span>
</td>
<td class="nump">$ 5,542<span></span>
</td>
<td class="nump">$ 4,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_PercentageOfNetRevenue', window );">Percentage of Revenue</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=anik_OtherLocationMember', window );">Other Location [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total Revenue</a></td>
<td class="nump">$ 1,709<span></span>
</td>
<td class="nump">$ 1,355<span></span>
</td>
<td class="nump">$ 3,416<span></span>
</td>
<td class="nump">$ 2,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_PercentageOfNetRevenue', window );">Percentage of Revenue</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total Revenue</a></td>
<td class="nump">$ 26,581<span></span>
</td>
<td class="nump">$ 22,904<span></span>
</td>
<td class="nump">$ 48,864<span></span>
</td>
<td class="nump">$ 38,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_anik_PercentageOfNetRevenue', window );">Percentage of Revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anik_PercentageOfNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anik_PercentageOfNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anik_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=anik_OtherLocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=anik_OtherLocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MC^AY%.!)T:'B1?4C9@,2[2F]@OIZ (4QOCLEFI2"(S>C@KN_V/P"4$L#!!0
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M]I3X@.3)DBQ^XH_OCKP/?K:S[MO:VF]L7VOC9VZ>5"$TL]'(%Y6LA?_3-M+
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MS0T^=_6P?$;/K\/8-:XDCIKR%WQ7[?)]AE\RAF7^ H$%XE+ )5F08D%Z4Y"
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M]\BY8CH37L6^5^L3]M9IV5&99JK; LX<Z"@^7(_0VSE>_ -02P,$%     @
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M E0@-J65B%'IO*69"5F._F;.H(<:JILC,Q9H8M:YH[0@DX;CI8:4AL<#+76
M,G]S9]!(_3L:SU\+PZCS%U*I8=XYX_D+*:84\]9C/( YC FA K3Y&SS3&,4
M#_X6SZ"A^@N^P>@ D]PHKVZ#T5DH;TDS&!UL\S>)-](&@^-\I2%Y]_=Y!FV5
M6E];9)C4U'D@7[!,$S6F6+"4+K"+-Q%PLF.9/_/08+. (P/WMU>>7,\\,F-.
M4R+SKY0W.IAYI,;,$^NC7'RE ;'A_M;*H8-EU,$!&:88]6:1+Y@0U#O*@G'_
MGL?,O_'& ]3Y6ROGU^O9PI#U#*DK]0RI:_7,86'UC OOJN;0RK*0Z/C[&(>.
MD7E?^25&1^+[")5X8+X0?HH /^5G/Y<5^?L7AT:14><.9+XH:I7F2$E.K-$"
M(2ZH$N;&8X8''*BX]@O3^"Y'"=-!PH :#[:4,!TB3#MA(N1:RM]3.;ZDDCL4
M^V[B;SQNAR+%_?+=#L6>JE))7 R5;EHJ^5A:XS=7@(WMGN;+USYZ:)^/ ]QJ
M+4^7"]ZO?+I"_/!\RVYSYGE>L-L2KF]?W6_6I^K)_E-U3X=C']VWP] V\_WB
M8]L.=ISPV$]6T=Y6N^5';1^'Z6LZA1\N<>''T)[<G?1R,;[Y'U!+ P04
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M00[MF996$A&2JY*4E?Y]^9 4NS"0B[B[FIF=Y:.<T+S9'L"1=R6U/=+>N>'
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MG3_9>  MH@/?/GO84=+[][,F$EH7PD<?FW2E4N)P6![(^DJK?U!+ P04
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M<.MCDZY42ASV\P-97FGY"5!+ P04    " !9A0%)'V5H):4!  "Q P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R%4]MNHS 0_17+'U 3DMXB@M1T
MM=I]6*GJ0_OLP !6;0]KF]#^?7T!FE21^H)GAG/.G/&E&-&\V0[ D7<EM=W1
MSKE^RYBM.E#<7F$/VO]IT"CN?&I:9GL#O(XD)5F>93=,<:%I6<3:DRD+')P4
M&IX,L8-2W'SL0>*XHRLZ%YY%V[E08&7!%EXM%&@K4!,#S8X^K+;[34!$P(N
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MSOV?U9'06&_>.EO')Q4=B\/R0=9?6GX!4$L#!!0    ( %F% 4G :H8JI $
M +$#   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;(53VV[C(!#]%<0'
M%,=)FBIR+#5=K;8/E:H^[#X3>VRC N,%''?_?KG8;E)%Z@O,#.><F6&@&-&\
MVP[ D0\EM3W0SKE^SYBM.E#<WF$/VI\T:!1WWC4ML[T!7D>2DBS/LGNFN-"T
M+&+LU90%#DX*#:^&V$$I;OX=0>)XH"LZ!]Y$V[D08&7!%EXM%&@K4!,#S8$^
MKO;'34!$P&\!H[VP2:C]A/@>G.?Z0+-0 DBH7%#@?CO#$T@9A'SBOY/F9\I
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MS'WV7Q)V=J<*3!>?CB4UCMJE*UVBR^M\R.-,ON!5.? ._G+3"6W) 9V?;!Q
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M20^1 Z6"2+^R&7F@E/\EXZ(F!Z$>4U4+,ZG-0M!N^/$8_W[R?U!+ P04
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M1"-^U.(\O+OW)O%/4CY/#U^W2S^:-(A&;-24HAHO+V(MFF;*-#+_LDG?.*?
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MR6J![QWQ"5V(>*/],[9K6*K  R5<_WJ'"Q>T&2R^UZ /T]:M;GOS)0/6YC9
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MLF1MTSC"$[C4]!WU/Z J(>"&!U03\6L<+H2B9I"81@.^9%NUHNWED]A6,KW
M50)W%(QQ] )/";RKP)\5^$K@+XT0*$&P-$*H!.&#P)*+)9:Z !1D*4:]03K
MWS]GQ7#,39BSP=:7L*T3GEAL7I9^9IZ=I-8G-[IC7,%L)!.YTT@A$6<D+):
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MD,Q:81&(4#Q +2P%)C!'CZFEI3#,)^ QM;(4 C!)QOM*O'TESI@GG$V] NF
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M!.R1P0XD.W8GH/X85OX#4$L#!!0    ( %F% 4G.C?U%UP(  -4+   9
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M=%@[A0A4E,5)4#\]5XG>^,%<Z<\;)$)*T\<9B"8U*Z&D)G/B#+AC]S-7">B
M!(X,3HI(VR!B:-/51]_'T?(HT\E:S4$$I$'F0%+?#IRT90#XDW4;9_PACN>/
M05@3APSX22/ [R].WEZ\O[B].+]1)Q_/U,WMY>EO?KQ\?W9^??.WO_Z'.O_M
MW<7M3ZV$W?A;I&K#[TFN=^(X#/S[( RR!@J!8HC76F7^9]VZ0ID8.R:[I%5#
MB^P=C[H466B8>0X\!GR4UU8_,[\#C';&&A.BV SX9/!) HT-TE)',UA<'7R,
M,ZUZ_:K$1-OB3;KQ9_I7WVSDE'SSO:I.3L)X%8=SD/Q(*&2V;%L[QL#M FK*
MTOM5I]L#I"8*CG.N?ZEZ7G_4];K=K@APY>?9"@[.G_4<F"PVWP:H'^9,1T?P
M?XVS*MJE!;XQ 4< XMR#XF,#O+VA-YE,O/%X0 _#RMW!V)MVIW^';9S,03J#
MM01LB?+E*(B.9OXF #9M.!WY.@])Z,NAB-= ZA6<%9@:F#6M\>:USL!LQ"/E
M)Q& W"*=TD:N:'[V?7$2:+]5CCIO'/O%RNO@RL=?5AJL0-".^VNS?;3)D^QO
M.8MLEGD<AGX"0@9H0!Q2,U]J$]2X;I?QTS9:V/ %(^/]K*[RF7KNILNCG[7C
MQJ%/;[=QV-Y[;>1(-*<U"U]@D,L-VN1P/)G73TL'3A3.0:.)9?;@<*;W!*<.
M]G;.:E89&!#S?):U*9[WP0QACI:>6H/1#_@"J65T2^*W#^0CW_*C( ?0;!1V
MW1R,4SIHF]WP7<,Y])/92OU/?[WY)>A1D)0QV4 U_05.".T#]*%&7X]'^/-U
M$)$GB5*V>1=Q#=P6"V*1Q&OS-%"^P:K20-H,:(F/-]I4,M.]!F]8RX-LF310
M[B%(T5V&1W<^^5&;):N_O/738$8R3<;;,UHC2#')GH>:YW[4P7*%Q\-_ +0L
M-:H>.GG/.G)G09CC)'M!:A[^.DM?-BA,@P=4G(>U]>^B1/LA":XEZ%!Y3.'*
M&@Q(4H!6D0#!JN/? >6#923&YFRK,,R1AAP:\>=_S-G[:>'5I\!MD(2U1U\D
M\<B!>Q?&CVF+8-LMPVCX@H:[QPB-)32 "&LU5)]8;*0JBU%1QV#L@M?B, I\
MCY_(K=S@F0$1J>ZW^RUPI@$YLT!P#W+/7V/TY,_T1:.)?'3O(Z*0 H R'BAB
MH]6JW_^8S^/\/EOD(<#,QLE34H'=TKI%!G[$/0C"19 QNMEP4_ZCGS309@7>
M(.LD!VODWQ%2'!^G3J*Z%?64A^Q5W6-<POI*S8[PV1,>U,=]6> IO@PH_/ $
MVP 59EK/9<C:S_#8;_&4!.W1BZL<%!DPSS,>VS2Z_ZU[SU-BML8]/+7O11"!
MP?W$OJ_U1J CD3!SK*S=*-*?=3(+>%,[6='NY4 V<UBB:!.4M2#CYQGQL\*@
MJ0K6&S1C $R<MD$=@S 'N [FFO\Z1 3.]@U6M4:UT 6\U\L@0N>*2$F.R[/&
M:_0JVT9^C-$?A$$7EM@G.QC6)5LS5Z&4"O,Y<Y!?"<BP;*Q$8>H@80 "-,)'
M/!!$Z[<Y&)>Z[G[BHR32WS%!0;,5VJ;VL)W.L;K_<*L_9^IM"*Q7S2&T1#QZ
MG0; 5%LF 9P,Y:ME&-_[H0<HR?22@_"@'U: OSD8/VO\/TY#ZL"/MG0B@@P?
M@[T!ZR'K F5 W($0E>CD!G9 )'X,LA68M&RPHGGJSCV'T^*;4!=8"#GF3F9H
MEW-8(,7CP$<#5P!&BQ]X$APP#Q8@+V&5@&#.BNUA,"$"D16!Q41D!WV?BR.#
M0IA@Y<A2GJ_IE(/=Y/$QWOA@9/,J^"WK9 =^@Y .(I2<(D0*,)Z*P493V6,,
M^YWY<T8$\A$H6SA]8M>S'^)'^0*.+(A4_,C.R'J-\@.M+MSL&FWG# XYN#S&
M@TB12# X^41::Y: ,41[01("_*RV00QD!61_^^M_I'0:DD!3XF.U!:\VB2-
MDS\#C97IV2J*PWBY+>V(QC7P@<+4RP+LIQBYAXRT@%9="&#HM%Y>W_YX^;N+
MFU/:VH?+C_3AD#YM@HT.<:*#TXN//YR\IR]__.GD_>6[DYM;W"!"?Q<%UCR#
M;8/)@B(&:9P>6G0@;8!:^@$Y@(F.DZ%_@MC[8PPLK19Y-",+!G@)E#1(GB!=
M(8;G^ $7^?&$CSYS&1 ]"T*TM4FE)S*EX8 X*A,>D)#F]W_4('^14X+T4VIT
M!GSF,Q.PW8'[N@_B N$T-2$69 /P!SBJ\-P<S,&$AZ"P(@ZYSS,5Q1BT70=\
M\CS74<2].317:#9E3!V=!8 ,XL5(/Q;4IC7-B8*3@?.!R ,;&8  X#_I+4KE
M-(XB#<(!4)YIQJ-(5\-/Q7:\$A/[YF'].1!%'<T)AH*;A?$W<.!P61(6=YV;
MCGH7QQQQ/$MR$/J.@PMS'OSMK__[W=G)W_[Z?YBC%N)L )'RT E8^!N4'>3"
M@P)(6/#"HB"5P)'&?Q%G$HA&:BV3^+%V=NZ-%,U629PO5SPM;!]YKMBP(O!
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M6^TG1SJJD%$&*JJY0)$V!WOL >F+&K%Z(@Q/-.V41=4\!B!07IE] S)1V\_
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M9B/8QH-M;G7PS?G5S3>U:\L-3S[?')]T&E<$-0%KDI;@2^SPB2[L^.%, O_
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ML^=#G"S]B"I!0KV51C*G<4>]?W]*VJ/\ "D2]XZ6K]X%G_%:!/5046X'3]9
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MRA2A6BO& WO-UAW+"^).G9=_Z_D^K^>HPP"_W]V<J8-7-6A.*Q[[F7CL?_A
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M-[\8PS+K4SB<BRF64?V\5/H;_<>YE%9)4$__-,D&QUB7\U^(@=:C_P59G(/
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M=&5N=%]4>7!E<UTN>&UL4$L! A0#%     @ 684!24AU!>[%    *P(   L
M             ( !"0(  %]R96QS+RYR96QS4$L! A0#%     @ 684!27H>
M7>+% 0  9QP  !H              ( !]P(  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 684!2= Q6D8W P  9 P  !
M     ( !] 0  &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !9A0%)3=)3
M\C\!  !I P  $0              @ %9"   9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " !9A0%)F5R<(Q &  "<)P  $P              @ ''"0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %F% 4F8P$^900(  -P)
M   -              "  0@0  !X;"]S='EL97,N>&UL4$L! A0#%     @
M684!2;<\=$!C!   DP\   \              ( !=!(  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( %F% 4D7LU*=> (  "4)   8              "
M 007  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !9A0%)
M+JM;(,X#   ,$@  &               @ &R&0  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ 684!23C&C4HU @  TP<  !@
M     ( !MAT  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M %F% 4EF[?W>N 0  "07   8              "  2$@  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " !9A0%)5J[V>DT$   B%0  &
M            @ $/)0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ 684!28!;;5&F 0  L0,  !@              ( !DBD  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( %F% 4EQ,,.@I $  +$#
M   8              "  6XK  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " !9A0%)'(>>J:,!  "Q P  &               @ %(+0
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 684!29J<4;.F
M 0  L0,  !@              ( !(2\  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( %F% 4ENJT->I@$  +$#   9              "
M ?TP  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 684!
M236+AFNF 0  L0,  !D              ( !VC(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " !9A0%)9C#JY*8!  "Q P  &0
M        @ &W-   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( %F% 4FYA VOIP$  +$#   9              "  90V  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 684!2?X?@W6E 0  L0,
M !D              ( !<C@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " !9A0%)![35?Z8!  "Q P  &0              @ %..@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %F% 4E<@;(_
MI@$  +$#   9              "  2L\  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ 684!29GL"0FE 0  L0,  !D
M ( !"#X  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !9
MA0%)@!FPOZ8!  "Q P  &0              @ 'D/P  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( %F% 4D$PUNAI@$  +$#   9
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M970R,RYX;6Q02P$"% ,4    " !9A0%)!]O)3:8!  "Q P  &0
M    @ $,2P  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M %F% 4G :H8JI $  +$#   9              "  >E,  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ 684!20JT4(NG 0  L0,  !D
M             ( !Q$X  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " !9A0%)P=; ":8!  "Q P  &0              @ &B4   >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %F% 4FJ]LB#L $
M !8$   9              "  7]2  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ 684!21RZCOEV 0  ]0(  !D              ( !
M9E0  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !9A0%)
M7T#2F,<!  #H!   &0              @ $35@  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( %F% 4G\MUID60(  #\)   9
M      "  1%8  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ 684!26UAT0EW @  "0D  !D              ( !H5H  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !9A0%)'2^^=R,"   T!P
M&0              @ %/70  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( %F% 4F$3E)F<0(  -T)   9              "  :E?  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 684!2=CD&:<^
M @  '0<  !D              ( !46(  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " !9A0%)G#F^ MH!   3!0  &0
M@ '&9   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( %F%
M 4EKU7B\Z $  "H%   9              "  ==F  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ 684!276Q#865 P  ;A(  !D
M         ( !]F@  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " !9A0%);"/(4.D!   B!0  &0              @ '";   >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %F% 4GSIJ?.%P(  *D&
M   9              "  >)N  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ 684!20PR /B- 0  :@,  !D              ( !,'$
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !9A0%)9%R?
MQQ,"  #.!@  &0              @ 'T<@  >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( %F% 4F.5@V<80(  %0(   9
M  "  3YU  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M684!286DK=J9 0  ;@,  !D              ( !UG<  'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " !9A0%)T Y7:Z8"  "2"0  &0
M            @ &F>0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( %F% 4G.C?U%UP(  -4+   9              "  8-\  !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 684!2=_7W[T?+P
M_K8  !0              ( !D7\  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L%
3!@     W #< \PX  .*N      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>90</ContextCount>
  <ElementCount>169</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Note 1 - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business</Role>
      <ShortName>Note 1 - Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 2 - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-2-basis-of-presentation-</Role>
      <ShortName>Note 2 - Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 3 - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-3-recent-accounting-pronouncements-</Role>
      <ShortName>Note 3 - Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 4 - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments</Role>
      <ShortName>Note 4 - Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 5 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements</Role>
      <ShortName>Note 5 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 6 - Equity Incentive Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan</Role>
      <ShortName>Note 6 - Equity Incentive Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 7 - Earnings Per Share ("EPS")</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps</Role>
      <ShortName>Note 7 - Earnings Per Share ("EPS")</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 8 - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories</Role>
      <ShortName>Note 8 - Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 9 - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets</Role>
      <ShortName>Note 9 - Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 10 - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill</Role>
      <ShortName>Note 10 - Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Document - Note 11 - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses</Role>
      <ShortName>Note 11 - Accrued Expenses</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 12 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies</Role>
      <ShortName>Note 12 - Commitments and Contingencies</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 13 - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases</Role>
      <ShortName>Note 13 - Leases</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 14 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes</Role>
      <ShortName>Note 14 - Income Taxes</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 15 - Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information</Role>
      <ShortName>Note 15 - Segment and Geographic Information</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 5 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-measurements-tables</Role>
      <ShortName>Note 5 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 6 - Equity Incentive Plan (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-tables</Role>
      <ShortName>Note 6 - Equity Incentive Plan (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-tables</Role>
      <ShortName>Note 7 - Earnings Per Share ("EPS") (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 8 - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-tables</Role>
      <ShortName>Note 8 - Inventories (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 9 - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-tables</Role>
      <ShortName>Note 9 - Intangible Assets (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 10 - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-10-goodwill-tables</Role>
      <ShortName>Note 10 - Goodwill (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 11 - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-tables</Role>
      <ShortName>Note 11 - Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 15 - Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-tables</Role>
      <ShortName>Note 15 - Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 1 - Nature of Business (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-1-nature-of-business-details-textual</Role>
      <ShortName>Note 1 - Nature of Business (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 4 - Investments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-4-investments-details-textual</Role>
      <ShortName>Note 4 - Investments (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 5 - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-5-fair-value-of-financial-instruments-details</Role>
      <ShortName>Note 5 - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 6 - Equity Incentive Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-6-equity-incentive-plan-details-textual</Role>
      <ShortName>Note 6 - Equity Incentive Plan (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 6 - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-6-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-awards-details</Role>
      <ShortName>Note 6 - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights Awards (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-7-earnings-per-share-eps-details-textual</Role>
      <ShortName>Note 7 - Earnings Per Share ("EPS") (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 7 - Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-7-basic-and-diluted-earnings-per-share-details</Role>
      <ShortName>Note 7 - Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 8 - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-8-inventories-details</Role>
      <ShortName>Note 8 - Inventories (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 9 - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details-textual</Role>
      <ShortName>Note 9 - Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 9 - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-9-intangible-assets-details</Role>
      <ShortName>Note 9 - Intangible Assets (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 10 - Changes in the Carrying Value of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-10-changes-in-the-carrying-value-of-goodwill-details</Role>
      <ShortName>Note 10 - Changes in the Carrying Value of Goodwill (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 11 - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-11-accrued-expenses-details</Role>
      <ShortName>Note 11 - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-12-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 12 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 13 - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-13-leases-details-textual</Role>
      <ShortName>Note 13 - Leases (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 14 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-14-income-taxes-details-textual</Role>
      <ShortName>Note 14 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 15 - Segment and Geographic Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-15-segment-and-geographic-information-details-textual</Role>
      <ShortName>Note 15 - Segment and Geographic Information (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 15 - Product Revenue by Product Group (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-product-group-details</Role>
      <ShortName>Note 15 - Product Revenue by Product Group (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="anik-20160630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 15 - Product Revenue by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anikatherapeutics.com/20160630/role/statement-note-15-product-revenue-by-geographic-location-details</Role>
      <ShortName>Note 15 - Product Revenue by Geographic Location (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>anik-20160630.xml</File>
    <File>anik-20160630.xsd</File>
    <File>anik-20160630_cal.xml</File>
    <File>anik-20160630_def.xml</File>
    <File>anik-20160630_lab.xml</File>
    <File>anik-20160630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001171843-16-011397-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-16-011397-xbrl.zip
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MX <KF\ ;EK^T]=4[P7)LRR'OA2D,UY_J"\N&+P-K07P!#G*"YRYT)_K5A^/
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M4][N>&7$'Q;LW=T".-)6(!<<@\^4"3GO-@EK]>%3]EG!=<1!P#[>3?4F^/)
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MMWESK@?<GI&!LP=A)8G-Q[[-SIH9='O.^]6RVE3BQ0=)[/_?["0X2C+V9R?
M%0+?>[J-U8N?_P]95:H>#*L!_C.>C%5EQ&;*'7-KRF05TJ7NWX2!#VH ]Y-<
M'3+JR^/T2KW^_B6&8;*U3'TZ)*"OCD:CX5#) %8P\Q:43.QA%;L>JD[4+-7D
M:WCQX1_$S\R?.^;FS%\L4'%7( <SUZO$$.WB0TI!"G2<]/29@3=GO24S[.ZM
M.P%JZ$K"!M."0M2%^SG,O"0A',?\G@![S2 ]>W:"S>G_YMJP1^@> [(2G4<7
M'[Z[Z9DVQMJ<ZN_$MO^/XSXY=[#QP>Y@7OM^2+PJ4XXWI^2,F4Q][^DH97>K
MQ8-K5YD*U")N-VRRS"AL\-#OSW1]^2Z]-68W4/\:5H@%>M2S#/)#MTQ0-O21
M7##HAGUN>W>B$=CNK:34@N6[JBR-^J%O]L$.ZF?5A#H<J*"+:U!QBPU(,/^'
MOD*3"HPO^,8+B?G5TA\L&X8@_B?88FS7!WMB;7&5EPA?'BH39=R*PNU;MNQ"
M]V:6TP_<Y3LA_45L$0_QNYSTGATN'1@O:R?_,_0#:[HJB'U1-/Z)H0SA,O%.
MT77,(&UN[[R)UE)4S7^0A]&> $:")GQ^7A+'CV)V.-#&QXF-\X2P,?7V:84Q
ME')7$"\VSR"[W\\XR<2!IEE.WJ Q+B3"!=>'#]N'X$Z%8$Y@7-MVGT <W^TQ
M_4;4;6;V]T+D++PE9AUF;!Q+TVQH(; [0$QDMYD4OSU40$MR&XZ=%<)+V&LS
MS)^(03=H09%.D&C(!>L5);><.OGP6$C62C[<]X8HUEUJZ4@SM&1A%Z.)#P*<
M-@6/V/2$1M([=6N"]QHNG5H<KO!B0AX;CA3MB8V&U9X@"+T<8%_ ;(!3$?5S
M^($7&G21&*X?%*R*\PGAZHV&!?&^KS"H3=U6VNU)J&@D0("^=$M\HGO&7)BA
MP^LEB+):5'KI%0JR<DAZG%@I__#<*?%]T,2Z+4Q)D8%R-OP:CSM%G"UI7[MV
M[#DHXBO;<G!.(? LW7XQAH6B=-*<D>:B3M:GEN:&H^:[$/F=L=EJU<"I+CZX
M<2:HR@F#M%NQ 94,%5YKUBY4N%"@AKUA99%ZA0&11XK;[HU&)V9&T1UFWFU6
MYI9_GTOZPIO^*+8G-X")W=XGX0I])16MH"F<:(6+#XH\4451Y (>S;D?7!H+
M\BN 2^7!-59$>6^X;HE!K$=\[#L)]J>:)/&@DU5M,LH%+V_J.D#N)*$D<X&4
MAEH^#4L!B<+*@GGO]6?BUQ"^$0]";2)MPI<_Z][ [9; ,0\X59J,:T"76N<8
M'HVV=.JK?<BH\2 =PJ:5!VDQ"(U O9N^0RY]0;LW#_6^8CH6Y4D-^I:4A'WE
M="PBY'O3L0BZM"/N"ZE%0.XF,QY/\B#D3%T/S)V4E+E[CHS::'\PPT5([URI
MR.*%K$?FQ/&M1\)4QE?7]T'?WDQ!=^RQ_D=<N/M#=1OR*M TC,I.I3#BJK+^
M<*ANR4H-5,!@#BCC,)SRVKG2EQ8<@%*!GOLP@KOC:A--'&:AWPE ?8!WDYN_
M,*7A6*L', ;)Z8Y!OKC>)["Z@VEH;YL9-6PP+NRRO"'S52!I%(G=-AIWZ4K#
M46-(+##B_]\T!.1F>NT$NC.S\.CA^R3(CW97-Z-_4PAHZ6CG(5?D%7&#"X50
MU(-82R#6=D+,53''A#@OPIH+,==2&AZ7QE)I&O,-^SH0.X%E6G88@'Z_(T;H
M41/F\[-AAR8QOWCN K> ,(@&^ZQ[CN7,_#A6'J8*-Q9I"59L1/>+_*2?+?%I
M MQC4:!@P6]00!)?( 6*%<@F!60N!>1SID#!\MZD@/8"*1")?OK/H^4?%>43
MC4]*:X_HF,VMVY]]3)'Z@94 O6"5:^N(?7'R>_(L<VW&-OHG M:Y8=&Y/Q'?
M\*PE R,>DA**E1K4G;\2W?Q7"'0GGA^'Z>T@U5A4T]94&'A]_U_3 -22DJ42
M!Z4-Q+>WP7)V*=];(,OR:--?D+?-<6;>[5'A>@)D!0Z)96>N89)S49<T=:BJ
M.0#D&ZS%<.PDA,PEA#0:JIOB4 #'HV[9:%:#S7VGVZDUQ27.[]?.(_&#...9
M90_BS=_4,K"6\<T4UH'K6\&N=3^:</V/LKQE17$!W1^AB,H-(L1?&-KXQ BY
MWM)%[?R)/ 3)&+M0&HO\>P"Q<8Q2NO0WS_7]GPXH,MOZ-WS4+0=='1_)U/5(
M6<_+)GNXY^E26%2 [B@([S1D1Q/NV?NP"'\,?<LAOI_:!&&G_*C[EH^;(?&Q
MA =^NV^"KBQW";K'3M"56YZ?2\4+$UC3 E8$<L-)N@=(#*V=YWL_)X)N&& 2
MZ\X*ZW^$CAZ:M/$ +#@3LZ/H7S0LB.9,32U'=PR,Y?3C>@%^)JG*<6%+%.;Z
M(Q$>"'$$,'GA\  _/*QHZO 5FTP Z]\/=3!N I=^[X4V\9-H S;D#+4+L,F/
M$X]3NQL^ 8;]7'=F=-2%1>\AA#?X'!WH?SR#<C#>WWV^2CZ:[W^A;UH.1=PS
MT:$(2RZ8T\]@_2,9EIX%2"X!(F%&'#BUV/8*?R=+1!'>Q3DR'1J$-^DI?]X)
MOUU>_LA,.\ "'?GT@\GP?$)'C:"@&//J>C ,X!D_?/#AO*-[0) !_!30A%]&
M8*SUX>L&(Q^^\*#;B&R:.<2V%@ 0H,&@6Q'=ZQ-G@^?1BX(_)R008!&9Q(/S
M%0@#*,LT4Q-\)^]ASDB2\E#N"0\AAJ*@TG6#-0& SH*YCOSP00+^%5J1\$0T
M133IG.[2<I#?0"?0V/J,#MS#GWRRIQSC)J.C9  8NHDZAWW_)DI_1]%P'1 %
MF--Q/=A3 4(02 ]_2+WP"^PD0&A?]U8HWE/=\N E.A$%?2=,U)R,D$LO&IV*
M19R5+.#>UV.KA_BAS80&Y<)E%<>0\[ !TR>"N4=(GPJ";SWW%X#J7%C2ND>^
M0#+M2>FX]$DTFWKT+T/WY\+4=I^2$:L-,ZBFP')T:&Y*?_M5H3]W0QLD&)FD
M4^4!H_PS=%BJ'=4\_"7D."'F@.3--+5LF(.^CRR_9(^RXD8@I0*8:XN$9I+8
M_S]KSN$RCYB5SA9G?***("5/C<B21^@ZCY<%V%Q "!//3Z!(8BF/)X4E ]3"
M[%R#TGD#:F1.#':"8 3_<"#@V0Q7,2AQ>).!)>@+IE43W0<KU]9ARYA:, =,
M"5R!F1;Q?F1$9^_H_67*:* D HR>=-1>@@6,,RC)W;C0'RHT=T&V+:*M6+CJ
MIG#6E([N(&G1$9!6U)JP0R#LYL<P^.X&_R !WE96OG])NQ-&_!@Y69*S7I6R
M #6%QHY+F2P:_+M&:=@(%OX<N(?_8!&E1S@M8?VDX$KW/-0I?]/MD.SA51*Y
METGCB21K&Y"7@*$1L'<ZH42N_T:2Q)$X.A'<Z@ZX1S(?;A'0WI24X]%[EWCS
MG7XBG(G%P\!=OYR6K':G]6.?UM66G]83%^4Q"VFU\8R^"Z[M[)FG=<+;)1QD
MLD>(K'UI)52F-EK*(@+;1H\]?WTPC/H^+'=J\M$'04O0IP)ZNA$>J<JBQFBX
M]@(*,S##F$D,"L*GYSD\<D>C"T9<8A!AU!-GHN!B,!O]>1W-%EE4/5CU]/'8
MQF9?"P&&'#/3-3XKS0E:W;H#VBCEK,=W3>:NQS__),L#30"M8L?%8?XD:X-Q
M\DV0<YS9LIE[:+JBM0J VJLL&*"G70:+$;O8 8"'0/ 35P8%9""F9\VWR]'H
M)-26WB8SV+H1E5VGX$2QS=,4(%OHPJ#;D/!$/M_"+;UKE-ELOH"PT9TI>9]_
M$;5^^..*7G%=H71'%]@.67W3O3](\ 463LXU1V9G'4O\^')0_%*)C34'\)/C
MFWYA_>=?+3C#>,9\]96 ,-.WU[]=.\LP\.D/\DZ2<6W6-I LO@EK3D1DOHA(
MRKB,C=Y&? \J(C)?1,Z"9"4O@3>0+K@#+F.AMQ;E@XJ*PK]F;@O5"H#G>D^&
MTE!IH9PWS[X"Y7A0"K#"_M>.@5TV")@R]-]ZSC"^IN_+DC:62V"3#U:3"%5Q
MB\G<Z&IE-%2;0@=OZ-A1 P=PZ44;<8SBA+]U9!O?!2D\^^\<RX83J!>2B[<U
M9ETOY-2L/(_AOK/6]Y:H8N<M.7KQ\;8'-Z0DCAY1,S+7.5#V=J!<.]1[@-=)
MT=4J+E9/-_ *.WTS^Z1[M-0@7A_1QX"G[@);:01S.%7CHTO/-4,#K_L#O+$.
MIS *O>7>N'F*GA/0H\!L+7:%C^X:@4RG!'Z+AL2ES3P:M@4+9Q4[>^)7X[&R
M+HF%'KDE(J!+@&BZT3W]%.^Z24]XM%QTP/300_  ZMZ8"SCTS\'=0%C"#^C4
M\>#Y +0' (Q7D\LX<)J6L>AA@())O0\>">@XS.V#CWD6P08B.!]>L\=7X32L
M86YYID#CT0?"#7QM&#K&?639$7,II)$;*",+!_U:_@9S=.H[">C(U+=EV[$7
M1?<LGU[XA^@IZC%T!,9K.H'#KB?1Z=6CWQNV;BWP.?H'=>M$I(ED)Z(W=?EX
M;$Y&&OP$=)K!<":A#(ZFBF7!T$,_B:%QR PT!](8!9&2+HI^\3?<?9N,MVB
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M=)]I1IN]$D;BGV.RLAS>[2#7:2;AC::EQ4Q-9P)GN$(S;H'IT1@H2'-BKW,
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M%T911@YK722"TLY/$P\P>B^LDYD%WTIJIKA8,R5G:LHQW2/IGXA%'S8M$*X
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M#(5S$,<]T=)M>R7,]4><S"13ND^F\? (3/UHD2> >TF AB;J%7@'D,!Q?$8
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M288GSTOB^"2=#+^=FOZD^\*?Q($B+"S;QK<P.1S3FH.Y1TA_ 6#-HW1T7R
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MCH'?4W"IZSS5Y:<\G<4&Z PBY+F@7A"5&49I.0@/DC-%Z[6T'E%+-+6F.7W
M@%J@AO6X!1AM.I3#EVQK+U#3('8+$ H=-V6@""QTUDLJ7FG65$ I .E:@"4O
MV-8?!-M-S>$%%!P61P</N*%M8FP<6[RN$ ; W'\3JC6F(>KD>)]C(+!=;4H\
M+U(2ZQ9+:]5!<4,!PV===J: 16-33PN&V0'L3[IG;BP)ES:THHW&(DEFS:Y
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MKNTI1=M$5Q?L.&Q0>IIX0C:TJ=A?UZ^M3B.>44\>JL? IRL95H(;:F^BG+B
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MM86-&W@P'/.$C3M_?7AWDE+EQAIHH_%FU-J>\*)678>5U28P-[Y@**D<@/D
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ML2RB#4=1,PT?);@>@BK6J7X%LGD$"8_%W\(E*Z$(,B*@ZL>1L7:7]=QGU>P
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M=\9LJ8HWG-??OZ1[QV7ZFSX_ ._Z2UA.%Q^D%#K<R;- WL")X%Y__@?Z DM
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MXW#[?KM9**D"**!?BJ,\F[O8VBDSVYH.J=EXY^5=LRUUR_S,@GMAIV'W2#2
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M)!6MZ=B&[=7KLV"'"V=I&IVZBB=J#A*()P"+HEB > (P ?'$X<43.D(!X@E
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MUIQ'WOV,\>5Z,0>Z!D^FL<(P?K;5APF*>A(@WK7Z^8,5E\F:/<M;OK]DN )
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MM;A%C+_XT19S%5,^KTWSK)XQ-<7)J?]<_#=!"QHB.ZH?GS$I5SRZ_X.%"11
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M.</BAH6[\I2:?KQ!V83]&R/4TOC+ZXQA?"NZ=#*=<%97Q.'JF'-]P0%[7 X
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ME>JVPL!/(BUCJL]/^8XS_!2 ?=N'=0\AK-O3R522K5^LB<@]B7(42_I96A:
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MM!OE[W .2_9J<-.V;JO>O919[3X&.3^KAZ%JG.!HTHZW1;5K>0#PY'JTC=O
M;GJ-S_+T69Y&6.%C[,X$&")64U,=/D;3+;-;E>.3:_O-<=(*@PPLM[9M3L#
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M\E>6M**D$$/-,]$QV(>:&R+C4 --Z-#T]()+<E;+O7N:6A;6!J=!C* 9>%/
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MW^S)]_(/#J[;R1E=5C]D*ROB]HR,WO$8?S(&" 0 48>U4?3U24&B6 Y%57[
M$ ",QF8SVQ5.)Z125]Z'L7P8ZY##6)H+ )PC7JU&:;T5!-L_5CL2M+$*AD>3
M=89/;27"(\0ZN/1(S& #?=Y!#=]G^1H<U-TH5.]8!;)C&!]/DIQ,@K);J"\
MT_$QJ=VFY>_%?^Y0BOEO_C]02P,$%     @ 684!25!&C4/W/P  K6<# !4
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M^ YL];RH#VY-9CL3T:^F.5O*?],TFBX97V9T_1C/A3*[C[#!""VB8[MB; #
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MX3I%).()T6&6J\Q*5M<%=SJ-(]!);A9=6ZC9S4/5B]V[1Q<U7^:YX/</>PS
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MY!D*YQ4:FS_(Q!<4WD?PEF<L7J8Z.U)?4^P+TY8NG3\D+6F.:3OJY2PW8==
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M;M-C2L'3F!Y#LIJQU,:(43DYY!VW +KC"P)6")U.ME$57_TN3FG@,2GDJOX
MN?2Z.W8>L#8R,YX&B[DYWSS+U9JE0L9_9K3+)]C2 BLY^YY\;<H-DIA-=Q!B
MC*%:T)-F0S5@5S+=,MM<@R&A596Z,G+U3$I;0>GXSII:\J+_<,K("R!V5)#!
MHT.LD5T)[Y UE?4%J5?5Z.6?WR7574&O4<E')G+YD KTLN#ICS1.H8C/&5OP
MC/44>;+9-W)I6L'@:_E: 6NW#*53+MFN6#DAS=):$B_9 R: F'P&F#^?D <)
MFR@9YF@GL;LVM$IBHJ?2[XYT2;-$H"TJ?:,W<*VW+7+':.W3^6N$BNA."PP;
MMM;/5V[$++_2<T83>/YX_\A8<0U3#_G+NJ,/5,V1,M35K?/7"25=(@F3FG+(
M& 0E@[DIU\++4V]<MOH#BS+E)S:[2ZI"1F=KL%DA6>$CM/?YC6>";F^,5%=#
M](7U98?^4E$3(!DV+*J3FUR?12%%Y5SH<$N>Q?^2@JS(^:/[H151:B/@,<MY
MZ!<CVKSN%#0U X<^V=S$233C]YNXN 9KQ.DR8S*UZ\UBD;,"HE[>TCD8J[?R
M[S</2;P\"#&K!,!2;ZBGGVBJKF5Q(#SS)Z0>.8&XK4MXTX)/<P&02 1D!W%"
M]B!)C;)J]!MAB967MW0%KWX@C@7^Q?<\6=0\221/^ XHV:01RP@E#P?\+9O1
M>KPAWN\.WPZXY6GT'#0*;^[%_(J9?X0<V:=I=,>*.&/1Q283D,O$V.6C_(X3
M&],%-HS4@)2W!/@&F%"9[9V.&9.R'@"1!B(9[59A(B6H709ZG7&["JG%R"6W
MP7C/[V;K,IVGN=AG\JJ"9W23WH$E%9">T3S.54'@V&ZP[VT-R3E_B]LH9%Y"
M(C4F(@ZP'2HB88VE6!]ZTMIJOZ)F8DB,Y[Q\/0RB_F7]#Y#R+QM27OWZ[V*.
M#@7I^ ^&DKCOP+5L?7A_-;N\(/>ST]GEO5<Y:6$2[QZYWWWKCM'D,A>J*!,[
M:\/7<P':YCR6JA&D3[M9W&9\S3)%?HFAW2'W,2Q9US(G\_X)%;VF&M;2,'AR
MN&V.>XY:.$S=6@)_41Y5_[W6P-ZPD0DXJJX%?9?AM\(EM=&V^KIC>NXU= :Y
MY6D9W\Y_P?)Y%LLJ3?N%W.-RL-*GPS.@D[;_@R"<)\/.)!F>!9J<]_PR<I_Q
ML-<=TMD.^^+Q97_.7S<V\E6&C1'I9B77YH]GK4%>R*J2K*</4)!LWO6.HK<M
M]L1OZ].YP)3D")7$OP]S//<RDQMQR',PVC\W93[5-4\%I-X;4V];;#!:6Y_.
M@]$D4;*C&O:NT\]6;L0KW\X <7:"R^(%LKQ'[]+Z!FWN[^G;MU#E(14G/2YS
M%.O&D!*BM*6_?'C0I1,ANK":(**=E"^'DPDF>^D4;(VYX 5-S!Q.-5'R6521
M_1R*',]Q>3.\YE50"*4RO8(.USTK&(L%FQ<WB\OG^2,46;X3^\Q-VHZ^2^]
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M70R977<&F!8DM^GX$)BW?F8.V+6[[CIT$00<CP2Z/&K]B+ #/=!U8I&($2R
M1?(A#)$8CEFP*#Z&(0J8>PLLE1_#D(H5N( %\BDD@4!@,%@R/X4D&2,Z XOD
MYY!$ L* 8-'\$I)HX'XPL'P^AR$?O=<5;K8%8LD"G.-PF01BRX*B1G"I!&+.
M L-^<+D$8ML:0LM^$B%B+N%7)F6C_B_G*4O4N[?1#4G5.[!1?DMID4?QTLJ*
MYM6'C,J,E E3[9:2N:5R'I(ZU.[J9=HM)UGTR ,L):.;!--1FO)[1?$I%\>\
MO"DF9;I^U.F2QI3=*7?/RLY^X2!N-<;V<VDWC)P+(L:BR@%+JBH*4D55=H^&
M08>>7ME:VFZCLKCE@OU%$SL[NAX#8*.RSL$L/&\] /+UX6>7+MMGY&)]SC;9
M*&Z=?3,'W"ZP3L-@QKAI[!V&P81]ZP![X16?O;OB,YX\WA"YX#FK@(3YLIA+
M5[R[A'>76EXX@*PRO,"DDP)>8,(+3,.[P.1)$K5^I@Y >7!+QBBH)IAEU_,3
MVDC(#(!V/5VAO63J$-6NIRNTETK[@.) $Q?<1./L2=SU[(7&XNE(S0PT@Z&E
M6%KIF(%F+K04"4#!;+T*U4&4D:(45-5JNEG=E(9'R:Q#^*@^9:<'*T]A$:8!
M%V'Z5BW?\60\E\M>;1"=-TW?$-W*>^=61N_K3KI,L'(4.E[1\1JNXQ4K1PUG
MG;B6&[:85QYAVX\1R^YH7E1GA"->J^WK Z@9"$&$]CQUB^2WJL*U_.?DSY+=
MD53197@^]V4>EVM_#RQ24<B#2DY(\_'DF,Y5Y/DKG=V\*IG@T,-'DIV8<ZDM
MZ#&]*:YH7 I6,)J;&8'TV7$\'0@;/MT"9X_*4MWT,< \?4/?1*\NAK*_JN/$
MN"G@'='7@;X.]'7L@AV.OHZ6,-:FV4.1A(%/WL  #,7/ 10+W)P,13#H)1R"
MEW#@F62PW>-J=X8B'?2AH@^U!Q]J0\^31]?J3Q&5A%;UZ-4[V>R.1O.4.%3<
MAXSBP]T*(JF5X_60$Y%(2XP)&DNL4N_U K1T@6<[X /6D'@AA:^7T.N_=C#E
MI3S:!(N+5=ZKW)@O?O,]8X7ALS7IOWVL/;J7B\OB(ZMMX],Y.9X<\=F<9GFU
M]2]IJK)NCWA>Y%7RX"&16OV"+*K%:'/W=S3JCOMJ V'#I\OY1)Y/?$%IM;?'
M<ZO3UMK>P^UMJ4=505.#+JAKXH]0HR>YOM'VB7VA]HV+PMC6.^G5B75Y]=V%
MA?H^&(=HPL+C,;1Y4(V$4&\Y5\?2X>+5454=WD\G>): ]DZ?4V$ !P,XC0(X
M_1![S8I4VGYG6<+N6%*2U"!G8]L!D/X[*VXKPU4E8-VR^34_T;_MTG(4#+5A
MJ,T.$$,10CV+O#76#R6JI)6/@V4;BBSL&T:/HD+9+[4<<HN_+I3XD'4S +%_
M*-477)6#"3.&LD;L2@)@;(:B+<RL<H= 2"A;!K,TAI"E,?#Z+5:]VK\;)Q2;
MS:J!.D'+H4A+9]U!7.^A;#Y, L(DH!Z2@#J-1WM,#?HYHD1D+)OFZK6$*%<D
M1W3N>@'3-HR/Y" 83:VR@T9Q3%-UDW:%B"[IO!3QK?SD^H03:)\.<F.^RGU
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M%VOGI=7",+3T0O9<8JK5]:7G;B3S4G+HZ8.MY>,&%RF1Z"!+E**9*X-4?WI
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M?VY(3N5O_C]02P$"% ,4    " !9A0%)PFJA7TAQ  "R#P8 $0
M    @ $     86YI:RTR,#$V,#8S,"YX;6Q02P$"% ,4    " !9A0%)AYI_
M0K,-  !\G@  $0              @ %W<0  86YI:RTR,#$V,#8S,"YX<V10
M2P$"% ,4    " !9A0%)4+,0[%H*  !BC0  %0              @ %9?P
M86YI:RTR,#$V,#8S,%]C86PN>&UL4$L! A0#%     @ 684!24#)%EH#+@
MB18$ !4              ( !YHD  &%N:6LM,C Q-C V,S!?9&5F+GAM;%!+
M 0(4 Q0    ( %F% 4E01HU#]S\  *UG P 5              "  1RX  !A
M;FEK+3(P,38P-C,P7VQA8BYX;6Q02P$"% ,4    " !9A0%):5RI$CDO  "%
M6P0 %0              @ %&^   86YI:RTR,#$V,#8S,%]P<F4N>&UL4$L%
3!@     &  8 B@$  +(G 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
